- This supplement contains the following items;1. Original protocol, final protocol, summary of changes2. Final statistical analysis plan (one version no further amendments made)

## **Table of contents**

Original protocol: page 3 Final protocol: page 101 Protocol amendment 1: page 199 Protocol amendment 2: page 203 Protocol amendment 3: page 211 Final statistical analysis plan: page 215 Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 1 of 98

Protocol

# Trial ID: NN9924-3790

**Original protocol** 

# Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes

Redacted protocol Includes redaction of personal identifiable information only.

Trial phase: 2

**Protocol originator:** 

Clinical Operations, GLP-1 & Obesity

This eonfidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

25 June 2013 | Novo Nordisk

#### Final 2 of 98

# **Table of contents**

Tał	ole of c	contents	2
Tał	ole of fi	figures	6
Tał	ole of t	ables	6
		breviations	
1		nary	
2		chart	
	2.1	Flow chart foot notes	
3	Backg	ground information and rationale for the trial	
	3.1	Type 2 diabetes mellitus and glucagon-like peptide-1	
	3.2	Semaglutide and SNAC	
		3.2.1 Nonclinical data	
		3.2.1.1 Thyroid C-cell tumours in rodents	
		3.2.1.2 Teratogenicity in rats	
		3.2.1.3 SNAC toxicology	
		3.2.2 Nonclinical pharmacology and pharmacokinetics	
		3.2.3 Clinical data	
		3.2.3.1 Data from literature	
		3.2.3.2 Clinical data of s.c. semaglutide	
		3.2.3.3 Clinical data of oral GLP-1	
		3.2.3.4 Clinical data of SNAC	
	3.3	Risks and benefits of the trial	
	3.4	Rationale for the trial	
4	Objec	ctive(s) and endpoint(s)	
	4.1	Objectives	
		4.1.1 Primary objective	
		4.1.2 Secondary objectives	
	4.2	Endpoints	
		4.2.1 Primary endpoint	
		4.2.2 Supportive secondary endpoints	
5	Trial	design	
	5.1	Type of trial	
	5.2	Rationale for trial design	
	5.3	Treatment of subjects	
		5.3.1 Dose levels and escalation regimen for oral dosing	<u>.</u>
		5.3.2 Dose levels and escalation regimen for s.c. dosing	
	5.4	Treatment after end of trial	
	5.5	Rationale for treatment	
6	Trial	population	
-	6.1	Number of subjects	
	6.2	Inclusion criteria	

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	3 of 98	

	6.3	Exclusio	on criteria	
	6.4 Rescue c		criteria	
	6.5	Withdra	wal criteria and discontinuation of trial product	
		6.5.1	Withdrawal from trial	
		6.5.2	Discontinuation of trial product	
	6.6	Rational	le for trial population	
7	Miles	tones		
8	Meth	ods and as	ssessments	
	8.1		ocedures	
		8.1.1	Introduction	
		8.1.2	Visit 1 (Screening)	
		8.1.3	Fasting visits	
		8.1.4	Unscheduled visits	
		8.1.5	Visit 2 (Randomisation)	
		8.1.6	Visit numbers	
		8.1.7	Visits 3-10 (Treatment)	
		8.1.8	Visits 11-12 (End-of-treatment and Follow-up)	
		8.1.9	Visit 11X (End-of-Trial – premature discontinuation)	
		8.1.10	Withdrawals	
		8.1.11	Investigator's assessment	
	8.2		related information.	
	0.2	8.2.1	Concomitant illness and medical history	
		8.2.2	Concomitant medication	
		8.2.3	Demography	
		8.2.4	Diagnosis of diabetes	
		8.2.5	Diabetes treatment history	
		8.2.6	History of gallbladder disease	
		8.2.7	History of cardiovascular disease	
		8.2.8	Renal impairment history	
		8.2.9	Post-dose fasting routines	
	8.3	0.1217	nents for efficacy	
	0.5	8.3.1	Blood samples	
		8.3.2	Body measurements	
		8.3.3	Patient reported outcomes	
	8.4		nents for safety	
	0.7	8.4.1	Hypoglycaemic episodes	
		8.4.2	Blood samples	
		8.4.3	Pregnancy test	
		8.4.4	Urinalysis	
		8.4.5	Antibodies	
		8.4. <i>5</i> 8.4.6		
		8.4.0 8.4.7	Vital signs Electrocardiogram – 12-lead	
		8.4.7 8.4.8		
			Fundoscopy/fundus photography	
		8.4.9 8.4.10	Physical examination	
		8.4.10 8.4.11	Pharmacokinetics	
	05		Calcitonin	
	8.5	Laborato	ory assessments	

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	4 of 98	

	8.6	Other assessmen	1ts	51
		8.6.1 Subje	ect diary	51
		8.6.2 Addit	tional safety assessments	
		8.6.2	.1 Thyroidectomy, tissue sample and genetic testing	51
		8.6.2	.2 Assessments in case of suspicion of acute pancreatitis	52
		8.6.2	.3 Assessments in case of suspicion of severe hypersensitivity	53
	8.7	Subject complian	nce	53
9				
	9.1	1		
	9.2	•		
	9.3			
	9.4	•	ility and destruction	
	9.5	Auxiliary suppli	es	56
10	Intera	ctive voice/web re	esponse system	57
11	Rando	misation procedu	ure and breaking of blinded codes	58
	11.1		ded codes	
12	Adver	se events, technic	al complaints and pregnancies	59
	12.1			
	12.2	Reporting of adv	verse events	62
	12.3 Follow-up of adverse events			
	12.4		laints and technical complaint samples	
		12.4.1 Repo	orting of technical complaints	66
		12.4.2 Colle	ection, storage and shipment of technical complaint samples	67
	12.5	Pregnancies		67
	12.6	Precautions and/	/or overdose	68
	12.7	Committees rela	ted to safety	69
			Nordisk safety committee	
		12.7.2 Even	t adjudication committee	69
		12.7.3 Calci	tonin monitoring committee	71
13	Case r	eport forms		72
	13.1	Corrections to ca	ase report forms	72
	13.2	*	n flow	
	13.3	Paper case repor	t forms	73
14	Monit	oring procedures		74
15	Data n	nanagement		75
16				
17	-	C C	ns	
± /	17.1		vulation	
	17.2	· ·	alysis sets	
	17.3	5		
	17.4	<b>v</b> 1	ndary endpoints	
	- / • •	* *	acy endpoints	
			y endpoints	
			macokinetics and/or pharmacodynamics modelling	

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	5 of 98	

18	Ethics		
	18.1 Informed consent		
	18.2 Data handling		
	18.3 Premature termination of the trial and/or trial site	85	
19	Protocol compliance	86	
20	Audits and inspections	87	
21	Critical documents	88	
22	Responsibilities	90	
23	Reports and publications	92	
	23.1 Communication of results		
	23.1.1 Authorship		
	23.1.2 Site-specific publication(s) by investigator(s)		
	23.2 Investigator access to data and review of results	93	
24	Retention of clinical trial documentation and human biospecimens	94	
	24.1 Retention of clinical trial documentation.		
	24.2 Retention of human biospecimens	94	
25	Institutional Review Boards/Independent Ethics Committees and regulatory authorities	95	
26	Indemnity statement	96	
27	27 References		

Appendix A – Monitoring of calcitonin

Appendix B – PRO questionnaire

Appendix C – Medical Events of Special Interests (MESI)

Attachment I – Global List of key staff and relevant departments Attachment II – Country List of key staff and relevant departments

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	6 of 98	

# Table of figures

## Page

Figure 5–1	Trial design of NN9924-3790	28
Figure 5–2	Dosing and fasting conditions for oral treatment (arms 1-8)	30
Figure 12–1	Initial reporting of AEs	64
Figure 17–1	ADA classification of hypoglycaemia	82

# **Table of tables**

	1	Page
Table 9–1	Trial products (IMP)	54
Table 9–2	Storage conditions for trial products	55

Date: Version: Status: Page:

1.0 Final 7 of 98

25 June 2013 | Novo Nordisk

# List of abbreviations

American Diabetes Association
adverse event
analysis of covariance
area under the curve
body mass index
calcitonin monitoring committee
case report form
computerised axial tomography
clinical trial report
cardiovascular disease
directions for use
dipeptidyl peptidase-4
dispensing unit number
event adjudication committee
electrocardiogram
electronic case report form
electronic data capture
ethinylestradiol
European Medicines Agency
electronic safety information form
full analysis set
Food and Drug Administration
fasting plasma glucose
first subject first visit
Good Clinical Practice
gastrointestinal
glucagon-like peptide-1
glycosylated haemoglobin

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

Date: Version: Status: Page:

hCG	human chorionic gonadotropin
HDL	high density lipoprotein
HOMA-B	homeostasis model assessment of beta-cell function
HOMA-IR	homeostasis model assessment of insulin resistance
IB	Investigator's Brochure
ICMJE	International Committee of Medical Journal Editors
IEC	independent ethics committee
IMP	investigational medicinal product
IRB	Institutional Review Board
IV/WRS	interactive voice/web response system
LDL	low density lipoprotein
LN	levonorgestrel
LOCF	last observation carried forward
LSFV	last subject first visit
MD	multiple dose
MedDRA	Medical Dictionary for Regulatory Activities
MEN2	multiple endocrine neoplasia type 2
MESI	medical event of special interest
MMRM	mixed model for repeated measurements
MRI	magnetic resonance imaging
NOAEL	no observed adverse effect level
NYHA	New York Heart Association
OAD	oral antidiabetic drug
OD	once-daily
OW	once-weekly
PD	pharmacodynamics
РК	pharmacokinetics
PRO	patient reported outcome
SAE	serious adverse event

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 9 of 98	Novo Nordisk
SAP	statistical analysis plan			
S.C.	subcutaneous			
SD	standard deviation			
SF-36	medical outcomes study 36	-item short-form hea	lth survey	
SIF	safety information form			
SNAC	sodium N-[8-(2-hydroxybe salcaprozate sodium	nzoyl) amino] capryl	ate /	
SUSAR	suspected unexpected serio	us adverse reaction		
T2D	type 2 diabetes			
TEAE	treatment emergent adverse	e events		
t <sub>max</sub>	time to maximal concentrat	tion		
TMM	Trial Materials Manual			
USP	United States Pharmacopei	a		
UTN	Universal Trial Number			
VLDL	very low density lipoprotei	n		

**CONFIDENTIAL** 

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 10 of 98

## 1 Summary

#### **Objectives and endpoints:**

#### **Primary objective**

• To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against placebo in subjects with T2D

#### Key secondary objectives

- To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against s.c. semaglutide in subjects with T2D
- To compare the safety and tolerability of three dose escalation schemes using a single end dose level during 26 weeks administration of oral semaglutide and SNAC in a tablet formulation in subjects with T2D

#### **Primary endpoint**

• Change in HbA<sub>1c</sub> from baseline to after 26 weeks of treatment

#### Key secondary endpoints

- Subjects who, after 26 weeks of treatment, achieve (yes/no) HbA<sub>1c</sub> <7% (53 mmol/mol)
- Change in body weight from baseline to after 26 weeks of treatment
- Change in waist circumference from baseline to after 26 weeks of treatment
- Change in body mass index (BMI) from baseline to after 26 weeks of treatment
- Number of treatment emergent adverse events (TEAEs) recorded from baseline until week 31
- Number of confirmed hypoglycaemic episodes recorded from baseline until week 31

## Trial design:

This is a randomised, partially-blinded, multiple-dose, multicentre trial with a total of nine treatment arms; seven oral semaglutide treatment arms, an oral placebo arm and an s.c. semaglutide arm in a parallel design. The trial will include subjects with T2D who have failed on diet and exercise and/or metformin.

Subjects with T2D will be randomised in an equal manner with 67 subjects planned to be randomised per treatment arm. Treatment arms 1-8 will include once-daily dosing of a tablet and will be blinded. Treatment arm 9 features once-weekly s.c. injection. All arms include 26 weeks of treatment and a 5 week follow-up period.

The trial medication will be add-on to previous metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.

Protocol
Trial ID: NN9924-3790
UTN: U1111-1136-4716
EudraCT No.: 2012-004994-16

#### **Trial population:**

A total of 603 subjects with T2D will be randomised.

Key inclusion criteria:

- Male or female, age  $\geq$  18 years at the time of signing inform consent
- BMI  $\geq$ 25 and  $\leq$ 40 kg/m<sup>2</sup>
- Subjects diagnosed with T2D treated with diet and exercise and/or who have been on a stable dose of metformin for at least 30 days prior to screening
- HbA<sub>1c</sub> 7.0-9.5% (53-80 mmol/mol) (both inclusive)

Key exclusion criteria

- Subjects on selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants
- History of chronic pancreatitis or idiopathic acute pancreatitis
- Chronic malabsorption, regardless of aetiology
- History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
- Treatment with glucose lowering agent(s) other than metformin as stated in the inclusion criteria in a period of 90 days before the screening visit

#### Assessments:

#### Efficacy assessment

Measurements of laboratory parameters (HbA<sub>1c</sub>, glucose metabolism parameters and lipids), BMI and waist circumference. Patient reported outcomes will be based on the SF-36 questionnaire and assessed at baseline and end of treatment.

#### Safety assessment

Adverse events, laboratory safety variables (haematology, biochemistry, calcitonin and urinalysis), vital signs, electrocardiograms, physical examinations and hypoglycaemic episodes recorded from the first trial-related activity and until completion of the post treatment follow-up visit of the trial.

#### PK assessment

Trough and peak plasma concentrations of semaglutide will be assessed throughout the trial.

#### Trial product(s):

The investigational medicinal products used in the trial will be for once-daily oral administration as tablets and once-weekly s.c. administration using a pen injector system. The investigational medicinal products are:

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

1.0 Final 12 of 98

25 June 2013 | Novo Nordisk

- Semaglutide 2.5 mg tablets •
- Semaglutide 5.0 mg tablets •
- Semaglutide 10 mg tablets •
- Semaglutide 20 mg tablets •
- Semaglutide 40 mg tablets •
- Placebo tablets •
- Semaglutide 1.34 mg/mL, solution for injection, 1.5 mL pre-filled PDS290 pen-injector ٠

Protocol	UTN: U1111-1136-4716	Date:	25 June 2013	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	13 of 98	

# 2 Flow chart

Trial Periods		Screening <sup>1</sup>	Randomisation		Treatment					End-of- treatment <sup>2</sup>	Follow- up <sup>2</sup>	End-of-trial – premature discontinuation <sup>3</sup>		
Visit number		1	2	3	4	5	6	7	8	9	10	11	12	11X
Timing of visit	Weeks	-2	0	2	4	6	8	12	16	20	24	26	31	26
Visit window	Days			±3	±3	±3	±3	±5	±5	±5	±3	±3	+5	±3
SUBJECT RELATED INFO/ASSESSMENTS														
Informed consent		х												
In- and exclusion criteria		х	х											
Concomitant medication		х	х	х	х	х	х	х	х	х	х	х		Х
Concomitant illness		х												
Demography		Х												
Diagnosis of diabetes		х												
Diabetes treatment history		х												
Medical history		х												
Smoking habits		х												
History of gallbladder disease		х												
History of cardiovascular disease		х												
Renal impairment history		х												
Randomisation			Х											
Withdrawal criteria			х	х	х	х	х	х	х	х	х	Х		
Post-dose fasting routines												х		
EFFICACY														
Height		Х												
Body weight		Х	X	х	х	х	х	х	х	х	х	Х		Х
Waist circumference			Х	х	х	х	х	х	х	х	х	Х		Х
HbA <sub>1c</sub>		Х	х		х		х		х			Х		Х
Glucose metabolism			x		х		х		х			Х		
Lipids			х						х			х		

Protocol	UTN: U1111-1136-4716	Date:	25 June 2013	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	14 of 98	

Trial Periods		Screening <sup>1</sup>	Randomisation				Treat	ment				End-of- treatment <sup>2</sup>	Follow- up <sup>2</sup>	End-of-trial – premature discontinuation <sup>3</sup>
Visit number		1	2	3	4	5	6	7	8	9	10	11	12	11X
Timing of visit	Weeks	-2	0	2	4	6	8	12	16	20	24	26	31	26
Visit window	Days			±3	±3	±3	±3	±5	±5	±5	±3	±3	+5	±3
SUBJECT RELATED INFO/ASSESSMENTS														
PRO questionnaire			Х									х		
SAFETY														
Adverse events			х	х	х	х	х	х	х	х	х	х	х	х
Hypoglycaemic episodes			Х	х	х	х	х	х	х	х	х	х	Х	Х
ECG, overall interpretation <sup>4</sup>			Х									х		
Fundoscopy/fundus photography			Х											
Physical examination		х										х		
Vital signs		Х	Х	Х	х	х	х	х	х	х	х	Х		
Antibodies <sup>5</sup>			Х						х			х	Х	
Biochemistry			Х						х			х		
Creatinine		Х							х			х		
Calcitonin		х							х			х		
Haematology			х						х			х		
PK sampling				х	х	х	х	х	х	х	х	х		
PK sampling (trough + peak) <sup>6</sup>					x				х			Х		
Blood pregnancy test <sup>7</sup>		Х	Х		х		х	х	х	х	х	х	Х	Х
Urinalysis			Х						х			Х		
TRIAL MATERIAL				_		_	_							
IV/IWRS call		Х	Х	Х	х	Х	Х	Х	х	х	х	Х		
Dispensing visit			Х	х	х	х	х	х	х	х	х			
Hand out directions for use of s.c. trial product			Х	x	x	x	x	х	x	x	x			
Drug accountability				х	х	х	х	х	х	х	х	Х		
REMINDERS														

Protocol	UTN: U1111-1136-4716	Date:	25 June 2013	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	15 of 98	l

Trial Periods		Screening <sup>1</sup>	Randomisation				Treat	ment				End-of- treatment <sup>2</sup>	Follow- up <sup>2</sup>	End-of-trial – premature discontinuation <sup>3</sup>
Visit number		1	2	3	4	5	6	7	8	9	10	11	12	11X
Timing of visit	Weeks	-2	0	2	4	6	8	12	16	20	24	26	31	26
Visit window	Days			±3	±3	±3	±3	±5	±5	±5	±3	±3	+5	±3
SUBJECT RELATED INFO/ASSESSMENTS														
Dispense glucose meter		Х												
Dispense subject identity card		х												
Dispense diary		х	Х	х	х	х	х	х	х	х	х	х		
Collect and review diary			Х	х	х	х	х	х	х	х	х	х	Х	
Attend visit fasting <sup>8</sup>			Х		х		х		х			Х	Х	
Affirmation statement or Case book signed <sup>9</sup>													Х	х
End of trial <sup>9</sup>													Х	Х

Abbreviations in table: ECG = electrocardiogram,  $HbA_{1c} = glycosylated$  haemoglobin, IV/WRS = interactive voice/web response system, PK = pharmacokinetics, PRO = patient reported outcome

Protocol	UTN: U1111-1136-4716	Date:	25 June 2013	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	16 of 98	I

#### 2.1 Flow chart foot notes

Footer	Description
x <sup>1</sup>	Subject can be randomised as soon as all inclusion and exclusion criteria are confirmed. The screening assessments must not exceed 2 weeks prior to randomisation (Visit 2).
x <sup>2</sup>	The End-of-treatment and Follow-up visits are applicable for all randomised subjects including subjects who have discontinued trial product prematurely.
x <sup>3</sup>	Subjects discontinuing trial product prematurely will be asked to attend the End-of-treatment (V11) as soon as possible after treatment discontinuation and the Follow-up – premature discontinuation (V12) five weeks later (+5 days visit window). Furthermore, they are asked to attend the End-of-trial – premature discontinuation visit (V11X) (see Section $\underline{8.1.9}$ ).
x <sup>4</sup>	An ECG performed for any reason unrelated to the trial within 30 days prior to the randomisation visit is acceptable as Visit 2 data, provided no clinical symptoms suggestive of cardiac disease has occurred in the meantime.
x <sup>5</sup>	At the randomisation visit, the antibody assessment must be done pre-dose.
x <sup>6</sup>	Trough and peak PK sampling is only applicable for subjects in the oral treatment arms. Subjects must attend the visit without having taken the tablet on the same day (see Section $\underline{8.4.10}$ )
x <sup>7</sup>	For women of child bearing potential: Serum pregnancy tests must be performed.
x <sup>8</sup>	Fasting is defined as having consumed only water since midnight. For the Follow-up visit (V12) attending fasting is defined as having consumed only water for at least the preceding 2 hours.
x <sup>9</sup>	Affirmation statement/case book signing and end of trial are at the Follow-up visit (V12). Only patients who have discontinued treatment prematurely are asked to attend the End-of-trial – premature discontinuation visit (V11X) which will then be end of trial.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 17 of 98

# **3** Background information and rationale for the trial

The trial will be conducted in compliance with this protocol, ICH GCP<sup>1</sup> and applicable regulatory requirements, and in accordance with the Declaration of Helsinki<sup>2</sup>.

In this document, the term investigator refers to the individual responsible for the overall conduct of the clinical trial at a trial site.

## 3.1 Type 2 diabetes mellitus and glucagon-like peptide-1

Type 2 diabetes (T2D) is a major global health problem. The disease aetiology is multi-factorial and includes genetic predisposition in combination with sedentary life style factors such as physical inactivity and obesity.

T2D is a multi-organ disease characterised by defective insulin sensitivity in liver and skeletal muscle and a relative impairment of insulin secretion capacity. Furthermore, a blunted secretion and/or action of incretin hormones (glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP)) from the gastrointestinal (GI) tract (L-cells) in response to meals are also characteristics of T2D. GLP-1 is an important post-prandial hormone secreted from the L-cells in the intestine with a stimulating effect on insulin secretion and an inhibitory role on glucagon secretion from the endocrine pancreas in a glucose-dependent manner. In addition, GLP-1 restores beta-cell sensitivity to glucose. Animal studies suggest that GLP-1 also increases beta-cell mass. Extra-pancreatic effects include delaying of gastric emptying and effects on insulin sensitivity, although the latter is less clear. Pharmacological levels of GLP-1 reduce food intake and induce weight loss. As the majority (>80%) of T2D patients are overweight, the weight reduction properties of GLP-1 analogues are perceived to be advantageous compared to many other therapies for T2D. Due to the beneficial effects of GLP-1 on both glycaemic and weight control, treatment of T2D patients with GLP-1 analogues is considered favourable.

## 3.2 Semaglutide and SNAC

Semaglutide is a long-acting GLP-1 analogue that has achieved clinical proof of concept when administered subcutaneously (s.c.). Currently, semaglutide is in clinical development (NN9535) as a once-weekly s.c. injection for the treatment of T2D. The NN9535 project is in phase 3 development, encompassing six major safety and efficacy trials (see Section <u>3.2.3.2</u> for clinical data on s.c. semaglutide).

Oral administration inherently represents a different absorption route to reach systemic circulation compared to s.c. administration.

Native GLP-1 and GLP-1 analogues have in general very low oral bioavailability when administered in a formulation without absorption enhancement. Formulation with an absorption enhancing excipient is therefore needed to increase the oral bioavailability. However, exposure

ProtocolDate:25 June 2013Novo NordiaTrial ID: NN9924-3790CONFIDENTIALVersion:1.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:18 of 98	UTN: U1111-1136-4716
--	----------------------

exhibits a substantially greater dose-to-dose variation following oral administration compared to s.c. administration. An oral drug product with this chemical structure and properties will, because of the compound's PK properties (i.e., very low clearance and long terminal half-life), and by using oncedaily administration, limit the variation in steady state plasma exposure. The initial side effects like nausea may therefore be low or absent following gradual dose escalation. Food interaction is expected to limit absorption, but a long-acting GLP-1 analogue product will allow dosing in the fasting state, without compromising the effective plasma profile. In addition, GLP-1 therapy generally does not induce hypoglycaemia on its own, which potentially could have been problematic given the large intra-patient plasma exposure variation.

Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate / salcaprozate sodium (SNAC) has been studied in combination with acyclovir, peptide tyrosine tyrosine (PYY), cromolyn, ibandronate and heparin. Impact on metformin when co-administering SNAC and metformin was investigated as part of another trial involving healthy volunteers. The trial did not show any increase in metformin exposure when adding SNAC<sup>3</sup>. When co-formulated with SNAC, exposure of ibandronate (a nitrogen-containing bisphosphonate), is increased by 11- and 17-fold (AUC and  $C_{max}$ , respectively). On the other hand, when co-administered with SNAC (in separate formulations) exposure was not affected compared to dosing ibandronate without SNAC, suggesting that the drug-drug interaction potential between SNAC and co-administered drugs with comparable physiochemical properties (compounds with permeability limited absorption) is low<sup>4</sup>.

The most extensive safety and PK data are available from the heparin formulated with SNAC programme including 32 phase 1 studies (daily SNAC doses ranged from 0.172 g - 10.5 g) of which three investigated SNAC alone. The studies covered formulation development, food effect, hepatic and renal impairment, age effect and drug-drug interactions. Three phase 2 and 3 studies have assessed effects of orally delivered heparin solution (>1.5 g SNAC three times daily). At present, no drugs containing SNAC have received regulatory approval.

#### 3.2.1 Nonclinical data

The non-clinical programme for semaglutide was designed according to the International Conference on Harmonisation (ICH) M3 guideline to support the clinical development. The standard non-clinical data package required to support phase 3 clinical trials has been completed. In addition, 2-year carcinogenicity studies and a pre- and postnatal development toxicity study have been completed.

Semaglutide is generally well tolerated, with expected GLP-1 effects on food intake and body weight being the dose limiting effects, when dosed s.c. for up to two years in studies with rats and mice. No signs of overt toxicity, including safety concerns related to effects on the GI tract, were observed after oral administration of semaglutide for up to 26 weeks in rats and 17 weeks in cynomolgus monkeys. Two potential safety issues have been identified.

Protocol	CONFIDENTIAL	Date:	25 June 2013
Trial ID: NN9924-3790		Version:	1.0
UTN: U1111-1136-4716		Status:	Final
EudraCT No.: 2012-004994-16		Page:	19 of 98

## 3.2.1.1 Thyroid C-cell tumours in rodents

Treatment-related non-genotoxic proliferative changes in the thyroid C-cells of mice and rats were observed in 2-year carcinogenicity studies with semaglutide. Early C-cell changes were also identified in repeated dose toxicity studies with semaglutide in mice. However this was not the case in other species including a 52-week repeat dose study in non-human primates at exposure levels up to 36-fold above the expected clinical exposure. The observed pattern of effects in mice and rats (thyroid C-cell proliferation preceded by increase in serum calcitonin) and lack of these effects in the non-human primate and in man suggest that the mechanism by which semaglutide acts on the thyroid C-cells in rodents is the same as has been demonstrated for other GLP-1 receptor agonists, including liraglutide. The relevance for human subjects is unknown.

#### 3.2.1.2 Teratogenicity in rats

Semaglutide has been concluded teratogenic in rats, with exposure at no observable adverse effect level (NOAEL) below expected human exposure. This effect is regarded to be caused by impairment of nutrient supply to the embryo across the inverted yolk sac with placental function which is specific to rats. Non-human primates and humans do not depend on a volk sac with placental function to supply nutrients to the embryo early in pregnancy. The effect on rat embryofoetal development is therefore not likely to be relevant to humans. Preliminary and main embryofoetal development (EFD) and pre- and postnatal development (PPND) studies with doses corresponding to 7-fold expected clinical exposure in cynomolgus monkeys have been finalised. In the main EFD study sporadic abnormalities were reported across all dose groups and in the PPND study a dose dependent increase in early pregnancy losses were observed. The findings observed across the three studies in cynomolgus monkeys are not indicative of teratogenic potential of semaglutide in this species. The increase in early pregnancy losses is indicative of embryo-toxicity, which may be related to the maternal effect of semaglutide (marked body weight loss). A developmental toxicity NOAEL was determined at an exposure 0.8-fold the expected clinical exposure (1 mg/week). A risk for the developing human embryo or foetus cannot be definitely ruled out, but the absence of findings indicative of teratogenicity in the EFD and PPND studies in cynomolgus monkey decrease the level of concern.

A comprehensive review of results from the non-clinical studies can be found in the IB for Semaglutide (subcutaneous administration), Edition  $8^{\frac{5}{2}}$  and the IB for Oral administration of semaglutide (NN9924), Edition  $5^{\frac{6}{2}}$ , or any updates of these documents

#### 3.2.1.3 SNAC toxicology

The nonclinical safety programme for SNAC includes safety pharmacology, metabolism and PK and toxicology and is in line with the ICH M3 guideline<sup>7</sup>. SNAC was developed as an absorption enhancing excipient for the oral route of administration.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 20 of 98	Novo Nordisk
--	--------------	---------------------------------------	--	--------------

SNAC is rapidly absorbed (time to maximal concentration  $(t_{max})$  within 1 hour) and eliminated  $(t_{\frac{1}{2}} = 1 \text{ and } 3 \text{ hours across species})$ . SNAC is metabolised mainly via stepwise beta-oxidation and deacetylation of the side chain and the parent compound and its metabolites also undergo conjugation with glucuronic acid. The main elimination route for SNAC metabolites is via urinary excretion.

SNAC was generally well tolerated in animals at and below oral doses of 500 mg/kg/day (NOAEL) for up to nine (Rhesus monkey) and twelve (rat) months. Although no overt specific organ toxicity has been observed, SNAC was associated with treatment-related and unexplained mortality at dose levels only 1.5- to 3-fold above NOAEL in rat studies. A series of nonclinical studies to explore possible cause of death have been initiated. These studies include investigations to expand the standard package of nonclinical studies on CV and respiratory function, and systematic investigations of histological changes in the GI tract and liver after dosing of high concentration/high volumes of SNAC. To support the assessment of exposure margins between rats and humans, extensive PK and metabolism studies in rats are carried out. The quantification of SNAC metabolites will also be assessed in the on-going multiple dose (MD) clinical trial (NN9924-3991).

In an on-going two-year carcinogenicity study with rats, one unexplained death occurred at a dose of 200 mg/kg/day. Several cases of unexplained death were observed at 900 mg/kg/day in repeat dose toxicity studies of 26 weeks and 52-weeks duration. A NOAEL for SNAC has been determined to be 90 mg/kg/day (corresponding to ~4 to 6 times a human dose of 300 mg based on exposure (area under curve)). Histological changes (perivascular lymphoid aggregates) have been observed in the lungs at all SNAC dose levels in the 6-month rat study. SNAC appeared to exacerbate these lesions which may be indicative of an immunosuppressant effect.

#### 3.2.2 Nonclinical pharmacology and pharmacokinetics

The focus of the studies done in relation to oral administration of semaglutide in combination with SNAC has been on the following issues:

#### Mechanism in vitro

SNAC increases absorption of drug compounds through the GI epithelium, which has been shown in humans (e.g., for endogenous GLP-1). *In vitro* studies have indicated that transport of compounds occurs mainly via the trans-cellular route and the effect is dependent on both the concentration of SNAC and the duration of incubation.

## Enhancement of absorption in vivo

SNAC enhances absorption of semaglutide from the stomach and small intestine in rats. There is considerable variability (coefficient of variation around 100%) with some animals showing no absorption. In the dog, there is higher bioavailability after oral dosing of tablets (1-2.5%) than after capsules (0.7%) or solution (0.07%). Semaglutide and SNAC have to be formulated in the same

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	21 of 98	
	•			

tablet to get increased oral bioavailability of semaglutide, indicating that close interaction between the two molecules is necessary for enhancing the absorption. There is a strong reduction of bioavailability to practically zero when given concomitantly with food in dogs, and also an increasing amount of water dosed with the tablet seems to reduce oral bioavailability of semaglutide in this model, mimicking recent results in a human trial. Doses of SNAC of 150, 300 and 600 mg have been tested in dogs, and there was a tendency towards an optimum at 300 mg in terms of bioavailability. Furthermore, there is a tendency for non-linearity in bioavailability when increasing the amount of both SNAC and semaglutide in combination or semaglutide alone with constant SNAC content, whereas increasing amounts of SNAC alone (300 (one tablet) to 900 mg (three tablets)) with constant amount of semaglutide do not seem to significantly increase bioavailability.

#### Pharmacodynamics after oral administration

Semaglutide dosed in combination with SNAC is able to induce the same type of PD effects on blood glucose, food intake and body weight as seen after s.c. administration of semaglutide and other marketed GLP-1 analogues. Thus, semaglutide in combination with SNAC lowered blood glucose and body weight in diabetic db/db mice, and reduced food intake and body weight in normal rats.

#### 3.2.3 Clinical data

## **3.2.3.1** Data from literature

Currently, no orally administered GLP-1 receptor agonist is available for the treatment of T2D.

There are, however, s.c. administered GLP-1 receptor agonists on the market and experience from their development has identified some potential safety issues for this class of compounds. Nonclinical thyroid C-cell tumours have been observed in rodents. Acute pancreatitis has been associated with chronic administration of GLP-1 receptor agonists in man. Elevated lipase has been observed in clinical studies but dose-response relationship and overall clinical significance is unclear. Hypoglycaemia, GI adverse events (i.e., nausea and vomiting), increased heart rate and renal dysfunction due to volume depletion following GI effects have also been observed.

## 3.2.3.2 Clinical data of s.c. semaglutide

As of 1 February 2013, 5 clinical pharmacology trials (NN9535-1820, -3679, -3633, -3616 and - 3819) and 1 phase 2 trial (NN9535-1821) have been completed using s.c. semaglutide. A total of 519 subjects have been exposed to s.c. semaglutide: 164 healthy subjects (both single and multiple dosing), 313 patients with T2D (up to 12 weeks of treatment) and 42 patients (4 subjects had T2D) with varying degrees of renal impairment (single dosing).

ProtocolDate:Trial ID: NN9924-3790CONFIDENTIALVersion:UTN: U1111-1136-4716Status:Status:EudraCT No.: 2012-004994-16Page:Page:	25 June 2013 Novo Nordisk 1.0 Final 22 of 98
---	---

#### **Pharmacokinetics**

Results from 2 phase 1 trials (NN9535-3616 and 3819) show that s.c. semaglutide has pharmacokinetics (PK) properties compatible with once-weekly administration, with a median time to maximum concentration (tmax) of 36 hours post dosing and an elimination half-life ( $t^{1/2}$ ) in the range of 165-184 hours (~7 days, harmonic mean). Overall, the PK properties of s.c. semaglutide appear similar in Caucasian and Japanese subjects, and also in healthy subjects and subjects with T2D. In a trial with subjects with different degrees of renal impairment (NN9535-3616), data suggested that severe renal impairment result in a slightly higher exposure compared to subjects with normal renal function (AUC0- $\infty$  increased by approximately 22%), whereas subjects with mild or moderate renal impairment and subjects on haemodialysis had exposure similar to subjects with normal renal function. No safety signals were identified in either of the renal groups, and tolerability profiles appeared similar across renal groups; thus, a dose-reduction in subjects with severe renal impairment does not appear to be warranted.

Interaction with oral contraceptives was assessed at semaglutide 1.0 mg steady-state exposures in postmenopausal women with T2D (NN9535-3819). Steady-state exposures (AUC0-24h) of ethinylestradiol (EE) and levonorgestrel (LN) were slightly increased (by 10% and 21%, respectively), with bioequivalence established for EE but not for LN; the increase was seen when oral contraceptives were co-administered with semaglutide compared to oral contraceptives alone.

Bioequivalence was demonstrated for  $C_{max}$  of both EE and LN. These data indicate that semaglutide does not decrease the exposure of oral contraceptives, and suggest that no adjustments of oral contraceptive dose are warranted for women of childbearing potential using a low-dose oral contraceptive.

#### Efficacy

As of 1 February 2013, efficacy of s.c. semaglutide in the target population – subjects with T2D – has been investigated in one phase 2 dose range finding trial (NN9535-1821). The trial was a 12-week, randomised, double-blind, placebo- and active-controlled trial in which 411 adults with T2D received once-weekly s.c. injection of 1 of 5 semaglutide dose levels (0.1-1.6 mg) once-daily, open-label liraglutide (1.2 mg or 1.8 mg) or once-weekly placebo. 12 weeks of treatment, equivalent to 5-7 weeks in steady state on maintenance dose, provided statistically significant and clinically relevant improvement in glycaemic control for dose levels of 0.2 mg and above. Changes in HbA<sub>1c</sub> from baseline was up to -1.19 % (placebo adjusted estimated treatment difference). Dose-dependent improvements in fasting plasma glucose (FPG) and postprandial plasma glucose were also observed. The improvement in glycaemic control was accompanied by weight loss for semaglutide doses of 0.8 mg and above (placebo adjusted estimated treatment difference up to -3.64 kg).

#### Safety

From the clinical trials conducted so far the following safety observations have been made.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	25 June 2013 1.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	23 of 98	

Consistent with findings with other GLP-1 receptor agonists, common adverse events (AEs) included nausea and vomiting; most of them were mild to moderate in intensity. Hypoglycaemia has occurred in subjects receiving semaglutide and these events have mainly been minor.

An increase in heart rate has been observed in subjects exposed to semaglutide in line with the increase seen with other GLP-1 analogous. The implications of this increase are unknown.

As is the case with all protein-based pharmaceuticals, subjects treated with s.c. semaglutide may develop immunogenic and allergic reactions. Few allergic reactions have been reported in connection with semaglutide. These have mainly been mild and transient. However, more generalised reactions may occur.

Injection site reactions have been infrequently reported. These have mainly been mild and transient in nature.

Please see appropriate  $IB^{5}$  for further details.

#### 3.2.3.3 Clinical data of oral GLP-1

Clinical trials with increasing doses of oral semaglutide up to two tablets with 10 mg semaglutide and 300 mg SNAC have shown this to be safe and well tolerated. The oral semaglutide had acceptable bioavailability and a PK profile of two tablets with 10 mg semaglutide was similar to 0.5 mg s.c. semaglutide. Variability of the day-to-day PK profile was 3-4 times higher than compared to 0.5 mg s.c. once-weekly semaglutide but acceptable for further development.

The oral bioavailability of human GLP-1 has been demonstrated to increase several fold when formulated with SNAC with a  $t_{max}$  of approximately 15-30 min. In addition, even in healthy subjects a glucose-dependent insulinotropic action of GLP-1 upon oral delivery was shown.

Five phase 1 trials with oral semaglutide and SNAC have been completed:

- Single dose trial (NN9924-3691)
- Multiple dose trial 1 (NN9924-3692)
- Dosing condition trial (NN9924-3794)
- Pharmaco-scintigraphy trial (NN9924-3957)
- Multiple dose trial 2 (NN9924-3991)

For details on the individual trials, please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

#### 3.2.3.4 Clinical data of SNAC

The largest safety data set exists from the programme of orally administrated SNAC and heparin (all sponsored by Emisphere): 29 phase 1 trials (doses up to 10.5 g of SNAC), one phase 2 trial

(doses 1.5 g and 2.25 g of SNAC three times daily for 5 days) and two phase 3 trials (doses: 1.5 and 2.25 g of SNAC three times daily for 30 days) have been reported.

Oral SNAC exposure has most extensively been investigated in the phase 3 trial, named ERP-12. The objective of the trial was to investigate prevention of venous thrombotic complications following total hip replacement. Enrolled subjects were randomised in three treatments arms:

- Low dose SNAC (1.5 g) and heparin (60,000 USP units) thrice-daily for 30 days
- High dose SNAC (2.25 g) and heparin (90,000 USP units) thrice-daily for 30 days
- Enoxaparin sodium 30 mg s.c. twice-daily for 10 days

Total daily dose of oral SNAC was 4.5 g (low dose), 6.75 g (high dose) or 0 g (heparin s.c.). A total of 2,264 patients were enrolled with approximately 750 in each group.

The most frequently reported AEs were GI disorders with a dose relationship of SNAC and heparin, which also reflected the most common AEs reported for discontinuation. The SAEs were evenly distributed between the groups for all system organ classes other than GI disorders. Likewise, all deaths were evenly distributed between the groups and their nature and diversity did not indicate any causal relationship to trial drug. No other clinical significant safety issue was identified in the trial<sup>8</sup>.

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

#### 3.3 Risks and benefits of the trial

There are s.c. administered GLP-1 receptor agonists on the market and experience from their development as well as experience from the s.c. semaglutide development programme have identified some potential safety issues for this class of compounds: 1) risk of teratogenicity, 2) risk of thyroid C-cell tumours, 3) risk associated to high doses of SNAC, 4) risk of carcinogenicity of SNAC, 5) risk of pancreatitis, 6) risk of antibody formation, 7) risk of allergic reactions, 8) risk of heart rate increase, 9) risk of severe risk of hypoglycaemia and 10) risk of altered renal function.

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

In this trial, most subjects will receive a treatment anticipated to be more efficacious than the treatment they receive at the time of randomisation into the trial. It is expected that subjects will benefit from the trial treatment with respect to optimised glycaemic control, a reduced risk of long-term diabetic complications and a potential weight loss. The subjects in this trial will receive trial drug and auxiliary free of charge. Furthermore it is expected that all subjects participating in the trial will benefit from participation through close contact with the study site and close follow-up of

Protocol	CONFIDENTIAL	Date:	25 June 2013 Novo Nordisk
Trial ID: NN9924-3790		Version:	1.0
UTN: U1111-1136-4716		Status:	Final
EudraCT No.: 2012-004994-16		Page:	25 of 98

their T2D. Such careful medical examination will most likely result in an intensified management of their diabetes.

It is concluded that the potential benefits from participating in the trial outweigh the potential risks. The safety profile of semaglutide generated from the clinical and nonclinical development programme has not revealed any safety issues that would prohibit administration of once-daily doses of 2.5 to 40 mg semaglutide with 300 mg SNAC or once-weekly doses of 1.0 mg semaglutide in accordance with the planned clinical trial. The risk to the subjects in this trial is low and acceptable in view of the benefits an oral GLP-1 analogue would provide to subjects with T2D.

#### **3.4** Rationale for the trial

The trial will compare efficacy of oral semaglutide formulated with a fixed dose of 300 mg SNAC. To facilitate the generation of clinical data in subjects with T2D, the NN9924-3790 trial has been designed to investigate a dose range expected to cover relevant therapeutic levels, including systemic exposure equivalent to 0.5 and 1.0 mg of once-weekly s.c. semaglutide. Additional dose levels are examined to elucidate a wider dose-response spectrum below and above the expected therapeutic range. In addition, the trial will explore the safety and tolerability of three different dose escalation approaches (i.e., slow, standard and fast). Finally, the trial will compare parameters of efficacy, safety and tolerability and population PK after 26 weeks of treatment between the treatment arms.

Data from the NN9924-3790 trial combined with the results of other trials investigating semaglutide will support the decision to continue into phase 3 development.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

25 June 2013 Novo Nordisk 1.0 Final 26 of 98

#### 4 **Objective(s) and endpoint(s)**

The objectives of the trial, addressed after 26 weeks of treatment, are as follows:

#### 4.1 **Objectives**

#### 4.1.1 **Primary objective**

To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against placebo in subjects with T2D

#### 4.1.2 **Secondary objectives**

- To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation • against s.c. semaglutide in subjects with T2D
- To compare the safety and tolerability of three dose escalation schemes using a single end dose • level during 26 weeks administration of oral semaglutide and SNAC in a tablet formulation in subjects with T2D
- To compare parameters of efficacy, safety and tolerability, and population PK as reflected by • endpoints below after 26 weeks of treatment

#### 4.2 **Endpoints**

#### 4.2.1 **Primary endpoint**

Change in HbA<sub>1c</sub> from baseline to after 26 weeks of treatment

#### 4.2.2 Supportive secondary endpoints

## Supportive secondary efficacy endpoints

- Subjects who, after 26 weeks of treatment, achieve (yes/no) HbA<sub>1c</sub> <7% (53 mmol/mol)\*
- Change in fasting plasma glucose (FPG), C-peptide, fasting insulin and glucagon from baseline ٠ to after 26 weeks of treatment
- Change in insulin resistance (homeostatic model assessment index of insulin resistance (HOMA-IR)) and beta-cell function (homeostatic model assessment index of beta-cell function (HOMA-B)) from baseline to after 26 weeks of treatment
- Change in fasting lipid profile (total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), triglycerides and free fatty acids) from baseline to after 26 weeks of treatment
- Change from baseline to week 26 in the patient reported outcome Medical Outcomes Study 36-• Item Short-Form Health Survey (SF-36) (generic questionnaire)
- Change in body weight from baseline to after 26 weeks of treatment\* ٠
- Change in waist circumference from baseline to after 26 weeks of treatment\*

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	27 of 98	

• Change in body mass index (BMI) from baseline to after 26 weeks of treatment\*

#### Supportive secondary safety endpoints

- Number of treatment emergent adverse events (TEAEs) recorded from baseline until week 31\*
- Number of confirmed hypoglycaemic episodes recorded from baseline until week 31\*
- Change in vital signs (pulse, systolic- and diastolic blood pressure) from baseline to after 26 weeks of treatment
- Change in electrocardiogram (ECG) from baseline to after 26 weeks of treatment
- Change in physical examination from baseline to after 26 weeks of treatment
- Change in laboratory safety variables (haematology, biochemistry, hormone and urinalysis) from baseline to after 26 weeks of treatment
- Occurrence of antibodies against semaglutide during 26 weeks of treatment (positive/negative):
  - Anti-semaglutide antibodies
  - Anti-semaglutide antibodies with *in vitro* neutralising effect
  - Anti-semaglutide antibodies cross reacting with endogenous GLP-1
  - Cross reacting antibodies with in vitro neutralising effect to endogenous GLP-1
  - Antibody level during 26 weeks of treatment

#### Supportive secondary pharmacokinetic endpoint

- Semaglutide concentrations to be evaluated in a population PK analysis
- \* Key supportive secondary endpoint prospectively selected for posting on <u>clinicaltrials.gov</u>

Trial ID: NN9924-3790         CONFIDENTIAL         Version:         1.0           UTN: U1111-1136-4716         Final         Final           EudraCT No.: 2012-004994-16         Page:         28 of 98	UTN: U1111-1136-4716		Status:		Novo Nordisk
---	----------------------	--	---------	--	--------------

## 5 Trial design

#### 5.1 Type of trial

This is a randomised, partially-blinded, dose range, dose escalation, multicentre trial including nine treatment arms in total; seven oral semaglutide treatment arms, an oral placebo arm and an s.c. semaglutide arm with a parallel design (see Figure 5–1). All treatment arms include subjects with T2D who have failed on diet and exercise and/or metformin. The placebo tablets do not contain SNAC.

	Week		) 2 4	6	81	2 1	6 2	0 24	4 26	31
	Oral OD	1	2.5 mg			:	:			Follow-up
range	Oral OD	2	2.5 mg	5.0 mg						Follow-up
e ra	Oral OD	3	5.0 mg	10 mg					ļ	Follow-up
Dose	Oral OD	4	5.0 mg	10 mg	20 mg				Ì	Follow-up
	Oral OD	5	5.0 mg	10 mg	20 mg	40 mg			ļ	Follow-up
- no	Oral OD	6	5.0 mg		10 mg		20 mg		40 I	Follow-up
Esca- lation	Oral OD	7	5.0 10	20 40 1	ng					Follow-up
Compa- rators	Oral OD	8	Placebo			1				Follow-up
Com	s.c. OW	9	0.25 mg	0.50 mg	1.0 mg	s.c. sema	glutide, o	pen-label		Follow-up
	OD: once-daily, OW:	once-w	eekly		1	1	1			1

Figure 5–1 Trial design of NN9924-3790

Subjects with T2D will be randomised in an equal manner with 67 subjects planned to be randomised per treatment arm. Treatment arms 1-8 will include once-daily dosing of a tablet and will be blinded. Treatment arm 9 features open-label once-weekly s.c. injection. All arms include 26 weeks of treatment and a 5 week follow-up period. Oral dosing will be performed following specified fasting conditions (see Figure 5–2).

The nine treatment arms will include:

- 1. Semaglutide tablets once-daily: 2.5 mg for 26 weeks
- 2. Semaglutide tablets once-daily: 2.5 mg for 4 weeks, then 5.0 mg for 22 weeks
- 3. Semaglutide tablets once-daily: 5.0 mg for 4 weeks, then 10 mg for 22 weeks
- 4. Semaglutide tablets once-daily: 5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	29 of 98	

- 5. Semaglutide tablets once-daily: 5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks
- 6. Semaglutide tablets once-daily: 5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks
- 7. Semaglutide tablets once-daily: 5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks
- 8. Placebo tablets once-daily for 26 weeks
- 9. Semaglutide injections once-weekly: 0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks

For all groups the trial medication will be add-on to previous metformin therapy or as monotherapy in the case where the subject with T2D is treated with diet and exercise alone. At randomisation, subjects will be stratified according to one stratification value with two strata: Treatment with metformin at screening (yes/no).

#### 5.2 Rationale for trial design

Parallel treatment groups and a randomised partially-blinded, controlled design have been chosen in accordance with the trial objectives. To avoid bias in the assessment of the different doses of oral semaglutide, the eight oral treatment arms are double-blind. The doses are escalated in standard four week intervals to limit gastrointestinal AEs. Escalation intervals of two weeks and six weeks are also being explored to investigate effect on onset of action and overall AEs.

The use of s.c. semaglutide as active comparator was chosen to confirm that oral semaglutide in at least one of the selected doses reach the same levels of systemic exposure as for s.c. semaglutide. The active comparator is open-label to limit unnecessary injections (e.g., by use of double-dummy) as the objectives of the trial are to investigate the effects of the oral formulation.

#### 5.3 Treatment of subjects

The subjects will attend a screening visit to determine their eligibility. If found eligible, the subjects will return for the first treatment visit where they will be randomised and receive treatment. The total duration of the trial will be 31 weeks for all subjects from randomisation to last visit. The highest dose for any trial subject will be 40 mg oral semaglutide once-daily or 1.0 mg s.c. semaglutide once-weekly.

Metformin is considered background medication (non-investigational medicinal product) and will not be provided by Novo Nordisk. Metformin should be used at the discretion of the investigator. Treatment with metformin extended/slow release formulations is allowed.

For the safety of the subjects, medications with a narrow therapeutic window may not be used in the trial (see the exclusion criteria, Section 6.3).


Protocol Trial ID: NN9924-3790	CONEIDENTIAL	Date: Version:	25 June 2013 1.0	Novo Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Status: Page:	Final 30 of 98	

Subjects will follow a fixed dose escalation regimen, which they have been randomised to, following the scheme in Figure 5-1.

#### 5.3.1 Dose levels and escalation regimen for oral dosing

Subjects on the oral dosing (treatment arms 1-8) must administer the dose following specific rules:

- Fasting for at least six hours (e.g., in the morning following an overnight fast) before tablet ingestion
- Water and oral concomitant medication is allowed two hours prior to dosing
- Intake of maximum 120 mL of water is allowed when swallowing the tablet
- Subjects are required to abstain from food and fluid intake for at least 30 minutes after ingestion of oral semaglutide or placebo
- Oral concomitant medication can be taken two hours post-dosing. If taken with food, concomitant medication can be administered 30 minutes after ingestion of the semaglutide or placebo tablet



See illustration of oral dosing and fasting rules in Figure 5–2.

#### Figure 5–2 Dosing and fasting conditions for oral treatment (arms 1-8)

#### 5.3.2 Dose levels and escalation regimen for s.c. dosing

Subjects randomised to the s.c. treatment arm will follow a fixed dose escalation for semaglutide. The maintenance dose of 1.0 mg will be reached after four doses (four weeks) of 0.25 mg, followed by four doses (four weeks) of 0.50 mg. The maintenance dose of 1.0 mg, once attained, may not be decreased for the duration of the study. Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections should be administered on the same day of the week during the trial.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	31 of 98	

#### 5.4 Treatment after end of trial

The trial products will not be available to subjects after the end of trial.

When discontinuing trial products the subject should be switched to a suitable marketed product at the discretion of the investigator.

#### 5.5 Rationale for treatment

The oral route of semaglutide administration investigated has been chosen to increase convenience and initiate earlier use of GLP-1 treatment of T2D patients, thus offering true GLP-1 benefits in a tablet format. The dose range of the oral treatment (2.5 mg, 5 mg, 10 mg, 20 mg and 40 mg) has been chosen based on phase 1 data and modelling derived from phase 1 trials with the aim to cover the same exposure as observed with s.c. semaglutide. The standard escalation scheme (i.e., dose escalation every four weeks to desired dose) has been chosen based on phase 1 data. The slow and fast dose escalation arms will investigate if AEs decrease or increase, respectively, compared to the standard dose escalation. The 26-week treatment period will provide additional data on safety and tolerability, investigate the variability at steady state exposure, test for efficacy and suggest which doses and escalation scheme to continue into pivotal development.

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	2
--	--------------	---------------------------------------	---

## 6 Trial population

#### 6.1 Number of subjects

Number of subjects planned to be screened:	1,005
Number of subjects planned to be randomised:	603
Number of subjects expected to complete the trial:	482

#### 6.2 Inclusion criteria

For an eligible subject, all inclusion criteria must be answered "yes".

- 1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
- 2. Male or female, age  $\geq$  18 years at the time of signing inform consent
- 3. BMI  $\geq$ 25 and  $\leq$ 40 kg/m<sup>2</sup>
- 4. Subjects diagnosed with T2D treated with diet and exercise and/or who have been on a stable dose of metformin for at least 30 days prior to screening
- 5. HbA<sub>1c</sub> 7.0-9.5% (53-80 mmol/mol) (both inclusive)

## 6.3 Exclusion criteria

For an eligible subject, all exclusion criteria must be answered "no".

- 1. Known or suspected hypersensitivity to trial product(s) or related products
- 2. Previous participation in this trial. Participation is defined as informed consent
- 3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) for the duration of the trial and for three months following last dose

<u>Germany</u>: Adequate contraceptive measures are implants, injectables, combined oral contraceptives, hormonal intrauterine device, sexual abstinence or vasectomised partner. <u>Sweden</u>: Adequate contraceptive measures are hormonal intrauterine devices, hormonal oral contraceptives, hormonal implants or injections, double barrier (a condom or diaphragm) with spermicide, sexual abstinence or vasectomised partner.

<u>United Kingdom</u>: Established use of oral, injected or implanted hormonal methods of contraception, intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilisation or true abstinence when in line with the preferred and usual lifestyle of the subject.

- 4. Participation in another clinical trial within 30 days before the screening visit
- 5. Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety, compliance with the protocol and/or ability to complete the study

Protocol	CONFIDENTIAL	Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790		Version:	1.0	
UTN: U1111-1136-4716		Status:	Final	
EudraCT No.: 2012-004994-16		Page:	33 of 98	

- 6. Subjects on selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants
- 7. History of chronic pancreatitis or idiopathic acute pancreatitis
- 8. Screening calcitonin value  $\geq$  50 ng/L
- 9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
- 10. Chronic malabsorption, regardless of aetiology
- 11. History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
- 12. Previous gastrointestinal surgery such as invasive and corrective procedures involving the oesophagus, stomach, duodenum, gallbladder, pancreas or intestinal resections. Exempt are subjects that underwent uncomplicated surgical and diagnostic procedures such as appendectomy, hernia surgery, polypectomy, biopsies, as wells as colonic- and gastric endoscopy
- 13. Surgery scheduled for the trial duration period (excluding minor surgical procedures performed in local anaesthesia, according to the opinion of the investigator)
- 14. Treatment with glucose lowering agent(s) other than metformin as stated in the inclusion criteria in a period of 90 days before the screening visit
- 15. Mental inability, unwillingness or language barrier precluding adequate understanding of or compliance with study procedures
- 16. Impaired renal function defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m<sup>2</sup> per Modification of Diet in Renal Disease (MDRD) formula
- 17. Heart failure, New York Heart Association (NYHA) class IV
- 18. Within the past 6 months before the screening visit, any of the following: Episode of unstable angina, acute coronary event, cerebral stroke/transient ischemic attack or other significant cardiovascular event as judged by the investigator
- 19. Uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥100 mmHg)
- 20. Known proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator
- 21. Diagnosis of malignant neoplasm in the previous five years from the screening visit (except basal cell skin cancer or squamous cell skin cancer)

#### 6.4 Rescue criteria

Subjects with unacceptable hyperglycaemia should be offered treatment intensification (rescue medication) according to local label at the discretion of the investigator as add-on to randomised treatment and should continue to follow the protocol-specified visit schedule. Rescue medication should exclude other incretin-based therapies such as other GLP-1 receptor agonists, DPP-4 inhibitors and amylin analogues.

Protocol	CONFIDENTIAL	Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790		Version:	1.0	
UTN: U1111-1136-4716		Status:	Final	
EudraCT No.: 2012-004994-16		Page:	34 of 98	

Unacceptable hyperglycaemia in this trial is defined as:

- FPG >15 mmol/L (270 mg/dL) from baseline to week 6
- FPG >13.3 mmol/L (240 mg/dL) from week 6 to week 12
- FPG >11.1 mmol/L (200 mg/dL) or HbA<sub>1c</sub> > 8.0% (64 mmol/mol) from week 12 to end of trial

#### 6.5 Withdrawal criteria and discontinuation of trial product

#### 6.5.1 Withdrawal from trial

The subject may withdraw at will at any time. The subject may be withdrawn from the trial at the discretion of the investigator due to a safety concern. Please see Section 8.1.10 for procedure to be performed in case of subject withdrawal.

A subject must be withdrawn from the trial if the following applies:

- 1. Included in the trial in violation of the inclusion and/or exclusion criteria
- 2. Pregnancy
- 3. Intention of becoming pregnant

Subjects should stay in the trial irrespective of lack of adherence to randomised treatment, lack of adherence to visit schedule, missing assessments, trial product discontinuation due to AE (see Section 6.5.2), unwillingness to cope with injection regimen, development of co-morbidities or clinical outcomes, hence this should <u>not</u> be considered as a valid reason for withdrawal from the trial.

Subjects considering withdrawing from the trial should be encouraged to have the procedures performed according to the End-of-treatment visit and the Follow-up visit, please see Section 8.1.8.

Subjects who are withdrawn will not be replaced.

#### 6.5.2 Discontinuation of trial product

The trial treatment must be discontinued if the subject meets one of the following criteria:

- 1. The investigator suspects acute pancreatitis. All drugs suspected to relate to this condition should be discontinued until confirmatory tests have been conducted and appropriate treatment should be initiated. Subjects who are diagnosed with acute pancreatitis must be discontinued from trial treatment. Diagnosis is based on at least 2 of the following 3 criteria:
  - a. characteristic abdominal pain
  - b. amylase and/or lipase > 3x upper normal range, or
  - c. characteristic findings on ultrasound / computerised axial tomography (CT) / magnetic resonance imaging (MRI)
- 2. Calcitonin level ≥50 ng/L. The subject should be referred to a specialist in thyroid disease. All drugs suspected to relate to this condition should be discontinued

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	25 June 2013 1.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	35 of 98	

3. Other safety concerns as evaluated by the investigator

A treatment discontinuation session must be performed in the interactive voice/web response system (IV/WRS). The primary reason for discontinuation of the IMP must be specified in the electronic case report form (eCRF).

Subjects discontinuing the IMP should be called in for the End-of-treatment visit as soon as possible after discontinuation of the IMP and for the Follow-up visit five weeks later. Furthermore, the subjects should attend the End-of-trial – premature discontinuation visit (see Section 8.1.9).

If the IMP is discontinued, the subject can be prescribed alternative therapy at the investigator's discretion.

#### 6.6 Rationale for trial population

This trial will include adult subjects with T2D and insufficient glycaemic control following treatment with diet/exercise or metformin. The T2D subjects will have an HbA<sub>1c</sub> of 7.0-9.5% and a BMI of 25-40 kg/m<sup>2</sup>. The trial will be carried out in Europe, North America and single countries in Africa, Asia and the Middle East as the first global, multicentre trial and will include both genders. This population is expected to mimic the target population in both a future phase 3 programme and once marketed.

	<ul> <li>Novo Nordisk</li> <li>nal</li> <li>98</li> </ul>
--	---

### 7 Milestones

Planned duration of recruitment period (i.e., first subject first visit (FSFV) on 2 Dec 2013 – last subject first visit on 21 Apr 2014): 20 weeks

End of trial is defined as last subject last visit: 8 Dec 2014

#### Recruitment

The clinical sites participating in the trial will recruit subjects according to a recruitment plan.

The screening and randomisation rate will be followed closely via the interactive voice/web response system (IV/WRS) in order to estimate when to stop screening. All investigators will be notified immediately when the recruitment period ends, after which no further subjects may be screened and the IV/WRS will be closed for further screening. All subjects included in the screening period and eligible for randomisation will be randomised.

#### **Trial registration**

Information of the trial will be disclosed at <u>clinicaltrials.gov</u> and <u>novonordisk-trials.com</u>. According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure, it will also be disclosed according to other requirements such as those of the International Committee of Medical Journal Editors (ICMJE)<sup>9</sup>, the Food and Drug Administration Amendment Act (FDAAA)<sup>10</sup>, European Commission Regulation for EudraCT<sup>11</sup> and other relevant recommendations or regulations. If a subject requests to be included in the trial via the Novo Nordisk e-mail contact at these web sites, Novo Nordisk may disclose the investigator's contact details to the subject. As a result of increasing requirements for transparency, some countries require public disclosure of investigator names and their affiliations.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 37 of 98

### 8 Methods and assessments

#### 8.1 Visit procedures

#### 8.1.1 Introduction

Throughout the trial the investigator must ensure working in accordance with ICH  $GCP^{\perp}$  and local regulations. The investigator must ensure that trial procedures are performed as described in the protocol. Any discrepancies will result in protocol and/or GCP deviations and the investigator must take appropriate actions to avoid recurrence of the detected discrepancies.

#### 8.1.2 Visit 1 (Screening)

For procedures and assessments performed at screening, please see flow chart Section  $\underline{2}$ .

Investigators must obtain informed consent for each subject no later than at Visit 1 prior to any protocol-related procedures. For information on informed consent procedure please see Section <u>18.1</u>.

All subjects will be provided with a copy of their own signed and dated informed consent form.

The IV/WRS must be contacted to register the subject as screened (see Section <u>10</u>) at the screening visit. Subject will be assigned a unique number (lowest available number allocated to site) which is maintained throughout the trial.

The investigator must keep a subject screening log, a subject identification code list and a subject enrolment log. The subject screening log and subject enrolment log may be combined in one list and may be generated from IV/WRS.

At screening, subjects will be provided with a card stating that they are participating in a trial and giving contact address(es) and telephone number(s) of relevant trial site staff. Subjects should be instructed to return the card to the investigator at the last trial visit or to destroy the card after the last visit.

For screening failures the screening failure form must be completed with the reason for not continuing in the trial. Serious and non-serious adverse events from screening failures must be transcribed by the investigator into the electronic case report form (eCRF). Follow-up of serious adverse events (SAEs) must be carried out according to Section <u>12.3</u>. A screening failure session must be made in the IV/WRS. The case book must be signed.

Re-screening of subjects having signed the informed consent is not allowed.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	38 of 98	

Once all data relating to Visit 1 have been obtained, these must be reviewed by the investigator to ensure that the subject is eligible to continue the trial.

#### 8.1.3 Fasting visits

The subjects should attend several visits in a fasting state (see Section 2). Fasting is defined as having consumed only water since midnight. An exception from this is the Follow-up visit where fasting is defined as having consumed only water for the last two hours.

Subjects are allowed to take the IMP and oral concomitant medication during fasting if following the conditions outlined in Section 5.3. An exception is at three visits in the oral treatment arms where peak and trough PK will be measured and the oral IMP will be administered at the site (see Section 8.4.10).

If a subject attends a fasting visit in a non-fasting condition or a peak and trough PK meeting having taken the oral dose the same day, then blood sampling and body weight must be re-scheduled within the visit window. The date for each fasting assessment or PK assessment at the specific visit must be updated accordingly in the eCRF. All other assessments can be performed. Re-scheduling of fasting visits or peak and trough PK visits are not considered unscheduled visits.

#### 8.1.4 Unscheduled visits

An unscheduled visit can be scheduled at any time at the discretion of the investigator. An unscheduled visit form must be completed in the eCRF indicating the reason for the visit. Coming to the site for any of the following reasons should not be considered as unscheduled visits:

- dispense additional trial products
- dispense additional auxiliary supplies
- re-test of blood- or urine sampling (not allowed if results are available)

In case of additional trial products being dispensed, a dispensing session should be made in the IV/WRS selecting additional medication.

### 8.1.5 Visit 2 (Randomisation)

For procedures and assessments performed at randomisation, see Section 2.

Visit 2 will take place within two weeks after Visit 1.

The randomisation session must be performed in the IV/WRS which will allocate the Dispensing Unit Number (DUN) of the IMP to be dispensed to the subject. Eligible subjects will be randomised into one of nine treatment arms.

UTN: U1111-1136-4/16     Status:     Final       EudraCT No.: 2012-004994-16     Page:     39 of 98	Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	1.0 Final	Novo Nordisk
---	--	--------------	---------------------------------------	--------------	--------------

The IMP will be dispensed to the subject by the trial site staff, hospital pharmacy staff or equivalent at each visit during the trial from randomisation to last visit before the End-of-treatment visit (see Section 2). The investigator must document that subjects are instructed in oral IMP administration at every dispensing visit.

For subjects randomised to the s.c. injection, the investigator must document that a direction for use (DFU) is handed out at each dispensing visit. Ability and willingness to self-inject can be tested by administration of injections with a test pen for subjects who do not have prior experience with self-injection. Novo Nordisk will provide the test pens.

Please see Section  $\underline{9}$  for further information about the IMPs.

#### 8.1.6 Visit numbers

For visit numbers, timing of site visits and visit windows during the trial period, please refer to the flow chart, Section  $\underline{2}$ . Planned visits can be re-scheduled within the allowed visit window.

It is the responsibility of the investigator to ensure that all site visits occur according to the flow chart (see Section  $\underline{2}$ ).

#### 8.1.7 Visits 3-10 (Treatment)

For procedures and assessments performed at visits 3, 4, 5, 6, 7, 8, 9, and 10, see the flow chart in Section  $\underline{2}$ .

#### 8.1.8 Visits 11-12 (End-of-treatment and Follow-up)

All subjects must attend the End-of-treatment visit (Visit 11) which should be scheduled when the subject has completed the treatment with the IMP and a Follow-up visit (Visit 12) should be performed at least 5 weeks after (+5 days visit window). A completion session must be performed in the IV/WRS. Please see the flow chart for details (Section  $\underline{2}$ ).

The Follow-up visit serves to collect AEs, technical complaints, hyperglycaemic episodes and blood samples for anti-semaglutide antibodies.

#### 8.1.9 Visit 11X (End-of-Trial – premature discontinuation)

For subjects who discontinue the IMP prematurely the End-of-treatment visit (Visit 11) should be scheduled shortly after the subject has discontinued the IMP. The Follow-Up visit (Visit 12) should be scheduled at least 5 weeks (+5 days visit window) after treatment discontinuation. Treatment discontinuation and drug accountability sessions must be done in the IV/WRS. Please see the flow chart for details (Section  $\underline{2}$ ).

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	40 of 98	

Subjects who discontinue their IMP prematurely must also be requested to attend the visit End-oftrial – premature discontinuation (Visit 11X) at the time of the scheduled end of treatment (i.e., 26 weeks after randomisation). Data on AEs and the primary endpoint from this final visit are important for the data quality of the trial.

### 8.1.10 Withdrawals

If a subject is withdrawn from the trial, the investigator must aim to undertake procedures similar to those for visit 11 (End-of-treatment) as soon as possible, and the Follow-up visit at least 5 weeks after. The end-of-trial form must be completed and the subject should return all trial products to the site to have final drug accountability performed. Drug accountability must be performed even if the subject is not able to come to the trial site. A treatment discontinuation session must be performed in the IV/WRS (see Section 10). The case book must be signed.

Although a subject is not obliged to give his/her reason(s) for withdrawing from a trial, the investigator must make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where the reasons are obtained, the primary reason for discontinuation must be specified on the end-of-trial form in the eCRF (see Section <u>6.5.1</u>):

#### 8.1.11 Investigator's assessment

Review of diaries, laboratory reports, ECGs, eye examination (fundoscopy/fundus photography), physical examination and patient reported outcome (PRO) questionnaires must be documented with the investigator's or delegated site staff's dated signature either on the front page of the documents or in the subject's medical record. The documents should be signed prior to the following visit and must be retained at the investigator site as source documentation.

For ECGs and eye examinations the evaluations must be in the following categories:

- Normal
- Abnormal
  - Was the finding clinically significant? (yes/no)

For laboratory report values outside the reference range, the investigator must specify whether the value is non-clinically or clinically significant. All laboratory printouts must be signed and dated by the investigator on the day of evaluation.

In case of abnormal clinically significant findings (e.g., in laboratory reports, ECGs, eye examination or physical examination), the investigator must state a comment in the subject's medical record and record this on the concomitant illness form in the eCRF at the screening or randomisation visits. At subsequent visits any clinically significant changes or new clinically significant findings must be reported as an AE according to Section <u>12.2</u>.

Protocol		Date:	25 June 2013 <b>N</b>	lovo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	41 of 98	

If clarification of entries or discrepancies in the diary or PROs is needed, the subject must be questioned and a conclusion made in the subject's medical record. Care must be taken not to bias the subject.

#### 8.2 Subject related information

#### 8.2.1 Concomitant illness and medical history

A **concomitant illness** is any illness that is present at the start of the trial (i.e., at the screening visit or found as a result of screening procedure). The concomitant illness should be recorded in the eCRF.

**Medical history** is a medical event that the subject has experienced in the past. Only medical history considered relevant by the investigator should be reported.

The information collected for concomitant illness and medical history should include diagnosis, date of onset and date of resolution or continuation, as applicable.

Any change to a concomitant illness should be recorded during the trial. A clinically significant worsening of a concomitant illness must be reported as an AE.

**Smoking habit**: Details of smoking habit must be recorded at the first visit. Smoking is defined as smoking at least one cigarette, cigar or pipe daily. The collected information should include whether or not the subject smokes or has smoked. If the subject smokes or has smoked, record approximately when the subject started smoking and, if applicable, when the subject stopped smoking.

**Diabetes complications** should be captured in the medical history or concomitant illness form and should include:

- diabetic retinopathy
- diabetic neuropathy
- diabetic nephropathy
- macroangiopathy including peripheral vascular disease
- other complications where relevant

#### 8.2.2 Concomitant medication

A **concomitant medication** is any medication, other than the trial products, which is taken during the trial, including the screening and follow-up periods.

Details of any concomitant medication must be recorded at the first visit. Changes in concomitant medication must be recorded at each visit as they occur.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	42 of 98	

The information collected for each concomitant medication includes:

- trade name or generic name
- indication
- start and stop date or continuation
- total daily dose (only applicable for antidiabetic medication)

If a change is due to an AE, then this must be recorded and reported according to Section <u>12.2</u>. If the change influences the subject's eligibility to continue in the trial, the monitor must be informed.

#### 8.2.3 Demography

Demography will be recorded in the eCRF at screening and consists of:

- date of birth or age (according to local regulation)
- sex
- race (according to local regulation)
- ethnicity (according to local regulation)

#### 8.2.4 Diagnosis of diabetes

The date of diagnosis of T2D will be recorded in the eCRF at screening.

#### 8.2.5 Diabetes treatment history

The dose and the date of initiating treatment with metformin will be recorded in the eCRF at screening if the subject is currently treated with metformin.

#### 8.2.6 History of gallbladder disease

Information related to history of gallbladder disease (i.e., pancreatitis, gallstone disease, cholecystis) will be recorded in the eCRF at screening visit.

#### 8.2.7 History of cardiovascular disease

Information related to history of cardiovascular disease (CVD) (i.e., heart failure including NYHA class, hypertension or ischaemic stroke) or other risk factors for CVD will be recorded in the eCRF at screening visit.

#### 8.2.8 Renal impairment history

Information related to history of renal impairment will be recorded in the eCRF at screening visit.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	43 of 98	

#### 8.2.9 **Post-dose fasting routines**

The fasting routines following oral trial product administration should be recorded in the subject's diary handed out at Visit 10 and transcribed to the eCRF by the investigator at the End-of-treatment visit to determine the usual fasting time after tablet ingestion during the trial.

The post-dose fasting routines are recorded as time in minutes from IMP administration until the usual time of:

- food consumption (i.e., meal or snack)
- drinking (i.e., any beverage including water)

#### 8.3 Assessments for efficacy

#### 8.3.1 Blood samples

Blood samples will be drawn according to flow chart (see Section  $\underline{2}$ ) and analysed at the central laboratory to determine levels of the following efficacy laboratory parameters:

Glucose metabolism:

- HbA<sub>1c</sub>
- Fasting plasma glucose (FPG)
- Fasting insulin
- Fasting C-peptide
- Fasting glucagon

Lipids (all fasting):

- Total cholesterol
- LDL-cholesterol
- VLDL-cholesterol
- HDL-cholesterol
- Triglycerides
- Free fatty acids

#### 8.3.2 Body measurements

#### **Body weight**

Body weight should be measured without shoes and only wearing light clothing. It should be recorded with one decimal and using the same set of scales throughout the trial (i.e., kg or lb)

#### Height

Height is measured without shoes in centimetres or inches and recorded to nearest  $\frac{1}{2}$  cm or  $\frac{1}{4}$  inch.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	25 June 2013 1.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	44 of 98	

#### Waist circumference

The waist circumference is defined as the minimal abdominal circumferences located midway between the lower rib margin and the iliac crest.

Three consecutive measurements of waist circumference should be performed and recorded in the eCRF. The waist circumferences will be measured using a non-stretchable measuring tape. It should be recorded to the nearest  $\frac{1}{2}$  cm or  $\frac{1}{4}$  inch using the same measuring tape throughout the trial.

The subject should be measured in a standing position with an empty bladder and wearing light clothing with accessible waist. The subject should be standing with arms down their side and feet together. The tape should touch the skin but not compress soft tissue and twists in the tape should be avoided. The subject should be asked to breathe normally and the measurement should be taken when the subject is breathing out gently.

#### BMI

BMI will be captured in the eCRF using the equation:

BMI = Body weight (kg)/(Height (m) x Height (m))  $[kg/m^2 = lb/in^2 x 703]$ 

#### 8.3.3 Patient reported outcomes

The PRO questionnaire used in this trial is SF-36v2<sup>TM</sup>.

The questionnaire should be completed by the subject as specified in the flow chart, see Section  $\underline{2}$ , preferably before any other trial-related activities. It takes approximately ten minutes to complete the questionnaire.

The questionnaire is checked by the investigator for completion and unreported AEs (see Section 8.1.11). The investigator or site staff must date and sign the document and enter the results in the eCRF.

The SF-36v2<sup>TM</sup> questionnaire will be used to assess subjects overall Health related Quality of Life and can also be used to estimate Quality-Adjusted Life Year which is used in cost effectiveness calculations. This instrument contains 36 items and measures the individual overall health related quality of life on eight domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.

Protocol	L Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	Version:	1.0	
UTN: U1111-1136-4716	Status:	Final	
EudraCT No.: 2012-004994-16	Page:	45 of 98	

#### 8.4 Assessments for safety

#### 8.4.1 Hypoglycaemic episodes

Plasma glucose should always be measured and recorded when a hypoglycaemic episode is suspected.

All plasma glucose values:

- $\leq 3.9 \text{ mmol/L} (70 \text{ mg/dL}) \text{ or}$
- > 3.9 mmol/L (70 mg/dL) when they occur in conjunction with hypoglycaemic symptoms,

should be recorded by the subject in the diary. These must be transcribed into the eCRF (hypoglycaemic episode form) throughout the trial from Visit 1-12.

The record should include the following information:

- Date and time of hypoglycaemic episode
- The plasma glucose level before treating the episode (if available)
- Whether the episode was symptomatic
- Whether the subject was able to treat him/herself
- Date and time of last trial product administration prior to episode
- Type of last trial product prior to episode
- Date and time of last main meal prior to episode
- Whether the episode occurred in relation to increased physical activity

The answer to the question: "Was subject able to treat him/herself?" must be answered "No" if oral carbohydrates, glucagon or IV glucose had to be administered to the subject by another person. Oral carbohydrates should not be given if the subject is unconscious.

A hypoglycaemic episode form must be filled in for each hypoglycaemic episode. If the hypoglycaemic episode fulfils the criteria for an SAE then an AE form and an electronic safety information form (eSIF) must also be filled in (see Section <u>12.2</u>)

For all FPG values measured by central laboratory that meet the definition of a hypoglycaemic episode, a hypoglycaemic episode form must be completed in the eCRF.

#### 8.4.2 Blood samples

Blood samples will be drawn according to flow chart (see Section  $\underline{2}$ ) and will be analysed at the central laboratory to determine levels of the following safety laboratory parameters:

Haematology:

• Differential count (basophils, eosinophils, lymphocytes, monocytes and neutrophils)

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 46 of 98

• Erythrocytes

- Haematocrit
- Haemoglobin
- Leucocytes
- Thrombocytes

Biochemistry:

- Alanine aminotransferase
- Albumin
- Alkaline phosphatase
- Amylase
- Aspartate aminotransferase
- Bilirubin, total
- Calcium, total
- Calcium, albumin corrected (ionized)
- Creatine kinase
- Creatinine
- Lipase
- Potassium
- Sodium
- Urea

Hormone:

• Calcitonin (see Section <u>8.4.11</u>)

Pregnancy test:

• Serum or plasma human chorionic gonadotropin (hCG)

#### 8.4.3 Pregnancy test

Females of childbearing potential will have a serum pregnancy test (i.e., beta-hCG) performed as specified in Section  $\underline{2}$  or as required by local law.

Pregnancy testing will not be required (unless required by local law) for subjects who are postmenopausal (defined as women who have undergone a hysterectomy, bilateral oophorectomy or bilateral tubal ligation or for women above the age of 50, who have been without menstrual period for at least 1 year).

Protocol         CONFIDENTL           Trial ID: NN9924-3790         CONFIDENTL           UTN: U1111-1136-4716         CONFIDENTL           EudraCT No.: 2012-004994-16         CONFIDENTL		25 June 2013   Novo Nordish 1.0 Final 47 of 98
---	--	---

#### 8.4.4 Urinalysis

Subjects will be asked to bring first morning urine during the trial (see Section 2). The urine samples will be analysed at the central laboratory to determine levels of the following safety laboratory parameters:

- Urinary albumin to creatinine ratio
- Urinalysis by urine dip-stick: erythrocytes, protein, glucose and ketones, pH

#### 8.4.5 Antibodies

Blood samples will be drawn during the trial and analysed at specialised laboratory for determination of serum antibodies to semaglutide, including cross reactivity to endogenous GLP-1 (see flow chart, section 2). Samples positive for antibodies against semaglutide will be further characterised for *in vitro* neutralising effect towards semaglutide. In addition, samples positive for antibodies cross-reacting with endogenous GLP-1 will be analysed for *in vitro* neutralising effect towards endogenous GLP-1. Furthermore, samples drawn at randomisation may be used for calculations of the neutralising effect in the *in vitro* neutralising antibody assays. The *in vitro* neutralising assays will be performed by Novo Nordisk.

At randomisation, the antibody assessment must be done pre-dose.

#### 8.4.6 Vital signs

The method for measuring systolic and diastolic blood pressure needs to follow the standard clinical practice at site but as a minimum; the following guideline must be adhered to: Avoid caffeine, smoking and exercise at least 30 minutes prior to measuring the blood pressure. The blood pressure should be measured in a sitting position, with the legs uncrossed, the back and arms supported and positioned at heart level. Subjects should be sitting for at least five minutes before the first measurement is taken. The subject should not talk during the measurement. Pulse (beats per minute) should be measured after resting for five minutes in a sitting position. Results are recorded in the eCRF.

In case of an "abnormal, clinically significant finding", the investigator must record the finding on the medical history or concomitant illness form if present at screening.

Any new abnormal, clinically significant finding during the trial and any clinically significant worsening from baseline must be reported as an AE.

#### 8.4.7 Electrocardiogram – 12-lead

12-lead ECG will be performed during the trial (see Section <u>2</u>). All ECGs will undergo central assessment.

	FIDENTIAL Date: Version: Status: Page:	25 June 2013 1.0 Final 48 of 98	Novo Nordisk
--	---	--	--------------

Sites will be informed of the central ECG evaluation in case this evaluation reveals an abnormal ECG reading. If the abnormality represents an unreported AE, SAE or MESI, such findings must be reported if the investigator finds the abnormality clinically significant (see Section 8.1.11).

Additional ECG recordings can be performed at the investigators site at the investigator's discretion at other visits than the planned ECG visits. All such ECGs will undergo central assessment.

An ECG performed for any reason unrelated to the trial within 30 days prior to the randomisation visit is acceptable as Visit 2 data, provided no clinical symptoms suggestive of cardiac disease has occurred in the meantime.

If the ECG is performed before the subject has signed the informed consent form, it must be documented in the medical records that the reason for performing the procedure was not related to this trial.

For electronic central ECG evaluation vendor details, see Attachment I.

#### 8.4.8 Fundoscopy/fundus photography

Fundoscopy/fundus photography will be performed at randomisation by the investigator or according to local practice. Results of the fundoscopy/fundus photography will be reviewed, signed and dated by the investigator (see Section 8.1.11). Dilation is not a requirement.

If fundoscopy/fundus photography has been performed within 90 days before the screening visit, the procedure does not need to be repeated unless worsening of visual function since the last examination. A subject cannot be randomised without results confirming there is not retinopathy or maculopathy requiring acute treatment.

If the fundoscopy/fundus photography is performed before the subject has signed the informed consent form, it must be documented in the medical records that the reason for performing the procedure was not related to this trial.

#### 8.4.9 Physical examination

A physical examination will be performed by the investigator according to local procedures, see Section  $\underline{2}$ ).

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16 Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 49 of 98

A physical examination must include:

- General appearance
- Central and peripheral nervous system
- Head, ears, eyes, nose, throat, neck
- Thyroid gland
- Respiratory system
- Cardiovascular system
- Gastrointestinal system including mouth
- Musculoskeletal system
- Skin
- Lymph node palpation

The results are recorded as described in Section 8.1.11.

#### 8.4.10 Pharmacokinetics

Blood samples for the population PK will be drawn from all subjects for bioanalysis of the plasma concentrations of semaglutide at Visits 3-11 (see flow chart, Section 2). The investigator must record the exact time for drawing the blood samples in the laboratory requisition form and transcribe the data to the eCRF.

Subjects on oral treatment will also have PK measured pre-dose and post-dose (trough and peak) at three visits (see Section 2). At the visits for trough and peak PK measurements, the investigator needs to ensure that the subjects on oral treatment follow these procedures:

- Attend the visit fasting
- Have the IMP administered at the visit (i.e., subjects must not self-administrate the tablet on the day of the visit)
- Ingest tablet at site
- Eat a meal 30-60 minutes after IMP administration
- Have an extra blood sample drawn 60-90 minutes after IMP administration

The exact time points of trial drug administration, start of meal and blood sampling must be recorded in the eCRF by the investigator.

For the oral treatments, the date and time of the latest trial drug administration must be recorded by the subject in the subject diary and transcribed to the eCRF by the investigator.

For the s.c. semaglutide arm, the date, time, dose and injection site of the two latest trial drug administrations must be transcribed to the eCRF by the investigator based on the subject's diary.

Protocol	DENTIAL Date:	25 June 2013
Trial ID: NN9924-3790	Version:	1.0
UTN: U1111-1136-4716	Status:	Final
EudraCT No.: 2012-004994-16	Page:	50 of 98

#### 8.4.11 Calcitonin

Blood samples for the measurement of calcitonin concentration will be drawn as per flow chart (see Section 2). Calcitonin values  $\geq 20$  ng/L will be submitted to an independent committee of thyroid experts. The Calcitonin Monitoring Committee (CMC) will provide guidance to the investigator with regards to treatment and further investigations. It is recommended that screening failure subjects with a calcitonin value  $\geq 10$  ng/L are referred to a thyroid expert for further evaluation. For details please refer to Appendix A.

#### 8.5 Laboratory assessments

The laboratory analyses will mainly be performed by a central laboratory. For analyses of antisemaglutide antibodies (see Section 8.4.5) and semaglutide plasma concentrations (see Section 8.4.10) a special laboratory will be used. Also, in the situation described in Section 8.6.2.1 a special laboratory will be used. Laboratory samples comprise both urine and blood samples. Descriptions of assay methods, laboratory supplies and procedures for collecting, handling, storing and shipping samples and information regarding who will perform the assessments will be described in the laboratory manual provided by the central laboratory (for central and special laboratory details, see Attachment I).

Samples will be coded in order to keep subject identity anonymous.

Laboratory samples not collected on the day of the actual visit should preferably be collected on another day within the visit window as stated in the flow chart (see Section 2). Please note that a laboratory sample pertaining to a specific visit must always be reported to that visit.

For some of the samples collected during the trial, subjects must attend the relevant site visits fasting (fasting is defined in Section 8.1.3).

At three visits (see Section <u>2</u>), the subjects on oral treatment must attend the relevant site without having taken the trial product the same day to have PK measured pre-dose and post-dose (trough and peak), see Section <u>8.4.10</u>.

The central laboratory will provide laboratory results to the investigator on an on-going basis and the investigator must review all laboratory results for concomitant illnesses and AEs and report these according to Section <u>12.2</u>.

An exception to this is that anti-semaglutide antibody and semaglutide plasma concentration results will not be available to the investigator during the trial. These results will be provided to the investigator upon request after the completion of the clinical trial report (CTR).

All laboratory samples will be destroyed at the latest at the completion of the CTR, except samples obtained for anti-semaglutide antibody analysis which may be kept up to ten years or stored until

Protocol         Date:         25 June 2013         No           Trial ID: NN9924-3790         CONFIDENTIAL         Version:         1.0         1.0           UTN: U1111-1136-4716         Status:         Final         Page:         51 of 98	Novo Nordisk
--	--------------

approval by health authorities. Antibody samples will only be analysed if requested by the health authorities or for safety.

The laboratory equipment may provide analyses not requested in the protocol but produced automatically in connection with the requested analyses according to specifications in the laboratory standard operating procedures. Such data will not be transferred to the trial database, but abnormal values must be reported to the investigator. The investigator must review all laboratory results for concomitant illnesses and AEs and report these according to this protocol.

#### 8.6 Other assessments

#### 8.6.1 Subject diary

The subject must be provided with diaries at all visits until the End-of-treatment visit. Entries in the diary are only to be made by the subject.

The investigator/delegate should instruct the subject in recording the following data in the diary:

- For all subjects:
  - date and time of first IMP administration
  - hypoglycaemic episodes
  - concomitant medication
  - AEs
- For subjects treated with <u>oral semaglutide</u>:
  - date and time of last IMP administration prior to each visit
  - post-dose fasting routines during the trial and recorded at the End-of-treatment visit
- For subjects treated with <u>s.c. semaglutide</u>:
  - date, time, dose and injection site of the last two IMP administrations before each visit

The diaries should be collected at the following visit. The recordings must be reviewed as described in Section 8.1.11.

#### 8.6.2 Additional safety assessments

#### 8.6.2.1 Thyroidectomy, tissue sample and genetic testing

#### Thyroidectomy pathology slides

In case a subject undergoes a thyroidectomy (partial or total) for any reason during the trial the subject will be asked to inform the investigator prior to the operation.

In addition to the review of the thyroid tissue routinely made by the hospital pathology laboratory, the pathology slides of the thyroid tissue will be sent centrally for a second review by a pathologist with expertise in thyroid and C-cell pathology. The central pathologist will be blinded to both

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAI	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	52 of 98	

randomised treatment and the diagnosis from the hospital pathology laboratory. Both the hospital pathology report and the central pathology report will be reviewed by an independent Event Adjudication Committee (EAC) (see Section <u>12.7.2</u>). Once the samples are re-examined they will be sent back to the hospital pathology laboratory.

The investigator will be informed of the results of central pathology report and if C-cell pathology is confirmed by the EAC, the CMC will provide guidance to the investigator with regards to treatment and further investigations.

#### Thyroid tissue sample collection in case of thyroidectomy (not applicable for Israel)

If C-cell pathology is confirmed (i.e., hyperplastic or neoplastic thyroid C-cells) the subject will be asked to consent to have a sample of the removed thyroid tissue tested for RET Y1062 phosphorylation in the thyroid C-cells, if allowed by local law. The tissue sample will be destroyed after examination.

# Blood sample for genetic testing in case of confirmed C-cell pathology (not applicable for Israel)

In addition, the subject will also be asked to consent to be tested (blood sample) to identify germline RET gene mutations associated with MEN2 syndrome. This RET gene mutation detection will only be conducted if the EAC has confirmed C-cell abnormality (medullary carcinoma or C-cell hyperplasia). The genetic testing will only be performed if allowed by local law.

The blood sample should be collected at the first visit to the clinic after the confirmation of C-cell pathology. The extraction of DNA will be performed by the central laboratory whereas the identification of gene mutations will be performed by a specialised laboratory. The blood sample will be destroyed as soon as the genetic analysis is complete.

#### 8.6.2.2 Assessments in case of suspicion of acute pancreatitis

In case of acute, severe persistent abdominal pain characteristic of acute pancreatitis, the IMP must promptly be interrupted until pancreatitis is excluded (see Section 6.5.2). Appropriate additional examinations should be performed according to local practice. If acute pancreatitis is not confirmed trial product should be re-initiated.

If pancreatitis is confirmed (as a minimum 2 of 3):

- characteristic abdominal pain
- blood amylase and/or lipase >3x upper normal range (UNR)
- characteristic findings on ultrasound/CT/MRI

Protocol         Date:         25 June 2013         Novo Nordisk           Trial ID: NN9924-3790         CONFIDENTIAL         Version:         1.0           UTN: U1111-1136-4716         Status:         Final           EudraCT No.: 2012-004994-16         Page:         53 of 98	UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	Novo Nordisk
--	----------------------	--------------	---------	-------	--------------

appropriate treatment and careful monitoring of the subject should be initiated. Trial product should not be re-initiated but subject should remain in the trial. The event should be reported as a MESI and will undergo assessment by the EAC (see Section 12.7.2).

#### 8.6.2.3 Assessments in case of suspicion of severe hypersensitivity

If a severe immediate hypersensitivity reaction to the IMP is suspected, blood sampling for assessment of anti-semaglutide IgE antibodies and anti-semaglutide binding antibodies should be collected after a suitable washout period (minimum 5 weeks). In these cases, it is also recommended to test for tryptase (total and/or mature tryptase) within three hours of the reaction.

Furthermore, a tryptase sample should be taken at the same time as the IgE sample is obtained. Tryptase concentrations (if measured) as well as results of anti-semaglutide antibody and IgE-isotype anti-semaglutide antibodies should be sent to Novo Nordisk.

#### 8.7 Subject compliance

Subject compliance will be assessed by monitoring of drug accountability. Prior to visits where drug accountability is performed the subject will be asked to return all used, partly used and unused IMPs. The investigator must assess the amount of IMPs returned compared to what was dispensed at the last dispensing visit and, in case of discrepancies, question the subject.

Throughout the trial the investigator will remind the subjects to follow the trial procedures and requirements to ensure subject compliance. If a subject is found to be non-compliant, the investigator will remind the subject of the importance of following the instructions given including taking the trial products as prescribed.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 54 of 98	Novo Nordisk
--	--------------	---------------------------------------	--	--------------

### 9 Trial supplies

Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial supplies can be found in the Trial Materials Manual (TMM).

Trial products must not be dispensed to any person not included in the trial.

For injectable products, the trial product must not be used if:

- it does not appear clear and colourless
- it has been frozen
- it has been exposed to excessive heat or direct sunlight

#### 9.1 Trial products

The following trial products will be provided by Novo Nordisk A/S, Denmark:

Active substance	Strength	Dosage form
Semaglutide	2.5 mg	tablet
Semaglutide	5.0 mg	tablet
Semaglutide	10 mg	tablet
Semaglutide	20 mg	tablet
Semaglutide	40 mg	tablet
Placebo	N/A	tablet
Semaglutide	1.34 mg/mL	solution for injection, 1.5 mL pre-filled PDS290 pen-injector

Table 9–1Trial products (IMP)

N/A: not applicable

The IMPs for oral use will be packed in 15 mL Duma containers (lid with desiccant). Each container will include ten tablets. Subjects in the oral treatment arms will be instructed in how to ingest the tablets following the condition rules. All tablets containing semaglutide or placebo are identical with regards to visual appearance, taste and smell.

The semaglutide, solution for injection will be delivered open-label with the pre-filled PDS290 peninjector. The direction for use of the pen-injector will be given to each subject in the s.c. treatment arm at each dispensing visit.

For further details, please see the current edition of the IB (Oral Administration of Semaglutide (NN9924) Edition  $5^{6}$  and any updates hereof.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudreCT No : 2012.004004.16	CONFIDENTIAL	Date: Version: Status:	25 June 2013 1.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	55 of 98	

Metformin may be used at the discretion of the investigator. Metformin will not be supplied by Novo Nordisk. However, metformin will be reimbursed if required by the country's Health Authority or independent ethics committee/Institutional Review Board (IEC/IRB).

#### 9.2 Labelling

Labelling of the trial products will be in accordance with Annex  $13^{12}$ , local regulations and trial requirements.

Each investigator site will be supplied with sufficient trial products for the trial on an on-going basis controlled by the IV/WRS. Dispensing unit numbers (DUNs) will be distributed to the sites according to enrolment and randomisation.

The investigator or delegate must document that direction for use of the device is handed out at each dispensing visit. This could be by signature in the subject's medical record.

#### 9.3 Storage

Tablets containing the SNAC enhancer are susceptible to degradation in humid environment. It is important to protect the tablets by following the storage conditions in <u>Table 9–2</u>. Before opening the Duma container for the first time, the container must acclimatise for 1 hour at room temperature due to risk of condensation.

Trial product	Storage conditions (not-in-use)	In-use conditions	In-use time*
Semaglutide and placebo tablets	<ul> <li>Must be stored in a refrigerator (2°C to 8°C) / (36°F to 46°F)</li> <li>Do not freeze</li> <li>Protect from light and humidity</li> </ul>	<ul> <li>Store below 30°C / 86°F</li> <li>Do not refrigerate</li> <li>Do not freeze</li> <li>Protect from light and humidity</li> <li>Container must be stored with lid tightly closed at all times</li> </ul>	Use within 4 weeks
Semaglutide, solution for injection	<ul> <li>Must be stored in a refrigerator (2°C to 8°C) / (36°F to 46°F)</li> <li>Do not freeze</li> <li>Protect from light</li> </ul>	<ul> <li>Store below 30°C / 86°F</li> <li>Do not refrigerate</li> <li>Do not freeze</li> <li>Protect from light</li> </ul>	Use within 1 month
Semaglutide placebo, solution for injection (test pen)	<ul> <li>Must be stored in a refrigerator (2°C to 8°C) / (36°F to 46°F)</li> <li>Do not freeze</li> <li>Protect from light</li> </ul>	• For single use only	For single use only

Table 9–2	Storage	conditions	for tria	l products
-----------	---------	------------	----------	------------

\* In-use time starts when first dose is taken.

The investigator must ensure the availability of proper storage conditions, record and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial product has been stored outside defined conditions (e.g., outside temperature range).

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16 Date: Version: Status: Page:	25 June 2013 1.0 Final 56 of 98	Novo Nordisk
---	--	--------------

Trial products that have been stored improperly must not be dispensed to any subject before it has been re-evaluated and approved for further use by Novo Nordisk. The investigator must take appropriate action to ensure correct storage.

#### 9.4 Drug accountability and destruction

Drug accountability is the responsibility of the investigator.

Returned trial product (used/partly used or unused including empty packaging material) can be stored at room temperature and must be stored separately from non-allocated trial product.

The trial products will be dispensed to each subject as required according to treatment group. The IV/WRS will allocate trial product to the subject at each dispensing visit. The correct dispensing unit number(s) (DUN(s)) must be dispensed to the subject.

The investigator or delegated person is responsible for ensuring that:

- Trial products are not dispensed to any person not included in the trial
- Drug accountability is performed using the IV/WRS drug accountability module
- Subjects are instructed to return all used, partly used and unused trial product including empty packaging material at every visit
- Returned trial product(s) (used, partially used or unused including empty packaging material) is kept and stored separately from non-allocated trial products

Destruction will be done according to local procedures after accountability is finalised and verified by the monitor. Destruction of products must be documented.

#### 9.5 Auxiliary supplies

Auxiliary supplies provided by Novo Nordisk:

- Blood glucose meters, including lancets, plasma-calibrated test strips and control solutions.
- Direction for use for devices (only subjects on s.c. semaglutide)
- Needles for pre-filled pen systems (only subjects on s.c. semaglutide)
- Test pens containing semaglutide placebo (only subjects on s.c. semaglutide)

Test pens containing semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 peninjector will be supplied at the randomisation visit to subjects randomised to injection treatment. Training with the test pen is optional and recommended for subjects without prior injection experience to ensure the subject's willingness and ability to self-inject. The test pen should be administered once and the training be performed at the clinical site. The subjects must not take the test pens home.

Details of the auxiliary supplies are provided in the TMM.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 1.0 Final 57 of 98

25 June 2013 Novo Nordisk

# 10 Interactive voice/web response system

A trial-specific IV/WRS will be set up which can be accessed at any time via the internet or telephone. Access to the IV/WRS must be restricted to and controlled by authorised persons.

IV/WRS is used for:

- Screening
- Screening failure
- Randomisation
- Medication arrival
- Dispensing
- Treatment discontinuation
- Completion
- Code break
- Drug accountability
- Data change

IV/WRS user manuals will be provided to each trial site.

During the trial, only DUNs allocated by the IV/WRS are allowed to be dispensed to a subject. This will ensure that:

- needed stock is available at a site for the subjects
- no allocation of IMP that will expire before the next dispensing contact
- drug accountability can be made in IV/WRS

If a subject needs IMP between dispensing visits, the investigator must make an additional dispensing session in the IV/WRS.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

1.0 Final 58 of 98

25 June 2013 Novo Nordisk

#### Randomisation procedure and breaking of blinded codes 11

The trial is partially blinded. The oral semaglutide arms and the oral placebo arm are double-blind whereas the s.c. semaglutide active comparator arm is open-label.

The randomisation is stratified according to one stratification factor with two strata: Treatment with metformin at screening (yes/no).

#### 11.1 **Breaking of blinded codes**

If the trial site needs to break the code, Novo Nordisk should, if possible, be contacted before the code is broken. The IV/WRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after the code is broken.

The code for a particular subject may be broken in a medical emergency if knowing the actual treatment would influence the treatment of the subject. Whenever a code is broken the person breaking the code must print the Code Break Confirmation Notification generated by the IV/WRS, record the reason and sign and date the document.

When the code is broken, the treatment allocation will be accessible to the investigator and the Novo Nordisk Global Safety department. If IV/WRS is not accessible at the time of code break the monitor should be contacted and if monitor cannot get access the IV/WRS vendor helpdesk should be contacted. Contact details are listed in Attachment I.

If the code has been broken, the subject should be discontinued from trial product but be asked to continue in the trial (see Section 8.1.9).

If the subject is withdrawn after the code has been broken, a treatment discontinuation session should be completed in IV/WRS.

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 59 of 98

## 12 Adverse events, technical complaints and pregnancies

#### 12.1 Definitions

#### Adverse event

An **adverse event** is any untoward medical occurrence in a subject administered a product, and which does not necessarily have a causal relationship with this treatment.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product.

An AE includes:

- A clinically significant worsening of a concomitant illness.
- A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a severity that requires active management. Active management includes active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to the abnormality.

The following should **not** be reported as AEs:

- Pre-existing conditions, including those found as a result of screening procedures (pre-existing conditions should be reported as medical history or concomitant illness).
- Pre-planned procedures unless the condition for which the procedure was planned has worsened from the first trial-related activity after the subject has signed the informed consent.
- Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic episode form instead of on an AE form (see Section <u>8.4.1</u>)

The following definitions are used when assessing an AE:

- Severity assessment:
  - Mild no or transient symptoms, no interference with the subject's daily activities, acceptable
  - **Moderate** marked symptoms, moderate interference with the subject's daily activities, but still acceptable
  - Severe considerable interference with the subject's daily activities; unacceptable

#### • Causality assessment

The following terms and definitions are used when assessing the relationship between an AE and the relevant trial product(s):

• Probable – Good reason and sufficient documentation to assume a causal relationship

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	60 of 98	

- **Possible** A causal relationship is conceivable and cannot be dismissed
- Unlikely The event is most likely related to aetiology other than the trial product
- Final outcome of an AE
  - **Recovered/resolved** The subject has fully recovered, or by medical or surgical treatment the condition has returned to the level observed at the first trial-related activity after the subject signed the informed consent.
  - **Recovering/resolving** This term is only applicable if the subject has completed the trial or has died from another AE. The condition is improving and the subject is expected to recover from the event.
  - **Recovered/resolved with sequelae** The subject has recovered/resolved from the condition, but with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE criterion, the AE must be reported as an SAE.
  - Not recovered/not resolved The condition of the subject has not improved and the symptoms are unchanged, or the outcome is not known at the time of reporting.
  - **Fatal** This term is only applicable if the subject died from a condition related to the reported AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an SAE.
  - Unknown This term is only applicable if the subject is lost to follow-up.

#### Serious adverse event

A serious adverse event is an experience that at any dose results in any of the following:

- Death
- A life-threatening<sup>a</sup> experience
- In-patient hospitalisation<sup>b</sup> or prolongation of existing hospitalisation
- A persistent or significant disability or incapacity<sup>c</sup>
- A congenital anomaly or birth defect
- Important medical events that may not result in death, be life threatening<sup>a</sup> or require hospitalisation<sup>b</sup> may be considered an SAE when based on appropriate medical judgement they may jeopardise the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition of SAE<sup>d</sup>. Suspicion of transmission of infectious agents via trial product must always be considered an SAE

<sup>a</sup> The term "life threatening" in the definition of SAE refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it was severe.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	61 of 98	

<sup>b</sup> The term "hospitalisation" is used when a subject:

- Is admitted to a hospital or in-patient, irrespective of the duration of physical stay, or
- Stays at the hospital for treatment or observation for more than 24 hours

Medical judgement must always be exercised, and when in doubt, the hospital contact should be regarded as a hospitalisation. Hospitalisations for administrative, trial-related and social purposes do not constitute AEs and should therefore not be reported as AEs or SAEs. Hospital admissions for surgical procedures, planned before trial inclusion, are not considered AEs or SAEs.

<sup>c</sup> A substantial disruption of a subject's ability to conduct normal life functions (e.g., following the event or clinical investigation the subject has significant, persistent or permanent change, impairment, damage or disruption in his/her body function or structure, physical activity and/or quality of life).

<sup>d</sup> For example intensive treatment in an emergency room or at home of allergic bronchospasm, blood dyscrasiasis or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse.

#### Non-serious adverse event

A non-serious AE is any AE which does not fulfil the definition of an SAE.

### Medical event of special interest

A medical event of special interest (MESI) is an event which, in the evaluation of safety, has a special focus. A MESI is an AE (SAE or non-serious AE) which fulfils one or more of the below defined MESI criteria.

- 1. Fatal Events (All events with fatal outcome) (A)
- 2. Acute Coronary Syndrome (Myocardial Infarction, Hospitalization for Unstable Angina) (A)
- 3. Cerebrovascular Events (Stroke, Transient Ischemic Attack) (A)
- 4. Coronary Revascularization Procedure (A)
- 5. Heart Failure requiring Hospital Admission (A)
- 6. Pancreatitis or clinical suspicion of pancreatitis (A)
- 7. Neoplasms (A)
- 8. Thyroid Disease ((A) if thyroidectomy is required)
- 9. Medication errors concerning trial products:
  - Administration of wrong drug
  - Wrong route of administration
  - Administration of a high dose with the intention to cause harm (e.g., suicide attempt)
  - Administration of a lower or higher dose than intended (e.g., taking more than the planned number of tablets); however, the administered dose must deviate from the intended dose to

ProtocolDate:25 June 2013Novo NordTrial ID: NN9924-3790CONFIDENTIALVersion:1.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:62 of 98	rdisk
--	-------

an extent where clinical consequences for the trial subject were likely to happen as judged by the investigator, although not necessarily did happen

MESIs marked with an '(A)' in the list above will undergo adjudication by an independent EAC (see Section 12.7.2).

Any event confirmed or suspected to be a MESI must be reported. In case the sponsor identifies potentially missed MESIs through predefined review of available data, the investigator will be asked to reconsider if this is a MESI. However, MESIs should not be reported for screening failures.

For further information regarding definitions of MESIs and an overview of which events that should undergo adjudication, please refer to Appendix C.

When reporting a MESI the following forms must be completed: AE form, eSIF, specific MESI follow-up questions (MESI form) and if applicable, the Event Adjudication Document Collection Form (only events for adjudication) in the eCRF.

#### **Technical complaint**

A technical complaint is any written, electronic, or oral communication that alleges product (medicine or device) defects. The technical complaint may be associated with an AE, but does not concern the AE itself.

Examples of technical complaints:

- The physical or chemical appearance of trial products (e.g., discoloration, particles or contamination)
- The packaging material (e.g., leakage, cracks, rubber membrane issues or errors in labelling text)
- Problems related to devices (e.g., to the injection mechanism, dose setting mechanism, glucose measurement, push button or interface between the pen and the needle)

#### 12.2 Reporting of adverse events

All events meeting the definition of an AE must be collected and reported. This includes events from the first trial-related activity after the subject has signed the informed consent until the end of the post-treatment follow-up period. The events must be recorded in the applicable eCRF forms in a timely manner (see timelines below and Figure 12–1).

During each contact with the trial site staff, the subject must be asked about AEs and technical complaints, for example by asking: "Have you experienced any problems since the last contact?"

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 63 of 98	Novo Nordisk
--	--------------	---------------------------------------	--	--------------

All AEs, either observed by the investigator or reported by the subject, must be reported by the investigator and evaluated. Novo Nordisk assessment of expectedness is performed according to the following reference document: IB (Oral Administration of Semaglutide (NN9924)), Edition  $5^{6}$  and any updates hereof.

All AEs must be recorded by the investigator on an AE form. The investigator should report the diagnosis, if available. If no diagnosis is available, the investigator should record each sign and symptom as individual AEs using separate AE forms.

For SAEs, an eSIF must be completed in addition to the AE form. If several symptoms or diagnoses occur as part of the same clinical picture, one safety information form can be used to describe all the SAEs.

MESIs, regardless of seriousness, must be reported using both the AE form, the safety information form and a MESI form. The MESI form is an electronic form tailored to collect specific information related to the individual MESIs. For MESIs qualifying for event adjudication, an Event Adjudication Document Collection Form will also have to be completed in the eCRF. The Event Adjudication Document Collection Form is a check list of clinical data to be provided from the site.

The AE form for a non-serious AE should be signed when the event is resolved or at the end of the trial.

#### **Timelines for initial reporting of AEs:**

The investigator must complete the following forms in the CRF/eCRF within the specified timelines:

• **SAEs**: The AE form **within 24 hours** and the safety information form **within 5 calendar** days of the investigator's first knowledge of the SAE

Both forms must be signed within 7 calendar days from the date the information was entered in the eCRF.

- **SAEs fulfilling the MESI criteria**: In addition to above, the MESI form **within 14 calendar days** of the investigator's first knowledge of the AE
- Non-serious AE fulfilling the MESI criteria: The AE form, and safety information form and MESI form within 14 calendar days of the investigator's first knowledge of the event.

If a MESI fulfils the Event Adjudication criteria the investigator must complete the Event Adjudication Document Collection Form within 14 calendar days of the investigator's first knowledge of the adverse event.

Protocol       CONFIDENTIAL         Trial ID: NN9924-3790       CONFIDENTIAL         UTN: U1111-1136-4716       CONFIDENTIAL         EudraCT No.: 2012-004994-16       CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 Novo Nordisk 1.0 Final 64 of 98
---	---------------------------------------	---

If the eCRF is unavailable, the concerned AE information must be reported on paper forms and sent to Novo Nordisk by fax, e-mail or courier within the same timelines as stated above. When the eCRF becomes available again, the investigator must re-enter the information on the appropriate forms in the eCRF.

Contact details (fax, telephone, e-mail and address) are provided in the investigator's trial file.




Figure 12–1 Initial reporting of AEs

#### Reporting of trial product-related SUSARs by the sponsor:

Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious adverse reactions (SUSARs) in accordance with local requirements and  $GCP^{1}$ . In addition, the investigator will be informed of any trial-related SAEs that may warrant a change to any trial procedure.

In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, including EMA, of trial product-related SUSARs. In addition, Novo Nordisk will inform the IRBs/IECs of trial product-related SUSARs in accordance with local requirement and GCP<sup>1</sup>, unless locally this is an obligation of the investigator.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 65 of 98	Novo Nordisk
--	--------------	---------------------------------------	--	--------------

#### 12.3 Follow-up of adverse events

During and following a subject's participation in the trial, the investigator should ensure that adequate medical care is provided to the subject for any AE, including significant laboratory values related to the trial. The investigator should inform the subject when medical care is needed for AE(s) of which the investigator becomes aware.

The investigator must record follow-up information by updating the forms in the eCRF.

Follow up information must be reported to Novo Nordisk according to the following:

• **SAEs:** All SAEs must be followed up until the outcome of the event is "recovered/resolved", "recovered/resolved with sequelae" or "fatal", and until all queries have been resolved. Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome "recovering/resolving" or "not recovered/not resolved". Cases can be closed with the outcome of "recovering/resolving" when the subject has completed the follow-up period and is expected by the investigator to recover.

The SAE follow-up information should only include new (e.g., corrections or additional) information and must be reported **within 24 hours** of the investigator's first knowledge of the information. This is also the case for previously non-serious AEs which subsequently become SAEs. The applicable forms must be signed within 7 calendar days from the date the new information was entered in the eCRF.

- Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is "recovering/resolving", "recovered/resolved" or "recovered(resolved with sequelae" or until the end of the follow-up period stated in the protocol, whichever comes first, and until all queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome "recovering/resolving" or "not recovered/not resolved". Cases can be closed with the outcome of "recovering/resolving" when the subject has completed the follow-up period and is expected by the investigator to recover.
- Non-serious AE fulfilling the MESI criteria: Follow-up information on MESIs should only include new (e.g., corrections or additional) information and must be reported within 14 calendar days of the investigator's first knowledge of the information. This is also the case for previously non-serious AEs which subsequently fulfil the MESI criteria.

The investigator must record follow-up information on non-serious AEs by updating the AE form in the eCRF.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	66 of 98	

The investigator must ensure that the worst case severity and seriousness of an event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up with re-assessment of severity and/or seriousness of the event.

Queries or follow-up requests from Novo Nordisk must be responded to **within 14 calendar days** from the date of receipt of the request, unless otherwise specified in the follow-up request.

#### 12.4 Technical complaints and technical complaint samples

#### 12.4.1 Reporting of technical complaints

All technical complaints on any of the following products:

- Semaglutide tablets
- Placebo tablets
- Semaglutide for s.c. injection, solution for injection, 1.5 mL pre-filled PDS290 pen injector
- Semaglutide placebo for s.c. injection, solution for injection, 1.5 mL pre-filled PDS290 peninjector (test pen)
- Novo Nordisk needles

which occur from the time of first usage of the product until the time of the last usage of the product, must be collected and reported to Customer Complaint Center, Novo Nordisk.

Contact details (fax, e-mail and address) are provided in the investigator's trial file.

The investigator must assess whether the technical complaint is related to any AEs, SAEs and/or MESI.

Technical complaints must be reported on a separate technical complaint form for each product listed. If the technical complaint involves more than one code number, lot number or DUN, a technical complaint form for each code number, lot number or DUN must be completed.

The investigator must complete the technical complaint form in the eCRF within the following timelines of the trial site obtaining knowledge of the technical complaint:

- Technical complaint assessed as related to an SAE within 24 hours
- All other technical complaints within 5 calendar days

If the eCRF is unavailable or when reporting a technical complaint that is not subject related, the information must be provided on a paper form by fax, e-mail or courier to Customer Complaint Center, Novo Nordisk, within the same timelines as stated above.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 67 of 98	Novo Nordisk
--	--------------	---------------------------------------	--	--------------

#### 12.4.2 Collection, storage and shipment of technical complaint samples

The investigator must collect the technical complaint sample and notify the monitor **within 5 calendar days** of obtaining the sample at trial site. The monitor must coordinate the shipment to Customer Complaint Center, Novo Nordisk (the address is provided in the investigator's trial file) and ensure that the sample is sent as soon as possible. A print of the technical complaint form must be sent with the sample.

The investigator must ensure that the technical complaint sample contains the code number and, if available, the DUN.

If the technical complaint sample is unobtainable, the investigator must specify on the technical complaint form why it is unobtainable.

Storage of the technical complaint sample must be done in accordance with the conditions prescribed for the product. The shipment of the technical complaint sample should be done in accordance with the same conditions as for storage (see Section  $\underline{9}$ ).

#### 12.5 Pregnancies

Female subjects must be instructed to notify the investigator immediately if they become pregnant during the trial. The investigator must report any pregnancy in subjects who have received trial product(s).

The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is one month of age.

The investigator must report information about the pregnancy, pregnancy outcome, and health of the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and newborn infant.

The following must be collected and reported by the investigator to Novo Nordisk – electronically (e.g., in PDF format), or by fax or courier:

#### 1. Reporting of pregnancy information

Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to be reported on Maternal Form 1A and 1B, respectively.

When the pregnancy outcome is abnormal (i.e., congenital anomalies, foetal death including spontaneous abortion and/or any anomalies of the foetus observed at gross examination or during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further information has to be reported for the female subject on Maternal Form 2. In addition, information from the male partner has to be reported on the Paternal Form, after an informed consent has been obtained from the male partner.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	68 of 98	

Initial reporting and follow-up information must be reported **within 14 calendar days** of the investigator's first knowledge of initial or follow-up information.

#### 2. Reporting of AE information

The investigator has to report AEs in connection with the pregnancy as well as in the foetus and newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal death (including spontaneous abortion), and congenital anomalies (including those observed at gross examination or during autopsy of the foetus), as well as other pregnancy complications fulfilling the criteria of an SAE.

#### Forms and timelines for reporting AEs:

Non-serious AEs:

• Paper AE form\* within 14 calendar days of the investigator's first knowledge of the initial or follow-up information to the non-serious AE

SAEs:

- Paper AE form\* within 24 hours of the investigator's first knowledge of the SAE
- Paper safety information form **within 5 calendar days** of the investigator's first knowledge of the SAE
- **SAE follow-up information** to the AE form and/or safety information form **within 24 hours** of the investigator's first knowledge of the follow-up information

\* It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the subject, foetus or newborn infant.

Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy forms must be responded to by the investigator **within 14 calendar days** from the date of receipt of the request, unless otherwise specified in the follow-up request.

#### 12.6 Precautions and/or overdose

There are no specific antidotes to semaglutide. Treatment of an overdose should be symptomatic.

There is a potential risk of hypoglycaemia during dosing with semaglutide. The typical signs and symptoms of confirmed hypoglycaemia include: hunger, slight headache, nausea, light-headedness, palpitations and sweating. Major hypoglycaemia (severe) may produce loss of consciousness. Symptoms of confirmed and not major hypoglycaemia should be treated by ingestion of carbohydrates.

Major hypoglycaemia resulting in loss of consciousness should be treated at the investigator's discretion according to best available medical practise.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 69 of 98	Novo Nordisk

One case of accidental overdose of oral semaglutide with SNAC was reported in the NN9924-3692 trial in a subject treated with 20 mg semaglutide with 300 mg SNAC. The subject accidentally took the trial product twice on Day 52 of the trial. No AEs were reported at the time. The medication error was discovered at the next scheduled visit. The subject did not report any symptoms and treatment was continued without any change.

One case of accidental overdose has been reported in s.c. semaglutide treated subjects. The case classified as moderate in severity and considered to be probably related to semaglutide was reported by a subject enrolled in trial NN9535-1821. No hospitalisation was needed. The subject inadvertently injected mg of semaglutide instead of mg, which corresponds to a 2.5-fold higher dose than the maximum dose included in that trial. After

	The subject was
withdrawn from the trial after	days of treatment due to an AE (diarrhoea).

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924) Edition  $5^{6}$  and any updates hereof.

### 12.7 Committees related to safety

#### 12.7.1 Novo Nordisk safety committee

Novo Nordisk will constitute an internal Oral GLP-1 safety committee to perform on-going safety surveillance. The Oral GLP-1 safety committee may recommend un-blinding of any data for further analysis, and in this case an independent ad hoc safety group will be established in order to maintain the blinding of the trial personnel.

### 12.7.2 Event adjudication committee

An external event adjudication committee (EAC) is established to perform qualitative or quantitative validation of selected AEs according to pre-defined diagnostic criteria. The validation is based on review of pre-defined clinical data related to the specific AE.

The events are reviewed by the EAC in an independent and blinded manner.

The EAC is composed of permanent members covering required medical specialities. EAC members must disclose potential conflicts of interest and must be independent of Novo Nordisk. The role of the EAC is solely to adjudicate events in a blinded manner. The EAC will have no authorisations to impact on trial conduct, trial protocol or amendments.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	70 of 98	

The EAC works in accordance with written guidelines included in the EAC Charter describing in details the composition, tasks, responsibilities, and work processes of the committee.

The events will be adjudicated according to FDA requirements and the adjudication vendor will ensure that the EAC gets access to all the documents provided by the investigator. The EAC will initiate the review and may ask for additional information that the investigator needs to provide if it is available.

The EAC will review copies in English (translated if necessary) of medical documentation received in the adjudication packages (e.g., X-ray images, ECGs, ultrasound images, discharge summaries, pathology reports and death certificates). The investigator must provide medical documentation within 4 weeks of event identification.

The assessments made by the EAC will be included in the CTR as well as assessments made by the investigator. However, the adjudication made by an EAC, given its independence and in-depth analysis of each event, will be attributed with greater importance of the two. The outcomes of adjudication will be kept in the clinical trial database.

The following AEs will be adjudicated in this trial:

- Fatal Events (All events with fatal outcome)
- Acute Coronary Syndrome (Myocardial Infarction, Hospitalization for Unstable Angina)
- Cerebrovascular Events (Stroke, Transient Ischemic Attack)
- Coronary Revascularization Procedure
- Heart Failure requiring Hospital Admission
- Pancreatitis or clinical suspicion of pancreatitis
- Neoplasms
- Thyroid Disease (if thyroidectomy is required)

Event adjudication will not be performed for AEs in screening failures.

There are two processes for capturing AEs for adjudication: Direct reporting of MESIs by the investigator and by potential missed MESI process.

Direct reporting of MESI by investigator: For each AE reported in the eCRF, the investigator must complete whether the event in his/her opinion is a MESI (yes/no).

By ticking YES:

- The investigator must specify the type of MESI event being reported
- The investigator must complete the event adjudication document collection form ('adjudication form') in the eCRF according to the timeline specified in Section <u>12.2</u>. This form indicates the data/documents required for adjudication

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	25 June 2013 1.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	71 of 98	

• For each required document the investigator should specify/indicate when/if the data/document will be available. If a document is unobtainable this needs to be specified. The investigator must provide medical documentation within 4 weeks of event identification

#### By ticking NO:

All NOs within the relevant MESI category are screened for being potential missed MESI.

- If needed, the investigator will be asked to provide an explanation of why the event is not reported as a MESI (alternative etiology)
- The vendor or EAC can evaluate an event not initially reported as a MESI for adjudication to be adjudicated. In this case the investigator must provide data/documents required for adjudication as soon as possible when receiving a request from Novo Nordisk or the vendor

A site manual will be provided to each site detailing the specifics surrounding the medical documentation that must be provided by site to the adjudication vendor including how this documentation should be provided.

#### 12.7.3 Calcitonin monitoring committee

The CMC will provide recommendations to the investigators with regards to further investigation and treatment of the individual subject (see Appendix A).

ProtocolDate:25 June 2013Novo NordisTrial ID: NN9924-3790CONFIDENTIALVersion:1.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:72 of 98	UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
--	----------------------	--------------	---------	-------	--

## 13 Case report forms

Novo Nordisk will provide a system for the eCRF. This system and support services to the system will be supplied by a vendor.

Ensure that all relevant questions are answered and that no empty data field exists. If a test or an assessment has not been done and will not be available, or if the question is irrelevant (e.g., is not applicable), indicate this according to the data entry instructions.

The following will be provided as paper CRFs:

Pregnancy forms

In addition paper AE forms, SIF and technical complaint forms will be provided. These must be used when access to the eCRF is revoked (i.e., EDC system not available).

On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. If a test/assessment has not been done and will not be available, indicate this by writing "ND" (not done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g., is not applicable) indicate this by writing "NA" (not applicable) in the appropriate answer field. Further guidance can be obtained from the instructions in the CRF.

The investigator must ensure that all information is consistent with the source documentation. By electronically signing the case book in the eCRF, the investigator confirms that the information in the eCRF and related forms is complete and correct.

### **13.1** Corrections to case report forms

Corrections to the eCRF data may be made by the investigator or the investigator's authorised staff. An audit trail will be maintained in the eCRF application containing as a minimum: the old and the new data, identification of the person entering the data, date and time of the entry and reason for the correction.

If corrections are made by the investigator's authorised staff after the date the investigator has signed the case book, the case book must be signed and dated again by the investigator.

#### 13.2 Case report form flow

The investigator must ensure that data are recorded in the eCRF as soon as possible after the visit, preferably within 5 days. Once data have been entered, they will be available to Novo Nordisk for data verification and validation purposes.

Protocol		Date:	25 June 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	73 of 98	

At the end of the trial the investigator must ensure that all remaining data have been entered into the eCRF, preferably within 3 days after the last subject's last visit at the site in order to ensure the planned lock of the database.

Site specific eCRF data (in an electronic readable format) will be provided to the trial site before access to the eCRF is revoked. This data must be retained at the trial site.

### **13.3** Paper case report forms

The pregnancy forms are paper based CRFs. Also, the SIF, technical complaint form and AE form will be provided in paper but are only to be used if for any reason the eCRF is unavailable.

The investigator must ensure that data are recorded in these forms as soon as possible after the visit and ensure that Novo Nordisk receives these forms within the required timelines (see Sections <u>12.2</u>, <u>12.4.1</u> and <u>12.5</u>).

Corrections to the data in the CRFs may only be made by drawing a straight line through the incorrect data and then writing the correct entry next to the data that were crossed out. Each correction must be initialled, dated and explained (if necessary) by the investigator or the investigator's authorised staff.

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 1.0 Final 74 of 98

## 14 Monitoring procedures

During the course of the trial, the monitor will visit the trial site to ensure that the protocol is adhered to, that all issues have been recorded, to perform source data verification and to monitor drug accountability. The first monitoring visit will be performed as soon as possible after FSFV and no later than 4 weeks after. The monitoring visit intervals will depend on the outcome of the remote monitoring of the eCRFs, the trial site's recruitment rate and the compliance of the trial site to the protocol and GCP, but will not exceed 4 weeks during the recruitment period (i.e., from FSFV to last subject first visit (LSFV)). After LSFV the monitoring visit intervals will not exceed 8 weeks.

The monitor must be given direct access to source documents (original documents, data and records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the electronic medical record does not have a visible audit trail, the investigator must provide the monitor with signed and dated printouts. In addition the relevant trial site staff should be available for discussions at monitoring visits and between monitoring visits (e.g., by telephone).

All data must be verifiable in source documentation other than the eCRF (except for BMI).

For all data recorded the source document must be defined in a source document agreement at each trial site. There must only be one source defined at any time for any data element.

For screening failures the monitor will ensure that relevant eCRF pages and other trial-related forms containing data from screening failures are completed. For screening failures the following data should be source verified: informed consent, reason for screening failure and AEs, if any.

Source data generated by the trial site can be corrected by another person than the person entering the source data if accepted by local regulations; any correction must be explained, signed and dated by the person making the correction.

The completed diaries will be collected from the subject at each site visit and must be kept as source data at the site. The investigator/delegate must transcribe the data into the eCRF.

The monitor will ensure that the eCRFs are completed on an ongoing basis and within agreed timelines.

Monitors must review the subject's medical records and other source data (e.g., the diaries and PROs) to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must be questioned about these.

A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring visit addressing any action to be taken.

CONFIDENTIAL

Date: Version: Status: Page:

Final 75 of 98

#### Data management 15

Data management is always the responsibility of Novo Nordisk. Data management may be delegated under an agreement of transfer of responsibilities to an external contract research organisation (CRO).

Appropriate measures, including encryption of data files containing person identifiable data, will be used to ensure confidentiality of subject data, when they are transmitted over open networks.

Data from central laboratories will be transferred electronically from the laboratory performing the analyses. In cases where laboratory data are transferred via non-secure electronic networks, data will be encrypted during transfer.

The subject and any biological material obtained from the subject will be identified by subject number and trial identification number. Appropriate measures such as encryption or leaving out certain identifiers will be enforced to protect the identity of subjects in all presentations and publications as required by local, regional and national requirements.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 76 of 98	Novo Nordisk
--	--------------	---------------------------------------	--	--------------

## 16 Computerised systems

Novo Nordisk will capture and process clinical data using computerised systems that are described in Novo Nordisk Standard Operating Procedures and IT architecture documentation. The use and control of these systems are documented.

Investigators working on the trial may use their own electronic systems to capture source data.

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 1.0 Final 77 of 98

## 17 Statistical considerations

If necessary, a statistical analysis plan (SAP) may be written in addition to the protocol, including a more technical and detailed elaboration of the statistical analyses. The SAP will be finalised before database lock.

Results from the statistical analysis will generally be presented by two-sided confidence intervals with a confidence level of 95% including a p-value for test of no difference between treatments.

The stratification variable referred to in the following is defined as the two level factor of treatment with metformin (yes/no).

The "planned comparisons between treatment arms" referred to in this section covers the following comparisons: a) between each of the oral semaglutide treatment arms and placebo, b) between the s.c. semaglutide arm and placebo, c) between each of the oral semaglutide treatment arms and s.c. semaglutide, and d) between the three treatment arms with an end dose of 40 mg.

A standard mixed model for repeated measurements (MMRM) will be used in the analysis of the primary and continuous secondary endpoints. The model will include treatment, country and the stratification variable as fixed factors, and the corresponding baseline value as covariate. All factors and the covariate will be nested within visit. Unless otherwise stated, the estimated differences with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms.

In order to describe the dose-response relation of oral semaglutide and estimate the relative potency vs. s.c. semaglutide with regards to selected key endpoints, an explorative analysis will be conducted. In this model data from oral semaglutide arms using the standard titration scheme will be included. One or both of the treatment arms with an end dose of 40 mg using an alternative titration scheme may be included and pooled with the oral semaglutide arm with an end dose of 40 mg and using the standard titration scheme, if deemed appropriate based on the planned pairwise comparisons between the arms. Data from the placebo arm (corresponding to a dose of zero mg) could be included if deemed appropriate. The model will developed ad hoc after unblinding and aim for a suitable fit of the dose-response relation using e.g. a linear or a four-parameter logistic relation of the endpoint of interest vs. the logarithm of the dose.

## 17.1 Sample size calculation

The primary endpoint, change from baseline to end of treatment (i.e., after 26 weeks of treatment) in HbA1c, will be analysed by the standard MMRM.

In order to demonstrate efficacy of oral semaglutide the sample size is based on an initial comparison of change from baseline to end of treatment (i.e., after 26 weeks of treatment) in  $HbA_{1c}$ 

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 78 of 98	Novo Nordisk
--	--------------	---------------------------------------	--	--------------

between a) the pool of the two treatment arms using standard and fast escalation regimens, respectively, to an end dose of 40 mg and b) placebo.

A standard deviation (SD) of 1.2% for change from baseline in  $HbA_{1c}$  is chosen as assumption for the sample size calculation. The SD observed in several phase 3 trials of 26 weeks duration with s.c. liraglutide suggests a standard deviation less than 1.1%. However, as it is uncertain if the added variation in exposure compared to s.c. liraglutide will transfer to an added variation in the therapeutic response, a SD of 1.2% is assumed.

In trial NN9535-1821 the withdrawal rate for the doses 0.2 mg-0.8 mg was 16%-24%. In the present trial, GI events are mitigated by dose escalation and based on this the drop-out rate is expected to be 20%, equally distributed among treatment arms. For completers the treatment difference between the pooled 40 mg arm and placebo is expected to be at least 0.64% whereas for dropouts the treatment difference is set conservatively to 0.32%, thus leading to a detectable mean difference of 0.58%. With these assumptions, and using a two-sided t-test with a significance level of 5%, 134 subjects should be randomised to the pooled 40 mg treatment arm and 67 to placebo in order to have 90% power to demonstrate superiority of the pooled 40 mg treatment arm versus placebo. For similarity between the treatment arms, 67 subjects should be randomised in each of the nine treatment arms.

In total, 603 subjects are to be randomised.

### 17.2 Definition of analysis sets

**Full Analysis Set (FAS):** includes all randomised subjects who have received at least one dose and have any post randomisation data. The statistical evaluation of the FAS will follow the intention-to-treat (ITT) principle and subjects will contribute to the evaluation "as randomised".

**Safety Analysis Set (SAS):** includes all subjects exposed to at least one dose of randomised liraglutide or liraglutide placebo. Subjects in the SAS will contribute to the evaluation "as treated".

Before data are locked for statistical analysis, a review of all data will take place. Any decision to exclude a subject or single observations from the statistical analysis is the joint responsibility of the members of the study group. Exclusion of data from analyses will be used restrictively and normally no data should be excluded from the FAS. The subjects or observations to be excluded, and the reasons for their exclusion, must be documented and signed by those responsible before database lock. The subjects and observations excluded from analysis sets, and the reason for this, will be described in the CTR.

### 17.3 Primary endpoint

The primary endpoint, change from baseline to end of treatment (i.e., after 26 weeks of treatment) in HbA1c, will be analysed by the standard MMRM.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:
--	--------------	---------------------------------------

1.0 Final 79 of 98

In order to confirm efficacy of oral semaglutide without risk of inflation of the type 1 error an initial comparison of the primary endpoint between a) the pool of the two treatment arms using standard and fast escalation regimens to an end dose of 40 mg and b) placebo. The comparison will be made using the MMRM by estimating the difference between the mean of means in the two 40 mg arms and the mean in placebo. The estimated difference with corresponding two sided p-value and 95% confidence interval at 26 weeks will be presented, and efficacy of oral semaglutide will be considered confirmed if the upper limit of the confidence interval is strictly less than zero.

If efficacy of oral semaglutide is confirmed the planned comparisons between the nine original treatment arms will be evaluated.

Subjects in the FAS and only measurements taken before treatment discontinuation or initiation of rescue therapy will be included in the analysis.

Due to the uncertainty in relation to if the added variation in the exposure in the oral semaglutide arms compared to s.c. liraglutide will transfer to an added variation in the therapeutic response, a sensitivity analysis allowing the within subject unstructured covariance matrix to be fitted separately for each treatment arm will be conducted.

Furthermore, the following sensitivity analyses will be conducted in order to investigate the sensitivity of the results due to the impact of missing values:

- An MMRM similar to the primary analysis but including all data recorded after randomisation regardless of the data being obtained when the subjects have received rescue therapy or have discontinued randomised treatment.
- An analysis of covariance (ANCOVA) model including subjects in the FAS and using • imputation of missing values according to the last observation carried forward (LOCF) method. The model will include fixed factors for treatment, country and the stratification variable and the baseline value as covariate. In accordance with the LOCF method, the dependent variable will be the last available value obtained within the 26 weeks period of the study.
- A completer analysis, i.e. an ANCOVA similar to the one above including only data obtained at 26 weeks from subjects who:
  - did not discontinue treatment prematurely
  - did not receive rescue therapy
  - had a valid HbA<sub>1c</sub> assessment at baseline and after 26 weeks of treatment •

#### 17.4 Supportive secondary endpoints

#### 17.4.1 **Efficacy endpoints**

The FAS will be used in all analyses of the supportive secondary efficacy endpoints.

Protocol	CONFIDENTIAL	Date:	25 June 2013
Trial ID: NN9924-3790		Version:	1.0
UTN: U1111-1136-4716		Status:	Final
EudraCT No.: 2012-004994-16		Page:	80 of 98

#### Subjects who, after 26 weeks of treatment, achieve (yes/no) HbA<sub>1c</sub> <7% (53 mmol/mol)

The binary endpoint will be analysed by a logistic regression model which will include fixed factors for treatment and the stratification variable and baseline HbA<sub>1c</sub> as a covariate. Estimated odds ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms. Missing response data at 26 weeks will be imputed from the MMRM used for the primary analysis of HbA<sub>1c</sub>.

## Change from baseline to week 26 in body weight, waist circumference and fasting plasma glucose.

These endpoints will be analysed by the standard MMRM.

# Change from baseline to week 26 in C-peptide, fasting insulin, glucagon, HOMA-IR, HOMA-B, total cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides and free fatty acids.

For each endpoint, the assessments at every week will be log-transformed and subsequently analysed by the standard MMRM. The estimated differences and corresponding 95% confidence intervals at 26 weeks will be back transformed and presented as ratios together with the two sided p-values.

The fasting HOMA endpoints (i.e., fasting HOMA-B and HOMA-IR) will be calculated based on fasting insulin and FPG as follows:

- 1. Fasting HOMA-B (%) = 20 x fasting insulin  $[\mu U/ml]/(FPG[mmol/L]-3.5)$
- 2. Fasting HOMA-IR (%) = fasting insulin  $[\mu U/ml] \times FPG [mmol/L]/22.5$

#### **PRO** outcomes

The outcomes from the SF-36 in terms of total scores overall and within each domain will be calculated and each of these scores will be analysed by the standard MMRM.

#### 17.4.2 Safety endpoints

All safety endpoints will be summarised and analysed using the safety analysis set. Unless otherwise specified safety endpoints will be analysed by descriptive statistics only.

#### Adverse events

All AEs will be coded using the most recent version of the Medical Dictionary for regulatory Activities (MedDRA) coding. A TEAE is defined as an event that has onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than the followup visit. TEAEs are summarised descriptively, whereas non-treatment emergent AEs are presented in listings.

Novo Nordisk

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 81 of 98

### Number of confirmed treatment emergent hypoglycaemic episodes

A hypoglycaemic episode will be defined as *treatment emergent* if the onset of the episode occurs on or after the first day of trial product administration and no later than the follow-up visit.

Hypoglycaemic episodes are classified according to the Novo Nordisk classification of confirmed hypoglycaemia and the ADA classification of hypoglycaemia (see Figure 17–1).

### Confirmed hypoglycaemia

In normal physiology, symptoms of hypoglycaemia occur below a plasma glucose level of 3.1 mmol/L  $(56 \text{ mg/dL})^{13}$ . Therefore, Novo Nordisk has included hypoglycaemia with plasma glucose levels below this cut-off point in the definition of confirmed hypoglycaemia.

Confirmed hypoglycaemic episodes are defined as episodes that are:

- severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) and/or
- biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia

## ADA classification of hypoglycaemia

- *Severe hypoglycaemia:* An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
- Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured plasma glucose concentration  $\leq$  3.9 mmol/L (70 mg/dL)
- *Documented symptomatic hypoglycaemia:* An episode during which typical symptoms of hypoglycaemia are accompanied by a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).
- *Relative hypoglycaemia:* An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia, and interprets those as indicative of hypoglycaemia, but with a measured plasma glucose concentration > 3.9 mmol/L (70 mg/dL).
- *Probable symptomatic hypoglycaemia:* An episode during which symptoms of hypoglycaemia are not accompanied by a plasma glucose determination (but that was presumably caused by a plasma glucose concentration ≤ 3.9 mmol/L [70 mg/dL]).




Figure 17–1 ADA classification of hypoglycaemia

Data on treatment emergent hypoglycaemic episodes will be summarised descriptively using the above definitions.

The number of confirmed treatment emergent hypoglycaemic episodes during 26 weeks treatment will be analysed using a negative binomial regression model with a log-link function and the logarithm of the time period in which an occurrence of a hypoglycaemic episode is considered treatment emergent as offset. The model will include treatment, country and stratification variable as fixed factors and baseline HbA<sub>1c</sub> as covariate. Estimated rate ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms.

## Change in pulse, systolic- and diastolic blood pressure from baseline to after 26 weeks of treatment

These endpoints will be analysed by the standard MMRM.

### Change in amylase and lipase from baseline to after 26 weeks of treatment

For each endpoint, the assessments at every week will be log-transformed and subsequently analysed by the standard MMRM. The estimated differences and corresponding 95% confidence intervals at 26 weeks will be back transformed and presented as ratios together with the two sided p-values.

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 83 of 98

# Change from baseline to after 26 weeks of treatment in electrocardiogram (ECG), physical examination, laboratory safety variables (haematology, biochemistry, hormone and urinalysis) other than amylase and lipase

These endpoints will be summarised by descriptive statistics.

Endpoints related to occurrence of anti-semaglutide antibodies during 26 weeks of treatment: Antibody level during 26 weeks of treatment, anti-semaglutide antibodies (positive/negative), anti-semaglutide antibodies with *in vitro* neutralising effect (positive/negative), antisemaglutide antibodies cross reacting with endogenous GLP-1 (positive/negative), cross reacting antibodies with *in vitro* neutralising effect to endogenous GLP-1 (positive/negative)

These endpoints will be summarised by descriptive statistics and correlated to PK and PD.

### 17.4.3 Pharmacokinetics and/or pharmacodynamics modelling

If relevant, population PK and PK/PD modelling will be used to evaluate semaglutide exposure and exposure-response relationship after oral and subcutaneous administration in subjects with T2D to inform dose selection in future trials.

The objectives of these exploratory analyses are to:

- assess the dose-dependence of semaglutide exposure in plasma
- explore the effects of covariates on semaglutide exposure
- explore the relationship between semaglutide exposure and response variables of interest

The modelling will be performed by Quantitative Clinical Pharmacology at Novo Nordisk A/S and will be reported separately from the CTR.

Protocol	
Trial ID: NN9924-3790	
UTN: U1111-1136-4716	
EudraCT No.: 2012-004994-16	

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 84 of 98

## 18 Ethics

The trial will be conducted in compliance with ICH GCP<sup>1</sup> and applicable regulatory requirements, and in accordance with the Declaration of Helsinki<sup>2</sup>.

All subjects will be included after a thorough evaluation in regards to in- and exclusion criteria defined in order to ensure that subjects are eligible for trial treatment. Subjects will be treated within a regimen anticipated to be better than or equal to the treatment they receive at the time of entry into the trial. However, they will have to spend some extra time, as additional assessments and visits to the clinic are required. It is the responsibility of the investigator to ensure the best possible care according to the principles outlined in Diabetes Care 2013, Standards of Medical Care in Diabetes<sup>14</sup>, or any updates thereof.

It is concluded that the potential benefits from participating in the trial outweigh the potential risks. The safety profile of semaglutide generated from the clinical and nonclinical development programme has not revealed any safety issues that would prohibit administration of once-daily oral doses of 2.5-40 mg semaglutide or once-weekly doses of 1.0 mg semaglutide in accordance with the planned clinical trial. Furthermore, a rescue strategy is implemented in this trial to ensure the safety of subjects experiencing deterioration of glycaemic control during the course of the trial to address the concern regarding the placebo arm and the inclusion of patients with an HbA<sub>1c</sub> up to 9.5%. It is concluded that the risk to the subjects in this trial is low and acceptable in view of the benefits a GLP-1 analogue in a tablet formulation would provide to people with T2D.

The trial products may be associated with AEs, but relevant precautions have been implemented in the design and planned conduct of the trial in order to minimise the risks and inconveniences of participation in the trial. These precautions include thorough information regarding the correct administration of the trial products and gradual dose adjustment. Furthermore, subjects are fully informed about possible AEs and inconveniences and will be instructed to contact the investigator in case of any concerns regarding the trial participation.

## 18.1 Informed consent

In seeking and documenting informed consent, the investigator must comply with applicable regulatory requirement(s) and adhere to ICH  $GCP^{1}$  and the requirements in the Declaration of Helsinki<sup>2</sup>.

Before any trial-related activity, the investigator must give the subject verbal and written information about the trial and the procedures involved in a form that the subject can read and understand. The subject is allowed to bring a companion when the oral information is provided.

The subjects must be fully informed of their rights and responsibilities while participating in the trial as well as possible disadvantages of being treated with the trial products.

Protocol Trial ID: NN9924-3790		Date: Version:	25 June 2013 1.0	Novo Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Status: Page:	Final 85 of 98	

The investigator must ensure the subject ample time to come to a decision whether or not to participate in the trial.

A voluntary, signed and personally dated informed consent form will be obtained from the subject before any trial-related activity.

The responsibility for seeking informed consent must remain with the investigator, but the task may be delegated by the investigator to a medically qualified person, in accordance with local requirements. The written informed consent must be signed and personally dated by the person who seeks the informed consent before any trial-related activity.

If information becomes available that may be relevant to the subject's willingness to continue participating in the trial, the investigator must inform the subject in a timely manner and a revised written subject information must be provided and a new informed consent must be obtained.

### 18.2 Data handling

If the subject is withdrawn from the trial or lost to follow-up, then the subject's data will be handled as follows:

- Data already collected will be retained by Novo Nordisk, entered into the database and used for the trial report
- Safety events will be reported to Novo Nordisk and regulatory authorities according to local and national requirements

If data are used, it will always be in accordance with local law and IRBs/IECs.

### **18.3** Premature termination of the trial and/or trial site

Novo Nordisk, the investigator, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial or a trial site at any time, but agreement on procedures to be followed must be obtained.

If a trial is suspended or prematurely terminated, the investigator must inform the subjects promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk should also promptly inform the IRBs/IECs and provide a detailed written explanation. The relevant regulatory authorities should be informed.

If, after the termination of the trial, the risk/benefit analysis changes, the new evaluation should be provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have participated in the trial. If it does have an impact, the actions needed to inform and protect the subjects should be described.

An interim analysis to allow for premature discontinuation of the trial has not been planned.

CONFIDENTIAL

Date: Version: Status: Page:

25 June 2013 Novo Nordisk 1.0 Final 86 of 98

## **19** Protocol compliance

Deviations from the protocol should be avoided.

If deviations do occur, the investigator must inform the monitor and the implications of the deviation must be reviewed and discussed.

Deviations must be documented and explained in a protocol deviation by stating the reason, date, and the action(s) taken. Some deviations, for which corrections are not possible, can be acknowledged and confirmed via edit checks in the eCRF or via listings from the clinical database.

Documentation on all protocol deviations must be kept in the investigator's trial file and Novo Nordisk trial master file.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 87 of 98	Novo Nordisk
Eudrac 1 No.: 2012-004994-10		rage.	87 01 98	

## 20 Audits and inspections

Any aspect of the clinical trial may be subject to audits conducted by Novo Nordisk or inspections from domestic or foreign regulatory authorities or from IRBs/IECs. Audits and inspections may take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff have an obligation to cooperate and assist in audits and inspections. This includes giving auditors and inspectors direct access to all source documents and other documents at the trial site relevant to the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are relevant to the evaluation of the trial.

Protocol
Trial ID: NN9924-3790
UTN: U1111-1136-4716
EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 88 of 98

## 21 Critical documents

Before a site is allowed to start screening subjects, the following documents must be available to Novo Nordisk:

- Regulatory approval and/or acknowledgement of notification as required
- Approval/favourable opinion from IRBs/IECs clearly identifying the documents reviewed as follows: protocol, any substantial protocol amendments, subject information/informed consent form, any other written information to be provided to the subject and subject recruitment materials
- List of IRB/IEC members and/or constitution
- Curricula vitae of the investigator and sub-investigator(s) (current, dated and signed must include documented GCP training or a certificate)
- Signed receipt of Investigator's Brochure
- Signed and dated agreement on the final protocol
- Signed and dated agreement on any substantial protocol amendment, if applicable
- Financial agreement(s)
- Source document agreement
- Central laboratory certification and normal ranges
- Insurance statement, if applicable
- Signed and dated Investigator Agreement
- Financial disclosure form for all investigators
- For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of Financial Conflict of Interest
- For US trial sites: FDA Form 1572 must be completed and signed by each investigator

### FDA form 1572:

For US sites:

- Intended for US sites
- Conducted under the IND
- All US investigators, as described above, will sign FDA form 1572

### FDA form 1572 (for sites outside the US):

For sites outside the US:

- Intended for participating sites outside of the US
- Not conducted under the IND
- All investigators outside of the US will not sign FDA form 1572

Novo Nordisk will analyse and report data from all sites together.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	25 June 2013 1.0 Final 89 of 98	Novo Nordisk
EudraC1 No.: 2012-004994-16		Page:	89 01 98	

By signing the protocol, each investigator agrees to comply fully with ICH GCP<sup>1</sup>, applicable regulatory requirements and the Declaration of Helsinki<sup>2</sup>.

By signing the protocol, each investigator also agrees to allow Novo Nordisk making investigator's name and information about site name and address publically available if this is required by national or international regulations.

CONFIDENTIAL

Date: Version: Status: Page: 25 Ju

25 June 2013 Novo Nordisk 1.0 Final 90 of 98

## 22 Responsibilities

The investigator is accountable for the conduct of the trial at his/her site. If any tasks are delegated, the investigator should maintain a list of appropriately qualified persons to whom he/she has delegated specified significant trial-related duties. The investigator should ensure that there is adequate training for all staff participating in the conduct of the trial. It is the investigator's responsibility to supervise the conduct of the trial and to protect the rights, safety and well-being of the subjects.

A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible for all trial-related medical decisions.

The investigator must ensure adequate supervision of the conduct of the trial at the trial site.

The investigator will follow instructions from Novo Nordisk when processing data.

The investigator is responsible for filing essential documents (i.e., those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced) in the investigator's trial file. The documents should be kept in a secure locked facility, so no unauthorized persons can get access to the data. The subject ID list should be kept securely and separate from the personal data.

The investigator will take all necessary technical and organisational safety measures to prevent accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any unauthorised access to data or any other processing of data against applicable law. The investigator must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that such technical and organisational safety measures have been taken.

During any period of unavailability, the investigator must delegate responsibility for medical care of subjects to a specific qualified physician who will be readily available to subjects during that time.

The investigator must keep a log of staff and delegation of task(s) at site. The investigator must sign the log of staff and delegation of task(s) at site at the time of delegation of tasks.

If the investigator is no longer able to fulfil the role of investigator (e.g., if he/she moves or retires), a new investigator will be appointed in consultation with Novo Nordisk.

The investigator and site personnel must have sufficient English skills according to their assigned task(s).

Protocol	Date:	25 June 2013 Novo Nordisk	
Trial ID: NN9924-3790	Version:	1.0	
UTN: U1111-1136-4716	Status:	Final	
EudraCT No.: 2012-004994-16	Page:	91 of 98	

Novo Nordisk will be responsible for the preparation of the protocol, eCRF, supply of trial products and stated equipment, monitoring, data management, statistics and the CTR as documented by Novo Nordisk procedures and internal specific agreements as well as the current GCP guidelines<sup>1</sup>.

Novo Nordisk will provide a system for EDC. This system and support services to the system will be supplied by a vendor. The activities of the vendor will be under the direction and supervision of Novo Nordisk. Furthermore, Novo Nordisk will be responsible for the IV/WRS.

A central laboratory will be responsible for providing all lab supplies for the analysis of all blood and urine samples taken during the trial. All results are received as paper copies at the sites as well as electronic transfer to Novo Nordisk clinical database.

The name of the central laboratories is listed in protocol attachment I.

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 1.0 Final 92 of 98

2013 Novo Nordisk 1.0 Final

## 23 Reports and publications

The information obtained during the conduct of this trial is considered confidential, and may be used by Novo Nordisk for regulatory purposes and for the general development of the trial product. All information supplied by Novo Nordisk in connection with this trial shall remain the sole property of Novo Nordisk and is to be considered confidential information. No confidential information shall be disclosed to others without prior written consent from Novo Nordisk. Such information shall not be used except in the performance of this trial. The information obtained during this trial may be made available to other physicians who are conducting other clinical trials with the trial product, if deemed necessary by Novo Nordisk.

The CTR will be reviewed and signed by one or more investigator(s) (signatory investigator) appointed by Novo Nordisk based on their experience in clinical research and input during the analysis phase.

## 23.1 Communication of results

Novo Nordisk commits to communicating, and otherwise making available for public disclosure, results of trials regardless of outcome. Public disclosure includes publication of a paper in a scientific journal, abstract submission with a poster or oral presentation at a scientific meeting, or disclosure by other means.

Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the CTR is available. This includes the right not to release the results of interim analyses, because the release of such information may invalidate the results of the entire trial.

At the end of the trial, one or more public disclosures may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.

The results of this trial will be subject to public disclosure on external web sites according to international regulations, as reflected in the Novo Nordisk Code of Conduct for Clinical Trial Disclosure.

In all cases the trial results will be reported in an objective, accurate, balanced and complete manner, with a discussion of the strengths and limitations. All authors will be given the relevant statistical tables, figures and reports needed to support the planned publication. In the event of any disagreement on the content of any publication, both the investigators' and Novo Nordisk opinions will be fairly and sufficiently represented in the publication.

Where required by the journal, the principal investigator from each trial site will be named in an acknowledgement or in the supplementary material, as specified by the journal.

Protocol	L Date:	25 June 2013 Nov	ovo Nordisk
Trial ID: NN9924-3790	Version:	1.0	
UTN: U1111-1136-4716	Status:	Final	
EudraCT No.: 2012-004994-16	Page:	93 of 98	

Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager before submission for comments. Comments will be given within four weeks from receipt of the planned communication.

## 23.1.1 Authorship

Authorship of publications should be in accordance with the Uniform Requirements of the International Committee of Medical Journal Editors (sometimes referred to as the Vancouver Criteria<sup>15</sup>).

At the end of the trial, one or more publications (abstracts, posters, manuscripts) will be prepared for submission to scientific congresses and peer-reviewed journals in collaboration between Novo Nordisk and investigator(s) appointed by Novo Nordisk. These investigator(s) must meet the ICMJE authorship criteria to be named authors on publications.

## 23.1.2 Site-specific publication(s) by investigator(s)

For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical limitations and frequently do not provide meaningful information for healthcare professionals or subjects, and therefore may not be supported by Novo Nordisk. It is a Novo Nordisk policy that such individual reports do not precede the primary manuscript and should always reference the primary manuscript of the trial.

Novo Nordisk reserves the right to prior review of such publications. Further to allow for the primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of individual site results until the primary manuscript is accepted for publication. As Novo Nordisk wants to live up to the industry publication policy, submission for publication of such primary policy will take place no later than 18 months after trial completion.

## 23.2 Investigator access to data and review of results

As owner of the trial database, Novo Nordisk has the discretion to determine who will have access to the database.

Individual investigators will have their own research participants' data and will be provided with the randomisation code after results are available.

CONFIDENTIAL

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 94 of 98

## 24 Retention of clinical trial documentation and human biospecimens

### 24.1 Retention of clinical trial documentation

Subject's medical records must be kept for the maximum period permitted by the hospital, institution or private practice.

The investigator must agree to archive the documentation (this includes both electronic and paperbased records) pertaining to the trial in an archive after completion or discontinuation of the trial if not otherwise notified. The investigator should not destroy any documents without prior permission from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk can refer the investigator to an independent archive provider that has a system in place to allow only the investigator to access the files.

The investigator must be able to access his/her trial documents without involving Novo Nordisk in any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper copies or prints) will be provided to the investigator before access is revoked to the systems and/or electronic devices supplied by Novo Nordisk. These data must be retained by the site. If the Novo Nordisk provided data (e.g., the CD-ROM) is not readable during the entire storage period, the investigator can request a new copy, as a copy of all data will be stored by Novo Nordisk.

Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the product is on the market plus 20 years.

The files from the investigator site/institution must be retained for 15 years after the completion of the trial, or longer if required by national regulations. The deletion process must ensure confidentiality of data and must be done in accordance with local regulatory requirements.

## 24.2 Retention of human biospecimens

Serum samples (3-4 mL) of antibodies to semaglutide will be stored at the CRO after finalisation of the CTR (see Section <u>8.5</u>). The retained antibody samples will only be used for further characterisation of antibodies against semaglutide if required by health authorities or for safety. The samples will remain anonymous (no personal data will be received).

Samples will be stored for up to ten years or until approval by health authorities. They may be transferred from the CRO to Novo Nordisk. Only Novo Nordisk and the CRO/laboratory will have access to the samples.

There are no potential consequences for the subjects or their relatives on the potential use of the antibody samples stored.

Date: Version: Status: Page: 25 June 2013 Novo Nordisk 1.0 Final 95 of 98

## 25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities

#### **IRB/IEC:**

Written approval or favourable opinion must be obtained from IRB/IEC prior to commencement of the trial.

During the trial, the investigator or sponsor, as applicable, must promptly report the following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs where a causal relationship cannot be ruled out, substantial protocol amendments, non-substantial protocol amendments according to local requirements, deviations to the protocol implemented to eliminate immediate hazards to the subjects, new information that may affect adversely the safety of the subjects or the conduct of the trial (including new risk/benefit analysis in case it will have an impact on the planned follow-up of the subjects), annually written summaries of the trial status and other documents as required by the local IRB/IEC.

Protocol amendments must not be implemented before approval or favourable opinion according to local regulations, unless necessary to eliminate immediate hazards to the subjects.

The investigator must maintain an accurate and complete record of all submissions made to the IRB/IEC. The records should be filed in the investigator's trial file and copies must be sent to Novo Nordisk.

#### **Regulatory Authorities**

Regulatory authorities will receive the clinical trial application (CTA) or clinical trial notification, protocol amendments, reports on SAEs and the CTR according to national requirements.

Protocol
Trial ID: NN9924-3790
UTN: U1111-1136-4716
EudraCT No.: 2012-004994-16

**CONFIDENTIAL** 

Date: Version: Status: Page:

Final 96 of 98

## 26 Indemnity statement

Novo Nordisk carries product liability for its products, and liability is assumed under the special laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown negligence.

Novo Nordisk assumes no liability in the event of negligence, or any other liability by the clinics or investigators conducting the trial, or by persons for whom the said site or investigator are responsible.

Novo Nordisk accepts liability in accordance with:

- For Germany: Drug Law dated August 24, 1976 last amended by Second Law for Changes in ٠ Regulations on Drugs and Other Issues dated October 19, 2012.
- For Spain: Royal decree 223/2004, of 6th February, establishing the requisites concerning ٠ clinical trials.

ProtocolDate:25 June 2013Novo NotTrial ID: NN9924-3790CONFIDENTIALVersion:1.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:97 of 98	vo Nordisk
---	------------

## 27 References

- 1 International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. 01-May-1996.
- 2 World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 59th WMA General Assembly, Seoul. 1-Oct-2008.
- 3 Bittner B, McIntyre C, Jordan P, Schmidt J. Drug-drug interaction study between a novel oral ibandronate formulation and metformin. Arzneimittelforschung 2011; 61(12):707-713.
- 4 McIntyre C, Schmidt J, Castelli M, Bittner B. Study on the impact of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) on the bioavailability of ibandronate (IBN) in postmenopausal women. J.Drug Del.Sci.Tech. 2011, 21 (6) 521-525.
- 5 Investigator's Brochure Semaglutide (subcutaneous administration), Edition 8. June 2013.
- 6 Investigator's Brochure Oral administration of semaglutide (NN9924), Edition 5. June 2013.
- 7 International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice. Fed Regist 2010; 75(13):3471-3472.
- 8 Emisphere Technologies I. ERP-12/7, clinical trial report: A Randomized, Double-Blind, Multicenter Study Comparing the Safety and Efficacy of Two Dosing Regimens of Oral EMISPHERE SNAC/Heparin with Subcutaneous Enoxaparin Sodium for the Prevention of Venous Thromboembolic Events Following Elective Total Hip Replacement Surgery. Nov. 2002.
- 9 De Angelis C., Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351(12):1250-1251.
- 10 Food and Drug Administration Amendments Act (FDAAA), VIII-CLINICAL TRIAL DATABASES, SEC. 801. EXPANDED CLINICAL TRIAL REGISTRY DATA BANK, 27-Sep-2007.
- 11 European Commission. Detailed guidance on the European clinical trials database (EUDRACT Database) April 2003 and successor documents CT 5.1 Amendment describing the Development of EurdaCT- Lot 1 for 1 May 2004 and CT 5.2 EudraCT core dataset.
- 12 European Union. The rules governing medicinal products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use; Annex 13, Investigational Medicinal Products Brussels, February 2010.

Protocol Trial ID: NN9924-3790		Date: Version:	25 June 2013	Novo Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Status: Page:	Final 98 of 98	

- 13 Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79(3):777-781.
- 14 Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11-S66.
- 15 International Committee of Medicinal Journal Editors. Uniform Requirements for Manuscripts submitted to Biomedical Journals. N Engl J Med 1997; 336:309-315.

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 1 of 98

## Protocol

**Updated protocol including:** Protocol, Final Version 1.0, dated 25 June 2013 Protocol Amendment no 1, Final Version 1.0, dated 05 September 2013 (Applicable to Sweden) Protocol Amendment no 2, Final Version 1.0, dated 16 January 2014

## Trial ID: NN9924-3790

## Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes

*Redacted protocol Includes redaction of personal identifiable information only.* 

Trial phase: 2

**Protocol originator:** 

Clinical Operations 2, Semaglutide & Oral GLP-1

This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

Date: Version: Status: Page:

## **Table of contents**

### Page

Tal	ble of c	ontents		2
Tal	ble of f	igures		6
1		•		
2				
	2.1		es	
3		ground information	and rationale for the trial	
	3.1		ellitus and glucagon-like peptide-1	
	3.2	e	NAC	
			ical data	
		3.2.1.1	Thyroid C-cell tumours in rodents	
		3.2.1.2	Teratogenicity in rats	
		3.2.1.3	SNAC toxicology	
			ical pharmacology and pharmacokinetics	
			data	
		3.2.3.1	Data from literature	
		3.2.3.2	Clinical data of s.c. semaglutide	
		3.2.3.3	Clinical data of oral GLP-1	
	2.2	3.2.3.4	Clinical data of SNAC	
	3.3		of the trial	
	3.4		ial	
4	Objec		t(s)	
	4.1			
		2	objective	
			ary objectives	
	4.2	*		
		2	endpoint	
		4.2.2 Support	ive secondary endpoints	
5	Trial	design		
	5.1			
	5.2		lesign	
	5.3		cts	
			vels and escalation regimen for oral dosing	
			vels and escalation regimen for s.c. dosing	
	5.4		l of trial	
	5.5	Rationale for treatr	nent	
6	Trial	population		
	6.1		5	
	6.2	Inclusion criteria		

Protocol	Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	Version:	3.0	
UTN: U1111-1136-4716	 Status:	Final	
EudraCT No.: 2012-004994-16	Page:	3 of 98	

	6.3		on criteria	
	6.4		criteria	
	6.5		wal criteria and discontinuation of trial product	
		6.5.1	Withdrawal from trial	
		6.5.2	Discontinuation of trial product	
	6.6	Kational	le for trial population	
7	Milest	tones		
8	Metho	ods and as	ssessments	
	8.1	Visit pro	ocedures	
		8.1.1	Introduction	
		8.1.2	Visit 1 (Screening)	
		8.1.3	Fasting visits	
		8.1.4	Unscheduled visits	
		8.1.5	Visit 2 (Randomisation)	
		8.1.6	Visit numbers	
		8.1.7	Visits 3-10 (Treatment)	
		8.1.8	Visits 11-12 (End-of-treatment and Follow-up)	
		8.1.9	Visit 11X (End-of-Trial – premature discontinuation)	
		8.1.10	Withdrawals	40
		8.1.11	Investigator's assessment	40
	8.2	Subject	related information	41
		8.2.1	Concomitant illness and medical history	41
		8.2.2	Concomitant medication	
		8.2.3	Demography	
		8.2.4	Diagnosis of diabetes	
		8.2.5	Diabetes treatment history	
		8.2.6	History of gallbladder disease	
		8.2.7	History of cardiovascular disease	
		8.2.8	Renal impairment history	
		8.2.9	Post-dose fasting routines	43
	8.3	Assessm	nents for efficacy	43
		8.3.1	Blood samples	
		8.3.2	Body measurements	
		8.3.3	Patient reported outcomes	44
	8.4	Assessm	nents for safety	45
		8.4.1	Hypoglycaemic episodes	
		8.4.2	Blood samples	45
		8.4.3	Pregnancy test	46
		8.4.4	Urinalysis	47
		8.4.5	Antibodies	47
		8.4.6	Vital signs	47
		8.4.7	Electrocardiogram – 12-lead	
		8.4.8	Fundoscopy/fundus photography	
		8.4.9	Physical examination	
		8.4.10	Pharmacokinetics	49
		8.4.11	Calcitonin	
	8.5	Laborate	ory assessments	

Protocol	Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	Version:	3.0	
UTN: U1111-1136-4716	 Status:	Final	
EudraCT No.: 2012-004994-16	Page:	4 of 98	

	8.6	Other assessmen	ts	51
			ect diary	
		8.6.2 Addit	tional safety assessments	51
		8.6.2.	1 Thyroidectomy, tissue sample and genetic testing	51
			2 Assessments in case of suspicion of acute pancreatitis	
		8.6.2.	3 Assessments in case of suspicion of severe hypersensitivity	53
	8.7	Subject compliar	nce	53
9				
	9.1	1		
	9.2			
	9.3		· · · · · · · · · · · · · · · · · · ·	
	9.4		lity and destruction	
	9.5		es	
10	Intera	ctive voice/web re	esponse system	57
11	Rando	misation procedu	re and breaking of blinded codes	58
	11.1	Breaking of blind	ded codes	58
12	Adver	se events, technic:	al complaints and pregnancies	59
	12.1	Definitions		59
	12.2	Reporting of adv	verse events	62
	12.3		verse events	
	12.4		aints and technical complaint samples	
			rting of technical complaints	
			ction, storage and shipment of technical complaint samples	
	12.5	U		
	12.6		or overdose	
	12.7		ted to safety	
			Nordisk safety committee	
			t adjudication committee	
		12.7.3 Calcit	tonin monitoring committee	71
13		<b>.</b>		
	13.1		ase report forms	
	13.2	1	n flow	
	13.3	1 1	t forms	
14	Monit	oring procedures		74
15	Data n	nanagement		75
16	Comp	uterised systems .		76
17	Statist	ical consideration	18	77
	17.1		ulation	
	17.2	-	ılysis sets	
	17.3		t	
	17.4		ndary endpoints	
		17.4.1 Effica	acy endpoints	80
			y endpoints	
		17.4.3 Pharm	nacokinetics and/or pharmacodynamics modelling	83

Protocol	Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	Version:	3.0	
UTN: U1111-1136-4716	 Status:	Final	
EudraCT No.: 2012-004994-16	Page:	5 of 98	

<ul> <li>18 Ethics</li></ul>	
<ul> <li>18.3 Premature termination of the trial and/or trial site</li></ul>	
<ul> <li>19 Protocol compliance</li></ul>	
<ul> <li>20 Audits and inspections</li> <li>21 Critical documents</li> <li>22 Responsibilities</li> <li>23 Reports and publications</li> <li>23.1 Communication of results</li> <li>23.1.1 Authorship</li> <li>23.1.2 Site-specific publication(s) by investigator(s)</li> <li>23.2 Investigator access to data and review of results</li> <li>24 Retention of clinical trial documentation and human biospecimens</li> <li>24.1 Retention of clinical trial documentation</li> </ul>	
<ul> <li>21 Critical documents</li></ul>	
<ul> <li>22 Responsibilities</li></ul>	87
<ul> <li>23 Reports and publications</li></ul>	
<ul> <li>23.1 Communication of results</li></ul>	90
<ul> <li>23.1 Communication of results</li></ul>	92
<ul> <li>23.1.2 Site-specific publication(s) by investigator(s)</li> <li>23.2 Investigator access to data and review of results</li> <li>24 Retention of clinical trial documentation and human biospecimens</li></ul>	
<ul> <li>23.2 Investigator access to data and review of results</li></ul>	
<ul> <li>24 Retention of clinical trial documentation and human biospecimens</li></ul>	
24.1 Retention of clinical trial documentation	93
24.1 Retention of clinical trial documentation	94
24.2 Detention of home of his survey his survey	
24.2 Retention of human biospecimens	94
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities	95
26 Indemnity statement	96
27 References	97

Appendix A – Monitoring of calcitonin

**Appendix B – PRO questionnaire** 

Appendix C – Medical Events of Special Interests (MESI)

Attachment I – Global List of key staff and relevant departments Attachment II – Country List of key staff and relevant departments

Protocol	Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	Version:	3.0	
UTN: U1111-1136-4716	 Status:	Final	
EudraCT No.: 2012-004994-16	Page:	6 of 98	

## Table of figures

## Page

Figure 5–1	Trial design of NN9924-3790	28
Figure 5–2	Dosing and fasting conditions for oral treatment (arms 1-8)	30
Figure 12–1	Initial reporting of AEs	64
Figure 17–1	ADA classification of hypoglycaemia	82

## **Table of tables**

	I	Page
Table 9–1	Trial products (IMP)	54
Table 9–2	Storage conditions for trial products	55

		_	

Date: Version: Status: Page:

21 January 2014 3.0 Final 7 of 98

## List of abbreviations

ADA	American Diabetes Association
AE	adverse event
ANCOVA	analysis of covariance
AUC	area under the curve
BMI	body mass index
СМС	calcitonin monitoring committee
CRF	case report form
СТ	computerised axial tomography
CTR	clinical trial report
CVD	cardiovascular disease
DFU	directions for use
DPP-4	dipeptidyl peptidase-4
DUN	dispensing unit number
EAC	event adjudication committee
ECG	electrocardiogram
eCRF	electronic case report form
EDC	electronic data capture
EE	ethinylestradiol
EMA	European Medicines Agency
eSIF	electronic safety information form
FAS	full analysis set
FDA	Food and Drug Administration
FPG	fasting plasma glucose
FSFV	first subject first visit
GCP	Good Clinical Practice
GI	gastrointestinal
GLP-1	glucagon-like peptide-1
HbA <sub>1c</sub>	glycosylated haemoglobin

Date: Version: Status: Page:

21 January 2014 3.0 Final 8 of 98

hCG	human chorionic gonadotropin
HDL	high density lipoprotein
HOMA-B	homeostasis model assessment of beta-cell function
HOMA-IR	homeostasis model assessment of insulin resistance
IB	Investigator's Brochure
ICMJE	International Committee of Medical Journal Editors
IEC	independent ethics committee
IMP	investigational medicinal product
IRB	Institutional Review Board
IV/WRS	interactive voice/web response system
LDL	low density lipoprotein
LN	levonorgestrel
LOCF	last observation carried forward
LSFV	last subject first visit
MD	multiple dose
MedDRA	Medical Dictionary for Regulatory Activities
MEN2	multiple endocrine neoplasia type 2
MESI	medical event of special interest
MMRM	mixed model for repeated measurements
MRI	magnetic resonance imaging
NOAEL	no observed adverse effect level
NYHA	New York Heart Association
OAD	oral antidiabetic drug
OD	once-daily
OW	once-weekly
PD	pharmacodynamics
РК	pharmacokinetics
PRO	patient reported outcome
SAE	serious adverse event

ProtocolDate:21 January 2014Novo NordiskTrial ID: NN9924-3790Version:3.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:9 of 98

SAP	statistical analysis plan
S.C.	subcutaneous
SD	standard deviation
SF-36	medical outcomes study 36-item short-form health survey
SIF	safety information form
SNAC	sodium N-[8-(2-hydroxybenzoyl) amino] caprylate / salcaprozate sodium
SUSAR	suspected unexpected serious adverse reaction
T2D	type 2 diabetes
TEAE	treatment emergent adverse events
t <sub>max</sub>	time to maximal concentration
TMM	Trial Materials Manual
USP	United States Pharmacopeia
UTN	Universal Trial Number
VLDL	very low density lipoprotein

\_\_\_\_\_

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 10 of 98

## 1 Summary

## **Objectives and endpoints:**

#### **Primary objective**

• To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against placebo in subjects with T2D

## Key secondary objectives

- To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against s.c. semaglutide in subjects with T2D
- To compare the safety and tolerability of three dose escalation schemes using a single end dose level during 26 weeks administration of oral semaglutide and SNAC in a tablet formulation in subjects with T2D

## **Primary endpoint**

• Change in HbA<sub>1c</sub> from baseline to after 26 weeks of treatment

## Key secondary endpoints

- Subjects who, after 26 weeks of treatment, achieve (yes/no) HbA<sub>1c</sub> <7% (53 mmol/mol)
- Change in body weight from baseline to after 26 weeks of treatment
- Change in waist circumference from baseline to after 26 weeks of treatment
- Change in body mass index (BMI) from baseline to after 26 weeks of treatment
- Number of treatment emergent adverse events (TEAEs) recorded from baseline until week 31
- Number of confirmed hypoglycaemic episodes recorded from baseline until week 31

## Trial design:

This is a randomised, partially-blinded, multiple-dose, multicentre trial with a total of nine treatment arms; seven oral semaglutide treatment arms, an oral placebo arm and an s.c. semaglutide arm in a parallel design. The trial will include subjects with T2D who have failed on diet and exercise and/or metformin.

Subjects with T2D will be randomised in an equal manner with 67 subjects planned to be randomised per treatment arm. Treatment arms 1-8 will include once-daily dosing of a tablet and will be blinded. Treatment arm 9 features once-weekly s.c. injection. All arms include 26 weeks of treatment and a 5 week follow-up period.

The trial medication will be add-on to previous metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.

\_\_\_\_\_

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 11 of 98

## **Trial population:**

A total of 603 subjects with T2D will be randomised.

Key inclusion criteria:

- Male or female, age  $\geq$  18 years at the time of signing inform consent
- BMI  $\geq$ 25 and  $\leq$ 40 kg/m<sup>2</sup>
- Subjects diagnosed with T2D treated with diet and exercise and/or who have been on a stable dose of metformin for at least 30 days prior to screening
- HbA<sub>1c</sub> 7.0-9.5% (53-80 mmol/mol) (both inclusive)

Key exclusion criteria

- Subjects on selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants
- History of chronic pancreatitis or idiopathic acute pancreatitis
- Chronic malabsorption, regardless of aetiology
- History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
- Treatment with glucose lowering agent(s) other than metformin as stated in the inclusion criteria in a period of 90 days before the screening visit

#### Assessments:

#### Efficacy assessment

Measurements of laboratory parameters (HbA<sub>1c</sub>, glucose metabolism parameters and lipids), BMI and waist circumference. Patient reported outcomes will be based on the SF-36 questionnaire and assessed at baseline and end of treatment.

#### Safety assessment


Adverse events, laboratory safety variables (haematology, biochemistry, calcitonin and urinalysis), vital signs, electrocardiograms, physical examinations and hypoglycaemic episodes recorded from the first trial-related activity and until completion of the post treatment follow-up visit of the trial.

#### PK assessment

Trough and peak plasma concentrations of semaglutide will be assessed throughout the trial.

## Trial product(s):

The investigational medicinal products used in the trial will be for once-daily oral administration as tablets and once-weekly s.c. administration using a pen injector system. The investigational medicinal products are:



Date: Version: Status: Page:

21 January 2014 Novo Nordisk 3.0 Final 12 of 98

- Semaglutide 2.5 mg tablets •
- Semaglutide 5.0 mg tablets •
- Semaglutide 10 mg tablets •
- Semaglutide 20 mg tablets •
- Semaglutide 40 mg tablets •
- Placebo tablets •
- Semaglutide 1.34 mg/mL, solution for injection, 1.5 mL pre-filled PDS290 pen-injector •

Trial ID: NN9924-3790         EudraCT No.: 2012-004994-16         Version:         3.0         Page:         13 of 98		UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	Date: Version:	21 January 2014 3.0			Novo Nordisk
---	--	---	-------------------	------------------------	--	--	--------------

# 2 Flow chart

Trial Periods		Screening <sup>1</sup>	Randomisation				Treat	ment				End-of- treatment <sup>2</sup>	Follow- up <sup>2</sup>	End-of-trial – premature discontinuation <sup>3</sup>
Visit number		1	2	3	4	5	6	7	8	9	10	11	12	11X
Timing of visit	Weeks	-2	0	2	4	6	8	12	16	20	24	26	31	26
Visit window	Days			±3	±3	±3	±3	±5	±5	±5	±3	±3	+5	±3
SUBJECT RELATED INFO/ASSESSMENTS														
Informed consent		х												
In- and exclusion criteria		х	х											
Concomitant medication		х	х	х	х	х	х	х	х	х	х	х		х
Concomitant illness		х												
Demography		х												
Diagnosis of diabetes		x												
Diabetes treatment history		х												
Medical history		x												
Smoking habits		x												
History of gallbladder disease		x												
History of cardiovascular disease		x												
Renal impairment history		x												
Randomisation			х											
Withdrawal criteria			х	х	х	х	х	х	х	х	х	х		
Post-dose fasting routines												х		
EFFICACY														
Height		x												
Body weight		х	x	x	x	х	x	х	х	х	х	х		x
Waist circumference			x	x	x	x	x	x	х	x	х	х		х
HbA <sub>1c</sub>		х	x		x		x		х			x		х
Glucose metabolism			х		x		х		х			х		
Lipids			х						х			х		

		Date: Version:	21 January 2014 3.0	Status: Page:
--	--	-------------------	------------------------	------------------

Trial Periods		Screening <sup>1</sup>	Randomisation				Treat	ment				End-of- treatment <sup>2</sup>	Follow- up <sup>2</sup>	End-of-trial – premature discontinuation <sup>3</sup>
Visit number		1	2	3	4	5	6	7	8	9	10	11	12	11X
Timing of visit	Weeks	-2	0	2	4	6	8	12	16	20	24	26	31	26
Visit window	Days			±3	±3	±3	±3	±5	±5	±5	±3	±3	+5	±3
SUBJECT RELATED INFO/ASSESSMENTS														
PRO questionnaire			х									х		
SAFETY														
Adverse events			х	х	х	х	х	х	х	х	х	x	х	х
Hypoglycaemic episodes			х	х	х	х	х	х	х	х	х	x	х	х
ECG, overall interpretation <sup>4</sup>			x									x		
Fundoscopy/fundus photography			x											
Physical examination		x										x		
Vital signs		x	х	х	х	х	х	х	х	х	х	х		
Antibodies <sup>5</sup>			х						х			x	х	
Biochemistry			х						х			x		
Creatinine		х							х			x		
Calcitonin		х							х			x		
Haematology			х						х			х		
PK sampling				х	х	х	х	х	х	х	х	х		
PK sampling (trough + peak) <sup>6</sup>					x				x			x		
Blood pregnancy test <sup>7</sup>		x	х		х		х	х	х	х	х	x	х	х
Urinalysis			х						х			х		
TRIAL MATERIAL														
IV/IWRS call		х	х	х	х	х	х	х	х	х	х	х		
Dispensing visit			х	х	х	х	х	х	х	х	х			
Hand out directions for use of s.c. trial product			х	x	x	x	x	x	x	x	x			
Drug accountability				х	х	х	х	х	х	х	х	х		
REMINDERS														

Protocol	UTN: U1111-1136-4716	Date:	21 January 2014	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	3.0	Page:	15 of 98	

Trial Periods		Screening <sup>1</sup>	Randomisation				Treat	ment				End-of- treatment <sup>2</sup>	Follow- up <sup>2</sup>	End-of-trial – premature discontinuation <sup>3</sup>
Visit number		1	2	3	4	5	6	7	8	9	10	11	12	11X
Timing of visit	Weeks	-2	0	2	4	6	8	12	16	20	24	26	31	26
Visit window	Days			±3	±3	±3	±3	±5	±5	±5	±3	±3	+5	±3
SUBJECT RELATED INFO/ASSESSMENTS														
Dispense glucose meter		х												
Dispense subject identity card		x												
Dispense diary		х	х	х	х	х	х	х	х	х	х	x		
Collect and review diary			х	х	х	x	x	х	х	х	x	x	х	
Attend visit fasting <sup>8</sup>			х		х		х		x			x	x	
Affirmation statement or Case book signed <sup>9</sup>													x	x
End of trial <sup>9</sup>													х	x

Abbreviations in table: ECG = electrocardiogram,  $HbA_{1c} = glycosylated$  haemoglobin, IV/WRS = interactive voice/web response system, PK = pharmacokinetics, PRO = patient reported outcome

Protocol	UTN: U1111-1136-4716	Date:	21 January 2014	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	3.0	Page:	16 of 98	

#### 2.1 Flow chart foot notes

Footer	Description
x <sup>1</sup>	Subject can be randomised as soon as all inclusion and exclusion criteria are confirmed. The screening assessments must not exceed 2 weeks prior to randomisation (Visit 2).
x <sup>2</sup>	The End-of-treatment and Follow-up visits are applicable for all randomised subjects including subjects who have discontinued trial product prematurely.
x <sup>3</sup>	Subjects discontinuing trial product prematurely will be asked to attend the End-of-treatment (V11) as soon as possible after treatment discontinuation and the Follow-up – premature discontinuation (V12) five weeks later (+5 days visit window). Furthermore, they are asked to attend the End-of-trial – premature discontinuation visit (V11X) (see Section $\underline{8.1.9}$ ).
x <sup>4</sup>	An ECG performed for any reason unrelated to the trial within 30 days prior to the randomisation visit is acceptable as Visit 2 data, provided no clinical symptoms suggestive of cardiac disease has occurred in the meantime.
x	At the randomisation visit, the antibody assessment must be done pre-dose.
x <sup>6</sup>	Trough and peak PK sampling is only applicable for subjects in the oral treatment arms and replaces the regular PK sampling at visits 4, 8 and 11. Subjects must attend the visit without having taken the tablet on the same day (see Section <u>8.4.10</u> )
x'	For women of child bearing potential: Serum pregnancy tests must be performed.
x <sup>8</sup>	Fasting for lab sampling is defined as having consumed only water since midnight. For the Follow-up visit (V12) attending fasting is defined as having consumed only water for at least the preceding 2 hours. For the trough and peak PK sampling visits (V4, 8, 11) the fasting is outlined in section $5.3.1$
x <sup>9</sup>	Affirmation statement/case book signing and end of trial are at the Follow-up visit (V12). Only patients who have discontinued treatment prematurely are asked to attend the End-of-trial – premature discontinuation visit (V11X) which will then be end of trial.

Page:

Date:

Version:

Status:

21 January 2014 | Novo Nordisk 3.0 Final 17 of 98

#### 3 **Background information and rationale for the trial**

The trial will be conducted in compliance with this protocol, ICH  $GCP^{1}$  and applicable regulatory requirements, and in accordance with the Declaration of Helsinki<sup>2</sup>.

In this document, the term investigator refers to the individual responsible for the overall conduct of the clinical trial at a trial site.

#### 3.1 Type 2 diabetes mellitus and glucagon-like peptide-1

Type 2 diabetes (T2D) is a major global health problem. The disease aetiology is multi-factorial and includes genetic predisposition in combination with sedentary life style factors such as physical inactivity and obesity.

T2D is a multi-organ disease characterised by defective insulin sensitivity in liver and skeletal muscle and a relative impairment of insulin secretion capacity. Furthermore, a blunted secretion and/or action of incretin hormones (glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP)) from the gastrointestinal (GI) tract (L-cells) in response to meals are also characteristics of T2D. GLP-1 is an important post-prandial hormone secreted from the L-cells in the intestine with a stimulating effect on insulin secretion and an inhibitory role on glucagon secretion from the endocrine pancreas in a glucose-dependent manner. In addition, GLP-1 restores beta-cell sensitivity to glucose. Animal studies suggest that GLP-1 also increases beta-cell mass. Extra-pancreatic effects include delaying of gastric emptying and effects on insulin sensitivity, although the latter is less clear. Pharmacological levels of GLP-1 reduce food intake and induce weight loss. As the majority (>80%) of T2D patients are overweight, the weight reduction properties of GLP-1 analogues are perceived to be advantageous compared to many other therapies for T2D. Due to the beneficial effects of GLP-1 on both glycaemic and weight control, treatment of T2D patients with GLP-1 analogues is considered favourable.

#### 3.2 Semaglutide and SNAC

Semaglutide is a long-acting GLP-1 analogue that has achieved clinical proof of concept when administered subcutaneously (s.c.). Currently, semaglutide is in clinical development (NN9535) as a once-weekly s.c. injection for the treatment of T2D. The NN9535 project is in phase 3 development, encompassing six major safety and efficacy trials (see Section 3.2.3.2 for clinical data on s.c. semaglutide).

Oral administration inherently represents a different absorption route to reach systemic circulation compared to s.c. administration.

Native GLP-1 and GLP-1 analogues have in general very low oral bioavailability when administered in a formulation without absorption enhancement. Formulation with an absorption enhancing excipient is therefore needed to increase the oral bioavailability. However, exposure



Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 18 of 98

exhibits a substantially greater dose-to-dose variation following oral administration compared to s.c. administration. An oral drug product with this chemical structure and properties will, because of the compound's PK properties (i.e., very low clearance and long terminal half-life), and by using oncedaily administration, limit the variation in steady state plasma exposure. The initial side effects like nausea may therefore be low or absent following gradual dose escalation. Food interaction is expected to limit absorption, but a long-acting GLP-1 analogue product will allow dosing in the fasting state, without compromising the effective plasma profile. In addition, GLP-1 therapy generally does not induce hypoglycaemia on its own, which potentially could have been problematic given the large intra-patient plasma exposure variation.

Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate / salcaprozate sodium (SNAC) has been studied in combination with acyclovir, peptide tyrosine tyrosine (PYY), cromolyn, ibandronate and heparin. Impact on metformin when co-administering SNAC and metformin was investigated as part of another trial involving healthy volunteers. The trial did not show any increase in metformin exposure when adding SNAC<sup>3</sup>. When co-formulated with SNAC, exposure of ibandronate (a nitrogen-containing bisphosphonate), is increased by 11- and 17-fold (AUC and  $C_{max}$ , respectively). On the other hand, when co-administered with SNAC (in separate formulations) exposure was not affected compared to dosing ibandronate without SNAC, suggesting that the drug-drug interaction potential between SNAC and co-administered drugs with comparable physiochemical properties (compounds with permeability limited absorption) is low<sup>4</sup>.

The most extensive safety and PK data are available from the heparin formulated with SNAC programme including 32 phase 1 studies (daily SNAC doses ranged from 0.172 g - 10.5 g) of which three investigated SNAC alone. The studies covered formulation development, food effect, hepatic and renal impairment, age effect and drug-drug interactions. Three phase 2 and 3 studies have assessed effects of orally delivered heparin solution (>1.5 g SNAC three times daily). At present, no drugs containing SNAC have received regulatory approval.

## 3.2.1 Nonclinical data

The non-clinical programme for semaglutide was designed according to the International Conference on Harmonisation (ICH) M3 guideline to support the clinical development. The standard non-clinical data package required to support phase 3 clinical trials has been completed. In addition, 2-year carcinogenicity studies and a pre- and postnatal development toxicity study have been completed.

Semaglutide is generally well tolerated, with expected GLP-1 effects on food intake and body weight being the dose limiting effects, when dosed s.c. for up to two years in studies with rats and mice. No signs of overt toxicity, including safety concerns related to effects on the GI tract, were observed after oral administration of semaglutide for up to 26 weeks in rats and 17 weeks in cynomolgus monkeys. Two potential safety issues have been identified.



Date: Version: Status: Page: 21 January 2014 Novo Nordisk 3.0 Final 19 of 98

## 3.2.1.1 Thyroid C-cell tumours in rodents

Treatment-related non-genotoxic proliferative changes in the thyroid C-cells of mice and rats were observed in 2-year carcinogenicity studies with semaglutide. Early C-cell changes were also identified in repeated dose toxicity studies with semaglutide in mice. However this was not the case in other species including a 52-week repeat dose study in non-human primates at exposure levels up to 36-fold above the expected clinical exposure. The observed pattern of effects in mice and rats (thyroid C-cell proliferation preceded by increase in serum calcitonin) and lack of these effects in the non-human primate and in man suggest that the mechanism by which semaglutide acts on the thyroid C-cells in rodents is the same as has been demonstrated for other GLP-1 receptor agonists, including liraglutide. The relevance for human subjects is unknown.

## 3.2.1.2 Teratogenicity in rats

Semaglutide has been concluded teratogenic in rats, with exposure at no observable adverse effect level (NOAEL) below expected human exposure. This effect is regarded to be caused by impairment of nutrient supply to the embryo across the inverted yolk sac with placental function which is specific to rats. Non-human primates and humans do not depend on a volk sac with placental function to supply nutrients to the embryo early in pregnancy. The effect on rat embryofoetal development is therefore not likely to be relevant to humans. Preliminary and main embryofoetal development (EFD) and pre- and postnatal development (PPND) studies with doses corresponding to 7-fold expected clinical exposure in cynomolgus monkeys have been finalised. In the main EFD study sporadic abnormalities were reported across all dose groups and in the PPND study a dose dependent increase in early pregnancy losses were observed. The findings observed across the three studies in cynomolgus monkeys are not indicative of teratogenic potential of semaglutide in this species. The increase in early pregnancy losses is indicative of embryo-toxicity, which may be related to the maternal effect of semaglutide (marked body weight loss). A developmental toxicity NOAEL was determined at an exposure 0.8-fold the expected clinical exposure (1 mg/week). A risk for the developing human embryo or foetus cannot be definitely ruled out, but the absence of findings indicative of teratogenicity in the EFD and PPND studies in cynomolgus monkey decrease the level of concern.

A comprehensive review of results from the non-clinical studies can be found in the IB for Semaglutide (subcutaneous administration), Edition  $8^{\frac{5}{2}}$  and the IB for Oral administration of semaglutide (NN9924), Edition  $5^{\frac{6}{2}}$ , or any updates of these documents

## 3.2.1.3 SNAC toxicology

The nonclinical safety programme for SNAC includes safety pharmacology, metabolism and PK and toxicology and is in line with the ICH M3 guideline<sup>2</sup>. SNAC was developed as an absorption enhancing excipient for the oral route of administration.

		_	

Date: Version: Status: Page: 21 January 2014 | Novo Nordisk 3.0 Final 20 of 98

SNAC is rapidly absorbed (time to maximal concentration  $(t_{max})$  within 1 hour) and eliminated  $(t_{\frac{1}{2}} = 1 \text{ and } 3 \text{ hours across species})$ . SNAC is metabolised mainly via stepwise beta-oxidation and deacetylation of the side chain and the parent compound and its metabolites also undergo conjugation with glucuronic acid. The main elimination route for SNAC metabolites is via urinary excretion.

SNAC was generally well tolerated in animals at and below oral doses of 500 mg/kg/day (NOAEL) for up to nine (Rhesus monkey) and twelve (rat) months. Although no overt specific organ toxicity has been observed, SNAC was associated with treatment-related and unexplained mortality at dose levels only 1.5- to 3-fold above NOAEL in rat studies. A series of nonclinical studies to explore possible cause of death have been initiated. These studies include investigations to expand the standard package of nonclinical studies on CV and respiratory function, and systematic investigations of histological changes in the GI tract and liver after dosing of high concentration/high volumes of SNAC. To support the assessment of exposure margins between rats and humans, extensive PK and metabolism studies in rats are carried out. The quantification of SNAC metabolites will also be assessed in the on-going multiple dose (MD) clinical trial (NN9924-3991).

In an on-going two-year carcinogenicity study with rats, one unexplained death occurred at a dose of 200 mg/kg/day. Several cases of unexplained death were observed at 900 mg/kg/day in repeat dose toxicity studies of 26 weeks and 52-weeks duration. A NOAEL for SNAC has been determined to be 90 mg/kg/day (corresponding to ~4 to 6 times a human dose of 300 mg based on exposure (area under curve)). Histological changes (perivascular lymphoid aggregates) have been observed in the lungs at all SNAC dose levels in the 6-month rat study. SNAC appeared to exacerbate these lesions which may be indicative of an immunosuppressant effect.

## 3.2.2 Nonclinical pharmacology and pharmacokinetics

The focus of the studies done in relation to oral administration of semaglutide in combination with SNAC has been on the following issues:

## Mechanism in vitro

SNAC increases absorption of drug compounds through the GI epithelium, which has been shown in humans (e.g., for endogenous GLP-1). *In vitro* studies have indicated that transport of compounds occurs mainly via the trans-cellular route and the effect is dependent on both the concentration of SNAC and the duration of incubation.

## Enhancement of absorption in vivo

SNAC enhances absorption of semaglutide from the stomach and small intestine in rats. There is considerable variability (coefficient of variation around 100%) with some animals showing no absorption. In the dog, there is higher bioavailability after oral dosing of tablets (1-2.5%) than after capsules (0.7%) or solution (0.07%). Semaglutide and SNAC have to be formulated in the same

Date: Version: Status: Page: 21 January 2014 Novo Nordisk 3.0 Final 21 of 98

tablet to get increased oral bioavailability of semaglutide, indicating that close interaction between the two molecules is necessary for enhancing the absorption. There is a strong reduction of bioavailability to practically zero when given concomitantly with food in dogs, and also an increasing amount of water dosed with the tablet seems to reduce oral bioavailability of semaglutide in this model, mimicking recent results in a human trial. Doses of SNAC of 150, 300 and 600 mg have been tested in dogs, and there was a tendency towards an optimum at 300 mg in terms of bioavailability. Furthermore, there is a tendency for non-linearity in bioavailability when increasing the amount of both SNAC and semaglutide in combination or semaglutide alone with constant SNAC content, whereas increasing amounts of SNAC alone (300 (one tablet) to 900 mg (three tablets)) with constant amount of semaglutide do not seem to significantly increase bioavailability.

## Pharmacodynamics after oral administration

Semaglutide dosed in combination with SNAC is able to induce the same type of PD effects on blood glucose, food intake and body weight as seen after s.c. administration of semaglutide and other marketed GLP-1 analogues. Thus, semaglutide in combination with SNAC lowered blood glucose and body weight in diabetic db/db mice, and reduced food intake and body weight in normal rats.

## 3.2.3 Clinical data

## **3.2.3.1** Data from literature

Currently, no orally administered GLP-1 receptor agonist is available for the treatment of T2D.

There are, however, s.c. administered GLP-1 receptor agonists on the market and experience from their development has identified some potential safety issues for this class of compounds. Nonclinical thyroid C-cell tumours have been observed in rodents. Acute pancreatitis has been associated with chronic administration of GLP-1 receptor agonists in man. Elevated lipase has been observed in clinical studies but dose-response relationship and overall clinical significance is unclear. Hypoglycaemia, GI adverse events (i.e., nausea and vomiting), increased heart rate and renal dysfunction due to volume depletion following GI effects have also been observed.

## 3.2.3.2 Clinical data of s.c. semaglutide

As of 1 February 2013, 5 clinical pharmacology trials (NN9535-1820, -3679, -3633, -3616 and - 3819) and 1 phase 2 trial (NN9535-1821) have been completed using s.c. semaglutide. A total of 519 subjects have been exposed to s.c. semaglutide: 164 healthy subjects (both single and multiple dosing), 313 patients with T2D (up to 12 weeks of treatment) and 42 patients (4 subjects had T2D) with varying degrees of renal impairment (single dosing).



Date: Version: Status: Page: 21 January 2014 Novo Nordisk 3.0 Final 22 of 98

## **Pharmacokinetics**

Results from 2 phase 1 trials (NN9535-3616 and 3819) show that s.c. semaglutide has pharmacokinetics (PK) properties compatible with once-weekly administration, with a median time to maximum concentration (tmax) of 36 hours post dosing and an elimination half-life ( $t^{1/2}$ ) in the range of 165-184 hours (~7 days, harmonic mean). Overall, the PK properties of s.c. semaglutide appear similar in Caucasian and Japanese subjects, and also in healthy subjects and subjects with T2D. In a trial with subjects with different degrees of renal impairment (NN9535-3616), data suggested that severe renal impairment result in a slightly higher exposure compared to subjects with normal renal function (AUC0-  $\infty$  increased by approximately 22%), whereas subjects with mild or moderate renal impairment and subjects on haemodialysis had exposure similar to subjects with normal renal function. No safety signals were identified in either of the renal groups, and tolerability profiles appeared similar across renal groups; thus, a dose-reduction in subjects with severe renal impairment does not appear to be warranted.

Interaction with oral contraceptives was assessed at semaglutide 1.0 mg steady-state exposures in postmenopausal women with T2D (NN9535-3819). Steady-state exposures (AUC0-24h) of ethinylestradiol (EE) and levonorgestrel (LN) were slightly increased (by 10% and 21%, respectively), with bioequivalence established for EE but not for LN; the increase was seen when oral contraceptives were co-administered with semaglutide compared to oral contraceptives alone.

Bioequivalence was demonstrated for  $C_{max}$  of both EE and LN. These data indicate that semaglutide does not decrease the exposure of oral contraceptives, and suggest that no adjustments of oral contraceptive dose are warranted for women of childbearing potential using a low-dose oral contraceptive.

## Efficacy

As of 1 February 2013, efficacy of s.c. semaglutide in the target population – subjects with T2D – has been investigated in one phase 2 dose range finding trial (NN9535-1821). The trial was a 12-week, randomised, double-blind, placebo- and active-controlled trial in which 411 adults with T2D received once-weekly s.c. injection of 1 of 5 semaglutide dose levels (0.1-1.6 mg) once-daily, open-label liraglutide (1.2 mg or 1.8 mg) or once-weekly placebo. 12 weeks of treatment, equivalent to 5-7 weeks in steady state on maintenance dose, provided statistically significant and clinically relevant improvement in glycaemic control for dose levels of 0.2 mg and above. Changes in HbA<sub>1c</sub> from baseline was up to -1.19 % (placebo adjusted estimated treatment difference). Dose-dependent improvements in fasting plasma glucose (FPG) and postprandial plasma glucose were also observed. The improvement in glycaemic control was accompanied by weight loss for semaglutide doses of 0.8 mg and above (placebo adjusted estimated treatment difference up to -3.64 kg).

## Safety

From the clinical trials conducted so far the following safety observations have been made.

		_	

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 23 of 98

Consistent with findings with other GLP-1 receptor agonists, common adverse events (AEs) included nausea and vomiting; most of them were mild to moderate in intensity. Hypoglycaemia has occurred in subjects receiving semaglutide and these events have mainly been minor.

An increase in heart rate has been observed in subjects exposed to semaglutide in line with the increase seen with other GLP-1 analogous. The implications of this increase are unknown.

As is the case with all protein-based pharmaceuticals, subjects treated with s.c. semaglutide may develop immunogenic and allergic reactions. Few allergic reactions have been reported in connection with semaglutide. These have mainly been mild and transient. However, more generalised reactions may occur.

Injection site reactions have been infrequently reported. These have mainly been mild and transient in nature.

Please see appropriate  $IB^{5}$  for further details.

## 3.2.3.3 Clinical data of oral GLP-1

Clinical trials with increasing doses of oral semaglutide up to two tablets with 10 mg semaglutide and 300 mg SNAC have shown this to be safe and well tolerated. The oral semaglutide had acceptable bioavailability and a PK profile of two tablets with 10 mg semaglutide was similar to 0.5 mg s.c. semaglutide. Variability of the day-to-day PK profile was 3-4 times higher than compared to 0.5 mg s.c. once-weekly semaglutide but acceptable for further development.

The oral bioavailability of human GLP-1 has been demonstrated to increase several fold when formulated with SNAC with a  $t_{max}$  of approximately 15-30 min. In addition, even in healthy subjects a glucose-dependent insulinotropic action of GLP-1 upon oral delivery was shown.

Five phase 1 trials with oral semaglutide and SNAC have been completed:

- Single dose trial (NN9924-3691)
- Multiple dose trial 1 (NN9924-3692)
- Dosing condition trial (NN9924-3794)
- Pharmaco-scintigraphy trial (NN9924-3957)
- Multiple dose trial 2 (NN9924-3991)

For details on the individual trials, please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

## 3.2.3.4 Clinical data of SNAC

The largest safety data set exists from the programme of orally administrated SNAC and heparin (all sponsored by Emisphere): 29 phase 1 trials (doses up to 10.5 g of SNAC), one phase 2 trial

Version:

Date:

Status:

Page:

(doses 1.5 g and 2.25 g of SNAC three times daily for 5 days) and two phase 3 trials (doses: 1.5 and 2.25 g of SNAC three times daily for 30 days) have been reported.

Oral SNAC exposure has most extensively been investigated in the phase 3 trial, named ERP-12. The objective of the trial was to investigate prevention of venous thrombotic complications following total hip replacement. Enrolled subjects were randomised in three treatments arms:

- Low dose SNAC (1.5 g) and heparin (60,000 USP units) thrice-daily for 30 days
- High dose SNAC (2.25 g) and heparin (90,000 USP units) thrice-daily for 30 days
- Enoxaparin sodium 30 mg s.c. twice-daily for 10 days

Total daily dose of oral SNAC was 4.5 g (low dose), 6.75 g (high dose) or 0 g (heparin s.c.). A total of 2,264 patients were enrolled with approximately 750 in each group.

The most frequently reported AEs were GI disorders with a dose relationship of SNAC and heparin, which also reflected the most common AEs reported for discontinuation. The SAEs were evenly distributed between the groups for all system organ classes other than GI disorders. Likewise, all deaths were evenly distributed between the groups and their nature and diversity did not indicate any causal relationship to trial drug. No other clinical significant safety issue was identified in the trial<sup>8</sup>

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

#### 3.3 **Risks and benefits of the trial**

There are s.c. administered GLP-1 receptor agonists on the market and experience from their development as well as experience from the s.c. semaglutide development programme have identified some potential safety issues for this class of compounds: 1) risk of teratogenicity, 2) risk of thyroid C-cell tumours, 3) risk associated to high doses of SNAC, 4) risk of carcinogenicity of SNAC, 5) risk of pancreatitis, 6) risk of antibody formation, 7) risk of allergic reactions, 8) risk of heart rate increase, 9) risk of severe risk of hypoglycaemia and 10) risk of altered renal function.

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

In this trial, most subjects will receive a treatment anticipated to be more efficacious than the treatment they receive at the time of randomisation into the trial. It is expected that subjects will benefit from the trial treatment with respect to optimised glycaemic control, a reduced risk of longterm diabetic complications and a potential weight loss. The subjects in this trial will receive trial drug and auxiliary free of charge. Furthermore it is expected that all subjects participating in the trial will benefit from participation through close contact with the study site and close follow-up of

\_\_\_\_\_

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 25 of 98

their T2D. Such careful medical examination will most likely result in an intensified management of their diabetes.

It is concluded that the potential benefits from participating in the trial outweigh the potential risks. The safety profile of semaglutide generated from the clinical and nonclinical development programme has not revealed any safety issues that would prohibit administration of once-daily doses of 2.5 to 40 mg semaglutide with 300 mg SNAC or once-weekly doses of 1.0 mg semaglutide in accordance with the planned clinical trial. The risk to the subjects in this trial is low and acceptable in view of the benefits an oral GLP-1 analogue would provide to subjects with T2D.

## **3.4** Rationale for the trial

The trial will compare efficacy of oral semaglutide formulated with a fixed dose of 300 mg SNAC. To facilitate the generation of clinical data in subjects with T2D, the NN9924-3790 trial has been designed to investigate a dose range expected to cover relevant therapeutic levels, including systemic exposure equivalent to 0.5 and 1.0 mg of once-weekly s.c. semaglutide. Additional dose levels are examined to elucidate a wider dose-response spectrum below and above the expected therapeutic range. In addition, the trial will explore the safety and tolerability of three different dose escalation approaches (i.e., slow, standard and fast). Finally, the trial will compare parameters of efficacy, safety and tolerability and population PK after 26 weeks of treatment between the treatment arms.

Data from the NN9924-3790 trial combined with the results of other trials investigating semaglutide will support the decision to continue into phase 3 development.

\_\_\_\_\_

Date:

Version:

Status:

Page:

21 January 2014 **Novo Nordisk** 3.0 Final 26 of 98

# 4 **Objective(s) and endpoint(s)**

The objectives of the trial, addressed after 26 weeks of treatment, are as follows:

## 4.1 **Objectives**

## 4.1.1 Primary objective

• To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against placebo in subjects with T2D

## 4.1.2 Secondary objectives

- To compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against s.c. semaglutide in subjects with T2D
- To compare the safety and tolerability of three dose escalation schemes using a single end dose level during 26 weeks administration of oral semaglutide and SNAC in a tablet formulation in subjects with T2D
- To compare parameters of efficacy, safety and tolerability, and population PK as reflected by endpoints below after 26 weeks of treatment

## 4.2 Endpoints

## 4.2.1 Primary endpoint

• Change in HbA<sub>1c</sub> from baseline to after 26 weeks of treatment

## 4.2.2 Supportive secondary endpoints

## Supportive secondary efficacy endpoints

- Subjects who, after 26 weeks of treatment, achieve (yes/no) HbA<sub>1c</sub> <7% (53 mmol/mol)\*
- Change in fasting plasma glucose (FPG), C-peptide, fasting insulin and glucagon from baseline to after 26 weeks of treatment
- Change in insulin resistance (homeostatic model assessment index of insulin resistance (HOMA-IR)) and beta-cell function (homeostatic model assessment index of beta-cell function (HOMA-B)) from baseline to after 26 weeks of treatment
- Change in fasting lipid profile (total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), very low density lipoprotein (VLDL), triglycerides and free fatty acids) from baseline to after 26 weeks of treatment
- Change from baseline to week 26 in the patient reported outcome Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) (generic questionnaire)
- Change in body weight from baseline to after 26 weeks of treatment\*
- Change in waist circumference from baseline to after 26 weeks of treatment\*

Protocol
Trial ID: NN9924-3790
UTN: U1111-1136-4716
EudraCT No.: 2012-004994-16

	_	

Date:

Version:

Status:

Page:

• Change in body mass index (BMI) from baseline to after 26 weeks of treatment\*

## Supportive secondary safety endpoints

- Number of treatment emergent adverse events (TEAEs) recorded from baseline until week 31\*
- Number of confirmed hypoglycaemic episodes recorded from baseline until week 31\*
- Change in vital signs (pulse, systolic- and diastolic blood pressure) from baseline to after 26 weeks of treatment
- Change in electrocardiogram (ECG) from baseline to after 26 weeks of treatment
- Change in physical examination from baseline to after 26 weeks of treatment
- Change in laboratory safety variables (haematology, biochemistry, hormone and urinalysis) from baseline to after 26 weeks of treatment
- Occurrence of antibodies against semaglutide during 26 weeks of treatment (positive/negative):
  - Anti-semaglutide antibodies
  - Anti-semaglutide antibodies with *in vitro* neutralising effect
  - Anti-semaglutide antibodies cross reacting with endogenous GLP-1
  - Cross reacting antibodies with in vitro neutralising effect to endogenous GLP-1
  - Antibody level during 26 weeks of treatment

## Supportive secondary pharmacokinetic endpoint

- Semaglutide concentrations to be evaluated in a population PK analysis
- \* Key supportive secondary endpoint prospectively selected for posting on <u>clinicaltrials.gov</u>

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No : 2012 004094 16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 28 of 98	Novo Nordisk
EudraCT No.: 2012-004994-16	l	Page:	28 of 98	

## 5 Trial design

## 5.1 Type of trial

This is a randomised, partially-blinded, dose range, dose escalation, multicentre trial including nine treatment arms in total; seven oral semaglutide treatment arms, an oral placebo arm and an s.c. semaglutide arm with a parallel design (see Figure 5–1). All treatment arms include subjects with T2D who have failed on diet and exercise and/or metformin. The placebo tablets do not contain SNAC.

	Week		) 2 4	6	81	2 1	6 2	0 24	4 26	31
	Oral OD	1	2.5 mg			:	:			Follow-up
range	Oral OD	2	2.5 mg	5.0 mg						Follow-up
e ra	Oral OD	3	5.0 mg	10 mg					ļ	Follow-up
Dose	Oral OD	4	5.0 mg	10 mg	20 mg				Ì	Follow-up
	Oral OD	5	5.0 mg	10 mg	20 mg	40 mg			ļ	Follow-up
- no	Oral OD	6	5.0 mg		10 mg		20 mg		40 I	Follow-up
Esca- lation	Oral OD	7	5.0 10	20 40 1	ng					Follow-up
Compa- rators	Oral OD	8	Placebo			1				Follow-up
Com	s.c. OW	9	0.25 mg	0.50 mg	1.0 mg	s.c. sema	glutide, o	pen-label		Follow-up
	OD: once-daily, OW:	once-w	eekly		1	1	1			1

Figure 5–1 Trial design of NN9924-3790

Subjects with T2D will be randomised in an equal manner with 67 subjects planned to be randomised per treatment arm. Treatment arms 1-8 will include once-daily dosing of a tablet and will be blinded. Treatment arm 9 features open-label once-weekly s.c. injection. All arms include 26 weeks of treatment and a 5 week follow-up period. Oral dosing will be performed following specified fasting conditions (see Figure 5–2).

The nine treatment arms will include:

- 1. Semaglutide tablets once-daily: 2.5 mg for 26 weeks
- 2. Semaglutide tablets once-daily: 2.5 mg for 4 weeks, then 5.0 mg for 22 weeks
- 3. Semaglutide tablets once-daily: 5.0 mg for 4 weeks, then 10 mg for 22 weeks
- 4. Semaglutide tablets once-daily: 5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks

Protocol		Date:	21 January 2014 Novo N	lordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CUNFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	29 of 98	

- 5. Semaglutide tablets once-daily: 5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks
- 6. Semaglutide tablets once-daily: 5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks
- 7. Semaglutide tablets once-daily: 5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks
- 8. Placebo tablets once-daily for 26 weeks
- 9. Semaglutide injections once-weekly: 0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks

For all groups the trial medication will be add-on to previous metformin therapy or as monotherapy in the case where the subject with T2D is treated with diet and exercise alone. At randomisation, subjects will be stratified according to one stratification value with two strata: Treatment with metformin at screening (yes/no).

## 5.2 Rationale for trial design

Parallel treatment groups and a randomised partially-blinded, controlled design have been chosen in accordance with the trial objectives. To avoid bias in the assessment of the different doses of oral semaglutide, the eight oral treatment arms are double-blind. The doses are escalated in standard four week intervals to limit gastrointestinal AEs. Escalation intervals of two weeks and eight weeks are also being explored to investigate effect on onset of action and overall AEs.

The use of s.c. semaglutide as active comparator was chosen to confirm that oral semaglutide in at least one of the selected doses reach the same levels of systemic exposure as for s.c. semaglutide. The active comparator is open-label to limit unnecessary injections (e.g., by use of double-dummy) as the objectives of the trial are to investigate the effects of the oral formulation.

## 5.3 Treatment of subjects

The subjects will attend a screening visit to determine their eligibility. If found eligible, the subjects will return for the first treatment visit where they will be randomised and receive treatment. The total duration of the trial will be 31 weeks for all subjects from randomisation to last visit. The highest dose for any trial subject will be 40 mg oral semaglutide once-daily or 1.0 mg s.c. semaglutide once-weekly.

Metformin is considered background medication (non-investigational medicinal product) and will not be provided by Novo Nordisk. Metformin should be used at the discretion of the investigator. Treatment with metformin extended/slow release formulations is allowed.

For the safety of the subjects, medications with a narrow therapeutic window may not be used in the trial (see the exclusion criteria, Section 6.3).


Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CUNFIDENHAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	30 of 98	

Subjects will follow a fixed dose escalation regimen, which they have been randomised to, following the scheme in Figure 5-1.

#### 5.3.1 Dose levels and escalation regimen for oral dosing

Subjects on the oral dosing (treatment arms 1-8) must administer the dose following specific rules:

- Fasting for at least six hours (e.g., in the morning following an overnight fast) before tablet ingestion
- Water and oral concomitant medication is allowed two hours prior to dosing
- Intake of maximum 120 mL of water is allowed when swallowing the tablet
- Subjects are required to abstain from food and fluid intake for at least 30 minutes after ingestion of oral semaglutide or placebo
- Oral concomitant medication can be taken two hours post-dosing. If taken with food, concomitant medication can be administered 30 minutes after ingestion of the semaglutide or placebo tablet



See illustration of oral dosing and fasting rules in Figure 5–2.

Figure 5–2 Dosing and fasting conditions for oral treatment (arms 1-8)

#### 5.3.2 Dose levels and escalation regimen for s.c. dosing

Subjects randomised to the s.c. treatment arm will follow a fixed dose escalation for semaglutide. The maintenance dose of 1.0 mg will be reached after four doses (four weeks) of 0.25 mg, followed by four doses (four weeks) of 0.50 mg. The maintenance dose of 1.0 mg, once attained, may not be decreased for the duration of the study. Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections should be administered on the same day of the week during the trial.

Trial ID: NN9924-3790 UTN: U1111-1136-4716CONFIDENTIALVersion: Status:	ary 2014 3.0 Final 31 of 98	Novo Nordisk
--	--------------------------------------	--------------

### 5.4 Treatment after end of trial

The trial products will not be available to subjects after the end of trial.

When discontinuing trial products the subject should be switched to a suitable marketed product at the discretion of the investigator.

#### 5.5 Rationale for treatment

The oral route of semaglutide administration investigated has been chosen to increase convenience and initiate earlier use of GLP-1 treatment of T2D patients, thus offering true GLP-1 benefits in a tablet format. The dose range of the oral treatment (2.5 mg, 5 mg, 10 mg, 20 mg and 40 mg) has been chosen based on phase 1 data and modelling derived from phase 1 trials with the aim to cover the same exposure as observed with s.c. semaglutide. The standard escalation scheme (i.e., dose escalation every four weeks to desired dose) has been chosen based on phase 1 data. The slow and fast dose escalation arms will investigate if AEs decrease or increase, respectively, compared to the standard dose escalation. The 26-week treatment period will provide additional data on safety and tolerability, investigate the variability at steady state exposure, test for efficacy and suggest which doses and escalation scheme to continue into pivotal development.

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924)) Edition  $5^{6}$  and any updates hereof.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No : 2012-004994-16	CONFIDENTIAL
EudraC1 No.: 2012-004994-16	

Date: Version: Status: Page:

# 6 Trial population

### 6.1 Number of subjects

Number of subjects planned to be screened:	1,005
Number of subjects planned to be randomised:	603
Number of subjects expected to complete the trial:	482

## 6.2 Inclusion criteria

For an eligible subject, all inclusion criteria must be answered "yes".

- 1. Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
- 2. Male or female, age  $\geq$  18 years at the time of signing inform consent
- 3. BMI  $\geq$ 25 and  $\leq$ 40 kg/m<sup>2</sup>
- 4. Subjects diagnosed with T2D treated with diet and exercise and/or who have been on a stable dose of metformin for at least 30 days prior to screening
- 5. HbA<sub>1c</sub> 7.0-9.5% (53-80 mmol/mol) (both inclusive)

## 6.3 Exclusion criteria

For an eligible subject, all exclusion criteria must be answered "no".

- 1. Known or suspected hypersensitivity to trial product(s) or related products
- 2. Previous participation in this trial. Participation is defined as informed consent
- 3. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) for the duration of the trial and for three months following last dose

<u>Germany</u>: Adequate contraceptive measures are implants, injectable, combined oral contraceptives, hormonal intrauterine device, sexual abstinence or vasectomised partner. <u>Sweden</u>: Oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable, or implanted hormonal contraceptives, intrauterine device, intrauterine system (for example, progestin-releasing coil), vasectomized male (with appropriate postvasectomy documentation of the absence of sperm in the ejaculate).

<u>United Kingdom</u>: Established use of oral, injected or implanted hormonal methods of contraception, intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilisation or true abstinence when in line with the preferred and usual lifestyle of the subject.

- 4. Participation in another clinical trial within 30 days before the screening visit
- 5. Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety, compliance with the protocol and/or ability to complete the study

Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	33 of 98	

- 6. Subjects on selected oral medication with a narrow therapeutic window, such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline, theophylline and anticonvulsants
- 7. History of chronic pancreatitis or idiopathic acute pancreatitis
- 8. Screening calcitonin value  $\geq$  50 ng/L
- 9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
- 10. Chronic malabsorption, regardless of aetiology
- 11. History of Crohn's disease, ulcerative colitis, or other inflammatory bowel disease
- 12. Previous gastrointestinal surgery such as invasive and corrective procedures involving the oesophagus, stomach, duodenum, gallbladder, pancreas or intestinal resections. Exempt are subjects that underwent uncomplicated surgical and diagnostic procedures such as appendectomy, hernia surgery, polypectomy, biopsies, as wells as colonic- and gastric endoscopy
- 13. Surgery scheduled for the trial duration period (excluding minor surgical procedures performed in local anaesthesia, according to the opinion of the investigator)
- 14. Treatment with glucose lowering agent(s) other than metformin as stated in the inclusion criteria in a period of 90 days before the screening visit
- 15. Mental inability, unwillingness or language barrier precluding adequate understanding of or compliance with study procedures
- 16. Impaired renal function defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m<sup>2</sup> per Modification of Diet in Renal Disease (MDRD) formula
- 17. Heart failure, New York Heart Association (NYHA) class IV
- 18. Within the past 6 months before the screening visit, any of the following: Episode of unstable angina, acute coronary event, cerebral stroke/transient ischemic attack or other significant cardiovascular event as judged by the investigator
- 19. Uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥100 mmHg)
- 20. Known proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator
- 21. Diagnosis of malignant neoplasm in the previous five years from the screening visit (except basal cell skin cancer or squamous cell skin cancer)

## 6.4 Rescue criteria

If any of the FPG values exceed the limits outlined below and no intercurrent cause of the hyperglycaemia can be identified the subject should be offered treatment intensification (rescue medication):

- 15.0 mmol/L (270 mg/dL) from randomisation to end of Week 5
- 13.3 mmol/L (240 mg/dL) from Week 6 to end of Week 11
- 11.1 mmol/L (200 mg/dL) from Week 12 to end of trial

ProtocolDate:21 January 2014Novo NordaTrial ID: NN9924-3790CONFIDENTIALVersion:3.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:34 of 98	ID: NN9924-3790 : U1111-1136-4716	CONFIDENTIAL Vo	Version: 3.0 tatus: Final	Novo Nordisk
--	--------------------------------------	-----------------	------------------------------	--------------

A confirmatory FPG should be obtained by central laboratory if related to a scheduled visit or by local laboratory if not related to scheduled visits. If the confirmatory FPG exceeds the values described above the subject should be offered treatment intensification (rescue medication) at the discretion of the investigator and in accordance with ADA/European Association for the Study of Diabetes<sup>9</sup> (preferably excluding GLP-receptor agonists, DPP-4 inhibitors and amylin analogues). Rescue medication (intensification of existing background medication and/or initiation of new medication) and any changes to this should be captured on the concomitant medication form in the eCRF. Rescue medication should be prescribed as add-on to randomised treatment and subjects should continue to follow the protocol-specified visit schedule.

### 6.5 Withdrawal criteria and discontinuation of trial product

### 6.5.1 Withdrawal from trial

The subject may withdraw at will at any time. The subject may be withdrawn from the trial at the discretion of the investigator due to a safety concern. Please see Section 8.1.10 for procedure to be performed in case of subject withdrawal.

A subject must be withdrawn from the trial if the following applies:

- 1. Included in the trial in violation of the inclusion and/or exclusion criteria
- 2. Pregnancy
- 3. Intention of becoming pregnant

Subjects should stay in the trial irrespective of lack of adherence to randomised treatment, lack of adherence to visit schedule, missing assessments, trial product discontinuation due to AE (see Section 6.5.2), unwillingness to cope with injection regimen, development of co-morbidities or clinical outcomes, hence this should <u>not</u> be considered as a valid reason for withdrawal from the trial.

Subjects considering withdrawing from the trial should be encouraged to have the procedures performed according to the End-of-treatment visit and the Follow-up visit, please see Section 8.1.8.

Subjects who are withdrawn will not be replaced.

#### 6.5.2 Discontinuation of trial product

The trial treatment must be discontinued if the subject meets one of the following criteria:

- 1. The investigator suspects acute pancreatitis. All drugs suspected to relate to this condition should be discontinued until confirmatory tests have been conducted and appropriate treatment should be initiated. Subjects who are diagnosed with acute pancreatitis must be discontinued from trial treatment. Diagnosis is based on at least 2 of the following 3 criteria:
  - a. characteristic abdominal pain

Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	35 of 98	

- b. amylase and/or lipase > 3x upper normal range, or
- c. characteristic findings on ultrasound / computerised axial tomography (CT) / magnetic resonance imaging (MRI)
- 2. Calcitonin level  $\geq$ 50 ng/L. The subject should be referred to a specialist in thyroid disease. All drugs suspected to relate to this condition should be discontinued
- 3. Other safety concerns as evaluated by the investigator

A treatment discontinuation session must be performed in the interactive voice/web response system (IV/WRS). The primary reason for discontinuation of the IMP must be specified in the electronic case report form (eCRF).

Subjects discontinuing the IMP should be called in for the End-of-treatment visit as soon as possible after discontinuation of the IMP and for the Follow-up visit five weeks later. Furthermore, the subjects should attend the End-of-trial – premature discontinuation visit (see Section 8.1.9).

If the IMP is discontinued, the subject can be prescribed alternative therapy at the investigator's discretion.

### 6.6 Rationale for trial population

This trial will include adult subjects with T2D and insufficient glycaemic control following treatment with diet/exercise or metformin. The T2D subjects will have an HbA<sub>1c</sub> of 7.0-9.5% and a BMI of 25-40 kg/m<sup>2</sup>. The trial will be carried out in Europe, North America and single countries in Africa, Asia and the Middle East as the first global, multicentre trial and will include both genders. This population is expected to mimic the target population in both a future phase 3 programme and once marketed.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 36 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

# 7 Milestones

Planned duration of recruitment period (i.e., first subject first visit (FSFV) on 2 Dec 2013 – last subject first visit on 21 Apr 2014): 20 weeks

End of trial is defined as last subject last visit: 8 Dec 2014

## Recruitment

The clinical sites participating in the trial will recruit subjects according to a recruitment plan.

The screening and randomisation rate will be followed closely via the interactive voice/web response system (IV/WRS) in order to estimate when to stop screening. All investigators will be notified immediately when the recruitment period ends, after which no further subjects may be screened and the IV/WRS will be closed for further screening. All subjects included in the screening period and eligible for randomisation will be randomised.

## **Trial registration**

Information of the trial will be disclosed at <u>clinicaltrials.gov</u> and <u>novonordisk-trials.com</u>. According to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure, it will also be disclosed according to other requirements such as those of the International Committee of Medical Journal Editors (ICMJE)<sup>10</sup>, the Food and Drug Administration Amendment Act (FDAAA)<sup>11</sup>, European Commission Regulation for EudraCT<sup>12</sup> and other relevant recommendations or regulations. If a subject requests to be included in the trial via the Novo Nordisk e-mail contact at these web sites, Novo Nordisk may disclose the investigator's contact details to the subject. As a result of increasing requirements for transparency, some countries require public disclosure of investigator names and their affiliations.

CONFIDENTIAL

Date: Version: Status: Page:

## 8 Methods and assessments

### 8.1 Visit procedures

## 8.1.1 Introduction

Throughout the trial the investigator must ensure working in accordance with ICH  $GCP^{\perp}$  and local regulations. The investigator must ensure that trial procedures are performed as described in the protocol. Any discrepancies will result in protocol and/or GCP deviations and the investigator must take appropriate actions to avoid recurrence of the detected discrepancies.

## 8.1.2 Visit 1 (Screening)

For procedures and assessments performed at screening, please see flow chart Section  $\underline{2}$ .

Investigators must obtain informed consent for each subject no later than at Visit 1 prior to any protocol-related procedures. For information on informed consent procedure please see Section <u>18.1</u>.

All subjects will be provided with a copy of their own signed and dated informed consent form.

The IV/WRS must be contacted to register the subject as screened (see Section <u>10</u>) at the screening visit. Subject will be assigned a unique number (lowest available number allocated to site) which is maintained throughout the trial.

The investigator must keep a subject screening log, a subject identification code list and a subject enrolment log. The subject screening log and subject enrolment log may be combined in one list and may be generated from IV/WRS.

At screening, subjects will be provided with a card stating that they are participating in a trial and giving contact address(es) and telephone number(s) of relevant trial site staff. Subjects should be instructed to return the card to the investigator at the last trial visit or to destroy the card after the last visit.

For screening failures the screening failure form must be completed with the reason for not continuing in the trial. Serious and non-serious adverse events from screening failures must be transcribed by the investigator into the electronic case report form (eCRF). Follow-up of serious adverse events (SAEs) must be carried out according to Section <u>12.3</u>. A screening failure session must be made in the IV/WRS. The case book must be signed.

Re-screening of subjects having signed the informed consent is not allowed.

Protocol Trial ID: NN9924-3790		Date: Version:	21 January 2014 3 0	Novo Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Status: Page:	Final 38 of 98	

Once all data relating to Visit 1 have been obtained, these must be reviewed by the investigator to ensure that the subject is eligible to continue the trial.

## 8.1.3 Fasting visits

The subjects should attend several visits in a fasting state (see Section 2). Fasting is defined as having consumed only water since midnight. An exception from this is the Follow-up visit where fasting is defined as having consumed only water for the last two hours.

Subjects are allowed to take the IMP and oral concomitant medication during fasting if following the conditions outlined in Section 5.3. An exception is at three visits in the oral treatment arms where peak and trough PK will be measured and the oral IMP will be administered at the site (see Section 8.4.10).

If a subject attends a fasting visit in a non-fasting condition or a peak and trough PK meeting having taken the oral dose the same day, then blood sampling and body weight must be re-scheduled within the visit window. The date for each fasting assessment or PK assessment at the specific visit must be updated accordingly in the eCRF. All other assessments can be performed. Re-scheduling of fasting visits or peak and trough PK visits are not considered unscheduled visits.

## 8.1.4 Unscheduled visits

An unscheduled visit can be scheduled at any time at the discretion of the investigator. An unscheduled visit form must be completed in the eCRF indicating the reason for the visit. Coming to the site for any of the following reasons should not be considered as unscheduled visits:

- dispense additional trial products
- dispense additional auxiliary supplies
- re-test of blood- or urine sampling (not allowed if results are available)

In case of additional trial products being dispensed, a dispensing session should be made in the IV/WRS selecting additional medication.

## 8.1.5 Visit 2 (Randomisation)

For procedures and assessments performed at randomisation, see Section 2.

Visit 2 will take place within two weeks after Visit 1.

The randomisation session must be performed in the IV/WRS which will allocate the Dispensing Unit Number (DUN) of the IMP to be dispensed to the subject. Eligible subjects will be randomised into one of nine treatment arms.

EudraCT No.: 2012-004994-16 Page: 39 of 98	Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 39 of 98	
--	--	--------------	---------------------------------------	---	--

The IMP will be dispensed to the subject by the trial site staff, hospital pharmacy staff or equivalent at each visit during the trial from randomisation to last visit before the End-of-treatment visit (see Section 2). The investigator must document that subjects are instructed in oral IMP administration at every dispensing visit.

For subjects randomised to the s.c. injection, the investigator must document that a direction for use (DFU) is handed out at each dispensing visit. Ability and willingness to self-inject can be tested by administration of injections with a test pen for subjects who do not have prior experience with self-injection. Novo Nordisk will provide the test pens.

Please see Section  $\underline{9}$  for further information about the IMPs.

## 8.1.6 Visit numbers

For visit numbers, timing of site visits and visit windows during the trial period, please refer to the flow chart, Section  $\underline{2}$ . Planned visits can be re-scheduled within the allowed visit window.

It is the responsibility of the investigator to ensure that all site visits occur according to the flow chart (see Section  $\underline{2}$ ).

## 8.1.7 Visits 3-10 (Treatment)

For procedures and assessments performed at visits 3, 4, 5, 6, 7, 8, 9, and 10, see the flow chart in Section  $\underline{2}$ .

## 8.1.8 Visits 11-12 (End-of-treatment and Follow-up)

All subjects must attend the End-of-treatment visit (Visit 11) which should be scheduled when the subject has completed the treatment with the IMP and a Follow-up visit (Visit 12) should be performed at least 5 weeks after (+5 days visit window). A completion session must be performed in the IV/WRS. Please see the flow chart for details (Section  $\underline{2}$ ).

The Follow-up visit serves to collect AEs, technical complaints, hyperglycaemic episodes and blood samples for anti-semaglutide antibodies.

## 8.1.9 Visit 11X (End-of-Trial – premature discontinuation)

For subjects who discontinue the IMP prematurely the End-of-treatment visit (Visit 11) should be scheduled shortly after the subject has discontinued the IMP. The Follow-Up visit (Visit 12) should be scheduled at least 5 weeks (+5 days visit window) after treatment discontinuation. Treatment discontinuation and drug accountability sessions must be done in the IV/WRS. Please see the flow chart for details (Section  $\underline{2}$ ).

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 40 of 98	Novo Nordisk
EudraC1 No.: 2012-004994-16		Page:	40 of 98	

Subjects who discontinue their IMP prematurely must also be requested to attend the visit End-oftrial – premature discontinuation (Visit 11X) at the time of the scheduled end of treatment (i.e., 26 weeks after randomisation). Data on AEs and the primary endpoint from this final visit are important for the data quality of the trial.

## 8.1.10 Withdrawals

If a subject is withdrawn from the trial, the investigator must aim to undertake procedures similar to those for visit 11 (End-of-treatment) as soon as possible, and the Follow-up visit at least 5 weeks after. The end-of-trial form must be completed and the subject should return all trial products to the site to have final drug accountability performed. Drug accountability must be performed even if the subject is not able to come to the trial site. A treatment discontinuation session must be performed in the IV/WRS (see Section  $\underline{10}$ ). The case book must be signed.

Although a subject is not obliged to give his/her reason(s) for withdrawing from a trial, the investigator must make a reasonable effort to ascertain the reason(s), while fully respecting the subject's rights. Where the reasons are obtained, the primary reason for discontinuation must be specified on the end-of-trial form in the eCRF (see Section 6.5.1):

## 8.1.11 Investigator's assessment

Review of diaries, laboratory reports, ECGs, eye examination (fundoscopy/fundus photography), physical examination and patient reported outcome (PRO) questionnaires must be documented with the investigator's or delegated site staff's dated signature either on the front page of the documents or in the subject's medical record. The documents should be signed prior to the following visit and must be retained at the investigator site as source documentation.

For ECGs and eye examinations the evaluations must be in the following categories:

- Normal
- Abnormal
  - Was the finding clinically significant? (yes/no)

For laboratory report values outside the reference range, the investigator must specify whether the value is non-clinically or clinically significant. All laboratory printouts must be signed and dated by the investigator on the day of evaluation.

In case of abnormal clinically significant findings (e.g., in laboratory reports, ECGs, eye examination or physical examination), the investigator must state a comment in the subject's medical record and record this on the concomitant illness form in the eCRF at the screening or randomisation visits. At subsequent visits any clinically significant changes or new clinically significant findings must be reported as an AE according to Section <u>12.2</u>.

Protocol Trial ID: NN9924-3790	CONFIDENTIAL	Date: Version:	3.0	o Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONTIDENTIAL	Status: Page:	Final 41 of 98	

If clarification of entries or discrepancies in the diary or PROs is needed, the subject must be questioned and a conclusion made in the subject's medical record. Care must be taken not to bias the subject.

### 8.2 Subject related information

#### 8.2.1 Concomitant illness and medical history

A **concomitant illness** is any illness that is present at the start of the trial (i.e., at the screening visit or found as a result of screening procedure). The concomitant illness should be recorded in the eCRF.

**Medical history** is a medical event that the subject has experienced in the past. Only medical history considered relevant by the investigator should be reported.

The information collected for concomitant illness and medical history should include diagnosis, date of onset and date of resolution or continuation, as applicable.

Any change to a concomitant illness should be recorded during the trial. A clinically significant worsening of a concomitant illness must be reported as an AE.

**Smoking habit**: Details of smoking habit must be recorded at the first visit. Smoking is defined as smoking at least one cigarette, cigar or pipe daily. The collected information should include whether or not the subject smokes or has smoked. If the subject smokes or has smoked, record approximately when the subject started smoking and, if applicable, when the subject stopped smoking.

**Diabetes complications** should be captured in the medical history or concomitant illness form and should include:

- diabetic retinopathy
- diabetic neuropathy
- diabetic nephropathy
- macroangiopathy including peripheral vascular disease
- other complications where relevant

## 8.2.2 Concomitant medication

A **concomitant medication** is any medication, other than the trial products, which is taken during the trial, including the screening and follow-up periods.

Details of any concomitant medication must be recorded at the first visit. Changes in concomitant medication must be recorded at each visit as they occur.

Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CONTIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	42 of 98	

The information collected for each concomitant medication includes:

- trade name or generic name
- indication
- start and stop date or continuation
- total daily dose (only applicable for antidiabetic medication)

If a change is due to an AE, then this must be recorded and reported according to Section <u>12.2</u>. If the change influences the subject's eligibility to continue in the trial, the monitor must be informed.

### 8.2.3 Demography

Demography will be recorded in the eCRF at screening and consists of:

- date of birth or age (according to local regulation)
- sex
- race (according to local regulation)
- ethnicity (according to local regulation)

### 8.2.4 Diagnosis of diabetes

The date of diagnosis of T2D will be recorded in the eCRF at screening.

## 8.2.5 Diabetes treatment history

The dose and the date of initiating treatment with metformin will be recorded in the eCRF at screening if the subject is currently treated with metformin.

## 8.2.6 History of gallbladder disease

Information related to history of gallbladder disease (i.e., pancreatitis, gallstone disease, cholecystis) will be recorded in the eCRF at screening visit.

#### 8.2.7 History of cardiovascular disease

Information related to history of cardiovascular disease (CVD) (i.e., heart failure including NYHA class, hypertension or ischaemic stroke) or other risk factors for CVD will be recorded in the eCRF at screening visit.

## 8.2.8 Renal impairment history

Information related to history of renal impairment will be recorded in the eCRF at screening visit.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 Evider CT No 2012, 004004, 16	CONFIDENTIAL	Date: Version: Status:	21 January 2014 3.0 Final 42 cf 08	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	43 of 98	

### 8.2.9 **Post-dose fasting routines**

The fasting routines following oral trial product administration should be recorded in the subject's diary handed out at Visit 10 and transcribed to the eCRF by the investigator at the End-of-treatment visit to determine the usual fasting time after tablet ingestion during the trial.

The post-dose fasting routines are recorded as time in minutes from IMP administration until the usual time of:

- food consumption (i.e., meal or snack)
- drinking (i.e., any beverage including water)

#### 8.3 Assessments for efficacy

#### 8.3.1 Blood samples

Blood samples will be drawn according to flow chart (see Section  $\underline{2}$ ) and analysed at the central laboratory to determine levels of the following efficacy laboratory parameters:

Glucose metabolism:

- HbA<sub>1c</sub>
- Fasting plasma glucose (FPG)
- Fasting insulin
- Fasting C-peptide
- Fasting glucagon

Lipids (all fasting):

- Total cholesterol
- LDL-cholesterol
- VLDL-cholesterol
- HDL-cholesterol
- Triglycerides
- Free fatty acids

#### 8.3.2 Body measurements

#### **Body weight**

Body weight should be measured without shoes and only wearing light clothing. It should be recorded with one decimal and using the same set of scales throughout the trial (i.e., kg or lb)

#### Height

Height is measured without shoes in centimetres or inches and recorded to nearest  $\frac{1}{2}$  cm or  $\frac{1}{4}$  inch.

ProtocolDate:Trial ID: NN9924-3790CONFIDENTIALVersion:UTN: U1111-1136-4716Status:Status:EudraCT No.: 2012-004994-16Page:Page:	21 January 2014 3.0 Final 44 of 98	Novo Nordisk
---	---	--------------

### Waist circumference

The waist circumference is defined as the minimal abdominal circumferences located midway between the lower rib margin and the iliac crest.

Three consecutive measurements of waist circumference should be performed and recorded in the eCRF. The waist circumferences will be measured using a non-stretchable measuring tape. It should be recorded to the nearest  $\frac{1}{2}$  cm or  $\frac{1}{4}$  inch using the same measuring tape throughout the trial.

The subject should be measured in a standing position with an empty bladder and wearing light clothing with accessible waist. The subject should be standing with arms down their side and feet together. The tape should touch the skin but not compress soft tissue and twists in the tape should be avoided. The subject should be asked to breathe normally and the measurement should be taken when the subject is breathing out gently.

### BMI

BMI will be captured in the eCRF using the equation:

BMI = Body weight (kg)/(Height (m) x Height (m))  $[kg/m^2 = lb/in^2 x 703]$ 

#### 8.3.3 Patient reported outcomes

The PRO questionnaire used in this trial is SF-36v2<sup>TM</sup>.

The questionnaire should be completed by the subject as specified in the flow chart, see Section  $\underline{2}$ , preferably before any other trial-related activities. It takes approximately ten minutes to complete the questionnaire.

The questionnaire is checked by the investigator for completion and unreported AEs (see Section 8.1.11). The investigator or site staff must date and sign the document and enter the results in the eCRF.

The SF-36v2<sup>TM</sup> questionnaire will be used to assess subjects overall Health related Quality of Life and can also be used to estimate Quality-Adjusted Life Year which is used in cost effectiveness calculations. This instrument contains 36 items and measures the individual overall health related quality of life on eight domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 45 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

#### 8.4 Assessments for safety

#### 8.4.1 Hypoglycaemic episodes

Plasma glucose should always be measured and recorded when a hypoglycaemic episode is suspected.

All plasma glucose values:

- $\leq 3.9 \text{ mmol/L} (70 \text{ mg/dL}) \text{ or}$
- > 3.9 mmol/L (70 mg/dL) when they occur in conjunction with hypoglycaemic symptoms,

should be recorded by the subject in the diary. These must be transcribed into the eCRF (hypoglycaemic episode form) throughout the trial from Visit 1-12.

The record should include the following information:

- Date and time of hypoglycaemic episode
- The plasma glucose level before treating the episode (if available)
- Whether the episode was symptomatic
- Whether the subject was able to treat him/herself
- Date and time of last trial product administration prior to episode
- Type of last trial product prior to episode
- Date and time of last main meal prior to episode
- Whether the episode occurred in relation to increased physical activity

The answer to the question: "Was subject able to treat him/herself?" must be answered "No" if oral carbohydrates, glucagon or IV glucose had to be administered to the subject by another person. Oral carbohydrates should not be given if the subject is unconscious.

A hypoglycaemic episode form must be filled in for each hypoglycaemic episode. If the hypoglycaemic episode fulfils the criteria for an SAE then an AE form and an electronic safety information form (eSIF) must also be filled in (see Section <u>12.2</u>)

For all FPG values measured by central laboratory that meet the definition of a hypoglycaemic episode, a hypoglycaemic episode form must be completed in the eCRF.

#### 8.4.2 Blood samples

Blood samples will be drawn according to flow chart (see Section  $\underline{2}$ ) and will be analysed at the central laboratory to determine levels of the following safety laboratory parameters:

Haematology:

• Differential count (basophils, eosinophils, lymphocytes, monocytes and neutrophils)

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 46 of 98

• Erythrocytes

- Haematocrit
- Haemoglobin
- Leucocytes
- Thrombocytes

Biochemistry:

- Alanine aminotransferase
- Albumin
- Alkaline phosphatase
- Amylase
- Aspartate aminotransferase
- Bilirubin, total
- Calcium, total
- Calcium, albumin corrected (ionized)
- Creatine kinase
- Creatinine
- Lipase
- Potassium
- Sodium
- Urea

Hormone:

• Calcitonin (see Section <u>8.4.11</u>)

Pregnancy test:

• Serum or plasma human chorionic gonadotropin (hCG)

#### 8.4.3 Pregnancy test

Females of childbearing potential will have a serum pregnancy test (i.e., beta-hCG) performed as specified in Section  $\underline{2}$  or as required by local law.

Pregnancy testing will not be required (unless required by local law) for subjects who are postmenopausal (defined as women who have undergone a hysterectomy, bilateral oophorectomy or bilateral tubal ligation or for women above the age of 50, who have been without menstrual period for at least 1 year).

CONFIDENTIAL	atus: 3.0	Novo Nordisk
--------------	-----------	--------------

#### 8.4.4 Urinalysis

Subjects will be asked to bring first morning urine during the trial (see Section 2). The urine samples will be analysed at the central laboratory to determine levels of the following safety laboratory parameters:

- Urinary albumin to creatinine ratio
- Urinalysis by urine dip-stick: erythrocytes, protein, glucose and ketones, pH

#### 8.4.5 Antibodies

Blood samples will be drawn during the trial and analysed at specialised laboratory for determination of serum antibodies to semaglutide, including cross reactivity to endogenous GLP-1 (see flow chart, section 2). Samples positive for antibodies against semaglutide will be further characterised for *in vitro* neutralising effect towards semaglutide. In addition, samples positive for antibodies cross-reacting with endogenous GLP-1 will be analysed for *in vitro* neutralising effect towards endogenous GLP-1. Furthermore, samples drawn at randomisation may be used for calculations of the neutralising effect in the *in vitro* neutralising antibody assays. The *in vitro* neutralising assays will be performed by Novo Nordisk.

At randomisation, the antibody assessment must be done pre-dose.

#### 8.4.6 Vital signs

The method for measuring systolic and diastolic blood pressure needs to follow the standard clinical practice at site but as a minimum; the following guideline must be adhered to: Avoid caffeine, smoking and exercise at least 30 minutes prior to measuring the blood pressure. The blood pressure should be measured in a sitting position, with the legs uncrossed, the back and arms supported and positioned at heart level. Subjects should be sitting for at least five minutes before the first measurement is taken. The subject should not talk during the measurement. Pulse (beats per minute) should be measured after resting for five minutes in a sitting position. Results are recorded in the eCRF.

In case of an "abnormal, clinically significant finding", the investigator must record the finding on the medical history or concomitant illness form if present at screening.

Any new abnormal, clinically significant finding during the trial and any clinically significant worsening from baseline must be reported as an AE.

#### 8.4.7 Electrocardiogram – 12-lead

12-lead ECG will be performed during the trial (see Section <u>2</u>). All ECGs will undergo central assessment.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	21 January 2014 3.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	48 of 98	

Sites will be informed of the central ECG evaluation in case this evaluation reveals an abnormal, clinically significant ECG reading. If the abnormality represents an unreported AE, SAE or MESI, such findings must be reported if the investigator finds the abnormality clinically significant (see Section 8.1.11).

Additional ECG recordings can be performed at the investigators site at the investigator's discretion at other visits than the planned ECG visits. All such ECGs will undergo central assessment.

An ECG performed for any reason unrelated to the trial within 30 days prior to the randomisation visit is acceptable as Visit 2 data, provided no clinical symptoms suggestive of cardiac disease has occurred in the meantime.

If the ECG is performed before the subject has signed the informed consent form, it must be documented in the medical records that the reason for performing the procedure was not related to this trial.

For electronic central ECG evaluation vendor details, see Attachment I.

#### 8.4.8 Fundoscopy/fundus photography

Fundoscopy/fundus photography will be performed at randomisation by the investigator or according to local practice. Results of the fundoscopy/fundus photography will be reviewed, signed and dated by the investigator (see Section 8.1.11). Dilation is not a requirement.

If fundoscopy/fundus photography has been performed within 90 days before the screening visit, the procedure does not need to be repeated unless worsening of visual function since the last examination. A subject cannot be randomised without results confirming there is not retinopathy or maculopathy requiring acute treatment.

If the fundoscopy/fundus photography is performed before the subject has signed the informed consent form, it must be documented in the medical records that the reason for performing the procedure was not related to this trial.

#### 8.4.9 Physical examination

A physical examination will be performed by the investigator according to local procedures, see Section  $\underline{2}$ ).

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

Date: Version: Status: Page:

3.0 Final 49 of 98

A physical examination must include:

- General appearance
- Central and peripheral nervous system •
- Head, ears, eyes, nose, throat, neck •
- Thyroid gland •
- Respiratory system
- Cardiovascular system •
- Gastrointestinal system including mouth •
- Musculoskeletal system ٠
- Skin •
- Lymph node palpation •

The results are recorded as described in Section 8.1.11.

#### 8.4.10 **Pharmacokinetics**

Blood samples for the population PK will be drawn from all subjects for bioanalysis of the plasma concentrations of semaglutide at Visits 3-11 (see flow chart, Section 2). The investigator must record the exact time for drawing the blood samples in the laboratory requisition form and transcribe the data to the eCRF

For subjects on oral treatment, three of the PK sampling assessments will be pre-dose and post-dose (trough and peak) only (see Section 2). At the visits for trough and peak PK measurements, the investigator needs to ensure that the subjects on oral treatment follow these procedures:

- Attend the visit fasting
- Have the IMP administered at the visit (i.e., subjects must not self-administrate the tablet on the • day of the visit)
- Ingest tablet at site
- Eat a meal 30-60 minutes after IMP administration
- Have an extra blood sample drawn 60-90 minutes after IMP administration

The exact time points of trial drug administration, start of meal and blood sampling must be recorded in the eCRF by the investigator.

For the oral treatments, the date and time of the latest trial drug administration must be recorded by the subject in the subject diary and transcribed to the eCRF by the investigator.

For the s.c. semaglutide arm, the date, time, dose and injection site of the two latest trial drug administrations must be transcribed to the eCRF by the investigator based on the subject's diary.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 50 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

#### 8.4.11 Calcitonin

Blood samples for the measurement of calcitonin concentration will be drawn as per flow chart (see Section 2). Calcitonin values  $\geq 20$  ng/L will be submitted to an independent committee of thyroid experts. The Calcitonin Monitoring Committee (CMC) will provide guidance to the investigator with regards to treatment and further investigations. It is recommended that screening failure subjects with a calcitonin value  $\geq 10$  ng/L are referred to a thyroid expert for further evaluation. For details please refer to Appendix A.

#### 8.5 Laboratory assessments

The laboratory analyses will mainly be performed by a central laboratory. For analyses of antisemaglutide antibodies (see Section 8.4.5) and semaglutide plasma concentrations (see Section 8.4.10) a special laboratory will be used. Also, in the situation described in Section 8.6.2.1 a special laboratory will be used. Laboratory samples comprise both urine and blood samples. Descriptions of assay methods, laboratory supplies and procedures for collecting, handling, storing and shipping samples and information regarding who will perform the assessments will be described in the laboratory manual provided by the central laboratory (for central and special laboratory details, see Attachment I).

Samples will be coded in order to keep subject identity anonymous.

Laboratory samples not collected on the day of the actual visit should preferably be collected on another day within the visit window as stated in the flow chart (see Section 2). Please note that a laboratory sample pertaining to a specific visit must always be reported to that visit.

For some of the samples collected during the trial, subjects must attend the relevant site visits fasting (fasting is defined in Section 8.1.3).

At three visits (see Section 2), the subjects on oral treatment must attend the relevant site without having taken the trial product the same day to have PK measured pre-dose and post-dose (trough and peak), see Section 8.4.10.

The central laboratory will provide laboratory results to the investigator on an on-going basis and the investigator must review all laboratory results for concomitant illnesses and AEs and report these according to Section <u>12.2</u>.

An exception to this is that anti-semaglutide antibody and semaglutide plasma concentration results will not be available to the investigator during the trial. These results will be provided to the investigator upon request after the completion of the clinical trial report (CTR).

All laboratory samples will be destroyed at the latest at the completion of the CTR, except samples obtained for anti-semaglutide antibody analysis which may be kept up to ten years or stored until

ProtocolDate:21 January 2014Novo NordaTrial ID: NN9924-3790CONFIDENTIALVersion:3.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:51 of 98	Nordisk
--	---------

approval by health authorities. Antibody samples will only be analysed if requested by the health authorities or for safety.

The laboratory equipment may provide analyses not requested in the protocol but produced automatically in connection with the requested analyses according to specifications in the laboratory standard operating procedures. Such data will not be transferred to the trial database, but abnormal values must be reported to the investigator. The investigator must review all laboratory results for concomitant illnesses and AEs and report these according to this protocol.

#### 8.6 Other assessments

#### 8.6.1 Subject diary

The subject must be provided with diaries at all visits until the End-of-treatment visit. Entries in the diary are only to be made by the subject.

The investigator/delegate should instruct the subject in recording the following data in the diary:

- For all subjects:
  - date and time of first IMP administration
  - hypoglycaemic episodes
  - concomitant medication
  - AEs
- For subjects treated with <u>oral semaglutide</u>:
  - date and time of last IMP administration prior to each visit
  - post-dose fasting routines during the trial and recorded at the End-of-treatment visit
- For subjects treated with <u>s.c. semaglutide</u>:
  - date, time, dose and injection site of the last two IMP administrations before each visit

The diaries should be collected at the following visit. The recordings must be reviewed as described in Section 8.1.11.

#### 8.6.2 Additional safety assessments

#### 8.6.2.1 Thyroidectomy, tissue sample and genetic testing

#### Thyroidectomy pathology slides

In case a subject undergoes a thyroidectomy (partial or total) for any reason during the trial the subject will be asked to inform the investigator prior to the operation.

In addition to the review of the thyroid tissue routinely made by the hospital pathology laboratory, the pathology slides of the thyroid tissue will be sent centrally for a second review by a pathologist with expertise in thyroid and C-cell pathology. The central pathologist will be blinded to both

Protocol		Date:	21 January 2014 Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAI	Version:	3.0
UTN: U1111-1136-4716	CUNFIDEN HAL	Status:	Final
EudraCT No.: 2012-004994-16		Page:	52 of 98

randomised treatment and the diagnosis from the hospital pathology laboratory. Both the hospital pathology report and the central pathology report will be reviewed by an independent Event Adjudication Committee (EAC) (see Section <u>12.7.2</u>). Once the samples are re-examined they will be sent back to the hospital pathology laboratory.

The investigator will be informed of the results of central pathology report and if C-cell pathology is confirmed by the EAC, the CMC will provide guidance to the investigator with regards to treatment and further investigations.

#### Thyroid tissue sample collection in case of thyroidectomy (not applicable for Israel)

If C-cell pathology is confirmed (i.e., hyperplastic or neoplastic thyroid C-cells) the subject will be asked to consent to have a sample of the removed thyroid tissue tested for RET Y1062 phosphorylation in the thyroid C-cells, if allowed by local law. The tissue sample will be destroyed after examination.

# Blood sample for genetic testing in case of confirmed C-cell pathology (not applicable for Israel)

In addition, the subject will also be asked to consent to be tested (blood sample) to identify germline RET gene mutations associated with MEN2 syndrome. This RET gene mutation detection will only be conducted if the EAC has confirmed C-cell abnormality (medullary carcinoma or C-cell hyperplasia). The genetic testing will only be performed if allowed by local law.

The blood sample should be collected at the first visit to the clinic after the confirmation of C-cell pathology. The extraction of DNA will be performed by the central laboratory whereas the identification of gene mutations will be performed by a specialised laboratory. The blood sample will be destroyed as soon as the genetic analysis is complete.

#### 8.6.2.2 Assessments in case of suspicion of acute pancreatitis

In case of acute, severe persistent abdominal pain characteristic of acute pancreatitis, the IMP must promptly be interrupted until pancreatitis is excluded (see Section 6.5.2). Appropriate additional examinations should be performed according to local practice. If acute pancreatitis is not confirmed trial product should be re-initiated.

If pancreatitis is confirmed (as a minimum 2 of 3):

- characteristic abdominal pain
- blood amylase and/or lipase >3x upper normal range (UNR)
- characteristic findings on ultrasound/CT/MRI

	DENTIAL Date: Version: Status: Page:	21 January 2014 3.0 Final 53 of 98
--	---	---

appropriate treatment and careful monitoring of the subject should be initiated. Trial product should not be re-initiated but subject should remain in the trial. The event should be reported as a MESI and will undergo assessment by the EAC (see Section 12.7.2).

#### 8.6.2.3 Assessments in case of suspicion of severe hypersensitivity

If a severe immediate hypersensitivity reaction to the IMP is suspected, blood sampling for assessment of anti-semaglutide IgE antibodies and anti-semaglutide binding antibodies should be collected after a suitable washout period (minimum 5 weeks). In these cases, it is also recommended to test for tryptase (total and/or mature tryptase) within three hours of the reaction.

Furthermore, a tryptase sample should be taken at the same time as the IgE sample is obtained. Tryptase concentrations (if measured) as well as results of anti-semaglutide antibody and IgE-isotype anti-semaglutide antibodies should be sent to Novo Nordisk.

#### 8.7 Subject compliance

Subject compliance will be assessed by monitoring of drug accountability. Prior to visits where drug accountability is performed the subject will be asked to return all used, partly used and unused IMPs. The investigator must assess the amount of IMPs returned compared to what was dispensed at the last dispensing visit and, in case of discrepancies, question the subject.

Throughout the trial the investigator will remind the subjects to follow the trial procedures and requirements to ensure subject compliance. If a subject is found to be non-compliant, the investigator will remind the subject of the importance of following the instructions given including taking the trial products as prescribed.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 54 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

## 9 Trial supplies

Trial supplies comprise trial products and auxiliary supplies. Additional details regarding trial supplies can be found in the Trial Materials Manual (TMM).

Trial products must not be dispensed to any person not included in the trial.

For injectable products, the trial product must not be used if:

- it does not appear clear and colourless
- it has been frozen
- it has been exposed to excessive heat or direct sunlight

#### 9.1 Trial products

The following trial products will be provided by Novo Nordisk A/S, Denmark:

Active substance	Strength	Dosage form
Semaglutide	2.5 mg	tablet
Semaglutide	5.0 mg	tablet
Semaglutide	10 mg	tablet
Semaglutide	20 mg	tablet
Semaglutide	40 mg	tablet
Placebo	N/A	tablet
Semaglutide	1.34 mg/mL	solution for injection, 1.5 mL pre-filled PDS290 pen-injector

Table 9–1Trial products (IMP)

N/A: not applicable

The IMPs for oral use will be packed in 15 mL Duma containers (lid with desiccant). Each container will include ten tablets. Subjects in the oral treatment arms will be instructed in how to ingest the tablets following the condition rules. All tablets containing semaglutide or placebo are identical with regards to visual appearance, taste and smell.

The semaglutide, solution for injection will be delivered open-label with the pre-filled PDS290 peninjector. The direction for use of the pen-injector will be given to each subject in the s.c. treatment arm at each dispensing visit.

For further details, please see the current edition of the IB (Oral Administration of Semaglutide (NN9924) Edition  $5^{6}$  and any updates hereof.

Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	55 of 98	

Metformin may be used at the discretion of the investigator. Metformin will not be supplied by Novo Nordisk. However, metformin will be reimbursed if required by the country's Health Authority or independent ethics committee/Institutional Review Board (IEC/IRB).

#### 9.2 Labelling

Labelling of the trial products will be in accordance with Annex  $13^{13}$ , local regulations and trial requirements.

Each investigator site will be supplied with sufficient trial products for the trial on an on-going basis controlled by the IV/WRS. Dispensing unit numbers (DUNs) will be distributed to the sites according to enrolment and randomisation.

The investigator or delegate must document that direction for use of the device is handed out at each dispensing visit. This could be by signature in the subject's medical record.

#### 9.3 Storage

Tablets containing the SNAC enhancer are susceptible to degradation in humid environment. It is important to protect the tablets by following the storage conditions in <u>Table 9–2</u>. Before opening the Duma container for the first time, the container must acclimatise for 1 hour at room temperature due to risk of condensation.

Trial product	Storage conditions (not-in-use)	In-use conditions	In-use time*
Semaglutide and placebo tablets	<ul> <li>Must be stored in a refrigerator (2°C to 8°C) / (36°F to 46°F)</li> <li>Do not freeze</li> <li>Protect from light and humidity</li> </ul>	<ul> <li>Store below 30°C / 86°F</li> <li>Do not refrigerate</li> <li>Do not freeze</li> <li>Protect from light and humidity</li> <li>Container must be stored with lid tightly closed at all times</li> </ul>	Use within 4 weeks
Semaglutide, solution for injection	<ul> <li>Must be stored in a refrigerator (2°C to 8°C) / (36°F to 46°F)</li> <li>Do not freeze</li> <li>Protect from light</li> </ul>	<ul> <li>Store below 30°C / 86°F</li> <li>Do not refrigerate</li> <li>Do not freeze</li> <li>Protect from light</li> </ul>	Use within 1 month
Semaglutide placebo, solution for injection (test pen)	<ul> <li>Must be stored in a refrigerator (2°C to 8°C) / (36°F to 46°F)</li> <li>Do not freeze</li> <li>Protect from light</li> </ul>	• For single use only	For single use only

Table 9–2	Storage	conditions	for trial	products
-----------	---------	------------	-----------	----------

\* In-use time starts when first dose is taken.

The investigator must ensure the availability of proper storage conditions, record and evaluate the temperature. The investigator must inform Novo Nordisk immediately if any trial product has been stored outside defined conditions (e.g., outside temperature range).

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 56 of 98	Novo Nordisk
EudraC1 No.: 2012-004994-16		Page:	56 01 98	

Trial products that have been stored improperly must not be dispensed to any subject before it has been re-evaluated and approved for further use by Novo Nordisk. The investigator must take appropriate action to ensure correct storage.

#### 9.4 Drug accountability and destruction

Drug accountability is the responsibility of the investigator.

Returned trial product (used/partly used or unused including empty packaging material) can be stored at room temperature and must be stored separately from non-allocated trial product.

The trial products will be dispensed to each subject as required according to treatment group. The IV/WRS will allocate trial product to the subject at each dispensing visit. The correct dispensing unit number(s) (DUN(s)) must be dispensed to the subject.

The investigator or delegated person is responsible for ensuring that:

- Trial products are not dispensed to any person not included in the trial
- Drug accountability is performed using the IV/WRS drug accountability module
- Subjects are instructed to return all used, partly used and unused trial product including empty packaging material at every visit
- Returned trial product(s) (used, partially used or unused including empty packaging material) is kept and stored separately from non-allocated trial products

Destruction will be done according to local procedures after accountability is finalised and verified by the monitor. Destruction of products must be documented.

#### 9.5 Auxiliary supplies

Auxiliary supplies provided by Novo Nordisk:

- Blood glucose meters, including lancets, plasma-calibrated test strips and control solutions.
- Direction for use for devices (only subjects on s.c. semaglutide)
- Needles for pre-filled pen systems (only subjects on s.c. semaglutide)
- Test pens containing semaglutide placebo (only subjects on s.c. semaglutide)

Test pens containing semaglutide placebo, solution for injection, 1.5 mL pre-filled PDS290 peninjector will be supplied at the randomisation visit to subjects randomised to injection treatment. Training with the test pen is optional and recommended for subjects without prior injection experience to ensure the subject's willingness and ability to self-inject. The test pen should be administered once and the training be performed at the clinical site. The subjects must not take the test pens home.

Details of the auxiliary supplies are provided in the TMM.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

21 January 2014 Novo Nordisk 3.0 Final 57 of 98

#### 10 Interactive voice/web response system

A trial-specific IV/WRS will be set up which can be accessed at any time via the internet or telephone. Access to the IV/WRS must be restricted to and controlled by authorised persons.

IV/WRS is used for:

- Screening •
- Screening failure •
- Randomisation •
- Medication arrival •
- Dispensing •
- Treatment discontinuation •
- Completion •
- Code break •
- Drug accountability •
- Data change •

IV/WRS user manuals will be provided to each trial site.

During the trial, only DUNs allocated by the IV/WRS are allowed to be dispensed to a subject. This will ensure that:

- needed stock is available at a site for the subjects •
- no allocation of IMP that will expire before the next dispensing contact •
- drug accountability can be made in IV/WRS •

If a subject needs IMP between dispensing visits, the investigator must make an additional dispensing session in the IV/WRS.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 58 of 98

## **11** Randomisation procedure and breaking of blinded codes

The trial is partially blinded. The oral semaglutide arms and the oral placebo arm are double-blind whereas the s.c. semaglutide active comparator arm is open-label.

The randomisation is stratified according to one stratification factor with two strata: Treatment with metformin at screening (yes/no).

#### 11.1 Breaking of blinded codes

If the trial site needs to break the code, Novo Nordisk should, if possible, be contacted before the code is broken. The IV/WRS will notify Novo Nordisk (monitor and the Global Safety department) immediately after the code is broken.

The code for a particular subject may be broken in a medical emergency if knowing the actual treatment would influence the treatment of the subject. Whenever a code is broken the person breaking the code must print the Code Break Confirmation Notification generated by the IV/WRS, record the reason and sign and date the document.

When the code is broken, the treatment allocation will be accessible to the investigator and the Novo Nordisk Global Safety department. If IV/WRS is not accessible at the time of code break the monitor should be contacted and if monitor cannot get access the IV/WRS vendor helpdesk should be contacted. Contact details are listed in Attachment I.

If the code has been broken, the subject should be discontinued from trial product but be asked to continue in the trial (see Section 8.1.9).

If the subject is withdrawn after the code has been broken, a treatment discontinuation session should be completed in IV/WRS.

Date: Version: Status: Page:

## 12 Adverse events, technical complaints and pregnancies

#### 12.1 Definitions

#### Adverse event

An **adverse event** is any untoward medical occurrence in a subject administered a product, and which does not necessarily have a causal relationship with this treatment.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of a product, whether or not considered related to the product.

An AE includes:

- A clinically significant worsening of a concomitant illness.
- A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is of a severity that requires active management. Active management includes active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to the abnormality.

The following should **not** be reported as AEs:

- Pre-existing conditions, including those found as a result of screening procedures (pre-existing conditions should be reported as medical history or concomitant illness).
- Pre-planned procedures unless the condition for which the procedure was planned has worsened from the first trial-related activity after the subject has signed the informed consent.
- Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic episode form instead of on an AE form (see Section <u>8.4.1</u>)

The following definitions are used when assessing an AE:

- Severity assessment:
  - Mild no or transient symptoms, no interference with the subject's daily activities, acceptable
  - **Moderate** marked symptoms, moderate interference with the subject's daily activities, but still acceptable
  - Severe considerable interference with the subject's daily activities; unacceptable

#### • Causality assessment

The following terms and definitions are used when assessing the relationship between an AE and the relevant trial product(s):

• Probable – Good reason and sufficient documentation to assume a causal relationship

Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	<b>CONFIDENTIAL</b>	Version:	3.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	60 of 98	

- **Possible** A causal relationship is conceivable and cannot be dismissed
- Unlikely The event is most likely related to aetiology other than the trial product
- Final outcome of an AE
  - **Recovered/resolved** The subject has fully recovered, or by medical or surgical treatment the condition has returned to the level observed at the first trial-related activity after the subject signed the informed consent.
  - **Recovering/resolving** This term is only applicable if the subject has completed the trial or has died from another AE. The condition is improving and the subject is expected to recover from the event.
  - **Recovered/resolved with sequelae** The subject has recovered/resolved from the condition, but with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE criterion, the AE must be reported as an SAE.
  - Not recovered/not resolved The condition of the subject has not improved and the symptoms are unchanged, or the outcome is not known at the time of reporting.
  - **Fatal** This term is only applicable if the subject died from a condition related to the reported AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an SAE.
  - Unknown This term is only applicable if the subject is lost to follow-up.

#### Serious adverse event

A serious adverse event is an experience that at any dose results in any of the following:

- Death
- A life-threatening<sup>a</sup> experience
- In-patient hospitalisation<sup>b</sup> or prolongation of existing hospitalisation
- A persistent or significant disability or incapacity<sup>c</sup>
- A congenital anomaly or birth defect
- Important medical events that may not result in death, be life threatening<sup>a</sup> or require hospitalisation<sup>b</sup> may be considered an SAE when based on appropriate medical judgement they may jeopardise the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition of SAE<sup>d</sup>. Suspicion of transmission of infectious agents via trial product must always be considered an SAE

<sup>a</sup> The term "life threatening" in the definition of SAE refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event which hypothetically might have caused death if it was severe.

Protocol		Date:	21 January 2014 Novo Nordi	isk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	61 of 98	

<sup>b</sup> The term "hospitalisation" is used when a subject:

- Is admitted to a hospital or in-patient, irrespective of the duration of physical stay, or
- Stays at the hospital for treatment or observation for more than 24 hours

Medical judgement must always be exercised, and when in doubt, the hospital contact should be regarded as a hospitalisation. Hospitalisations for administrative, trial-related and social purposes do not constitute AEs and should therefore not be reported as AEs or SAEs. Hospital admissions for surgical procedures, planned before trial inclusion, are not considered AEs or SAEs.

<sup>c</sup> A substantial disruption of a subject's ability to conduct normal life functions (e.g., following the event or clinical investigation the subject has significant, persistent or permanent change, impairment, damage or disruption in his/her body function or structure, physical activity and/or quality of life).

<sup>d</sup> For example intensive treatment in an emergency room or at home of allergic bronchospasm, blood dyscrasiasis or convulsions that do not result in hospitalisation, or development of drug dependency or drug abuse.

#### Non-serious adverse event

A non-serious AE is any AE which does not fulfil the definition of an SAE.

#### Medical event of special interest

A medical event of special interest (MESI) is an event which, in the evaluation of safety, has a special focus. A MESI is an AE (SAE or non-serious AE) which fulfils one or more of the below defined MESI criteria.

- 1. Fatal Events (All events with fatal outcome) (A)
- 2. Acute Coronary Syndrome (Myocardial Infarction, Hospitalization for Unstable Angina) (A)
- 3. Cerebrovascular Events (Stroke, Transient Ischemic Attack) (A)
- 4. Coronary Revascularization Procedure (A)
- 5. Heart Failure requiring Hospital Admission (A)
- 6. Pancreatitis or clinical suspicion of pancreatitis (A)
- 7. Neoplasms (A)
- 8. Thyroid Disease ((A) if thyroid neoplasm or resulting in thyroidectomy)
- 9. Medication errors concerning trial products:
  - Administration of wrong drug
  - Wrong route of administration
  - Administration of a high dose with the intention to cause harm (e.g., suicide attempt)
  - Administration of a lower or higher dose than intended (e.g., taking more than the planned number of tablets); however, the administered dose must deviate from the intended dose to

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	21 January 2014 3.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	62 of 98	

an extent where clinical consequences for the trial subject were likely to happen as judged by the investigator, although not necessarily did happen

MESIs marked with an '(A)' in the list above will undergo adjudication by an independent EAC (see Section 12.7.2).

Any event confirmed or suspected to be a MESI must be reported. In case the sponsor identifies potentially missed MESIs through predefined review of available data, the investigator will be asked to reconsider if this is a MESI. However, MESIs should not be reported for screening failures.

For further information regarding definitions of MESIs and an overview of which events that should undergo adjudication, please refer to Appendix C.

When reporting a MESI the following forms must be completed: AE form, eSIF, specific MESI follow-up questions (MESI form) and if applicable, the Event Adjudication Document Collection Form (only events for adjudication) in the eCRF.

#### **Technical complaint**

A technical complaint is any written, electronic, or oral communication that alleges product (medicine or device) defects. The technical complaint may be associated with an AE, but does not concern the AE itself.

Examples of technical complaints:

- The physical or chemical appearance of trial products (e.g., discoloration, particles or contamination)
- The packaging material (e.g., leakage, cracks, rubber membrane issues or errors in labelling text)
- Problems related to devices (e.g., to the injection mechanism, dose setting mechanism, glucose measurement, push button or interface between the pen and the needle)

#### 12.2 Reporting of adverse events

All events meeting the definition of an AE must be collected and reported. This includes events from when the subject has signed the informed consent until the end of the post-treatment follow-up period. The events must be recorded in the applicable eCRF forms in a timely manner (see timelines below and Figure 12–1).

During each contact with the trial site staff, the subject must be asked about AEs and technical complaints, for example by asking: "Have you experienced any problems since the last contact?"

ProtocolDate:21 January 2014Novo NordisTrial ID: NN9924-3790CONFIDENTIALVersion:3.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:63 of 98	UTN: U1111-1136-4716
---	----------------------

All AEs, either observed by the investigator or reported by the subject, must be reported by the investigator and evaluated. Novo Nordisk assessment of expectedness is performed according to the following reference document: IB (Oral Administration of Semaglutide (NN9924)) section 6.2.6.1 Reference safety information, Edition  $5^{6}$  and any updates hereof.

All AEs must be recorded by the investigator on an AE form. The investigator should report the diagnosis, if available. If no diagnosis is available, the investigator should record each sign and symptom as individual AEs using separate AE forms.

For SAEs, an eSIF must be completed in addition to the AE form. If several symptoms or diagnoses occur as part of the same clinical picture, one safety information form can be used to describe all the SAEs.

MESIs, regardless of seriousness, must be reported using both the AE form, the safety information form and a MESI form. The MESI form is an electronic form tailored to collect specific information related to the individual MESIs. For MESIs qualifying for event adjudication, an Event Adjudication Document Collection Form will also have to be completed in the eCRF. The Event Adjudication Document Collection Form is a check list of clinical data to be provided from the site.

The AE form for a non-serious AE should be signed when the event is resolved or at the end of the trial.

#### **Timelines for initial reporting of AEs:**

The investigator must complete the following forms in the CRF/eCRF within the specified timelines:

• **SAEs**: The AE form **within 24 hours** and the safety information form **within 5 calendar** days of the investigator's first knowledge of the SAE

Both forms must be signed within 7 calendar days from the date the information was entered in the eCRF.


- **SAEs fulfilling the MESI criteria**: In addition to above, the MESI form **within 14 calendar days** of the investigator's first knowledge of the AE
- Non-serious AE fulfilling the MESI criteria: The AE form, and safety information form and MESI form within 14 calendar days of the investigator's first knowledge of the event.

If a MESI fulfils the Event Adjudication criteria the investigator must complete the Event Adjudication Document Collection Form within 14 calendar days of the investigator's first knowledge of the adverse event.

Inia ID: NN9924-3790         CONFIDENTIAL         Version         3.0           UTN: U1111-1136-4716         Status:         Final           EudraCT No.: 2012-004994-16         Page:         64 of 98		CONFIDENTIAL			Novo Nordisk
---	--	--------------	--	--	--------------

If the eCRF is unavailable, the concerned AE information must be reported on paper forms and sent to Novo Nordisk by fax, e-mail or courier within the same timelines as stated above. When the eCRF becomes available again, the investigator must re-enter the information on the appropriate forms in the eCRF.

Contact details (fax, telephone, e-mail and address) are provided in the investigator's trial file.



#### Figure 12-1 Initial reporting of AEs

#### Reporting of trial product-related SUSARs by the sponsor:

Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious adverse reactions (SUSARs) in accordance with local requirements and  $GCP^1$ . In addition, the investigator will be informed of any trial-related SAEs that may warrant a change to any trial procedure.

In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, including EMA, of trial product-related SUSARs. In addition, Novo Nordisk will inform the IRBs/IECs of trial product-related SUSARs in accordance with local requirement and GCP<sup>1</sup>, unless locally this is an obligation of the investigator.

Protocol         CONFIDEN           Trial ID: NN9924-3790         CONFIDEN           UTN: U1111-1136-4716         CONFIDEN           EudraCT No.: 2012-004994-16         CONFIDEN		21 January 2014 Novo Nordisk 3.0 Final 65 of 98
---	--	--

#### 12.3 Follow-up of adverse events

During and following a subject's participation in the trial, the investigator should ensure that adequate medical care is provided to the subject for any AE, including significant laboratory values related to the trial. The investigator should inform the subject when medical care is needed for AE(s) of which the investigator becomes aware.

The investigator must record follow-up information by updating the forms in the eCRF.

Follow up information must be reported to Novo Nordisk according to the following:

• **SAEs:** All SAEs must be followed up until the outcome of the event is "recovered/resolved", "recovered/resolved with sequelae" or "fatal", and until all queries have been resolved. Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome "recovering/resolving" or "not recovered/not resolved". Cases can be closed with the outcome of "recovering/resolving" when the subject has completed the follow-up period and is expected by the investigator to recover.

The SAE follow-up information should only include new (e.g., corrections or additional) information and must be reported **within 24 hours** of the investigator's first knowledge of the information. This is also the case for previously non-serious AEs which subsequently become SAEs. The applicable forms must be signed within 7 calendar days from the date the new information was entered in the eCRF.

- Non-serious AEs: Non-serious AEs must be followed until the outcome of the event is "recovering/resolving", "recovered/resolved" or "recovered(resolved with sequelae" or until the end of the follow-up period stated in the protocol, whichever comes first, and until all queries related to these AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome "recovering/resolving" or "not recovered/not resolved". Cases can be closed with the outcome of "recovering/resolving" when the subject has completed the follow-up period and is expected by the investigator to recover.
- Non-serious AE fulfilling the MESI criteria: Follow-up information on MESIs should only include new (e.g., corrections or additional) information and must be reported within 14 calendar days of the investigator's first knowledge of the information. This is also the case for previously non-serious AEs which subsequently fulfil the MESI criteria.

The investigator must record follow-up information on non-serious AEs by updating the AE form in the eCRF.

Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	66 of 98	

The investigator must ensure that the worst case severity and seriousness of an event is kept throughout the trial. A worsening of an unresolved AE must be reported as follow up with re-assessment of severity and/or seriousness of the event.

Queries or follow-up requests from Novo Nordisk must be responded to **within 14 calendar days** from the date of receipt of the request, unless otherwise specified in the follow-up request.

#### 12.4 Technical complaints and technical complaint samples

#### 12.4.1 Reporting of technical complaints

All technical complaints on any of the following products:

- Semaglutide tablets
- Placebo tablets
- Semaglutide for s.c. injection, solution for injection, 1.5 mL pre-filled PDS290 pen injector
- Semaglutide placebo for s.c. injection, solution for injection, 1.5 mL pre-filled PDS290 peninjector (test pen)
- Novo Nordisk needles

which occur from the time of first usage of the product until the time of the last usage of the product, must be collected and reported to Customer Complaint Center, Novo Nordisk.

Contact details (fax, e-mail and address) are provided in the investigator's trial file.

The investigator must assess whether the technical complaint is related to any AEs, SAEs and/or MESI.

Technical complaints must be reported on a separate technical complaint form for each product listed. If the technical complaint involves more than one code number, lot number or DUN, a technical complaint form for each code number, lot number or DUN must be completed.

The investigator must complete the technical complaint form in the eCRF within the following timelines of the trial site obtaining knowledge of the technical complaint:

- Technical complaint assessed as related to an SAE within 24 hours
- All other technical complaints within 5 calendar days

If the eCRF is unavailable or when reporting a technical complaint that is not subject related, the information must be provided on a paper form by fax, e-mail or courier to Customer Complaint Center, Novo Nordisk, within the same timelines as stated above.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 67 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

#### 12.4.2 Collection, storage and shipment of technical complaint samples

The investigator must collect the technical complaint sample and notify the monitor **within 5 calendar days** of obtaining the sample at trial site. The monitor must coordinate the shipment to Customer Complaint Center, Novo Nordisk (the address is provided in the investigator's trial file) and ensure that the sample is sent as soon as possible. A print of the technical complaint form must be sent with the sample.

The investigator must ensure that the technical complaint sample contains the code number and, if available, the DUN.

If the technical complaint sample is unobtainable, the investigator must specify on the technical complaint form why it is unobtainable.

Storage of the technical complaint sample must be done in accordance with the conditions prescribed for the product. The shipment of the technical complaint sample should be done in accordance with the same conditions as for storage (see Section  $\underline{9}$ ).

#### 12.5 Pregnancies

Female subjects must be instructed to notify the investigator immediately if they become pregnant during the trial. The investigator must report any pregnancy in subjects who have received trial product(s).

The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is one month of age.

The investigator must report information about the pregnancy, pregnancy outcome, and health of the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and newborn infant.

The following must be collected and reported by the investigator to Novo Nordisk – electronically (e.g., in PDF format), or by fax or courier:

#### 1. Reporting of pregnancy information

Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to be reported on Maternal Form 1A and 1B, respectively.

When the pregnancy outcome is abnormal (i.e., congenital anomalies, foetal death including spontaneous abortion and/or any anomalies of the foetus observed at gross examination or during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further information has to be reported for the female subject on Maternal Form 2. In addition, information from the male partner has to be reported on the Paternal Form, after an informed consent has been obtained from the male partner.

ProtocolDate:Trial ID: NN9924-3790CONFIDENTIALVersion:UTN: U1111-1136-4716Status:Status:EudraCT No.: 2012-004994-16Page:	21 January 2014 3.0 Final 68 of 98	Novo Nordisk
--	---	--------------

Initial reporting and follow-up information must be reported **within 14 calendar days** of the investigator's first knowledge of initial or follow-up information.

#### 2. Reporting of AE information

The investigator has to report AEs in connection with the pregnancy as well as in the foetus and newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal death (including spontaneous abortion), and congenital anomalies (including those observed at gross examination or during autopsy of the foetus), as well as other pregnancy complications fulfilling the criteria of an SAE.

#### Forms and timelines for reporting AEs:

Non-serious AEs:

• Paper AE form\* within 14 calendar days of the investigator's first knowledge of the initial or follow-up information to the non-serious AE

SAEs:

- Paper AE form\* within 24 hours of the investigator's first knowledge of the SAE
- Paper safety information form **within 5 calendar days** of the investigator's first knowledge of the SAE
- **SAE follow-up information** to the AE form and/or safety information form **within 24 hours** of the investigator's first knowledge of the follow-up information

\* It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in the subject, foetus or newborn infant.

Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy forms must be responded to by the investigator **within 14 calendar days** from the date of receipt of the request, unless otherwise specified in the follow-up request.

#### 12.6 Precautions and/or overdose

There are no specific antidotes to semaglutide. Treatment of an overdose should be symptomatic.

There is a potential risk of hypoglycaemia during dosing with semaglutide. The typical signs and symptoms of confirmed hypoglycaemia include: hunger, slight headache, nausea, light-headedness, palpitations and sweating. Major hypoglycaemia (severe) may produce loss of consciousness. Symptoms of confirmed and not major hypoglycaemia should be treated by ingestion of carbohydrates.

Major hypoglycaemia resulting in loss of consciousness should be treated at the investigator's discretion according to best available medical practise.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 69 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

One case of accidental overdose of oral semaglutide with SNAC was reported in the NN9924-3692 trial in a subject treated with 20 mg semaglutide with 300 mg SNAC. The subject accidentally took the trial product twice on Day 52 of the trial. No AEs were reported at the time. The medication error was discovered at the next scheduled visit. The subject did not report any symptoms and treatment was continued without any change.

One case of accidental overdose has been reported in s.c. semaglutide treated subjects. The case classified as moderate in severity and considered to be probably related to semaglutide was reported by a subject enrolled in trial NN9535-1821. No hospitalisation was needed. The subject inadvertently injected mg of semaglutide instead of mg, which corresponds to a 2.5-fold higher dose than the maximum dose included in that trial. After

For further details please see the current edition of the IB (Oral Administration of Semaglutide (NN9924) Edition  $5^{6}$  and any updates hereof.

#### 12.7 Committees related to safety

#### 12.7.1 Novo Nordisk safety committee

Novo Nordisk will constitute an internal Oral GLP-1 safety committee to perform on-going safety surveillance. The Oral GLP-1 safety committee may recommend un-blinding of any data for further analysis, and in this case an independent ad hoc safety group will be established in order to maintain the blinding of the trial personnel.

#### 12.7.2 Event adjudication committee

An external event adjudication committee (EAC) is established to perform qualitative or quantitative validation of selected AEs according to pre-defined diagnostic criteria. The validation is based on review of pre-defined clinical data related to the specific AE.

The events are reviewed by the EAC in an independent and blinded manner.

The EAC is composed of permanent members covering required medical specialities. EAC members must disclose potential conflicts of interest and must be independent of Novo Nordisk. The role of the EAC is solely to adjudicate events in a blinded manner. The EAC will have no authorisations to impact on trial conduct, trial protocol or amendments.

Protocol Trial ID: NN9924-3790		Date: Version:	21 January 2014 3.0	Novo Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Status: Page:	Final 70 of 98	

The EAC works in accordance with written guidelines included in the EAC Charter describing in details the composition, tasks, responsibilities, and work processes of the committee.

The events will be adjudicated according to FDA requirements and the adjudication vendor will ensure that the EAC gets access to all the documents provided by the investigator. The EAC will initiate the review and may ask for additional information that the investigator needs to provide if it is available.

The EAC will review copies in English (translated if necessary) of medical documentation received in the adjudication packages (e.g., X-ray images, ECGs, ultrasound images, discharge summaries, pathology reports and death certificates). The investigator must provide medical documentation within 4 weeks of event identification.

The assessments made by the EAC will be included in the CTR as well as assessments made by the investigator. However, the adjudication made by an EAC, given its independence and in-depth analysis of each event, will be attributed with greater importance of the two. The outcomes of adjudication will be kept in the clinical trial database.

The following AEs will be adjudicated in this trial:

- Fatal Events (All events with fatal outcome)
- Acute Coronary Syndrome (Myocardial Infarction, Hospitalization for Unstable Angina)
- Cerebrovascular Events (Stroke, Transient Ischemic Attack)
- Coronary Revascularization Procedure
- Heart Failure requiring Hospital Admission
- Pancreatitis or clinical suspicion of pancreatitis
- Neoplasms
- Thyroid Disease (if thyroid neoplasm or resulting in thyroidectomy)

Event adjudication will not be performed for AEs in screening failures.

There are two processes for capturing AEs for adjudication: Direct reporting of MESIs by the investigator and by potential missed MESI process.

Direct reporting of MESI by investigator: For each AE reported in the eCRF, the investigator must complete whether the event in his/her opinion is a MESI (yes/no).

By ticking YES:

- The investigator must specify the type of MESI event being reported
- The investigator must complete the event adjudication document collection form ('adjudication form') in the eCRF according to the timeline specified in Section <u>12.2</u>. This form indicates the data/documents required for adjudication

EudraCT No. 2012-004994-16 Page 71 of 98	Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 71 of 98	Novo Nordisk
--	--	--------------	---------------------------------------	---	--------------

• For each required document the investigator should specify/indicate when/if the data/document will be available. If a document is unobtainable this needs to be specified. The investigator must provide medical documentation within 4 weeks of event identification

#### By ticking NO:

All NOs within the relevant MESI category are screened for being potential missed MESI.

- If needed, the investigator will be asked to provide an explanation of why the event is not reported as a MESI (alternative etiology)
- The vendor or EAC can evaluate an event not initially reported as a MESI for adjudication to be adjudicated. In this case the investigator must provide data/documents required for adjudication as soon as possible when receiving a request from Novo Nordisk or the vendor

A site manual will be provided to each site detailing the specifics surrounding the medical documentation that must be provided by site to the adjudication vendor including how this documentation should be provided.

#### 12.7.3 Calcitonin monitoring committee

The CMC will provide recommendations to the investigators with regards to further investigation and treatment of the individual subject (see Appendix A).

Protocol	NTIAL Date:	21 January 2014 Novo Nordisk
Trial ID: NN9924-3790	Version:	3.0
UTN: U1111-1136-4716	Status:	Final
EudraCT No.: 2012-004994-16	Page:	72 of 98

### 13 Case report forms

Novo Nordisk will provide a system for the eCRF. This system and support services to the system will be supplied by a vendor.

Ensure that all relevant questions are answered and that no empty data field exists. If a test or an assessment has not been done and will not be available, or if the question is irrelevant (e.g., is not applicable), indicate this according to the data entry instructions.

The following will be provided as paper CRFs:

Pregnancy forms

In addition paper AE forms, SIF and technical complaint forms will be provided. These must be used when access to the eCRF is revoked (i.e., EDC system not available).

On the paper CRF forms print legibly, using a ballpoint pen. Ensure that all questions are answered, and that no empty data blocks exist. Ensure that no information is recorded outside the data blocks. If a test/assessment has not been done and will not be available, indicate this by writing "ND" (not done) in the appropriate answer field in the CRF. If the question is irrelevant (e.g., is not applicable) indicate this by writing "NA" (not applicable) in the appropriate answer field. Further guidance can be obtained from the instructions in the CRF.

The investigator must ensure that all information is consistent with the source documentation. By electronically signing the case book in the eCRF, the investigator confirms that the information in the eCRF and related forms is complete and correct.

#### **13.1** Corrections to case report forms

Corrections to the eCRF data may be made by the investigator or the investigator's authorised staff. An audit trail will be maintained in the eCRF application containing as a minimum: the old and the new data, identification of the person entering the data, date and time of the entry and reason for the correction.

If corrections are made by the investigator's authorised staff after the date the investigator has signed the case book, the case book must be signed and dated again by the investigator.

#### 13.2 Case report form flow

The investigator must ensure that data are recorded in the eCRF as soon as possible after the visit, preferably within 5 days. Once data have been entered, they will be available to Novo Nordisk for data verification and validation purposes.

Protocol		Date:	21 January 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0	
UTN: U1111-1136-4716	CUNFIDENHAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	73 of 98	

At the end of the trial the investigator must ensure that all remaining data have been entered into the eCRF, preferably within 3 days after the last subject's last visit at the site in order to ensure the planned lock of the database.

Site specific eCRF data (in an electronic readable format) will be provided to the trial site before access to the eCRF is revoked. This data must be retained at the trial site.

#### **13.3** Paper case report forms

The pregnancy forms are paper based CRFs. Also, the SIF, technical complaint form and AE form will be provided in paper but are only to be used if for any reason the eCRF is unavailable.

The investigator must ensure that data are recorded in these forms as soon as possible after the visit and ensure that Novo Nordisk receives these forms within the required timelines (see Sections <u>12.2</u>, <u>12.4.1</u> and <u>12.5</u>).

Corrections to the data in the CRFs may only be made by drawing a straight line through the incorrect data and then writing the correct entry next to the data that were crossed out. Each correction must be initialled, dated and explained (if necessary) by the investigator or the investigator's authorised staff.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 3.0 Final 74 of 98

## 14 Monitoring procedures

During the course of the trial, the monitor will visit the trial site to ensure that the protocol is adhered to, that all issues have been recorded, to perform source data verification and to monitor drug accountability. The first monitoring visit will be performed as soon as possible after FSFV and no later than 4 weeks after. The monitoring visit intervals will depend on the outcome of the remote monitoring of the eCRFs, the trial site's recruitment rate and the compliance of the trial site to the protocol and GCP, but will not exceed 4 weeks during the recruitment period (i.e., from FSFV to last subject first visit (LSFV)). After LSFV the monitoring visit intervals will not exceed 8 weeks.

The monitor must be given direct access to source documents (original documents, data and records). Direct access includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important to the evaluation of the trial. If the electronic medical record does not have a visible audit trail, the investigator must provide the monitor with signed and dated printouts. In addition the relevant trial site staff should be available for discussions at monitoring visits and between monitoring visits (e.g., by telephone).

All data must be verifiable in source documentation other than the eCRF (except for BMI).

For all data recorded the source document must be defined in a source document agreement at each trial site. There must only be one source defined at any time for any data element.

For screening failures the monitor will ensure that relevant eCRF pages and other trial-related forms containing data from screening failures are completed. For screening failures the following data should be source verified: informed consent, reason for screening failure and AEs, if any.

Source data generated by the trial site can be corrected by another person than the person entering the source data if accepted by local regulations; any correction must be explained, signed and dated by the person making the correction.

The completed diaries will be collected from the subject at each site visit and must be kept as source data at the site. The investigator/delegate must transcribe the data into the eCRF.

The monitor will ensure that the eCRFs are completed on an ongoing basis and within agreed timelines.

Monitors must review the subject's medical records and other source data (e.g., the diaries and PROs) to ensure consistency and/or identify omissions compared to the eCRF. If discrepancies are found, the investigator must be questioned about these.

A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring visit addressing any action to be taken.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 Novo Nordisk 3.0 Final 75 of 98

## 15 Data management

Data management is always the responsibility of Novo Nordisk. Data management may be delegated under an agreement of transfer of responsibilities to an external contract research organisation (CRO).

Appropriate measures, including encryption of data files containing person identifiable data, will be used to ensure confidentiality of subject data, when they are transmitted over open networks.

Data from central laboratories will be transferred electronically from the laboratory performing the analyses. In cases where laboratory data are transferred via non-secure electronic networks, data will be encrypted during transfer.

The subject and any biological material obtained from the subject will be identified by subject number and trial identification number. Appropriate measures such as encryption or leaving out certain identifiers will be enforced to protect the identity of subjects in all presentations and publications as required by local, regional and national requirements.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 76 of 98	Novo Nordisk

## 16 Computerised systems

Novo Nordisk will capture and process clinical data using computerised systems that are described in Novo Nordisk Standard Operating Procedures and IT architecture documentation. The use and control of these systems are documented.

Investigators working on the trial may use their own electronic systems to capture source data.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16

**CONFIDENTIAL** 

Date: Version: Status: Page: 21 January 2014 | **Novo Nordisk** 3.0 Final 77 of 98

## 17 Statistical considerations

If necessary, a statistical analysis plan (SAP) may be written in addition to the protocol, including a more technical and detailed elaboration of the statistical analyses. The SAP will be finalised before database lock.

Results from the statistical analysis will generally be presented by two-sided confidence intervals with a confidence level of 95% including a p-value for test of no difference between treatments.

The stratification variable referred to in the following is defined as the two level factor of treatment with metformin (yes/no).

The "planned comparisons between treatment arms" referred to in this section covers the following comparisons: a) between each of the oral semaglutide treatment arms and placebo, b) between the s.c. semaglutide arm and placebo, c) between each of the oral semaglutide treatment arms and s.c. semaglutide, and d) between the three treatment arms with an end dose of 40 mg.

A standard mixed model for repeated measurements (MMRM) will be used in the analysis of the primary and continuous secondary endpoints. The model will include treatment, country and the stratification variable as fixed factors, and the corresponding baseline value as covariate. All factors and the covariate will be nested within visit. Unless otherwise stated, the estimated differences with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms.

In order to describe the dose-response relation of oral semaglutide and estimate the relative potency vs. s.c. semaglutide with regards to selected key endpoints, an explorative analysis will be conducted. In this model data from oral semaglutide arms using the standard titration scheme will be included. One or both of the treatment arms with an end dose of 40 mg using an alternative titration scheme may be included and pooled with the oral semaglutide arm with an end dose of 40 mg and using the standard titration scheme, if deemed appropriate based on the planned pairwise comparisons between the arms. Data from the placebo arm (corresponding to a dose of zero mg) could be included if deemed appropriate. The model will developed ad hoc after unblinding and aim for a suitable fit of the dose-response relation using e.g. a linear or a four-parameter logistic relation of the endpoint of interest vs. the logarithm of the dose.

#### 17.1 Sample size calculation

The primary endpoint, change from baseline to end of treatment (i.e., after 26 weeks of treatment) in HbA1c, will be analysed by the standard MMRM.

In order to demonstrate efficacy of oral semaglutide the sample size is based on an initial comparison of change from baseline to end of treatment (i.e., after 26 weeks of treatment) in HbA<sub>1c</sub>

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 78 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

between a) the pool of the two treatment arms using standard and fast escalation regimens, respectively, to an end dose of 40 mg and b) placebo.

A standard deviation (SD) of 1.2% for change from baseline in  $HbA_{1c}$  is chosen as assumption for the sample size calculation. The SD observed in several phase 3 trials of 26 weeks duration with s.c. liraglutide suggests a standard deviation less than 1.1%. However, as it is uncertain if the added variation in exposure compared to s.c. semaglutide will transfer to an added variation in the therapeutic response, a SD of 1.2% is assumed.

In trial NN9535-1821 the withdrawal rate for the doses 0.2 mg-0.8 mg was 16%-24%. In the present trial, GI events are mitigated by dose escalation and based on this the drop-out rate is expected to be 20%, equally distributed among treatment arms. For completers the treatment difference between the pooled 40 mg arm and placebo is expected to be at least 0.64% whereas for dropouts the treatment difference is set conservatively to 0.32%, thus leading to a detectable mean difference of 0.58%. With these assumptions, and using a two-sided t-test with a significance level of 5%, 134 subjects should be randomised to the pooled 40 mg treatment arm and 67 to placebo in order to have 90% power to demonstrate superiority of the pooled 40 mg treatment arm versus placebo. For similarity between the treatment arms, 67 subjects should be randomised in each of the nine treatment arms.

In total, 603 subjects are to be randomised.

#### 17.2 Definition of analysis sets

**Full Analysis Set (FAS):** includes all randomised subjects who have received at least one dose and have any post randomisation data. The statistical evaluation of the FAS will follow the intention-to-treat (ITT) principle and subjects will contribute to the evaluation "as randomised".

**Safety Analysis Set (SAS):** includes all subjects exposed to at least one dose of randomised semaglutide or semaglutide placebo. Subjects in the SAS will contribute to the evaluation "as treated".

Before data are locked for statistical analysis, a review of all data will take place. Any decision to exclude a subject or single observations from the statistical analysis is the joint responsibility of the members of the study group. Exclusion of data from analyses will be used restrictively and normally no data should be excluded from the FAS. The subjects or observations to be excluded, and the reasons for their exclusion, must be documented and signed by those responsible before database lock. The subjects and observations excluded from analysis sets, and the reason for this, will be described in the CTR.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 79 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

#### 17.3 Primary endpoint

The primary endpoint, change from baseline to end of treatment (i.e., after 26 weeks of treatment) in HbA1c, will be analysed by the standard MMRM.

In order to confirm efficacy of oral semaglutide without risk of inflation of the type 1 error an initial comparison of the primary endpoint between a) the pool of the two treatment arms using standard and fast escalation regimens to an end dose of 40 mg and b) placebo. The comparison will be made using the MMRM by estimating the difference between the mean of means in the two 40 mg arms and the mean in placebo. The estimated difference with corresponding two sided p-value and 95% confidence interval at 26 weeks will be presented, and efficacy of oral semaglutide will be considered confirmed if the upper limit of the confidence interval is strictly less than zero.

If efficacy of oral semaglutide is confirmed the planned comparisons between the nine original treatment arms will be evaluated.

Subjects in the FAS and only measurements taken before treatment discontinuation or initiation of rescue therapy will be included in the analysis.

Due to the uncertainty in relation to if the added variation in the exposure in the oral semaglutide arms compared to s.c. semaglutide will transfer to an added variation in the therapeutic response, a sensitivity analysis allowing the within subject unstructured covariance matrix to be fitted separately for each treatment arm will be conducted.

Furthermore, the following sensitivity analyses will be conducted in order to investigate the sensitivity of the results due to the impact of missing values:

- An MMRM similar to the primary analysis but including all data recorded after randomisation regardless of the data being obtained when the subjects have received rescue therapy or have discontinued randomised treatment.
- An analysis of covariance (ANCOVA) model including subjects in the FAS and using imputation of missing values according to the last observation carried forward (LOCF) method. The model will include fixed factors for treatment, country and the stratification variable and the baseline value as covariate. In accordance with the LOCF method, the dependent variable will be the last available value obtained within the 26 weeks period of the study.
- A completer analysis, i.e. an ANCOVA similar to the one above including only data obtained at 26 weeks from subjects who:
  - did not discontinue treatment prematurely
  - did not receive rescue therapy
  - had a valid HbA<sub>1c</sub> assessment at baseline and after 26 weeks of treatment

#### 17.4 Supportive secondary endpoints

#### 17.4.1 Efficacy endpoints

The FAS will be used in all analyses of the supportive secondary efficacy endpoints.

#### Subjects who, after 26 weeks of treatment, achieve (yes/no) HbA<sub>1c</sub> <7% (53 mmol/mol)

The binary endpoint will be analysed by a logistic regression model which will include fixed factors for treatment and the stratification variable and baseline  $HbA_{1c}$  as a covariate. Estimated odds ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms. Missing response data at 26 weeks will be imputed from the MMRM used for the primary analysis of  $HbA_{1c}$ .

## Change from baseline to week 26 in body weight, waist circumference and fasting plasma glucose.

These endpoints will be analysed by the standard MMRM.

# Change from baseline to week 26 in C-peptide, fasting insulin, glucagon, HOMA-IR, HOMA-B, total cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides and free fatty acids.

For each endpoint, the assessments at every week will be log-transformed and subsequently analysed by the standard MMRM. The estimated differences and corresponding 95% confidence intervals at 26 weeks will be back transformed and presented as ratios together with the two sided p-values.

The fasting HOMA endpoints (i.e., fasting HOMA-B and HOMA-IR) will be calculated based on fasting insulin and FPG as follows:

- 1. Fasting HOMA-B (%) = 20 x fasting insulin  $[\mu U/ml]/(FPG[mmol/L]-3.5)$
- 2. Fasting HOMA-IR (%) = fasting insulin  $[\mu U/ml]$  x FPG [mmol/L]/22.5

#### **PRO** outcomes

The outcomes from the SF-36 in terms of total scores overall and within each domain will be calculated and each of these scores will be analysed by the standard MMRM.

#### 17.4.2 Safety endpoints

All safety endpoints will be summarised and analysed using the safety analysis set. Unless otherwise specified safety endpoints will be analysed by descriptive statistics only.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 81 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

## **Adverse events**

All AEs will be coded using the most recent version of the Medical Dictionary for regulatory Activities (MedDRA) coding. A TEAE is defined as an event that has onset date (or increase in severity) on or after the first day of exposure to randomised treatment and no later than the followup visit. TEAEs are summarised descriptively, whereas non-treatment emergent AEs are presented in listings.

## Number of confirmed treatment emergent hypoglycaemic episodes

A hypoglycaemic episode will be defined as *treatment emergent* if the onset of the episode occurs on or after the first day of trial product administration and no later than the follow-up visit.

Hypoglycaemic episodes are classified according to the Novo Nordisk classification of confirmed hypoglycaemia and the ADA classification of hypoglycaemia (see Figure 17–1).

## Confirmed hypoglycaemia

In normal physiology, symptoms of hypoglycaemia occur below a plasma glucose level of 3.1 mmol/L (56 mg/dL)<sup> $\frac{14}{1}$ </sup>. Therefore, Novo Nordisk has included hypoglycaemia with plasma glucose levels below this cut-off point in the definition of confirmed hypoglycaemia.


*Confirmed* hypoglycaemic episodes are defined as episodes that are:

- severe according to the ADA classification below and/or
- biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia

# ADA classification<sup>15</sup> of hypoglycaemia

- *Severe hypoglycaemia:* An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose back to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
- Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured plasma glucose concentration  $\leq$  3.9 mmol/L (70 mg/dL)
- *Documented symptomatic hypoglycaemia:* An episode during which typical symptoms of hypoglycaemia are accompanied by a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).
- *Pseudo-hypoglycaemia:* An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured plasma glucose concentration > 3.9 mmol/L (70 mg/dL) but approaching that level.

 Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a plasma glucose determination (but that was presumably caused by a plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).



#### Figure 17–1 ADA classification of hypoglycaemia

Data on treatment emergent hypoglycaemic episodes will be summarised descriptively using the above definitions.

The number of confirmed treatment emergent hypoglycaemic episodes during 26 weeks treatment will be analysed using a negative binomial regression model with a log-link function and the logarithm of the time period in which an occurrence of a hypoglycaemic episode is considered treatment emergent as offset. The model will include treatment, country and stratification variable as fixed factors and baseline HbA<sub>1c</sub> as covariate. Estimated rate ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms.

# Change in pulse, systolic- and diastolic blood pressure from baseline to after 26 weeks of treatment

These endpoints will be analysed by the standard MMRM.

#### Change in amylase and lipase from baseline to after 26 weeks of treatment

For each endpoint, the assessments at every week will be log-transformed and subsequently analysed by the standard MMRM. The estimated differences and corresponding 95% confidence

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 83 of 98

intervals at 26 weeks will be back transformed and presented as ratios together with the two sided p-values.

Change from baseline to after 26 weeks of treatment in electrocardiogram (ECG), physical examination, laboratory safety variables (haematology, biochemistry, hormone and urinalysis) other than amylase and lipase

These endpoints will be summarised by descriptive statistics.

Endpoints related to occurrence of anti-semaglutide antibodies during 26 weeks of treatment: Antibody level during 26 weeks of treatment, anti-semaglutide antibodies (positive/negative), anti-semaglutide antibodies with *in vitro* neutralising effect (positive/negative), antisemaglutide antibodies cross reacting with endogenous GLP-1 (positive/negative), cross reacting antibodies with *in vitro* neutralising effect to endogenous GLP-1 (positive/negative)

These endpoints will be summarised by descriptive statistics and correlated to PK and PD.

# 17.4.3 Pharmacokinetics and/or pharmacodynamics modelling

If relevant, population PK and PK/PD modelling will be used to evaluate semaglutide exposure and exposure-response relationship after oral and subcutaneous administration in subjects with T2D to inform dose selection in future trials.

The objectives of these exploratory analyses are to:

- assess the dose-dependence of semaglutide exposure in plasma
- explore the effects of covariates on semaglutide exposure
- explore the relationship between semaglutide exposure and response variables of interest

The modelling will be performed by Quantitative Clinical Pharmacology at Novo Nordisk A/S and will be reported separately from the CTR.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:
--	--------------	---------------------------------------

21 January 2014 | Novo Nordisk 3.0 Final 84 of 98

# 18 Ethics

The trial will be conducted in compliance with ICH GCP<sup>1</sup> and applicable regulatory requirements, and in accordance with the Declaration of Helsinki<sup>2</sup>.

All subjects will be included after a thorough evaluation in regards to in- and exclusion criteria defined in order to ensure that subjects are eligible for trial treatment. Subjects will be treated within a regimen anticipated to be better than or equal to the treatment they receive at the time of entry into the trial. However, they will have to spend some extra time, as additional assessments and visits to the clinic are required. It is the responsibility of the investigator to ensure the best possible care according to the principles outlined in Diabetes Care 2013, Standards of Medical Care in Diabetes<sup>16</sup>, or any updates thereof.

It is concluded that the potential benefits from participating in the trial outweigh the potential risks. The safety profile of semaglutide generated from the clinical and nonclinical development programme has not revealed any safety issues that would prohibit administration of once-daily oral doses of 2.5-40 mg semaglutide or once-weekly doses of 1.0 mg semaglutide in accordance with the planned clinical trial. Furthermore, a rescue strategy is implemented in this trial to ensure the safety of subjects experiencing deterioration of glycaemic control during the course of the trial to address the concern regarding the placebo arm and the inclusion of patients with an HbA<sub>1c</sub> up to 9.5%. It is concluded that the risk to the subjects in this trial is low and acceptable in view of the benefits a GLP-1 analogue in a tablet formulation would provide to people with T2D.

The trial products may be associated with AEs, but relevant precautions have been implemented in the design and planned conduct of the trial in order to minimise the risks and inconveniences of participation in the trial. These precautions include thorough information regarding the correct administration of the trial products and gradual dose adjustment. Furthermore, subjects are fully informed about possible AEs and inconveniences and will be instructed to contact the investigator in case of any concerns regarding the trial participation.

# 18.1 Informed consent

In seeking and documenting informed consent, the investigator must comply with applicable regulatory requirement(s) and adhere to ICH  $GCP^{1}$  and the requirements in the Declaration of Helsinki<sup>2</sup>.

Before any trial-related activity, the investigator must give the subject verbal and written information about the trial and the procedures involved in a form that the subject can read and understand. The subject is allowed to bring a companion when the oral information is provided.

The subjects must be fully informed of their rights and responsibilities while participating in the trial as well as possible disadvantages of being treated with the trial products.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716	<b>CONFIDENTIAL</b>	Date: Version: Status:	21 January 2014 3.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	85 of 98	

The investigator must ensure the subject ample time to come to a decision whether or not to participate in the trial.

A voluntary, signed and personally dated informed consent form will be obtained from the subject before any trial-related activity.

The responsibility for seeking informed consent must remain with the investigator, but the task may be delegated by the investigator to a medically qualified person, in accordance with local requirements. The written informed consent must be signed and personally dated by the person who seeks the informed consent before any trial-related activity.

If information becomes available that may be relevant to the subject's willingness to continue participating in the trial, the investigator must inform the subject in a timely manner and a revised written subject information must be provided and a new informed consent must be obtained.

# 18.2 Data handling

If the subject is withdrawn from the trial or lost to follow-up, then the subject's data will be handled as follows:

- Data already collected will be retained by Novo Nordisk, entered into the database and used for the trial report
- Safety events will be reported to Novo Nordisk and regulatory authorities according to local and national requirements

If data are used, it will always be in accordance with local law and IRBs/IECs.

#### **18.3** Premature termination of the trial and/or trial site

Novo Nordisk, the investigator, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial or a trial site at any time, but agreement on procedures to be followed must be obtained.

If a trial is suspended or prematurely terminated, the investigator must inform the subjects promptly and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk should also promptly inform the IRBs/IECs and provide a detailed written explanation. The relevant regulatory authorities should be informed.

If, after the termination of the trial, the risk/benefit analysis changes, the new evaluation should be provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have participated in the trial. If it does have an impact, the actions needed to inform and protect the subjects should be described.

An interim analysis to allow for premature discontinuation of the trial has not been planned.

**CONFIDENTIAL** 

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 86 of 98

# **19 Protocol compliance**

Deviations from the protocol should be avoided.

If deviations do occur, the investigator must inform the monitor and the implications of the deviation must be reviewed and discussed.

Deviations must be documented and explained in a protocol deviation by stating the reason, date, and the action(s) taken. Some deviations, for which corrections are not possible, can be acknowledged and confirmed via edit checks in the eCRF or via listings from the clinical database.

Documentation on all protocol deviations must be kept in the investigator's trial file and Novo Nordisk trial master file.

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 87 of 98	Novo Nordisk

# 20 Audits and inspections

Any aspect of the clinical trial may be subject to audits conducted by Novo Nordisk or inspections from domestic or foreign regulatory authorities or from IRBs/IECs. Audits and inspections may take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff have an obligation to cooperate and assist in audits and inspections. This includes giving auditors and inspectors direct access to all source documents and other documents at the trial site relevant to the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) and report(s) that are relevant to the evaluation of the trial.

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 88 of 98

# 21 Critical documents

Before a site is allowed to start screening subjects, the following documents must be available to Novo Nordisk:

- Regulatory approval and/or acknowledgement of notification as required
- Approval/favourable opinion from IRBs/IECs clearly identifying the documents reviewed as follows: protocol, any substantial protocol amendments, subject information/informed consent form, any other written information to be provided to the subject and subject recruitment materials
- List of IRB/IEC members and/or constitution
- Curricula vitae of the investigator and sub-investigator(s) (current, dated and signed must include documented GCP training or a certificate)
- Signed receipt of Investigator's Brochure
- Signed and dated agreement on the final protocol
- Signed and dated agreement on any substantial protocol amendment, if applicable
- Financial agreement(s)
- Source document agreement
- Central laboratory certification and normal ranges
- Insurance statement, if applicable
- Signed and dated Investigator Agreement
- Financial disclosure form for all investigators
- For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of Financial Conflict of Interest
- For US trial sites: FDA Form 1572 must be completed and signed by each investigator

# FDA form 1572:

For US sites:

- Intended for US sites
- Conducted under the IND
- All US investigators, as described above, will sign FDA form 1572

# FDA form 1572 (for sites outside the US):

For sites outside the US:

- Intended for participating sites outside of the US
- Not conducted under the IND
- All investigators outside of the US will not sign FDA form 1572

Novo Nordisk will analyse and report data from all sites together.

ProtocolDate:21 January 2014Novo NordiaTrial ID: NN9924-3790CONFIDENTIALVersion:3.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:89 of 98	Trial ID: NN9924-3790 UTN: U1111-1136-4716	<b>CONFIDENTIAL</b>	Version: Status:	3.0 Final	Novo Nordisk
---	---	---------------------	---------------------	--------------	--------------

By signing the protocol, each investigator agrees to comply fully with ICH GCP<sup>1</sup>, applicable regulatory requirements and the Declaration of Helsinki.<sup>2</sup>

By signing the protocol, each investigator also agrees to allow Novo Nordisk making investigator's name and information about site name and address publically available if this is required by national or international regulations.

CONFIDENTIAL

Date: Version: Status: Page:

3.0 Final 90 of 98

#### **Responsibilities** 22

The investigator is accountable for the conduct of the trial at his/her site. If any tasks are delegated, the investigator should maintain a list of appropriately qualified persons to whom he/she has delegated specified significant trial-related duties. The investigator should ensure that there is adequate training for all staff participating in the conduct of the trial. It is the investigator's responsibility to supervise the conduct of the trial and to protect the rights, safety and well-being of the subjects.

A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible for all trial-related medical decisions.

The investigator must ensure adequate supervision of the conduct of the trial at the trial site.

The investigator will follow instructions from Novo Nordisk when processing data.

The investigator is responsible for filing essential documents (i.e., those documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced) in the investigator's trial file. The documents should be kept in a secure locked facility, so no unauthorized persons can get access to the data. The subject ID list should be kept securely and separate from the personal data.

The investigator will take all necessary technical and organisational safety measures to prevent accidental or wrongful destruction, loss or deterioration of data. The investigator will prevent any unauthorised access to data or any other processing of data against applicable law. The investigator must be able to provide the necessary information or otherwise demonstrate to Novo Nordisk that such technical and organisational safety measures have been taken.

During any period of unavailability, the investigator must delegate responsibility for medical care of subjects to a specific qualified physician who will be readily available to subjects during that time.

The investigator must keep a log of staff and delegation of task(s) at site. The investigator must sign the log of staff and delegation of task(s) at site at the time of delegation of tasks.

If the investigator is no longer able to fulfil the role of investigator (e.g., if he/she moves or retires), a new investigator will be appointed in consultation with Novo Nordisk.

The investigator and site personnel must have sufficient English skills according to their assigned task(s).

Protocol Trial ID: NN9924-3790 UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2014 3.0 Final 91 of 98	Novo Nordisk
--	--------------	---------------------------------------	---	--------------

Novo Nordisk will be responsible for the preparation of the protocol, eCRF, supply of trial products and stated equipment, monitoring, data management, statistics and the CTR as documented by Novo Nordisk procedures and internal specific agreements as well as the current GCP guidelines<sup>1</sup>.

Novo Nordisk will provide a system for EDC. This system and support services to the system will be supplied by a vendor. The activities of the vendor will be under the direction and supervision of Novo Nordisk. Furthermore, Novo Nordisk will be responsible for the IV/WRS.

A central laboratory will be responsible for providing all lab supplies for the analysis of all blood and urine samples taken during the trial. All results are received as paper copies at the sites as well as electronic transfer to Novo Nordisk clinical database.

The name of the central laboratories is listed in protocol attachment I.

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 3.0 Final 92 of 98

# 23 Reports and publications

The information obtained during the conduct of this trial is considered confidential, and may be used by Novo Nordisk for regulatory purposes and for the general development of the trial product. All information supplied by Novo Nordisk in connection with this trial shall remain the sole property of Novo Nordisk and is to be considered confidential information. No confidential information shall be disclosed to others without prior written consent from Novo Nordisk. Such information shall not be used except in the performance of this trial. The information obtained during this trial may be made available to other physicians who are conducting other clinical trials with the trial product, if deemed necessary by Novo Nordisk.

The CTR will be reviewed and signed by one or more investigator(s) (signatory investigator) appointed by Novo Nordisk based on their experience in clinical research and input during the analysis phase.

# 23.1 Communication of results

Novo Nordisk commits to communicating, and otherwise making available for public disclosure, results of trials regardless of outcome. Public disclosure includes publication of a paper in a scientific journal, abstract submission with a poster or oral presentation at a scientific meeting, or disclosure by other means.

Novo Nordisk reserves the right to defer the release of data until specified milestones are reached, for example when the CTR is available. This includes the right not to release the results of interim analyses, because the release of such information may invalidate the results of the entire trial.

At the end of the trial, one or more public disclosures may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.

The results of this trial will be subject to public disclosure on external web sites according to international regulations, as reflected in the Novo Nordisk Code of Conduct for Clinical Trial Disclosure.

In all cases the trial results will be reported in an objective, accurate, balanced and complete manner, with a discussion of the strengths and limitations. All authors will be given the relevant statistical tables, figures and reports needed to support the planned publication. In the event of any disagreement on the content of any publication, both the investigators' and Novo Nordisk opinions will be fairly and sufficiently represented in the publication.

Where required by the journal, the principal investigator from each trial site will be named in an acknowledgement or in the supplementary material, as specified by the journal.

Protocol Trial ID: NN9924-3790	<b>CONFIDENTIAL</b>	Date: Version:	21 January 2014 3.0	Novo Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16		Status: Page:	Final 93 of 98	

Novo Nordisk maintains the right to be informed of plans by any investigator to publish and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager before submission for comments. Comments will be given within four weeks from receipt of the planned communication.

# 23.1.1 Authorship

Authorship of publications should be in accordance with the Uniform Requirements of the International Committee of Medical Journal Editors (sometimes referred to as the Vancouver Criteria<sup>17</sup>).

At the end of the trial, one or more publications (abstracts, posters, manuscripts) will be prepared for submission to scientific congresses and peer-reviewed journals in collaboration between Novo Nordisk and investigator(s) appointed by Novo Nordisk. These investigator(s) must meet the ICMJE authorship criteria to be named authors on publications.

# 23.1.2 Site-specific publication(s) by investigator(s)

For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical limitations and frequently do not provide meaningful information for healthcare professionals or subjects, and therefore may not be supported by Novo Nordisk. It is a Novo Nordisk policy that such individual reports do not precede the primary manuscript and should always reference the primary manuscript of the trial.

Novo Nordisk reserves the right to prior review of such publications. Further to allow for the primary manuscript to be published as the first, Novo Nordisk asks for deferment of publication of individual site results until the primary manuscript is accepted for publication. As Novo Nordisk wants to live up to the industry publication policy, submission for publication of such primary policy will take place no later than 18 months after trial completion.

# 23.2 Investigator access to data and review of results

As owner of the trial database, Novo Nordisk has the discretion to determine who will have access to the database.

Individual investigators will have their own research participants' data and will be provided with the randomisation code after results are available.

CONFIDENTIAL

Date: Version: Status: Page:

# 24 Retention of clinical trial documentation and human biospecimens

# 24.1 Retention of clinical trial documentation

Subject's medical records must be kept for the maximum period permitted by the hospital, institution or private practice.

The investigator must agree to archive the documentation (this includes both electronic and paperbased records) pertaining to the trial in an archive after completion or discontinuation of the trial if not otherwise notified. The investigator should not destroy any documents without prior permission from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk can refer the investigator to an independent archive provider that has a system in place to allow only the investigator to access the files.

The investigator must be able to access his/her trial documents without involving Novo Nordisk in any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper copies or prints) will be provided to the investigator before access is revoked to the systems and/or electronic devices supplied by Novo Nordisk. These data must be retained by the site. If the Novo Nordisk provided data (e.g., the CD-ROM) is not readable during the entire storage period, the investigator can request a new copy, as a copy of all data will be stored by Novo Nordisk.

Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the product is on the market plus 20 years.

The files from the investigator site/institution must be retained for 15 years after the completion of the trial, or longer if required by national regulations. The deletion process must ensure confidentiality of data and must be done in accordance with local regulatory requirements.

# 24.2 Retention of human biospecimens

Serum samples (3-4 mL) of antibodies to semaglutide will be stored at the CRO after finalisation of the CTR (see Section <u>8.5</u>). The retained antibody samples will only be used for further characterisation of antibodies against semaglutide if required by health authorities or for safety. The samples will remain anonymous (no personal data will be received).

Samples will be stored for up to ten years or until approval by health authorities. They may be transferred from the CRO to Novo Nordisk. Only Novo Nordisk and the CRO/laboratory will have access to the samples.

There are no potential consequences for the subjects or their relatives on the potential use of the antibody samples stored.

Date: Version: Status: Page:

# 25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities

#### **IRB/IEC:**

Written approval or favourable opinion must be obtained from IRB/IEC prior to commencement of the trial.

During the trial, the investigator or sponsor, as applicable, must promptly report the following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs where a causal relationship cannot be ruled out, protocol amendments according to local requirements, deviations to the protocol implemented to eliminate immediate hazards to the subjects, new information that may affect adversely the safety of the subjects or the conduct of the trial (including new risk/benefit analysis in case it will have an impact on the planned follow-up of the subjects), annually written summaries of the trial status and other documents as required by the local IRB/IEC.

The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.

Protocol amendments must not be implemented before approval or favourable opinion according to local regulations, unless necessary to eliminate immediate hazards to the subjects.

The investigator must maintain an accurate and complete record of all submissions made to the IRB/IEC. The records should be filed in the investigator's trial file and copies must be sent to Novo Nordisk.

# **Regulatory Authorities**

Regulatory authorities will receive the clinical trial application (CTA) or clinical trial notification, protocol amendments, reports on SAEs and the CTR according to national requirements.

Protocol
Trial ID: NN9924-3790
UTN: U1111-1136-4716
EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2014 **Novo Nordisk** 3.0 Final 96 of 98

# 26 Indemnity statement

Novo Nordisk carries product liability for its products, and liability is assumed under the special laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown negligence.

Novo Nordisk assumes no liability in the event of negligence, or any other liability by the clinics or investigators conducting the trial, or by persons for whom the said site or investigator are responsible.

Novo Nordisk accepts liability in accordance with:

- For Germany: Drug Law dated August 24, 1976 last amended by Second Law for Changes in Regulations on Drugs and Other Issues dated October 19, 2012.
- For Spain: Royal decree 223/2004, of 6th February, establishing the requisites concerning clinical trials.

ProtocolDate:21 January 2014NovoTrial ID: NN9924-3790CONFIDENTIALVersion:3.0UTN: U1111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:97 of 98	lovo Nordisk
--	--------------

# 27 References

- 1 International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. 01-May-1996.
- 2 World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 59th WMA General Assembly, Seoul. 1-Oct-2008. Last amended by the 64<sup>th</sup> WMA General Assembly, Fortaleza, Brazil, October 2013.
- 3 Bittner B, McIntyre C, Jordan P, Schmidt J. Drug-drug interaction study between a novel oral ibandronate formulation and metformin. Arzneimittelforschung 2011; 61(12):707-713.
- 4 McIntyre C, Schmidt J, Castelli M, Bittner B. Study on the impact of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) on the bioavailability of ibandronate (IBN) in postmenopausal women. J.DRUG DEL.SCI.TECH., 21 (6) 521-525 2011.
- 5 Investigator's Brochure Semaglutide (subcutaneous administration), Edition 8. 7 Jun 2013.
- 6 Investigator's Brochure Oral administration of semaglutide (NN9924), Edition 5. 21 Jun 2013.
- 7 International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice. Fed Regist 2010; 75(13):3471-3472.
- 8 Emisphere Technologies I. ERP-12/7, clinical trial report: A Randomized, Double-Blind, Multicenter Study Comparing the Safety and Efficacy of Two Dosing Regimens of Oral EMISPHERE SNAC/Heparin with Subcutaneous Enoxaparin Sodium for the Prevention of Venous Thromboembolic Events Following Elective Total Hip Replacement Surgery. 20 Nov 2002.
- 9 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012 Jun;35(6):1364-79.
- 10 De Angelis C., Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351(12):1250-1251.
- 11 Food and Drug Administration Amendments Act (FDAAA), VIII-CLINICAL TRIAL DATABASES, SEC. 801. EXPANDED CLINICAL TRIAL REGISTRY DATA BANK, 27-Sep-2007.

Protocol		Date:	21 January 2014 Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	3.0
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final
EudraCT No.: 2012-004994-16		Page:	98 of 98

- 12 European Commission. Detailed guidance on the European clinical trials database (EUDRACT Database) April 2003 and successor documents CT 5.1 Amendment describing the Development of EurdaCT- Lot 1 for 1 May 2004 and CT 5.2 EudraCT core dataset.
- 13 European Union. The rules governing medicinal products in the European Union, volume 4, Annex 13, Manufacture of Investigational Medicinal Products - Brussels. 3 Feb 2010.
- 14 Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79(3):777-781.
- 15 Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36(5):1384-1395.
- 16 Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 Suppl 1:S11-S66.
- 17 International Committee of Medicinal Journal Editors. Uniform Requirements for Manuscripts submitted to Biomedical Journals. N Engl J Med 1997; 336:309-315.

**CONFIDENTIAL** 

Date: Version: Status: Page:

05 September 2013 Novo Nordisk 1.0 Final 1 of 4

# **Protocol Amendment**

**no** 1 to Protocol, Final Version 1.0 dated 25 June 2013

# **Trial ID:NN9924-3790**

# Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes

**Trial phase: 2** 

**Applicable to Sweden** 

Amendment originator:

Clinical Research, Sweden

This eonfidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

Protocol Amendment		Date:	05 September 2013	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	2 of 4	

# **Table of contents**

Page

1	Introduction including rationale for the protocol amendment	3
2	Changes	4

CONFIDENTIAL

Date: Version: Status: Page:

05 September 2013 Novo Nordisk 1.0 Final 3 of 4

#### 1 Introduction including rationale for the protocol amendment

This local substantial amendment for Sweden implements the requirement for a changed definition on adequate contraceptive measures for patients participating in the trial in Sweden as requested by the Medical Products Agency (MPA).

In this protocol amendment:

- Any new text is written in italics. •
- Any text deleted from the protocol is written using strike through. ٠

#### 2 Changes

#### 2.1. **6.3 Exclusion criteria** Section

The following text will be changed under exclusion criteria No 3:

Sweden: Adequate contraceptive measures are hormonal intrauterine devices, hormonal oral contraceptives, hormonal implants or injections, double barrier (a condom or diaphragm) with spermicide, sexual abstinence or vasectomised partner.

is re-written according to the explicit request by the MPA to:

Sweden: Oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable, or implanted hormonal contraceptives, intrauterine device, intrauterine system (for example, progestin-releasing coil), vasectomized male (with appropriate postvasectomy documentation of the absence of sperm *in the ejaculate).* 

**CONFIDENTIAL** 

Date: Version: Status: Page:

16 January 2014 Novo Nordisk 1.0 Final 1 of 8

# **Protocol Amendment**

no 2 to Protocol, final version 1.0 dated 25 June 2013 including all amendments

# **Trial ID: NN9924-3790**

Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes

**Trial phase: 2** 

Applicable to all countries

Amendment originator:

Clinical Operations 2, Semaglutide & Oral GLP-1

This eonfidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

CONFIDENTIAL

Date: Version: Status: Page:

# Table of contents

1	Introd	uction including rationale for the protocol amendment	3
2	Chang	jes	4
	2.1	Section 2.1 Flow chart foot notes	4
	2.2	Section 5.2 Rationale for trial design.	4
	2.3	Section 6.4 Rescue criteria.	
	2.4	Section 8.4.7 Electrocardiogram – 12-lead	
	2.5	Section 8.4.10 Pharmacokinetics	
	2.6	Section 12.1 Definitions	5
	2.7	Section 12.2 Reporting of adverse events	5
	2.8	Section 12.7.2 Event adjudication committee	
	2.9	Section 17.1 Sample size calculation	
	2.10	Section 17.2 Definition of analysis sets	
	2.11	Section 17.3 Primary endpoint	6
	2.12	Section 17.4.2 Safety endpoints	6
	2.13	Section 25 Institutional Review Boards/Independent Ethics Committees and regulatory	
		authorities	7
	2.14	Section 27 References	8

CONFIDENTIAL

Date: Version: Status: Page: 16 January 2014 Novo Nordisk 1.0 Final 3 of 8

# **1** Introduction including rationale for the protocol amendment

The HbA<sub>1c</sub> criterion will be removed as part of the rescue criteria during the treatment period. It has been judged that there is a risk of having an inappropriately high proportion of the subjects requiring rescue due to high HbA<sub>1c</sub> levels during the trial. Hence it has been decided to only assess the need for rescue medication based on confirmed fasting plasma glucose levels. As described in the statistical section, subjects on rescue medication will not be included in the primary analysis (only data up to the point of rescue) meaning that a high number of subjects on rescue medication could potentially invalidate the data and trial results. The investigator can at anytime during the trial decide to discontinue trial product and initiate other treatment if any safety issues are seen, consequently this change is not assessed to have any safety risks for the subjects.

The process of reporting central ECG evaluation back to investigator has been changed. Only clinically significant abnormal findings as evaluated by the central reader will be sent to the investigator. The investigators will do their own assessment at site, hence it is not relevant to inform the investigator of all findings as this would increase the workload significantly at the site without adding value with regards to the safety of the subject.

The ADA classification of hypoglycaemia has recently been updated. The protocol has been updated to be aligned with the new definition. Furthermore, the section on IRB and IEC has been updated to comply with the recent update of the Declaration of Helsinki.

The definition of thyroid events for adjudication has been updated to add clarity and to be aligned with the Event Adjudication Charter. Thyroid events must be reported for adjudication both in case of thyroid neoplasm AND in case of thyroidectomies regardless of indication.

In addition, minor inconsistencies and errors have been corrected.

In this protocol amendment:

- Any new text is written *in italics*.
- Any text deleted from the protocol is written using strike through.

CONFIDENTIAL

Date: Version: Status: Page:

# 2 Changes

# 2.1 Section 2.1 Flow chart foot notes

 $x^6$ : Trough and peak PK sampling is only applicable for subjects in the oral treatment arms *and replaces the regular PK sampling for these subjects at visits 4, 8 and 11*. Subjects must attend the visit without having taken the tablet on the same day (see Section 8.4.10)

 $x^8$ : Fasting *for lab sampling* is defined as having consumed only water since midnight. For the Follow-up visit (V12) attending fasting is defined as having consumed only water for at least the preceding 2 hours. *For the trough and peak PK sampling visits (V4, 8, 11) the fasting is outlined in section 5.3.1.* 

# 2.2 Section 5.2 Rationale for trial design

Parallel treatment groups and a randomised partially-blinded, controlled design have been chosen in accordance with the trial objectives. To avoid bias in the assessment of the different doses of oral semaglutide, the eight oral treatment arms are double-blind. The doses are escalated in standard four week intervals to limit gastrointestinal AEs. Escalation intervals of two weeks and six *eight* weeks are also being explored to investigate effect on onset of action and overall AEs.

# 2.3 Section 6.4 Rescue criteria

Subjects with unacceptable hyperglycaemia should be offered treatment intensification (rescue medication) according to local label at the discretion of the investigator as add-on to randomised treatment and should continue to follow the protocol-specified visit schedule. Rescue medication should exclude other incretin-based therapies such as other GLP-1 receptor agonists, DPP-4 inhibitors and amylin analogues.

Unacceptable hyperglycaemia in this trial is defined as:

- FPG >15 mmol/L (270 mg/dL) from baseline to week 6
- FPG >13.3 mmol/L (240 mg/dL) from week 6 to week 12
- FPG >11.1 mmol/L (200 mg/dL) or HbA<sub>1e</sub> > 8.0% (64 mmol/mol) from week 12 to end of trial

# If any of the FPG values exceed the limits outlined below and no intercurrent cause of the hyperglycaemia can be identified the subject should be offered treatment intensification (rescue medication):

- 15.0 mmol/L (270 mg/dL) from randomisation to end of Week 5
- 13.3 mmol/L (240 mg/dL) from Week 6 to end of Week 11
- 11.1 mmol/L (200 mg/dL) from Week 12 to end of trial

Protocol Amendment	Date:	16 January 2014 Novo Nordisk
Trial ID: NN9924-3790	Version:	1.0
UTN: U1111-1136-4716	Status:	Final
EudraCT No.: 2012-004994-16	Page:	5 of 8

A confirmatory FPG should be obtained by central laboratory if related to a scheduled visit or by local laboratory if not related to scheduled visits. If the confirmatory FPG exceeds the values described above the subject should be offered treatment intensification (rescue medication) at the discretion of the investigator and in accordance with ADA/European Association for the Study of Diabetes<sup>a</sup> (preferably excluding GLP-receptor agonists, DPP-4 inhibitors and amylin analogues). Rescue medication (intensification of existing background medication and/or initiation of new medication) and any changes to this should be captured on the concomitant medication form in the eCRF. Rescue medication should be prescribed as add-on to randomised treatment and subjects should continue to follow the protocol-specified visit schedule.

## Reference a added see section 2.14

## 2.4 Section 8.4.7 Electrocardiogram – 12-lead

Sites will be informed of the central ECG evaluation in case this evaluation reveals an abnormal, *clinically significant* ECG reading. If the abnormality represents an unreported AE, SAE or MESI, such findings must be reported if the investigator finds the abnormality clinically significant (see Section 8.1.11).

## 2.5 Section 8.4.10 Pharmacokinetics

For subjects on oral treatment, three of the PK sampling assessments will be pre-dose and postdose (trough and peak) only Subjects on oral treatment will also have PK measured pre-dose and post-dose (trough and peak) at three visits (see Section 2). At the visits for trough and peak PK measurements, the investigator needs to ensure that the subjects on oral treatment follow these procedures:

#### 2.6 Section 12.1 Definitions

#### Medical event of special interest

A medical event of special interest (MESI) is an event which, in the evaluation of safety, has a special focus. A MESI is an AE (SAE or non-serious AE) which fulfils one or more of the below defined MESI criteria.

8. Thyroid Disease ((A) if thyroidectomy is required)((A) if thyroid neoplasm or resulting in thyroidectomy)

#### 2.7 Section 12.2 Reporting of adverse events

All events meeting the definition of an AE must be collected and reported. This includes events from *when* the first trial-related activity after the subject has signed the informed consent until the end of the post-treatment follow-up period. The events must be recorded in the applicable eCRF forms in a timely manner (see timelines below and Figure 12–1).

All AEs, either observed by the investigator or reported by the subject, must be reported by the investigator and evaluated. Novo Nordisk assessment of expectedness is performed according to the

Protocol Amendment Trial ID: NN9924-3790		Date: Version:	16 January 2014	Novo Nordisk
UTN: U1111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Status: Page:	Final 6 of 8	

following reference document: IB (Oral Administration of Semaglutide (NN9924)) *section 6.2.6.1 Reference safety information*, Edition 5<sup>6</sup> and any updates hereof.

## 2.8 Section 12.7.2 Event adjudication committee

• Thyroid Disease (if thyroidectomy is required if thyroid neoplasm or resulting in thyroidectomy))

## 2.9 Section 17.1 Sample size calculation

A standard deviation (SD) of 1.2% for change from baseline in HbA1c is chosen as assumption for the sample size calculation. The SD observed in several phase 3 trials of 26 weeks duration with s.c. liraglutide suggests a standard deviation less than 1.1%. However, as it is uncertain if the added variation in exposure compared to s.c. liraglutidesemaglutide will transfer to an added variation in the therapeutic response, a SD of 1.2% is assumed.

#### 2.10 Section 17.2 Definition of analysis sets

**Safety Analysis Set (SAS):** includes all subjects exposed to at least one dose of randomised *liraglutidesemaglutide* or *liraglutidesemaglutide* placebo. Subjects in the SAS will contribute to the evaluation "as treated".

#### 2.11 Section 17.3 Primary endpoint

Due to the uncertainty in relation to if the added variation in the exposure in the oral semaglutide arms compared to s.c. *liraglutide semaglutide* will transfer to an added variation in the therapeutic response, a sensitivity analysis allowing the within subject unstructured covariance matrix to be fitted separately for each treatment arm will be conducted.

# 2.12 Section 17.4.2 Safety endpoints

#### **Confirmed hypoglycaemia**

In normal physiology, symptoms of hypoglycaemia occur below a plasma glucose level of 3.1mmol/L (56 mg/dL)<sup>13</sup>. Therefore, Novo Nordisk has included hypoglycaemia with plasma glucose levels below this cut-off point in the definition of confirmed hypoglycaemia.

Confirmed hypoglycaemic episodes are defined as episodes that are:

- severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions)according to the ADA classification below and/or
- biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia

ADA classification<sup>b</sup> of hypoglycaemia

• Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, *or take other corrective actions*. other resuscitative

Protocol Amendment Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	16 January 2014 1.0 Final	Novo Nordisk
UIN: UIIII-1136-4716 EudraCT No.: 2012-004994-16		Status: Page:	Final 7 of 8	

actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose back to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

- Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL)
- Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).
- RelativePseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia, and interprets those as indicative of hypoglycaemia, but with a measured plasma glucose concentration > 3.9 mmol/L (70 mg/dL) but approaching that level.
- Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a plasma glucose determination (but that was presumably caused by a plasma glucose concentration ≤ 3.9 mmol/L ({70 mg/dL}).




Figure 17-1 ADA classification of hypoglycaemia

#### Reference b added see section 2.14

# 2.13 Section 25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities

#### **IRB/IEC:**

Protocol Amendment Trial ID: NN9924-3790 UTN: U1111-1136-4716	CONFIDENTIAL	Date: Version: Status:	1.0 Final	ovo Nordisk
EudraCT No.: 2012-004994-16		Page:	8 of 8	

Written approval or favourable opinion must be obtained from IRB/IEC prior to commencement of the trial.

During the trial, the investigator or sponsor, as applicable, must promptly report the following to the IRB/IEC, in accordance with local requirements: updates to IB, unexpected SAEs where a causal relationship cannot be ruled out, substantial protocol amendments, non-substantial protocol amendments according to local requirements, deviations to the protocol implemented to eliminate immediate hazards to the subjects, new information that may affect adversely the safety of the subjects or the conduct of the trial (including new risk/benefit analysis in case it will have an impact on the planned follow-up of the subjects), annually written summaries of the trial status and other documents as required by the local IRB/IEC.

The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.

## 2.14 Section 27 References

2 World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 59th WMA General Assembly, Seoul. 1-Oct-2008. Last amended by the 64<sup>th</sup> WMA General Assembly, Fortaleza, Brazil, October 2013

a Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012 Jun;35(6):1364-79.

*b* Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L et al: Hypoglycemia and Diabetes: A report of a Workgroup of the American Diabetes Association and The Endocrine Society. Diabetes Care 36: 1384-1395, 2013

CONFIDENTIAL

Date: Version: Status: Page: 28 April 2014 | Novo Nordisk 1.0 Final 1 of 4

# **Protocol Amendment**

no 3 to Protocol, final version 1.0 dated 25 June 2013 including all amendments

# Trial ID: NN9924-3790

Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes

**Trial phase: 2** 

**Applicable to Germany** 

Amendment originator:

Clinical, Medical & Regulatory

This eonfidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

**CONFIDENTIAL** 

Date: Version: Status: Page:

# Table of contents

Page

1	Introd	uction including rationale for the protocol amendment	3
2	Chang	es	4
		Section 6.4 Rescue criteria.	

CONFIDENTIAL

Date: Version: Status: Page: 28 April 2014 1.0 Final 3 of 4

# **1** Introduction including rationale for the protocol amendment

According to the deficiency letter from BfArM (German National Health Authority) from 28-Feb-2014, the global substantial Amendment no 2 to Protocol, final version 1.0 dated 25 June 2013, final version 1.0, dated 16 January 2014 will be amended by this document for Germany.

The HbA1c criterion will be removed as part of the rescue criteria during the treatment period. It has been judged that there is a risk of having an inappropriately high proportion of the subjects requiring rescue due to high HbA1c levels during the trial. Hence it has been decided to only assess the need for rescue medication based on confirmed fasting plasma glucose levels. As described in the statistical section, subjects on rescue medication will not be included in the primary analysis (only data up to the point of rescue) meaning that a high number of subjects on rescue medication could potentially invalidate the data and trial results. The investigator can at any time during the trial decide to discontinue trial product and initiate other treatment if any safety issues are seen, consequently this change is not assessed to have any safety risks for the subjects. *To ensure proper treatment respectively treatment intensification of subjects, the rescue FPG criteria will be lowered from 200 mg/dl to 180 mg/dl from week 12 and onwards.* 

In this protocol amendment:

- Any new text is written *in italics*.
- Any text deleted from the protocol is written using strike through.

Protocol Amendment		Date:	28 April 2014	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U1111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	4 of 4	

# 2 Changes

#### 2.1 Section 6.4 Rescue criteria

Subjects with unacceptable hyperglycaemia should be offered treatment intensification (rescue medication) according to local label at the discretion of the investigator as add on to randomised treatment and should continue to follow the protocol-specified visit schedule. Rescue medication should exclude other incretin-based therapies such as other GLP-1 receptor agonists, DPP-4 inhibitors and amylin analogues.

Unacceptable hyperglycaemia in this trial is defined as:

- FPG >15 mmol/L (270 mg/dL) from baseline to week 6
- FPG >13.3 mmol/L (240 mg/dL) from week 6 to week 12
- FPG >11.1 mmol/L (200 mg/dL) or HbA<sub>1e</sub> > 8.0% (64 mmol/mol) from week 12 to end of trial

If any of the FPG values exceed the limits outlined below and no intercurrent cause of the hyperglycaemia can be identified the subject should be offered treatment intensification (rescue medication):

- 15.0 mmol/L (270 mg/dL) from randomisation to end of Week 5
- 13.3 mmol/L (240 mg/dL) from Week 6 to end of Week 11
- <u>11.1 mmol/L (200 mg/dL)</u> 10.0 mmol/L (180 mg/dL) from Week 12 to end of trial

A confirmatory FPG should be obtained by central laboratory if related to a scheduled visit or by local laboratory if not related to scheduled visits. If the confirmatory FPG exceeds the values described above the subject should be offered treatment intensification (rescue medication) at the discretion of the investigator and in accordance with ADA/European Association for the Study of Diabetes<sup>a</sup> (preferably excluding GLP-receptor agonists, DPP-4 inhibitors and amylin analogues). Rescue medication (intensification of existing background medication and/or initiation of new medication) and any changes to this should be captured on the concomitant medication form in the eCRF. Rescue medication should be prescribed as add-on to randomised treatment and subjects should continue to follow the protocol-specified visit schedule.

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

21 January 2015 Novo Nordisk 1.0 Final 1 of 551

**Statistical Analysis Plan** 

# **Trial ID: NN9924-3790**

# Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes

Author:

Click here to enter text.

Click here to enter text.

This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant parties.

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EudraCT No.: 2012-004994-16

**Table of contents** 

CONFIDENTIAL

Date: Version: Status: Page:

## Page

Ta	ble of c	ontents	2
Lis	t of ab	breviations	4
1	Intro	duction	
-	1.1	Trial information	
	1.2	Scope of the statistical analysis plan	
2	Static	tical considerations	
4	2.1	Sample size calculation	
	2.1	Definition of analysis sets	
	2.2	Definition of baseline	
	2.3	Definition of observation periods	
	2.1	In-trial observation period.	
		On-treatment observation period	
		On-treatment without rescue:	
	2.5	Imputation of missing observations	
	2.6	Primary endpoint	
	2.7	Supportive secondary endpoints	
	2.7	2.7.1 Efficacy endpoints	
		2.7.2 Safety endpoints	
		2.7.3 Pharmacokinetics and/or pharmacodynamics modelling	
	2.8	End of text outputs for subject disposition and demographics	
	2.9	End of text outputs for efficacy endpoints	
	2.10	End of text outputs for safety endpoints	
	2.11	Listings	
3	Chan	ges to the statistical analyses planned in the protocol	
4		efined groups of adverse events	
4	4.1	Gastrointestinal adverse events	
	4.2	Allergic reactions	
	4.3	Antibody adverse events	
	4.4	Calcitonin adverse events	
	4.5	Cardiovascular adverse events	
	4.6	Gallbladder disease adverse events	
	4.7	Immune complex adverse events	
	4.8	Injection site reactions	
	4.9	Elevated lipase and/or amylase adverse events	
	4.10	Medication error adverse events	
	4.11	Neoplasm adverse events	
	4.12	Overdose adverse events	
	4.13	Pancreatic carcinoma adverse events	
	4.14	Pancreatitis adverse events	
	4.15	Thyroid adverse events	
	4.16	Transmission adverse events	
	4.17	Rare adverse events	

Statistical An Trial ID: NN9 UTN: U111-1 EudraCT No.	9924-3790	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2015 1.0 Final 3 of 551	Novo Nordisk
4.18 4.19 5 Refere	Malignant tumour ad	events verse events			449 452

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

21 January 2015 | Novo Nordisk 1.0 Final

4 of 551

# List of abbreviations

AE	Adverse event
ANCOVA	Analysis of covariance
BMI	Body mass index
CI	Confidence interval
CRF	Case report form
CTR	Clinical trial report
EoT	End-of-text
LOCF	Last observation carried forward
LLOQ	Lower limit of quantification
MedDRA	Medical Dictionary for Regulatory Activities
PD	Pharmacodynamics
PK	Pharmacokinetics
PP	Per protocol
SAE	Serious adverse event
SAP	Statistical analysis plan
SD	Standard deviation
SE	Standard error
TEAE	Treatment emergent adverse event
MMRM	Mixed model for repeated measures

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

21 January 2015 Novo Nordisk 1.0 Final 5 of 551

#### Introduction 1

#### 1.1 **Trial information**

This is a randomised, partially-blinded, multiple-dose, multicentre trial with a total of nine treatment arms; seven oral semaglutide treatment arms, one oral placebo arm and one open-label subcutaneous (s.c.) semaglutide arm in a parallel design. The trial will include subjects with T2D who have failed on diet and exercise and/or metformin.

The primary objective of the trial is to compare the efficacy on glycaemic control of oral semaglutide in a SNAC formulation against placebo in subjects with T2D.

#### 1.2 Scope of the statistical analysis plan

This statistical analysis plan (SAP) is based on the protocol "3790-consolidated-protocol-fileprotocol-version-3 0", that is, the consolidated version 3 which includes protocol amendments one and two.

This SAP contains a more technical and detailed elaboration of the statistical analyses specified in the statistical section of the protocol. .

#### 2 Statistical considerations

Results from the statistical analysis will generally be presented by two-sided confidence intervals with a confidence level of 95% including a p-value for test of no difference between treatments.

The stratification variable referred to in the following is defined as the two level factor of treatment with metformin (yes/no).

The "planned comparisons between treatment arms" referred to in this section covers the following comparisons: a) between each of the oral semaglutide treatment arms and placebo, b) between the s.c. semaglutide arm and placebo, c) between each of the oral semaglutide treatment arms and s.c. semaglutide, and d) between the three oral semaglutide treatment arms with an end dose of 40 mg.

A standard mixed model for repeated measurements (from now on referred to as "the standard MMRM") will be used in the analysis of the primary and continuous secondary endpoints. The model will include treatment, country and the stratification variable as fixed factors, and the corresponding baseline value as covariate. All factors and the covariate will be nested within visit. The model will assume an unstructured covariance matrix within subject.

Unless otherwise stated, the estimated differences with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms.

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716	CONFIDENTIAL	Date: Version: Status:	1.0 Final	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	6 of 551	

The patient years observation time (PYO) used in e.g. the calculation of AE rates will for an observation period be calculated as the difference between start-date and end-date, both inclusive.

Values of laboratory parameters below the blower limit of quantification (LLOQ) will be set to LLOQ/2.

The stratification variable "Treatment with metformin at screening (yes/no)" will based on the actual information on concomitant medication recorded through the eCRF.

# 2.1 Sample size calculation

Please refer to section 17.1 of the protocol.

# 2.2 Definition of analysis sets

**Full Analysis Set (FAS):** includes all randomised subjects who have received at least one dose of randomised semaglutide (oral or s.c.) or semaglutide placebo. Subjects in the FAS will contribute to the evaluation based on their randomised treatment.

**Safety Analysis Set (SAS):** includes all randomised subjects who have received at least one dose of randomised semaglutide (oral or s.c.) or semaglutide placebo. Subjects in the SAS will contribute to the evaluation based on their actual treatment.

Before data are locked for statistical analysis, a review of all data will take place. Any decision to exclude a subject or single observations from the statistical analysis is the joint responsibility of the members of the study group. Exclusion of data from analyses will be used restrictively and normally no data should be excluded from the FAS. The subjects or observations to be excluded, and the reasons for their exclusion, must be documented and signed by those responsible before database lock. The subjects and observations excluded from analysis sets, and the reason for this, will be described in the clinical trial report (CTR).

# 2.3 Definition of baseline

For each lab parameter and each vital sign, the baseline assessment is defined as the last valid measurement at or before the randomisation visit (visit 2). This specifically implies that if a visit 2 assessment is missing (whether it's planned or not planned) then the screening assessment (from visit 1) will be used as the baseline assessment, if available.

# 2.4 Definition of observation periods

Unless subjects withdraw their informed consent, data collection will continue for the full duration of the trial.

The data for all tables, listings and figures developed for this trial will be selected in a two-step fashion.

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2015 1.0 Final 7 of 551	Novo Nordisk
EudraC1 No.: 2012-004994-16	I	Page:	/ 01 551	

In the first step, the population of subjects for the specific analysis is selected based on the specified analysis set (either the full analysis set or the safety analysis set).

In the second step, observations for the subjects in the analysis set are selected according to whether or not they belong to a specified observation period.- Observations that do not belong to the specified observation period, will be treated as missing for the specific output.

In this trial, three observation periods will be defined, as described below. One observation period will be primary when selecting data related to efficacy and another will be primary when selecting data related to safety. The last observation period is considered supportive. Notice that for adjudicated events, onset date will be the EAC adjudicated onset date.

The three observation periods are:

# In-trial observation period

*In-trial:* This observation period represents the time period in which a subject is considered a participant and where data are collected systematically. This observation period will be used for supportive analyses of both efficacy and safety. The in-trial observation period includes observations recorded at or after randomisation and not after the last subject-investigator contact, which is scheduled to take place 5 weeks after planned last dose of trial treatment at a follow-up visit (visit 12).

For subjects that prematurely discontinue treatment, their in-trial observation period will end with visit 11X if this comes after their follow-up visit.

For subjects that withdraw their informed consent and do not attend visit 11, nor visit 12, their intrial observation period ends at their date of withdrawal.

If a subject is lost to follow-up, the end of the in-trial observation period is defined as the date of the last subject-investigator contact (site or phone visit).

### **On-treatment observation period**

*On-treatment:* This observation period is a subset of the in-trial observation period, namely the part where the subject is considered to be exposed to trial treatment.

For adverse events and hypoglycaemic episodes, this period includes those observations from the in-trial observation period that are recorded on or after the date of first dose of trial treatment and not after the end of the 5 week washout period that follows the date of last dose of trial treatment. The follow-up visit is scheduled to take place 5 weeks after the date of last dose of trial product with a visit window of +5 days. For adverse events and hypoglycaemic episodes, the end-date for

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EndraCT No : 2012-00/4994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2015 1.0 Final 8 of 551	Novo Nordisk
EudraCT No.: 2012-004994-16		Page:	8 of 551	

the on-treatment observation period is therefore defined as the first date encountered after randomisation of the following dates [date of visit 12, date of last dose + 40 days, end-date for the in-trial observation period], using the convention that a missing date is set to infinity.

For other endpoints than adverse events and hypoglycaemic episodes, including both safety and efficacy, but with the exception of anti-semaglutide antibodies, the end-date for the on-treatment observation period will be defined as [date of visit 12, date of last dose + 7 days, end-date for the in-trial observation period], that is, similarly to above, but adding the s.c. dosing interval of 1 week to the date of last dose instead of 40 days. The on-treatment observation period will not be used to analyse anti-semaglutide antibodies.

The on-treatment observation period is the primary observation period for examination of safety endpoints including adverse events and hypoglycaemic episodes.

The definition of the on-treatment period for adverse events and hypoglycaemic episodes corresponds to the protocol definition of the treatment emergent period.

# **On-treatment without rescue:**

*On-treatment without rescue:* This observation period is a subset of the on-treatment observation period. To avoid potential confounding of initiation of anti-diabetic rescue therapies on efficacy endpoints, information that is collected after initiation of anti-diabetic rescue therapies are excluded from this observation period. Specifically, it includes observations recorded at or after date of first dose of trial treatment and not after the first occurrence of the following

- the end-date of the on-treatment observation period
- initiation of rescue medication

This observation period is the primary observation period for examination of efficacy endpoints.

We will use the convention that all baseline assessments belong to each of the observation periods.

# 2.5 Imputation of missing observations

Missing observations for laboratory parameters and vital signs will be imputed with two methods: last observation carried forward (LOCF), where missing observations are imputed as the last postbaseline available value obtained prior to the missing assessment, and by prediction from the standard MMRM for the specific endpoint, where missing observations are imputed as the value that is predicted by the MMRM model. The MMRM imputations will be based on the randomised treatment and carried out for those endpoints where the standard MMRM analysis is part of the examination.

For subjects that have no post-baseline assessment of a given endpoint, no imputation will be done for this endpoint.

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	9 of 551	

Note that the LOCF and MMRM imputations depend on the considered observation period, and separate imputation for the three observation periods will be carried out.

# 2.6 Primary endpoint

The primary endpoint, change from baseline to end of treatment (i.e., after 26 weeks of treatment) in HbA1c, will be analysed by the standard MMRM.

In order to confirm efficacy of oral semaglutide without risk of inflation of the type 1 error an initial comparison of the primary endpoint\_will be made between a) the pool of the two treatment arms using standard and fast escalation regimens to an end dose of 40 mg and b) placebo. The comparison will be made by pooling the standard 40 mg arm and the fast 40 mg arm and then estimating the treatment difference between this pooled group and the placebo group by the standard MMRM. The estimated treatment difference with corresponding two sided p-value and 95% confidence interval at 26 weeks will be presented, and efficacy of oral semaglutide will be considered confirmed if the upper limit of the confidence interval is strictly less than zero.

If efficacy of oral semaglutide is confirmed, the planned comparisons between the nine original treatment arms will be evaluated.

Subjects in the FAS and only measurements belonging to the on-treatment without rescue observation period will be included in the analysis.

Due to the uncertainty in relation to if the added variation in the exposure in the oral semaglutide arms compared to s.c. semaglutide will transfer to an added variation in the therapeutic response, a sensitivity analysis allowing the within subject unstructured covariance matrix to be fitted separately for each treatment arm will be conducted.

Furthermore, the following sensitivity analyses will be conducted in order to investigate the sensitivity of the results due to the impact of missing values:

- An MMRM similar to the primary analysis but for the in-trial observation period.
- An analysis of covariance (ANCOVA) model including subjects in the FAS and using imputation of missing values according to the last observation carried forward (LOCF) method. The model will include fixed factors for treatment, country and the stratification variable and the baseline value as covariate and will be based on the on-treatment period.
- A complete case analysis, i.e. an ANCOVA similar to the one above including only data obtained at 26 weeks from subjects who:
  - did not discontinue treatment prematurely

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CUNFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	10 of 551	

- o did not receive rescue therapy
- o had a valid HbA1c assessment at baseline and after 26 weeks of treatment

### 2.7 Supportive secondary endpoints

# 2.7.1 Efficacy endpoints

The FAS will be used in all analyses of the supportive secondary efficacy endpoints. The ontreatment without rescue observation period\_will be the primary observation period for examination of efficacy endpoints. The specific outputs developed for efficacy endpoints will be detailed in section 2.7.3.

### Subjects who, after 26 weeks of treatment, achieve (yes/no) HbA1c <7% (53 mmol/mol)

The binary endpoint will be analysed by a logistic regression model which will include fixed factors for treatment and the stratification variable and baseline HbA1c as a covariate. Estimated odds ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms. Missing response data at 26 weeks will be imputed from the MMRM used for the primary analysis of HbA1c.

# Change from baseline to week 26 in body weight, waist circumference and fasting plasma glucose

These endpoints will be analysed by the standard MMRM. Both absolute (kg) and relative change from baseline (%) in body weight will be analysed.

# Subjects with at least 5 % weight loss after 26 weeks of treatment (yes/no) and subjects with more than 10 % weight loss added after 26 weeks of treatment (yes/no)

These binary endpoints will be analysed by separate logistic regression models which will include fixed factors for treatment and the stratification variable and baseline body weight as a covariate. Estimated odds ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms. Missing response data at 26 weeks will be imputed from the MMRM used for the analysis of body weight.

# Change from baseline to week 26 in C-peptide, fasting insulin, glucagon, HOMA-IR, HOMA-B, total cholesterol, LDL-cholesterol, HDL-cholesterol, VLDL-cholesterol, triglycerides and free fatty acids

For each endpoint, the assessments at every week will be log-transformed and subsequently analysed by the standard MMRM. The estimated differences and corresponding 95% confidence intervals at 26 weeks will be back transformed and presented as ratios together with the two sided

Statistical Analysis Plan Trial ID: NN9924-3790		Date: Version:	21 January 2015 1.0	Novo Nordisk
UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Status: Page:	Final 11 of 551	

p-values. Standard errors of the back transformed estimated means will be calculated using the Delta-method<sup>i</sup>.

The fasting HOMA endpoints (i.e., fasting HOMA-B and HOMA-IR) will be calculated based on fasting insulin and FPG as follows:

1. Fasting HOMA-B (%) = 20 x fasting insulin  $[\mu U/ml]/(FPG[mmol/L]-3.5)$ 

2. Fasting HOMA-IR (%) = fasting insulin  $[\mu U/ml]$  x FPG [mmol/L]/22.5

# **PRO** outcomes

The outcomes from the SF-36 questionnaire in terms of total scores overall and within each domain will be calculated. Each of these scores will be analysed by the standard MMRM.

# 2.7.2 Safety endpoints

All safety endpoints will be summarised and analysed using the safety analysis set. The ontreatment observation period will be the primary observation period for examination of all safety endpoints.

# **Adverse events**

All AEs will be coded using the most recent version of the Medical Dictionary for regulatory Activities (MedDRA) coding. This is version 17.1. A TEAE is an event that has onset date (or increase in severity) during the on-treatment observation period. On-treatment AEs are summarised descriptively. These are supported by outputs including all in-trial adverse events, i.e. AEs with onset date (or increase in severity) during the in-trial observation period. Adverse events with onset after the end of the in-trial observation period will be reported in a listing.

Most frequent adverse events will be defined as preferred terms that are experienced by at least 5% of the subjects in any of the treatment arms.

Based on MedDRA searches, 19 pre-defined groups of adverse events will be evaluated. These are defined by Global Safety and consist of pre-specified preferred terms. The groups are the following:

- Gastrointestinal adverse events
- Allergic reactions
- Antibody adverse events
- Calcitonin adverse events
- Cardiovascular adverse events
- Gallbladder disease adverse events
- Immune complex adverse events
- Injection site reactions

l	Statistical Analysis Plan
	Trial ID: NN9924-3790
	UTN: U111-1136-4716
	EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page: 21 January 2015 1.0 Final 12 of 551

- Elevated lipase and/or amylase adverse events

- Medication error adverse events
- Neoplasm adverse events
- Overdose adverse events
- Pancreatic carcinoma adverse events
- Pancreatitis adverse events
- Thyroid adverse events
- Transmission adverse events
- Rare adverse events
- Renal failure adverse events
- Malignant tumour adverse events

The definition of rare adverse events is based on a publication by Shakir from 2005 (Pharmacoepidemiology, Fourth Edition), called "Prescription-Event Monitoring". For complete listings of preferred terms included in the pre-defined groups of adverse events see section 4.

# Number of confirmed treatment emergent hypoglycaemic episodes

A hypoglycaemic episode will be defined as treatment emergent if the onset of the episode occurs during the on-treatment period. Hypoglycaemic episodes are classified according to the Novo Nordisk classification of confirmed hypoglycaemia and the ADA classification of hypoglycaemia (see Figure 1: ADA classification of hypoglycaemia).

# Confirmed hypoglycaemia

In normal physiology, symptoms of hypoglycaemia occur below a plasma glucose level of 3.1 mmol/L (56 mg/dL)<sup>ii</sup>. Therefore, Novo Nordisk has included hypoglycaemia with plasma glucose

levels below this cut-off point in the definition of confirmed hypoglycaemia.

Confirmed hypoglycaemic episodes are defined as episodes that are:

- severe according to the ADA classification below and/or
- biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia


# Severe or BG confirmed symptomatic hypoglycaemia

- severe according to the ADA classification below and/or
- biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with symptoms consistent with hypoglycaemia

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CUNFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	13 of 551	

# ADA classification<sup>iii</sup> of hypoglycaemia

- Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose back to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
- Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL)
- Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).
- Pseudo-hypoglycaemia: An episode during which the person with diabetes reports any of the typical symptoms of hypoglycaemia with a measured plasma glucose concentration > 3.9 mmol/L (70 mg/dL) but approaching that level.
- Probable symptomatic hypoglycaemia: An episode during which symptoms of hypoglycaemia are not accompanied by a plasma glucose determination (but that was presumably caused by a plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).



# Figure 1: ADA classification of hypoglycaemia

Data on treatment emergent hypoglycaemic episodes will be summarised descriptively using the above definitions.

The number of confirmed treatment emergent hypoglycaemic episodes during 26 weeks treatment will be analysed using a negative binomial regression model with a log-link function and the logarithm of the time period in which an occurrence of a hypoglycaemic episode is considered treatment emergent as offset. The model will include treatment, country and stratification variable as fixed factors and baseline HbA1c as covariate. Estimated rate ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms.

The number of subjects experiencing one or more confirmed treatment emergent hypoglycaemic episode will be analysed using a logistic regression model with fixed factors for treatment and the stratification variable and baseline HbA1c as a covariate. Estimated odds ratios with corresponding two sided p-values and 95% confidence intervals at 26 weeks will be presented for the planned comparisons between treatment arms.

Similar analyses for severe or BG confirmed symptomatic hypoglycaemic episodes will be conducted.

Change in pulse, systolic- and diastolic blood pressure from baseline to after 26 weeks of treatment

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CUNFIDENHAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	15 of 551	

These endpoints will be analysed by the standard MMRM.

# Change in amylase and lipase from baseline to after 26 weeks of treatment

For each endpoint, the assessments at every week will be log-transformed and subsequently analysed by the standard MMRM. The estimated differences and corresponding 95% confidence intervals at 26 weeks will be back transformed and presented as ratios together with the two sided p-values. Standard errors of the means will be calculated using the Delta-method.

# Change from baseline to after 26 weeks of treatment in electrocardiogram (ECG), physical examination, laboratory safety variables (haematology, biochemistry, hormone and urinalysis) other than amylase and lipase

These endpoints will be summarised by descriptive statistics.

Endpoints related to occurrence of anti-semaglutide antibodies during 26 weeks of treatment: Antibody level during 26 weeks of treatment, anti-semaglutide antibodies (positive/negative), antisemaglutide antibodies with in vitro neutralising effect (positive/negative), antisemaglutide antibodies cross reacting with endogenous GLP-1 (positive/negative), cross reacting antibodies with in vitro neutralising effect to endogenous GLP-1 (positive/negative)

These endpoints will be summarised by descriptive statistics and correlated to PK and PD. Categorical summary tables for the occurrence of antibodies by treatment week as well as for occurrence of antibodies versus mean HbA1c and versus mean trough PK value will be produced. In addition, scatter plots of antibody level (%B/T) vs. HbA1c and vs. trough PK value will be developed.

# 2.7.3 Pharmacokinetics and/or pharmacodynamics modelling

The modelling will be performed by Quantitative Clinical Pharmacology at Novo Nordisk A/S and will be reported separately from the CTR.

EudraCT No.: 2012-004994-16 Page: 16 of 551	Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	CONFIDENTIAL	Date: Version: Status: Page:	21 January 2015 1.0 Final 16 of 551	Novo Nordisk
---	--	--------------	---------------------------------------	--	--------------

# 2.8 End of text outputs for subject disposition and demographics

To describe the trial population, descriptive tables for the disposition of subjects amongst the two analysis sets and treatment/trial completion statuses will be developed.

The time from randomisation to withdrawal, premature treatment discontinuation and initiation of rescue medication, and the duration of the three observation periods will be examined with descriptive figures.

Baseline characteristics for continuous and categorical variables will be summarised in descriptive tables.

Descriptive tables for general medical history, history of cardiovascular and gall bladder disease and concomitant medication will be developed.

# 2.9 End of text outputs for efficacy endpoints

As mentioned above, the primary observation period used for examination of efficacy endpoints will be the on-treatment without rescue observation period. For safety endpoints the primary observation period will be the on-treatment observation period. Outputs will be based on data in SI units, and where applicable they will be repeated for conventional units. This will among other endpoints apply to HbA1c, where data is collected in both "%" and "mmol/mol". The analysis of HbA1c in "%" is considered primary.

The specific outputs developed for the different endpoints are detailed here below.

# **Continuous efficacy endpoints**

For continuous efficacy endpoints the end of text outputs will constitute of:

- Tables with descriptive statistics for observed values as well as change from baseline
- Tables with results of statistical analyses including estimated means (LS means) for week 26 values as well as for change from baseline to week 26, and in addition estimated treatment differences/ratios for the planned comparisons of treatment arms
- Panel plots with mean of observed as well as change from baseline values over time grouped by the time of last observation. There will be a panel for each treatment arm in these plots and they serve to illustrate the observed means over time for different time-patterns of missing data.
- Plots with estimated mean values over time. These plots present the estimated means from the statistical analyses.
- Bar plots with estimated means at week 26 from the statistical analyses.

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	17 of 551	

- Forest plots with the estimated treatment differences/ratios from the statistical analyses for the planned comparisons, where deemed relevant
- Cumulative distribution functions presenting the distribution of the endpoints at week 26, including MMRM imputed values

# **Categorical efficacy endpoints**

For HbA1c and body weight, binary responder endpoints have been defined. The outputs for assessment of these include:

- Categorical summary tables with counts and percentages of the response categories.
- Tables with results of statistical analyses including estimated odds at week 26 values as well as odds ratios for the planned comparisons of treatment arms
- Bar plots with observed proportions of subjects achieving the responses
- Forest plots with estimated odds ratios at week 26 based on the statistical analyses

Statistical Analysis Plan Trial ID: NN9924-3790 UTN: U111-1136-4716 EudraCT No.: 2012-004994-16

CONFIDENTIAL

Date: Version: Status: Page:

#### 2.10 End of text outputs for safety endpoints

#### Adverse events

Adverse events will be evaluated with

- Overview tables that summarise the events across treatment arms in relation to seriousness. severity, relationship to trial product, outcome and whether they led to premature treatment discontinuation
  - These will be developed for all adverse events and serious adverse events based on both  $\cap$ the on-treatment and the in-trial observation period. For most frequent adverse events, adverse events leading to premature treatment discontinuation and pre-defined MedDRA searches they will be developed for the on-treatment observation period.
- Summary tables describing the distribution of adverse events across treatment arms by system organ classes and preferred terms
  - These will be developed for all adverse events, serious adverse events, adverse events 0 with fatal outcome and pre-defined MedDRA searches based on both the on-treatment and the in-trial observation period. For adverse events leading to premature treatment discontinuation and adverse events by severity they will be developed for the ontreatment observation period alone.
- Figures presenting the time to first event as well as the average number of events over time
  - These will be developed based on the on-treatment observation period for all adverse events, serious adverse events, most frequent adverse events and pre-defined MedDRA searches.
- Plots summarising the incidence by preferred term
  - These will be developed for most frequent adverse events, adverse events leading to 0 premature treatment discontinuation and pre-defined MedDRA searches.
- Plots of the incidence over time by treatment and incidence over time by severity.
  - These will be developed for all gastro-intestinal adverse events, nausea, vomiting and diarrhoea. These plots will both serve for comparison between treatment arms of incidences over times as well as assessment of the distribution over time of the severity of the adverse events.

### Number of confirmed treatment emergent hypoglycaemic episodes

Trial ID: NN9924-3790CONFIDENTIALDate:21 standary 2013IncompareUTN: U111-1136-4716CONFIDENTIALVersion:1.0EudraCT No.: 2012-004994-16Page:19 of 551	UTN: U111-1136-4716	CONFIDENTIAL	Status:	Final	Novo Nordisk
--	---------------------	--------------	---------	-------	--------------

Hypoglycaemic episodes will be summarized based on ADA-classification and the combined categories "Confirmed" and "Severe or BG confirmed symptomatic hypoglycaemia".

The number of events and the number subjects experiencing an event will be evaluated for the two combined categories using statistical analyses as described above and using plots for time to first episode and average number of episodes over time.

# **Continuous safety lab parameters**

Safety lab parameters that are treated as continuous variables will be reported in groups defined below. Except for eosinophils and basophils, all examinations of continuous safety lab parameters will be done on logarithmic scale. Where applicable, outputs will be repeated for conventional units.

- 1. Pancreatic enzymes and hepatic laboratory parameters
  - a. Lipase
  - b. Amylase
  - c. Bilirubin, total
  - d. Aspartate aminotransferase (AST)
  - e. Alanine aminotransferase (ALT)
  - f. Alkaline phosphatase
- 2. Renal laboratory parameters
  - a. Creatinine
  - b. Urea
  - c. Urinary albumin/creatinine ratio
- 3. Electrolytes
  - a. Potassium
  - b. Sodium
  - c. Calcium (total)

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	20 of 551	

- d. Calcium, albumin corrected (calcium, ionized)
- 4. Hormones
  - a. Calcitonin
- 5. Other
  - a. Creatinine kinase
  - b. Albumin
- 6. Haematology
  - a. Haemoglobin
  - b. Haematocrit
  - c. Erythrocytes
  - d. Thrombocytes
  - e. Leucocytes
  - f. Differential count (eosinophils, neutrophils, basophils, lymphocytes and monocytes)
- 7. Urinalysis:
  - a. Albumin, urine

Descriptive outputs for these will be similar to those produced for continuous efficacy endpoints but based on the on-treatment observation period. The descriptive outputs are:

- Tables with descriptive statistics for observed values as well as change from baseline and ratio to baseline
- Categorical summary tables and shift tables for assessments outside of normal ranges.
- Tables with descriptive tables of the maximum post-baseline value
- Panel plots with mean of observed as well as change from baseline values over time grouped by the time of last observation. There will be a panel for each treatment arm in these plots and the serve to illustrate the observed means over time for different time-patterns of missing data.

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CONFIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	21 of 551	

- Cumulative distribution functions presenting the distribution of the maximum value observed post-baseline.

Amylase and lipase will in addition to descriptive examinations also be subject to statistical analyses. These will be done on log-scale and reported with the following statistical outputs:

- Tables with results of statistical analyses including estimated means (LS means) for week 26 values as well as for the ratio to baseline at week 26, and in addition estimated treatment ratios for the planned comparisons of treatment arms
- Plots with estimated mean values over time. These plots present the estimated means from the statistical analyses.

# **Categorical safety lab parameters**

Pregnancy test based on hCG serum assessments and results of the urinalysis will be evaluated as categorical parameters. For pregnancy test, a categorical summary table by treatment week will be produced. The parameters included in the urinalysis are:

a. Blood (erythrocytes)
b. Protein
c. Glucose
d. ketones
e. pH

For these parameters, categorical summary tables and shift tables will be produced.

### Vital signs

Pulse, diastolic blood pressure and systolic blood pressure will be evaluated with outputs similar to the continuous safety lab parameters but on observed scale. The evaluation will be based on the on-treatment observation period.

Electrocardiograms (ECGs) will be evaluated based on the on-treatment observation period with categorical summary tables and shift tables by treatment week based on the investigator's assessment.

Physical examination will be evaluated similarly to ECG. For eye examination a categorical summary table of the baseline assessment will be developed.

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CUNTIDENTIAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	22 of 551	

# 2.11 Listings

# Subject disposition and demographics

Continuous and categorical subject characteristics will be listed. Separate listings for medical history, concomitant illnesses, concomitant medication and diabetes medication will be prepared.

# **Efficacy endpoints**

Listings with individual response data will be produced for HbA1c, body weight, waist circumference, BMI, fasting plasma glucose, Fasting C-peptide, fasting insulin, glucagon and lipids.

In addition, a listing with data points excluded from the efficacy analyses will be prepared.

# Safety endpoints

Listings based on the on-treatment period for serious adverse events, adverse events with fatal outcome, adverse events leading to premature treatment discontinuation and adverse events leading to dose reduction.

These will be supplemented by a listing of adverse events occurring before randomisation, a listing of all adverse events during the in-trial observation period as well as a listing for those occurring after the end of the in-trial observation period.

Finally adverse events related to a technical complaint will be listed.

Separate listings for all hypoglycaemic episodes and severe hypoglycaemic episodes will be prepared.

Listings with observations outside the reference ranges will be produced for continuous safety lab parameters.

For amylase, lipase and calcitonin, listings with individual response data will be produced.

Listings for vital signs, overall ECG interpretation and anti-semaglutide antibodies will also be developed.

# **3** Changes to the statistical analyses planned in the protocol

The definition of the FAS is changed to exclude the requirement that a subject must have postbaseline data. Effectively, the FAS and the SAS will be identical, but subjects will contribute to the evaluations differently ("as randomised" as opposed to "as treated").

A clear definition of baseline has been added, and imputations of missing data have been clarified.

Statistical Analysis PlanDate:21 January 2015Novo NordTrial ID: NN9924-3790CONFIDENTIALVersion:1.0UTN: U111-1136-4716Status:FinalEudraCT No.: 2012-004994-16Page:23 of 551	JTN: U111-1136-4716	CONFIDENTIAL	Status:	1.0 Final	Novo Nordisk
--	---------------------	--------------	---------	--------------	--------------

It has been clarified that the analysis to confirm efficacy of oral semaglutide will be based on a comparison of the pool of two treatment arms (40 mg standard and 40 mg fast) to placebo using the standard MMRM model.

The exploratory analysis to describe the dose-response relation of oral semaglutide and estimate the relative potency vs. s.c. semaglutide with regards to selected key endpoints, will be conducted by Quantitative Clinical Pharmacology.

Statistical analysis of the number of subjects experiencing a confirmed hypoglycaemic episode during the on-treatment observation period is added to the planned analyses. In addition, severe or BG confirmed symptomatic hypoglycaemic episodes will be analysed in the same way as confirmed hypoglycaemic episodes.

Analyses of relative change from baseline in body weight, of subjects with at least 5 % weight loss and of subjects with more than 10 % weight loss added after 26 weeks of treatment added in order to align with other projects.

Evaluations of severe or BG confirmed symptomatic hypoglycaemia have been added to the planned investigations.

Due to sparse data, country will not be included in the negative binomial model for hypoglycaemic episodes.

Treatment emergent adverse events and hypoglycaemic episodes are referred to as on-treatment adverse event / on-treatment hypoglycaemic episodes.

It has been clarified that the stratification variable "Treatment with metformin at screening (yes/no)" will based on the actual information on concomitant medication recorded through the eCRF.

It has been clarified that values of laboratory parameters below the blower limit of quantification (LLOQ) will be set to LLOQ/2.

The evaluations of the pre-defined groups of adverse events have been added to the overview of planned investigations.

Statistical Analysis Plan Trial ID: NN9924-3790

# 4 Pre-defined groups of adverse events

# 4.1 Gastrointestinal adverse events

Preferred term	High level term	High level group term	System organ class	
Abdominal adhesions	Peritoneal and retroperitoneal fibrosis and adhesions	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Abdominal discomfort	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal distension	Flatulence, bloating and distension	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal mass	Abdominal findings abnormal	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal pain	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal pain lower	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal pain upper	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal rigidity	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal tenderness	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abnormal faeces	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Achlorhydria	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Acute abdomen	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Amalgam tattoo	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	
Anal dilatation	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders	
Anal fissure	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders	
Anal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Anal leukoplakia	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	25 of 551	I

Anal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Anal skin tags	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Anal spasm	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Anal stenosis	Anal and rectal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Anal ulcer	Anal and rectal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Anastomotic ulcer perforation	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Anastomotic ulcer, obstructive	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Anorectal stenosis	Anal and rectal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Anorectal ulcer	Anal and rectal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Anorectal disorder	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Aphthous stomatitis	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Aptyalism	Oral dryness and saliva altered	Salivary gland conditions	Gastrointestinal disorders
Ascites	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Barrett's oesophagus	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Bezoar	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Breath odour	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Buccoglossal syndrome	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Cardiospasm	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Change of bowel habit	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Cheilitis	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders

		1		1		
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final   Novo Nordisi	(
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	26 of 551	

Cheilosis	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Coeliac artery compression syndrome	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Coeliac disease	Malabsorption syndromes	Malabsorption conditions	Gastrointestinal disorders
Colitis	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Colitis ischaemic	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Colitis ulcerative	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Colonic fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Colonic haematoma	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Constipation	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Crohn's disease	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Defaecation urgency	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Dental alveolar anomaly	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Dental caries	Dental and periodontal infections and inflammations	Dental and gingival conditions	Gastrointestinal disorders
Dental necrosis	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Dental pulp disorder	Dental pulp disorders	Dental and gingival conditions	Gastrointestinal disorders
Diabetic gastropathy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Diaphragmatic hernia	Diaphragmatic hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Diaphragmatic hernia, obstructive	Diaphragmatic hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Diarrhoea	Diarrhoea (excl infective)	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Diarrhoea haemorrhagic	Diarrhoea (excl infective)	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders

	1	1		1		
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	27 of 551	

Diarrhoea neonatal	Diarrhoea (excl infective)	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Diverticular fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Diverticulitis intestinal haemorrhagic	Diverticulum inflammations	Diverticular disorders	Gastrointestinal disorders
Diverticulitis oesophageal	Diverticulum inflammations	Diverticular disorders	Gastrointestinal disorders
Diverticulum	Diverticula	Diverticular disorders	Gastrointestinal disorders
Diverticulum gastric	Diverticula	Diverticular disorders	Gastrointestinal disorders
Diverticulum intestinal	Diverticula	Diverticular disorders	Gastrointestinal disorders
Diverticulum intestinal haemorrhagic	Diverticula	Diverticular disorders	Gastrointestinal disorders
Diverticulum oesophageal	Diverticula	Diverticular disorders	Gastrointestinal disorders
Dry mouth	Oral dryness and saliva altered	Salivary gland conditions	Gastrointestinal disorders
Duodenal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Duodenal obstruction	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Duodenal perforation	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Duodenal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Duodenal ulcer	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Duodenal ulcer haemorrhage	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Duodenal ulcer perforation	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Duodenal ulcer perforation, obstructive	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Duodenal ulcer, obstructive	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Duodenitis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	28 of 551	

Duodenitis haemorrhagic	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Dyskinesia oesophageal	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Dyspepsia	Dyspeptic signs and symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Dysphagia	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Enamel anomaly	Dental surface disorders	Dental and gingival conditions	Gastrointestinal disorders
Enteritis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Enteritis leukopenic	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Enterocele	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Enterocolitis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Enterocolitis haemorrhagic	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Eructation	Dyspeptic signs and symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Faecal incontinence	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Faeces discoloured	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Faeces hard	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Faeces pale	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Femoral hernia	Femoral hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Femoral hernia, obstructive	Femoral hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Flatulence	Flatulence, bloating and distension	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Fluorosis dental	Dental surface disorders	Dental and gingival conditions	Gastrointestinal disorders
Food poisoning	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	29 of 551	

Frequent bowel movements	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gallstone ileus	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Gastric atony	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastric dilatation	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastric haemorrhage	Gastric and oesophageal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Gastric mucosal hypertrophy	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastric perforation	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastric polyps	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Gastric ulcer	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastric ulcer haemorrhage	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastric ulcer haemorrhage, obstructive	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastric ulcer perforation	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastric ulcer perforation, obstructive	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastric ulcer, obstructive	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastritis	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Gastritis alcoholic	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Gastritis alcoholic haemorrhagic	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Gastritis erosive	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastritis haemorrhagic	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Gastritis hypertrophic	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	30 of 551	l

Gastrointestinal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastrooesophageal reflux disease	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastroduodenal ulcer	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastroenteritis eosinophilic	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Gastrointestinal angiodysplasia	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders
Gastrointestinal angiodysplasia haemorrhagic	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders
Gastrointestinal disorder	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastrointestinal haemorrhage	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Gastrointestinal mucocoele	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastrointestinal mucosal necrosis	Gastrointestinal necrosis and gangrene (excl gangrenous hernia)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Gastrointestinal necrosis	Gastrointestinal necrosis and gangrene (excl gangrenous hernia)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Gastrointestinal pain	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Gastrointestinal perforation	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastrointestinal stenosis	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Gastrointestinal tract mucosal discolouration	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastroptosis	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Giant cell epulis	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival atrophy	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival bleeding	Gingival haemorrhages	Dental and gingival conditions	Gastrointestinal disorders
Gingival discolouration	Gingival discolourations	Dental and gingival conditions	Gastrointestinal disorders

Gingival disorder	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival erosion	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival hyperplasia	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival hypertrophy	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival hypoplasia	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival pain	Gingival pains	Dental and gingival conditions	Gastrointestinal disorders
Gingival polyp	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Gingival recession	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Gingival swelling	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Gingivitis ulcerative	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Glossitis	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Glossodynia	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Haematemesis	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Haematochezia	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Haemorrhoids	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Haemorrhoids thrombosed	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Hiatus hernia	Diaphragmatic hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Hypercementosis	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Hyperchlorhydria	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Hypertrophy of tongue papillae	Tongue disorders	Tongue conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	32 of 551	ĺ

Ileal perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Ileal stenosis	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Ileal ulcer	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Ileal ulcer perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Ileus	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Ileus paralytic	Non-mechanical ileus	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Ileus spastic	Non-mechanical ileus	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Impaired gastric emptying	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Infantile colic	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Inflammatory bowel disease	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Inguinal hernia	Inguinal hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Inguinal hernia, obstructive	Inguinal hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Intestinal angina	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Intestinal dilatation	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Intestinal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Intestinal infarction	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Intestinal ischaemia	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Intestinal obstruction	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Intestinal perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Intestinal stenosis	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	33 of 551	

Intestinal ulcer	Intestinal ulcers and perforation NEC	Intestinal ulcers and perforation NEC Gastrointestinal ulceration and perforation	
Intussusception	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Irritable bowel syndrome	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Ischiatic hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Ischiorectal hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Jejunal perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Jejunal stenosis	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Jejunal ulcer	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Jejunal ulcer perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Large intestinal ulcer	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Large intestine perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Leukoplakia oesophageal	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Leukoplakia oral	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Lip discolouration	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Lip dry	Oral dryness and saliva altered	Salivary gland conditions	Gastrointestinal disorders
Lip oedema	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Lip pain	Oral soft tissue pain and paraesthesia	Oral soft tissue conditions	Gastrointestinal disorders
Lip swelling	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Lip ulceration	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Lumbar hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders

	LUTNI 11111 1106 4716		21.1 2015		T' 1	Novo Nordisk
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	NOVO NOPAISK
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	34 of 551	

Lymphangiectasia intestinal	Malabsorption syndromes	tion syndromes Malabsorption conditions	
Lymphoid hyperplasia of appendix	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Malabsorption	Malabsorption syndromes	Malabsorption conditions	Gastrointestinal disorders
Mallory-Weiss syndrome	Gastric and oesophageal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Meconium ileus	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Megacolon	Non-mechanical ileus	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Melaena	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Melanosis coli	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Mesenteric arterial occlusion	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric artery embolism	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric artery stenosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric artery thrombosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric fibrosis	Peritoneal and retroperitoneal fibrosis and adhesions	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Mesenteric vascular insufficiency	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric vein thrombosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric venous occlusion	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mouth cyst	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Mouth haemorrhage	Oral soft tissue haemorrhages	Oral soft tissue conditions	Gastrointestinal disorders
Mouth ulceration	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Mucous stools	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	35 of 551	

Nausea	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Neonatal intestinal obstruction	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Obstruction gastric	Gastric and pyloric stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Obturator hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Odynophagia	Oral soft tissue pain and paraesthesia	Oral soft tissue conditions	Gastrointestinal disorders
Oedema mouth	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Oesophageal achalasia	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Oesophageal dilatation	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Oesophageal haemorrhage	Gastric and oesophageal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Oesophageal obstruction	Oesophageal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Oesophageal pain	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Oesophageal perforation	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Oesophageal spasm	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Oesophageal stenosis	Oesophageal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Oesophageal ulcer	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Oesophageal ulcer haemorrhage	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Oesophageal varices haemorrhage	Gastric and oesophageal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Oesophagitis	Oesophagitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Oesophagitis haemorrhagic	Oesophagitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Oral discharge	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders

Statistical Analysis Plan Trial ID: NN9924-3790	UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	Date: Version:	21 January 2015 1.0	D	Final 36 of 551	Novo Nordisk
--	--	-------------------	------------------------	---	--------------------	--------------

Oral discomfort	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders		
Oral lichen planus	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders		
Oral mucosal blistering	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders		
Oral mucosal discolouration	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders		
Oral mucosal eruption	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders		
Oral pain	Oral soft tissue pain and paraesthesia	Oral soft tissue conditions	Gastrointestinal disorders		
Oral papule	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders		
Oral submucosal fibrosis	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders		
Pancreatic atrophy	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatic cyst	Cystic pancreatic disorders	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatic disorder	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatic enzyme abnormality	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatic haemorrhage	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatic insufficiency	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatic pseudocyst	Cystic pancreatic disorders	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatitis acute	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatitis chronic	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatitis haemorrhagic	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders		
Pancreatitis necrotising	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders		

Statistical Analysis PlanUTN: U111-1136-4716Trial ID: NN9924-3790EudraCT No.: 2012-004994-16	Date: Version:	21 January 2015 1.0		Final 37 of 551	Novo Nordisk
--	-------------------	------------------------	--	--------------------	--------------

Pancreatitis relapsing	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Parotid duct obstruction	Salivary gland stenosis and obstruction	Salivary gland conditions	Gastrointestinal disorders
Parotid gland enlargement	Salivary gland enlargements	Salivary gland conditions	Gastrointestinal disorders
Peptic ulcer	Peptic ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Peptic ulcer haemorrhage	Peptic ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Peptic ulcer perforation	Peptic ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Peptic ulcer perforation, obstructive	Peptic ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Peptic ulcer, obstructive	Peptic ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Periodontal disease	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Peristalsis visible	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Peritoneal adhesions	Peritoneal and retroperitoneal fibrosis and adhesions	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Peritoneal fibrosis	Peritoneal and retroperitoneal fibrosis and adhesions	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Peritoneal haemorrhage	Peritoneal and retroperitoneal haemorrhages	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Peritonitis sclerosing	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Pigmentation buccal	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Pigmentation lip	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Plicated tongue	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Pouchitis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Proctalgia	Anal and rectal pains	Anal and rectal conditions NEC	Gastrointestinal disorders
Proctitis	Rectal inflammations NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	38 of 551	

Proctitis haemorrhagic	Rectal inflammations NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Proctitis ulcerative	Rectal inflammations NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Protrusion tongue	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Pseudodiverticular disease	Diverticula	Diverticular disorders	Gastrointestinal disorders
Pseudopolyposis	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Pudendal hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Pylorospasm	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Radicular cyst	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Ranula	Salivary gland enlargements	Salivary gland conditions	Gastrointestinal disorders
Rectal haemorrhage	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Rectal perforation	Anal and rectal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Rectal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Rectal prolapse	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Rectal stenosis	Anal and rectal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Rectal ulcer	Anal and rectal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Rectal ulcer haemorrhage	Anal and rectal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Retching	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Retroperitoneal fibrosis	Peritoneal and retroperitoneal fibrosis and adhesions	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Retroperitoneal haemorrhage	Peritoneal and retroperitoneal haemorrhages	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Retroperitoneal hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final <b>N</b>	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	39 of 551	

Retroperitoneal oedema	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Saliva altered	Oral dryness and saliva altered	Salivary gland conditions	Gastrointestinal disorders
Salivary duct obstruction	Salivary gland stenosis and obstruction	Salivary gland conditions	Gastrointestinal disorders
Salivary duct stenosis	Salivary gland stenosis and obstruction	Salivary gland conditions	Gastrointestinal disorders
Salivary gland atrophy	Salivary gland stenosis and obstruction	Salivary gland conditions	Gastrointestinal disorders
Salivary gland calculus	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Salivary gland enlargement	Salivary gland enlargements	Salivary gland conditions	Gastrointestinal disorders
Salivary gland fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Salivary gland pain	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Salivary hypersecretion	Oral dryness and saliva altered	Salivary gland conditions	Gastrointestinal disorders
Sciatic hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Sensitivity of teeth	Dental pain and sensation disorders	Dental and gingival conditions	Gastrointestinal disorders
Sideropenic dysphagia	Oesophageal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Small intestinal obstruction	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Small intestinal perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Small intestine ulcer	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Spigelian hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Splenic artery aneurysm	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders
Stasis syndrome	Malabsorption syndromes	Malabsorption conditions	Gastrointestinal disorders
Steatorrhoea	Malabsorption syndromes	Malabsorption conditions	Gastrointestinal disorders

	U111-1136-4716 Date: CT No.: 2012-004994-16 Version:	5	atus: Final age: 40 of 551	Novo Nordisk
--	---	---	-------------------------------	--------------

Stomatitis	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Stomatitis haemorrhagic	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Stomatitis necrotising	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Stress ulcer	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Submaxillary gland enlargement	Salivary gland enlargements	Salivary gland conditions	Gastrointestinal disorders
Supernumerary teeth	Dental developmental disorders and anomalies	Dental and gingival conditions	Gastrointestinal disorders
Swollen tongue	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Teeth brittle	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Teething	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Thrombosis mesenteric vessel	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Tongue blistering	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Tongue coated	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Tongue discolouration	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Tongue disorder	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Tongue geographic	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Tongue haematoma	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Tongue movement disturbance	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Tongue oedema	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Tongue spasm	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Tongue ulceration	Tongue disorders	Tongue conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	41 of 551	

Tooth ankylosis	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Tooth delamination	Dental surface disorders	Dental and gingival conditions	Gastrointestinal disorders
Tooth deposit	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Tooth development disorder	Dental developmental disorders and anomalies	Dental and gingival conditions	Gastrointestinal disorders
Tooth discolouration	Dental surface disorders	Dental and gingival conditions	Gastrointestinal disorders
Tooth disorder	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Tooth erosion	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Tooth impacted	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Tooth loss	Tooth missing	Dental and gingival conditions	Gastrointestinal disorders
Tooth malformation	Dental developmental disorders and anomalies	Dental and gingival conditions	Gastrointestinal disorders
Tooth resorption	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Toothache	Dental pain and sensation disorders	Dental and gingival conditions	Gastrointestinal disorders
Toxic dilatation of intestine	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Umbilical hernia	Umbilical hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Umbilical hernia, obstructive	Umbilical hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Upper gastrointestinal haemorrhage	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Varicose veins sublingual	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Volvulus	Large intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Vomiting	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Vomiting projectile	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	42 of 551	

Pneumoperitoneum	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Vasculitis gastrointestinal	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Lip disorder	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Buccal mucosal roughening	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Intestinal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Neurogenic bowel	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastroduodenitis haemorrhagic	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Gastroduodenitis	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Peritoneal hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Parotid lipomatosis	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Chapped lips	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Sialectasia	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Saliva discolouration	Oral dryness and saliva altered	Salivary gland conditions	Gastrointestinal disorders
Pancreatic mass	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Oesophagitis ulcerative	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Rectal discharge	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Necrotising gastritis	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Pancreatic fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Ankyloglossia acquired	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Heyde's syndrome	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders

Statistical Analysis PlanUTN: U111-1136-4Trial ID: NN9924-3790EudraCT No.: 2012		21 January 2015   Status 1.0   Page:	s: Final 43 of 551	Novo Nordisk
---	--	---	-----------------------	--------------

Lip haemorrhage	Oral soft tissue haemorrhages	Oral soft tissue conditions	Gastrointestinal disorders
Gingival blister	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Gingival oedema	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Gingival pruritus	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Lip blister	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Gingival ulceration	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Short-bowel syndrome	Malabsorption syndromes	Malabsorption conditions	Gastrointestinal disorders
Intestinal villi atrophy	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Anal haemorrhage	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Gingival hyperpigmentation	Gingival discolourations	Dental and gingival conditions	Gastrointestinal disorders
Tongue dry	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Abdominal migraine	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Melaena neonatal	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Anal sphincter atony	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Aphagia	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Tongue haemorrhage	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Faecal volume increased	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Duodenal stenosis	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Gastrointestinal dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Enterochromaffin cell hyperplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	44 of 551	

Gastric dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Oesophageal dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Oral mucosa atrophy	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Prepyloric stenosis	Gastric and pyloric stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Anal inflammation	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Faecal volume decreased	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Anovulvar fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Paresis anal sphincter	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Subileus	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Chronic gastrointestinal bleeding	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Oral dysaesthesia	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Portal hypertensive gastropathy	Gastric and oesophageal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Lower gastrointestinal haemorrhage	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Duodenal varices	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Gastric varices	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Cheilitis granulomatosa	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Diabetic gastroparesis	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Parotid gland haemorrhage	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Dyschezia	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Pancreatolithiasis	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	45 of 551	

Gastrointestinal mucosal dystrophies and secretion		Gastrointestinal conditions NEC	Gastrointestinal disorders
Mechanical ileus	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Small bowel angioedema	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Buccal polyp	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Enterocutaneous fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Mikulicz's disease	Salivary gland enlargements	Salivary gland conditions	Gastrointestinal disorders
Proctoparalysis	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Strawberry tongue	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Sialocele	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Intestinal mucosal hypertrophy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastric antral vascular ectasia	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders
Large intestine polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Necrotising colitis	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Abdominal wall cyst	Abdominal wall conditions NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Chilaiditi's syndrome	Abdominal findings abnormal	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Tongue dysplasia	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Retroperitoneum cyst	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Hypoaesthesia teeth	Dental pain and sensation disorders	Dental and gingival conditions	Gastrointestinal disorders
Sordes	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Tongue cyst	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	46 of 551	

Oesophageal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Peritoneal cyst	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Uvulitis	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Internal hernia	Abdominal hernias, site unspecified	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Lip erosion	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Anogenital dysplasia	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Tongue eruption	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Fibrosing colonopathy	Large intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Gastrointestinal hypomotility	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Oesophageal rupture	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Salivary gland cyst	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Mikulicz's syndrome	Salivary gland enlargements	Salivary gland conditions	Gastrointestinal disorders
Oedematous pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Gastrointestinal hypermotility	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastric hypomotility	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastric hypermotility	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Palatal disorder	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Palatal dysplasia	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Oesophageal ulcer perforation	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Abdominal rebound tenderness	Gastrointestinal and abdominal pains (excl oral and throat)	Gastrointestinal signs and symptoms	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	47 of 551	

Large intestinal ulcer perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Small intestinal ulcer perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Large intestinal haemorrhage	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Small intestinal haemorrhage	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Gastric volvulus	Gastric and pyloric stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Pancreatic duct obstruction	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Aerophagia	Flatulence, bloating and distension	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Acquired oesophageal web	Oesophageal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Oral pruritus	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Epigastric discomfort	Dyspeptic signs and symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Abdominal strangulated hernia	Abdominal hernias, site unspecified	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Colitis psychogenic	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Oesophageal discomfort	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Gastroduodenal haemorrhage	Gastric and oesophageal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Dental discomfort	Dental pain and sensation disorders	Dental and gingival conditions	Gastrointestinal disorders
Haemorrhoidal haemorrhage	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Diverticular hernia	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Peritoneal lesion	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Rectal lesion	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Gingival cyst	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	48 of 551	

Pancreatic enlargement	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Tongue atrophy	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Painful defaecation	Anal and rectal pains	Anal and rectal conditions NEC	Gastrointestinal disorders
Necrotising enterocolitis neonatal	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Necrotising oesophagitis	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Varices oesophageal	Oesophageal varices	Gastrointestinal vascular conditions	Gastrointestinal disorders
Perianal erythema	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Faecaloma	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Distal intestinal obstruction syndrome	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Anal trichiasis	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Dolichocolon acquired	Large intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Salivary duct inflammation	Salivary gland infections and inflammations	Salivary gland conditions	Gastrointestinal disorders
Diabetic enteropathy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Diabetic gastroenteropathy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastrointestinal ulcer haemorrhage	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Gastric disorder	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Pancreatic phlegmon	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Alcoholic pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Gastric cyst	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Colitis microscopic	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders

	LITNI 11111 1106 4716		21.1 2015		E' 1	Novo Nordisk
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	NOVO NOI UISK
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	49 of 551	

Dental plaque	Dental surface disorders	Dental and gingival conditions	Gastrointestinal disorders
Faecalith	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Intestinal prolapse	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Enterocolonic fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Brunner's gland hyperplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastrointestinal mucosal disorder	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Palatal oedema	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Salivary gland mass	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Oesophageal mass	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Rectal spasm	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Pneumatosis intestinalis	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Rectal tenesmus	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Meconium plug syndrome	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Colonic pseudo-obstruction	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastrointestinal tract mucosal pigmentation	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Pylorus dilatation	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Eosinophilic colitis	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Oral leukoedema	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Hypoaesthesia oral	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Paraesthesia oral	Oral soft tissue pain and paraesthesia	Oral soft tissue conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	50 of 551	l

Hernial eventration	Abdominal hernias, site unspecified	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders	
Gastric varices haemorrhage	Gastric and oesophageal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders	
Sclerosing encapsulating peritonitis	Peritoneal and retroperitoneal fibrosis and adhesions	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Reflux gastritis	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders	
Epulis	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	
Appendiceal mucocoele	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Gastric ileus	Gastric and pyloric stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders	
Gastrointestinal oedema	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Peritoneal haematoma	Peritoneal and retroperitoneal haemorrhages	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Pancreatic necrosis	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders	
Meconium peritonitis	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Colitis erosive	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders	
Retroperitoneal haematoma	Peritoneal and retroperitoneal haemorrhages	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Stomach granuloma	Gastric and gastroenteric infections	Gastrointestinal infections	Gastrointestinal disorders	
Hypertrophic anal papilla	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders	
Oral toxicity	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders	
Abdominal compartment syndrome	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Acquired macroglossia	Tongue disorders	Tongue conditions	Gastrointestinal disorders	
Neonatal intestinal dilatation	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders	
Acetonaemic vomiting	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	51 of 551	

Intestinal mass Gastrointestinal disorders NEC		Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastrointestinal toxicity	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Gastrointestinal ischaemia	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Glossoptosis	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Infrequent bowel movements	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Intestinal haemorrhage	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Poor dental condition	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Auriculotemporal syndrome	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Gastrointestinal amyloidosis	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Protein-losing gastroenteropathy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Allergic colitis	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Abdominal wall disorder	Abdominal wall conditions NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Haemorrhagic ascites	Peritoneal and retroperitoneal haemorrhages	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Hypergastrinaemia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Presbyoesophagus	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastrointestinal erosion	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Mesenteric haemorrhage	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Duodenogastric reflux	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Salivary gland mucocoele	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Abdominal hernia obstructive	Abdominal hernias, site unspecified	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	52 of 551	

Abdominal symptom	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Abdominal hernia	Abdominal hernias, site unspecified	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders	
Appendix disorder	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Apical granuloma	Dental and periodontal infections and inflammations	Dental and gingival conditions	Gastrointestinal disorders	
Gastric mucosal lesion	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Gastrointestinal motility disorder	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders	
Intestinal ulcer perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders	
Intra-abdominal haemorrhage	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders	
Large intestinal ulcer haemorrhage	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders	
Malocclusion	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	
Oesophageal disorder	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Peritoneal disorder	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Gastrointestinal ulcer	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders	
Small intestinal ulcer haemorrhage	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders	
Diverticular perforation	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders	
Salivary gland disorder	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders	
Gastric stenosis	Gastric and pyloric stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders	
Gastrointestinal obstruction	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders	
Gastrointestinal ulcer perforation	Gastrointestinal ulcers and perforation, site unspecified	Gastrointestinal ulceration and perforation	Gastrointestinal disorders	
Intestinal cyst	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	53 of 551	

Large intestinal obstruction	Large intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Small intestinal stenosis	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Truncus coeliacus thrombosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Erosive duodenitis	Duodenal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Enterovesical fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastrooesophageal sphincter insufficiency	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Gastrolithiasis	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Peritonitis lupus	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Cronkhite-Canada syndrome	Gastrointestinal neoplasms NEC	Malignant and unspecified neoplasms gastrointestinal NEC	Gastrointestinal disorders
Gastric hypertonia	Gastrointestinal spastic and hypermotility disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Cyclic vomiting syndrome	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Oral mucosal hypertrophy	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Neutropenic colitis	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Abdominal wall mass	Abdominal wall conditions NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Mesenteric panniculitis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Appendicitis noninfective	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Infantile spitting up	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Bowel movement irregularity	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Retroperitoneal effusion	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Erosive oesophagitis	Oesophageal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	54 of 551	

Intestinal strangulation	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Uraemic gastropathy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Visceroptosis	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Anal ulcer haemorrhage	Anal and rectal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Pelvic floor dyssynergia	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Gastrointestinal inflammation	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Eosinophilic oesophagitis	Oesophagitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Angina bullosa haemorrhagica	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Epiploic appendagitis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Douglas' pouch mass	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Oesophageal oedema	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Dysbacteriosis	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Lip exfoliation	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Oral mucosal exfoliation	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Tongue exfoliation	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders
Oral mucosa erosion	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Peritoneal perforation	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Faecal vomiting	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Portal venous gas	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Intestinal diaphragm disease	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders

	_					
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	55 of 551	

Creatorrhoea	Malabsorption syndromes	Malabsorption conditions	Gastrointestinal disorders
Pancreatic duct dilatation	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Gastrointestinal telangiectasia	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders
Tooth socket haemorrhage	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Rectal fissure	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Oroantral fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Anal prolapse	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Mesenteric arteriosclerosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Oesophageal food impaction	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Intestinal congestion	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Loose tooth	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Volvulus of small bowel	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Pancreatic duct stenosis	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Peritoneal necrosis	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Rectal obstruction	Anal and rectal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Gastric fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Jejunal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Oral cavity fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Ileal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Oesophageal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	56 of 551	

Tongue amyloidosis	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Sialometaplasia	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Ischaemic pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Oesophageal mucosal hyperplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Sandifer's syndrome	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Enlarged uvula	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Post-tussive vomiting	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Lip haematoma	Oral soft tissue haemorrhages	Oral soft tissue conditions	Gastrointestinal disorders
Visceral congestion	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Localised intraabdominal fluid collection	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Stomach mass	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Aorto-oesophageal fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Rectourethral fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Anal sphincter hypertonia	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Umbilical hernia perforation	Umbilical hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Peritoneal cloudy effluent	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Gastropleural fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Regurgitation	Nausea and vomiting symptoms	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Anal erosion	Anal and rectal ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Coeliac artery stenosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders

	LITENT 11111 1126 4716		21.1 2015		E' 1	Novo Nordick
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	57 of 551	

Hiatus hernia, obstructive	Diaphragmatic hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Tongue necrosis	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Abdominal wall haematoma	Abdominal wall conditions NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Oral mucosal erythema	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Gingival erythema	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Bloody peritoneal effluent	Peritoneal and retroperitoneal haemorrhages	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Contact stomatitis	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Glycogenic acanthosis	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Inguinal hernia strangulated	Inguinal hernias	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Gastric xanthoma	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Malignant dysphagia	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Oral disorder	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Gastrointestinal sounds abnormal	Abdominal findings abnormal	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Lupus enteritis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Dieulafoy's vascular malformation	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders
Intestinal mucosal atrophy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Lupus pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Oesophageal hypomotility	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Papilla of Vater stenosis	Duodenal and small intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Malacoplakia gastrointestinal	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	58 of 551	

Haemorrhagic erosive gastritis	Gastric ulcers and perforation	Gastrointestinal ulceration and perforation	Gastrointestinal disorders
Abdominal wall haemorrhage	Abdominal wall conditions NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Gastrointestinal mucosal exfoliation	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Melanoplakia oral	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Burning mouth syndrome	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders
Anal pruritus	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Pancreatic infarction	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Anorectal discomfort	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Anorectal squamous cell metaplasia	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Traumatic occlusion	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Pneumoretroperitoneum	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Levator syndrome	Anal and rectal pains	Anal and rectal conditions NEC	Gastrointestinal disorders
Gastrosplenic fistula	Gastrointestinal fistulae	Gastrointestinal conditions NEC	Gastrointestinal disorders
Pancreatic calcification	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Portal hypertensive enteropathy	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Anorectal varices	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Anorectal varices haemorrhage	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Intestinal steatosis	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Autoimmune pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Atrophic glossitis	Tongue disorders	Tongue conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	59 of 551	

Tongue pigmentation	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders	
Myochosis	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Ultrafiltration failure	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Mesenteritis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders	
Bile acid malabsorption	Malabsorption syndromes	Malabsorption conditions	Gastrointestinal disorders	
Intestinal haematoma	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders	
Omental infarction	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders	
Tongue pruritus	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders	
Tooth crowding	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	
Gastrointestinal vascular malformation	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders	
Ischaemic gastritis	Gastritis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders	
Gastrocoele	Abdominal cavity hernias NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders	
Cemento osseous dysplasia	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	
Intrinsic factor deficiency	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Retained deciduous tooth	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	
Lip pruritus	Oral soft tissue signs and symptoms	Oral soft tissue conditions	Gastrointestinal disorders	
Oesophageal irritation	Oesophagitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders	
Gastrointestinal tract irritation	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders	
Nicotinic stomatitis	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders	
Gastric mucosa erythema	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	60 of 551	

Colon dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Traumatic tooth displacement	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Functional gastrointestinal disorder	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Mastocytic enterocolitis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Salivary gland induration	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Pancreatic cyst rupture	Cystic pancreatic disorders	Exocrine pancreas conditions	Gastrointestinal disorders
Intestinal varices	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Oesophageal atony	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Mesenteric haematoma	Intestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Noninfectious peritonitis	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Retroperitoneal mass	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Oesophageal fibrosis	Oesophageal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Tooth pulp haemorrhage	Dental pulp disorders	Dental and gingival conditions	Gastrointestinal disorders
Oesophageal mucosa erythema	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Varicose veins of abdominal wall	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Narcotic bowel syndrome	Non-mechanical ileus	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Duodenal vascular ectasia	Gastrointestinal vascular malformations	Gastrointestinal vascular conditions	Gastrointestinal disorders
Oesophageal mucosal dissection	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Oesophageal motility disorder	Gastrointestinal dyskinetic disorders	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Periodontal inflammation	Dental and periodontal infections and inflammations	Dental and gingival conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	61 of 551	

Gingival inflammation	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Duodenal papillitis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Tooth demineralisation	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Pharyngo-oesophageal diverticulum	Diverticula	Diverticular disorders	Gastrointestinal disorders
Pancreatic steatosis	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Peritoneal mesothelial hyperplasia	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Intestinal fibrosis	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Intestinal smooth muscle hypertrophy	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Pyloric sphincter insufficiency	Gastrointestinal atonic and hypomotility disorders NEC	Gastrointestinal motility and defaecation conditions	Gastrointestinal disorders
Peripancreatic varices	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Small intestine polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Anal paraesthesia	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders
Intestinal calcification	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Large intestinal stenosis	Large intestinal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Ischaemic enteritis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Pyostomatitis vegetans	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Oesophageal compression	Oesophageal stenosis and obstruction	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Biliary ascites	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Neonatal gastrointestinal haemorrhage	Non-site specific gastrointestinal haemorrhages	Gastrointestinal haemorrhages NEC	Gastrointestinal disorders
Neonatal intestinal perforation	Intestinal ulcers and perforation NEC	Gastrointestinal ulceration and perforation	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	62 of 551	

Meconium cyst	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders	
Fixed bowel loop	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Palatal swelling	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders	
Gastrointestinal polyp haemorrhage	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders	
Abdominal hernia perforation	Abdominal hernias, site unspecified	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders	
Appendicolith	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Mesenteric phlebosclerosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders	
Anorectal swelling	Anal and rectal signs and symptoms	Anal and rectal conditions NEC	Gastrointestinal disorders	
Tongue infarction	Tongue disorders	Tongue conditions	Gastrointestinal disorders	
Mesenteric vascular occlusion	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders	
Scalloped tongue	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders	
Apoptotic colonopathy	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Richter's hernia	Abdominal hernias, site unspecified	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders	
Tongue polyp	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders	
Oral mucosa haematoma	Oral soft tissue haemorrhages	Oral soft tissue conditions	Gastrointestinal disorders	
Gastric prolapse	Gastrointestinal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Alveolar bone resorption	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	
Pancreatic fibrosis	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders	
Faeces soft	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders	
Noninfective gingivitis	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	63 of 551	

## 4.2 Allergic reactions

Preferred term	Yerred term     High level term     High level group term		System organ class	
Allergic myocarditis	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders	
Alveolitis allergic	Lower respiratory tract inflammatory and immunologic conditions	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders	
Anaphylactic reaction	Anaphylactic responses	Allergic conditions	Immune system disorders	
Anaphylactic shock	Anaphylactic responses	Allergic conditions	Immune system disorders	
Anaphylactoid reaction	Anaphylactic responses	Allergic conditions	Immune system disorders	
Anaphylaxis treatment	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures	
Angioedema	Angioedemas	Angioedema and urticaria	Skin and subcutaneous tissue disorders	
Application site dermatitis	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions	
Application site rash	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions	
Atopy	Atopic disorders	Allergic conditions	Immune system disorders	
Blepharitis allergic	Lid, lash and lacrimal infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders	
Blood immunoglobulin E abnormal	Immunoglobulin analyses	Immunology and allergy investigations	Investigations	
Blood immunoglobulin E increased	Immunoglobulin analyses	Immunology and allergy investigations	Investigations	
Bromoderma	Dermatitis ascribed to specific agent	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Bronchospasm	Bronchospasm and obstruction	Bronchial disorders (excl neoplasms)	Respiratory, thoracic and mediastinal disorders	
Circulatory collapse	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders	
Conjunctival oedema	Conjunctival infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders	
Conjunctivitis allergic	Conjunctival infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders	
Contrast media reaction	Non-site specific procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications	
Corneal oedema	Corneal infections, oedemas and inflammations	Ocular infections, irritations and inflammations	Eye disorders	
Cutaneous vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders	
Dermatitis	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Dermatitis acneiform	Acnes	Skin appendage conditions	Skin and subcutaneous tissue disorders	
Dermatitis allergic	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	64 of 551	

Dermatitis atopic	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Dermatitis bullous	Bullous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Dermatitis contact	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Dermatitis exfoliative	Exfoliative conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Dermatitis exfoliative generalised	Exfoliative conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Dermatitis herpetiformis	Bullous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Dermatitis infected	Skin structures and soft tissue infections	Infections - pathogen unspecified	Infections and infestations
Drug eruption	Dermatitis ascribed to specific agent	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Drug hypersensitivity	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders
Eczema	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Eczema infantile	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Eczema nummular	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Encephalopathy allergic	Encephalopathies NEC	Encephalopathies	Nervous system disorders
Epidermolysis bullosa	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Epiglottic oedema	Laryngeal spasm, oedema and obstruction	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Erythema multiforme	Bullous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Erythema nodosum	Panniculitides	Skin and subcutaneous tissue disorders NEC	Skin and subcutaneous tissue disorders
Eye allergy	Ocular infections, inflammations and associated manifestations	Ocular infections, irritations and inflammations	Eye disorders
Eye swelling	Ocular disorders NEC	Eye disorders NEC	Eye disorders
Eyelid oedema	Lid, lash and lacrimal infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Face oedema	Oedema NEC	General system disorders NEC	General disorders and administration site conditions
Giant papillary conjunctivitis	Conjunctival infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Gingival swelling	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Henoch-Schonlein purpura	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Hereditary angioedema	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Hypersensitivity	Allergic conditions NEC	Allergic conditions	Immune system disorders
Hypersensitivity vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	65 of 551	

Idiopathic urticaria	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Injection site dermatitis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site hypersensitivity	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site rash	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site urticaria	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Laryngeal oedema	Laryngeal spasm, oedema and obstruction	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Laryngospasm	Laryngeal spasm, oedema and obstruction	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Laryngotracheal oedema	Laryngeal spasm, oedema and obstruction	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Lip oedema	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Lip swelling	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Multiple allergies	Allergic conditions NEC	Allergic conditions	Immune system disorders
Nephritis allergic	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Nikolsky's sign	Exfoliative conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Oculomucocutaneous syndrome	Bullous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Oedema mouth	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Oropharyngeal spasm	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Oropharyngeal swelling	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Periorbital oedema	Ocular disorders NEC	Eye disorders NEC	Eye disorders
Pharyngeal oedema	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Radioallergosorbent test positive	Immunoglobulin analyses	Immunology and allergy investigations	Investigations
Rash	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Rash erythematous	Erythemas	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Rash follicular	Pustular conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Rash generalised	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Rash macular	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Rash maculo-papular	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	66 of 551	

Rash morbilliform	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Rash neonatal	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Rash papulosquamous	Papulosquamous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Rash pruritic	Pruritus NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Rash pustular	Skin structures and soft tissue infections	Infections - pathogen unspecified	Infections and infestations	
Rash scarlatiniform	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Rash vesicular	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Reaction to azo-dyes	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders	
Reaction to colouring	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders	
Red man syndrome	Erythemas	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Rhinitis allergic	Nasal congestion and inflammations	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders	
Scrotal oedema	Scrotal disorders NEC	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorders	
Serum sickness	Allergic conditions NEC	Allergic conditions	Immune system disorders	
Serum sickness-like reaction	Allergic conditions NEC	Allergic conditions	Immune system disorders	
Shock	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders	
Skin necrosis	Dermal and epidermal conditions NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Skin reaction	Dermal and epidermal conditions NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Skin test positive	Immunology skin tests NEC	Immunology and allergy investigations	Investigations	
Solar urticaria	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders	
Solvent sensitivity	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders	
Stevens-Johnson syndrome	Bullous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Swelling face	Angioedemas	Angioedema and urticaria	Skin and subcutaneous tissue disorders	
Swollen tongue	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders	
Tongue oedema	Tongue signs and symptoms	Tongue conditions	Gastrointestinal disorders	
Toxic epidermal necrolysis	Bullous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders	
Tracheal oedema	Tracheal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders	
Type I hypersensitivity	Allergic conditions NEC	Allergic conditions	Immune system disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015		1 mai	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	67 of 551	

Urticaria	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Urticaria cholinergic	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Urticaria contact	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Urticaria papular	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Urticaria physical	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Urticaria pigmentosa	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Urticaria vesiculosa	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Vaginal ulceration	Vulvovaginal disorders NEC	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Vasculitic rash	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Vulval ulceration	Vulvovaginal disorders NEC	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Allergic granulomatous angiitis	Vasculitides	Immune disorders NEC	Immune system disorders
Acute generalised exanthematous pustulosis	Pustular conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Allergic sinusitis	Paranasal sinus disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Gingival oedema	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Rash maculovesicular	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Application site eczema	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site urticaria	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Vulvovaginal ulceration	Vulvovaginal disorders NEC	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Allergic pharyngitis	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Anti-neutrophil cytoplasmic antibody positive vasculitis	Vasculitides	Immune disorders NEC	Immune system disorders
Scleritis allergic	Scleral infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Allergic cystitis	Bladder infections and inflammations	Bladder and bladder neck disorders (excl calculi)	Renal and urinary disorders
Small bowel angioedema	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Kaposi's varicelliform eruption	Viral infections NEC	Viral infectious disorders	Infections and infestations
Iodine allergy	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders
Eye oedema	Ocular disorders NEC	Eye disorders NEC	Eye disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	68 of 551	

Circumoral oedema	Angioedemas	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Catheter site rash	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Catheter site urticaria	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Urticaria chronic	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Allergic bronchitis	Bronchial conditions NEC	Bronchial disorders (excl neoplasms)	Respiratory, thoracic and mediastinal disorders
Epidermolysis	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Type IV hypersensitivity reaction	Allergic conditions NEC	Allergic conditions	Immune system disorders
Type III immune complex mediated reaction	Allergic conditions NEC	Allergic conditions	Immune system disorders
Allergic cough	Coughing and associated symptoms	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Type II hypersensitivity	Allergic conditions NEC	Allergic conditions	Immune system disorders
Allergy to vaccine	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders
Eczema weeping	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Allergy test positive	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Encephalitis allergic	Encephalitis NEC	Central nervous system infections and inflammations	Nervous system disorders
Mucocutaneous rash	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Palpable purpura	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Palatal oedema	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Allergic keratitis	Corneal infections, oedemas and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Scleral oedema	Scleral infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Toxic skin eruption	Dermatitis ascribed to specific agent	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Rash rubelliform	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Dermatitis psoriasiform	Psoriatic conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Eczema vesicular	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Hand dermatitis	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Stoma site rash	Stoma complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Epidermal necrosis	Dermal and epidermal conditions NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Allergic colitis	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	69 of 551	

Haemorrhagic urticaria	Urticarias	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Infusion site rash	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Allergic oedema	Allergic conditions NEC	Allergic conditions	Immune system disorders
Arthritis allergic	Arthropathies NEC	Joint disorders	Musculoskeletal and connective tissue disorders
Allergic otitis media	Middle ear infections and inflammations	Middle ear disorders (excl congenital)	Ear and labyrinth disorders
Heparin-induced thrombocytopenia	Thrombocytopenias	Platelet disorders	Blood and lymphatic system disorders
Dennie-Morgan fold	Dermatitis and eczema	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Anaphylactoid shock	Anaphylactic responses	Allergic conditions	Immune system disorders
Pruritus allergic	Pruritus NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Allergic respiratory symptom	Respiratory signs and symptoms NEC	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Allergic respiratory disease	Respiratory tract disorders NEC	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Application site hypersensitivity	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Implant site rash	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Implant site urticaria	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Implant site dermatitis	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Implant site hypersensitivity	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Antiallergic therapy	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Documented hypersensitivity to administered drug	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Vaginal exfoliation	Vulvovaginal disorders NEC	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Exfoliative rash	Exfoliative conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Reaction to drug excipients	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders
Reaction to preservatives	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders
Laryngitis allergic	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Infusion site dermatitis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site hypersensitivity	Infusion site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	70 of 551	

Infusion site urticaria	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Antiendomysial antibody positive	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Eczema vaccinatum	Orthopox viral infections	Viral infectious disorders	Infections and infestations
Allergic transfusion reaction	Transfusion related complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Gleich's syndrome	Angioedemas	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Contrast media allergy	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders
Anaphylactic transfusion reaction	Transfusion related complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Immediate post-injection reaction	Therapeutic and nontherapeutic responses	Therapeutic and nontherapeutic effects (excl toxicity)	General disorders and administration site conditions
Oculorespiratory syndrome	Conjunctival infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Contact stomatitis	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Oropharyngeal blistering	Upper respiratory tract signs and symptoms	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Interstitial granulomatous dermatitis	Granulomatous and deep cutaneous inflammatory conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Injection site vasculitis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
First use syndrome	Anaphylactic responses	Allergic conditions	Immune system disorders
Oral allergy syndrome	Allergies to foods, food additives, drugs and other chemicals	Allergic conditions	Immune system disorders
Vaccination site hypersensitivity	Vaccination site reactions	Administration site reactions	General disorders and administration site conditions
Kounis syndrome	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Henoch-Schonlein purpura nephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Vaccination site dermatitis	Vaccination site reactions	Administration site reactions	General disorders and administration site conditions
Vaccination site rash	Vaccination site reactions	Administration site reactions	General disorders and administration site conditions
Vaccination site exfoliation	Vaccination site reactions	Administration site reactions	General disorders and administration site conditions
Vaccination site urticaria	Vaccination site reactions	Administration site reactions	General disorders and administration site conditions
Vaccination site vesicles	Vaccination site reactions	Administration site reactions	General disorders and administration site conditions
Limbal swelling	Ocular infections, inflammations and associated manifestations	Ocular infections, irritations and inflammations	Eye disorders
Distributive shock	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	71 of 551	

Immune tolerance induction	Prophylactic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Administration site rash	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Allergic hepatitis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Chronic hyperplastic eosinophilic sinusitis	Paranasal sinus disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Chronic eosinophilic rhinosinusitis	Paranasal sinus disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Vulvovaginal rash	Vulvovaginal signs and symptoms	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Incision site dermatitis	Non-site specific procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Idiopathic angioedema	Angioedemas	Angioedema and urticaria	Skin and subcutaneous tissue disorders
Incision site rash	Non-site specific procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Drug reaction with eosinophilia and systemic symptoms	Dermatitis ascribed to specific agent	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Catheter site dermatitis	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Catheter site eczema	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Catheter site hypersensitivity	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Catheter site vasculitis	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions
Allergy to immunoglobulin therapy	Allergic conditions NEC	Allergic conditions	Immune system disorders
Pathergy reaction	Dermal and epidermal conditions NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Drug provocation test	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Palatal swelling	Oral soft tissue swelling and oedema	Oral soft tissue conditions	Gastrointestinal disorders
Stoma site hypersensitivity	Stoma complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Immune thrombocytopenic purpura	Thrombocytopenias	Platelet disorders	Blood and lymphatic system disorders
Infusion site eczema	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site vasculitis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	72 of 551	l

## 4.3 Antibody adverse events

Preferred term	term High level term High level group term		System organ class
Coagulation factor XIII level	Coagulation and bleeding analyses	Haematology investigations (incl blood groups)	Investigations
Coagulation factor XIII level decreased	Coagulation and bleeding analyses	Haematology investigations (incl blood groups)	Investigations
Drug specific antibody present	Therapeutic drug monitoring analyses	Toxicology and therapeutic drug monitoring	Investigations
Factor XIII deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Factor VIII inhibition	Coagulopathies	Coagulopathies and bleeding diatheses (excl thrombocytopenic)	Blood and lymphatic system disorders
Anti factor VIII antibody positive	Coagulation and bleeding analyses	Haematology investigations (incl blood groups)	Investigations
Anti-insulin antibody	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Factor IX inhibition	Coagulopathies	Coagulopathies and bleeding diatheses (excl thrombocytopenic)	Blood and lymphatic system disorders
Anti-insulin antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Anti-insulin antibody increased	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Haemophilia A with anti factor VIII	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Haemophilia B with anti factor IX	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Acquired haemophilia with anti FVIII, XI, or XIII	Coagulation factor deficiencies	Coagulopathies and bleeding diatheses (excl thrombocytopenic)	Blood and lymphatic system disorders
Inhibiting antibodies	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Neutralising antibodies	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Anti factor VII antibody positive	Coagulation and bleeding analyses	Haematology investigations (incl blood groups)	Investigations
Anti factor IX antibody positive	Coagulation and bleeding analyses	Haematology investigations (incl blood groups)	Investigations
Factor XIII Inhibition	Coagulopathies	Coagulopathies and bleeding diatheses (excl thrombocytopenic)	Blood and lymphatic system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	73 of 551	

Autoantibody test	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Autoantibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Antibody test	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Antibody test abnormal	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Antibody test positive	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Coagulation factor XIII level abnormal	Coagulation and bleeding analyses	Haematology investigations (incl blood groups)	Investigations
Neutralising antibodies positive	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Non-neutralising antibodies positive	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Anti factor VIII antibody test	Coagulation and bleeding analyses	Haematology investigations (incl blood groups)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	74 of 551	

## 4.4 Calcitonin adverse events

Preferred term	High level term	High level group term	System organ class
Blood calcitonin	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Blood calcitonin abnormal	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Blood calcitonin increased	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Calcitonin secretion disorder	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Ectopic calcitonin production	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Hypercalcitoninaemia	Calcium metabolism disorders	Bone, calcium, magnesium and phosphorus metabolism disorders	Metabolism and nutrition disorders

## 4.5 Cardiovascular adverse events

Preferred term	High level term	High level group term	System organ class
Acquired cardiac septal defect	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Acute myocardial infarction	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Acute prerenal failure	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Acute pulmonary oedema	Pulmonary oedemas	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders
Acute respiratory failure	Respiratory failures (excl neonatal)	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Adams-Stokes syndrome	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Allergic myocarditis	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders
Amaurosis	Blindness (excl colour blindness)	Vision disorders	Eye disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	75 of 551	

Amaurosis fugax	Blindness (excl colour blindness)	Vision disorders	Eye disorders
Anaphylactic reaction	Anaphylactic responses	Allergic conditions	Immune system disorders
Anaphylactic shock	Anaphylactic responses	Allergic conditions	Immune system disorders
Anaphylactoid reaction	Anaphylactic responses	Allergic conditions	Immune system disorders
Angina pectoris	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Angina unstable	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Angioplasty	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Anomalous atrioventricular excitation	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Anuria	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Aortic embolus	Aortic embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Aortic thrombosis	Aortic embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Aortitis	Aortic inflammatory disorders	Vascular inflammations	Vascular disorders
Aphasia	Cortical dysfunction NEC	Neurological disorders NEC	Nervous system disorders
Arrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Arrhythmia neonatal	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Arrhythmia supraventricular	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Arterectomy with graft replacement	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Arterial thrombosis	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Arteriovenous fistula thrombosis	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Arteriogram carotid abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	76 of 551	

		tests)	
Arteriogram coronary abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Arteriosclerosis coronary artery	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Arteriospasm coronary	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Arteritis	Arterial inflammations	Vascular inflammations	Vascular disorders
Arteritis coronary	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Ascites	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Atrial fibrillation	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Atrial flutter	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Atrial septal defect acquired	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Atrial tachycardia	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Atrioventricular block	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Atrioventricular block complete	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Atrioventricular block first degree	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Atrioventricular block second degree	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Axillary vein thrombosis	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Basilar artery stenosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Behcet's syndrome	Vasculitides NEC	Vascular inflammations	Vascular disorders
Biopsy heart abnormal	Cardiac histopathology procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	77 of 551	

Blindness transient	Blindness (excl colour blindness)	Vision disorders	Eye disorders
Blood creatine phosphokinase abnormal	Skeletal and cardiac muscle analyses	Enzyme investigations NEC	Investigations
Blood creatine phosphokinase increased	Skeletal and cardiac muscle analyses	Enzyme investigations NEC	Investigations
Blood creatine phosphokinase MB abnormal	Skeletal and cardiac muscle analyses	Enzyme investigations NEC	Investigations
Blood creatine phosphokinase MB increased	Skeletal and cardiac muscle analyses	Enzyme investigations NEC	Investigations
Blood pressure diastolic abnormal	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Blood pressure diastolic decreased	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Blood pressure diastolic increased	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Blood pressure fluctuation	Blood pressure disorders NEC	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Blood pressure immeasurable	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Blood pressure systolic abnormal	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Blood pressure systolic decreased	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Blood pressure systolic increased	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Bradycardia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Bradycardia foetal	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Brain hypoxia	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Brain stem haemorrhage	Central nervous system haemorrhages and	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	78 of 551	

	cerebrovascular accidents		
Brain stem infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Brain stem ischaemia	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Budd-Chiari syndrome	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Bundle branch block	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Bundle branch block bilateral	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Bundle branch block left	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Bundle branch block right	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Cardiac amyloidosis	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Cardiac aneurysm	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Cardiac arrest	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Cardiac arrest neonatal	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Cardiac asthma	Heart failure signs and symptoms	Heart failures	Cardiac disorders
Cardiac failure	Heart failures NEC	Heart failures	Cardiac disorders
Cardiac failure acute	Heart failures NEC	Heart failures	Cardiac disorders
Cardiac failure chronic	Heart failures NEC	Heart failures	Cardiac disorders
Cardiac failure congestive	Heart failures NEC	Heart failures	Cardiac disorders
Cardiac failure high output	Heart failures NEC	Heart failures	Cardiac disorders
Cardiac hypertrophy	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	79 of 551	

Cardiac index abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac index decreased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac index increased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac output decreased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac sarcoidosis	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Cardio-respiratory arrest	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Cardio-respiratory arrest neonatal	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Cardiogenic shock	Heart failures NEC	Heart failures	Cardiac disorders
Cardiomegaly	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Cardiomyopathy alcoholic	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Cardiothoracic ratio increased	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiovascular disorder	Cardiac disorders NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Cardiovascular function test abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Carotid arterial embolus	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Carotid artery aneurysm	Central nervous system aneurysms and dissections	Central nervous system vascular disorders	Nervous system disorders
Carotid artery stenosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	80 of 551	I

Carotid artery thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Carotid endarterectomy	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Cavernous sinus thrombosis	Central nervous system and spinal infections	Infections - pathogen unspecified	Infections and infestations
Central venous pressure increased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cerebellar artery thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebellar haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebellar infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral aneurysm ruptured syphilitic	Treponema infections	Bacterial infectious disorders	Infections and infestations
Cerebral arteriovenous malformation haemorrhagic	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Cerebral arteritis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cerebral artery embolism	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral artery occlusion	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral artery thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral circulatory failure	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cerebral haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral haemorrhage neonatal	Central nervous system haemorrhages and	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	81 of 551	

	cerebrovascular accidents		
Cerebral infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral infarction foetal	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral ischaemia	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral venous thrombosis	Cerebrovascular venous and sinus thrombosis	Central nervous system vascular disorders	Nervous system disorders
Cerebrovascular accident	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebrovascular disorder	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Chest pain	Pain and discomfort NEC	General system disorders NEC	General disorders and administration site conditions
Chest X-ray abnormal	Respiratory tract and thoracic imaging procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Circulatory collapse	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Conduction disorder	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Cor pulmonale	Right ventricular failures	Heart failures	Cardiac disorders
Cor pulmonale acute	Right ventricular failures	Heart failures	Cardiac disorders
Cor pulmonale chronic	Right ventricular failures	Heart failures	Cardiac disorders
Coronary artery bypass	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures         Surgical and medical procedures	
Coronary artery disease	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	82 of 551	

Coronary artery embolism	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Coronary artery occlusion	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Coronary artery stenosis	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Coronary artery thrombosis	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Coronary endarterectomy	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Coronary ostial stenosis	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Coxsackie carditis	Coxsackie viral infections	Viral infectious disorders	Infections and infestations
Coxsackie myocarditis	Coxsackie viral infections	Viral infectious disorders	Infections and infestations
Cryoglobulinaemia	Vasculitides NEC	Vascular inflammations	Vascular disorders
Cryoglobulins present	Immunoglobulin analyses	Immunology and allergy investigations	Investigations
Cutaneous vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Cytotoxic cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Defect conduction intraventricular	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Diabetic cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Diffuse vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Dilatation atrial	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Dilatation ventricular	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Diplegia	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Directional Doppler flow tests abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Dissecting coronary artery aneurysm	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	83 of 551	

Disseminated intravascular coagulation	Coagulopathies	Coagulopathies and bleeding diatheses (excl thrombocytopenic)	Blood and lymphatic system disorders
Disseminated intravascular coagulation in newborn	Coagulopathies	Coagulopathies and bleeding diatheses (excl thrombocytopenic)	Blood and lymphatic system disorders
Dysarthria	Speech and language abnormalities	Neurological disorders NEC	Nervous system disorders
Dyspnoea	Breathing abnormalities	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Dyspnoea paroxysmal nocturnal	Breathing abnormalities	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Ejection fraction abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram ambulatory abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram delta waves abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram PR shortened	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram QRS complex prolonged	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram QT prolonged	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram ST segment abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram ST segment depression	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram ST segment elevation	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	84 of 551	

Electrocardiogram T wave inversion	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Embolic stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Embolism arterial	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Embolism venous	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Endarterectomy	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Endocardial fibroelastosis	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Endotoxic shock	Sepsis, bacteraemia, viraemia and fungaemia NEC	Infections - pathogen unspecified	Infections and infestations
Eosinophilic myocarditis	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders
Erythema induratum	Tuberculous infections	Mycobacterial infectious disorders	Infections and infestations
Exercise electrocardiogram abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Exercise test abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Extradural haematoma	Cerebral injuries NEC	Injuries NEC	Injury, poisoning and procedural complications
Extrasystoles	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Foetal arrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Goodpasture's syndrome	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Grey syndrome neonatal	Heart failures NEC	Heart failures	Cardiac disorders
Haemorrhage intracranial	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Haemorrhagic cerebral infarction	Central nervous system haemorrhages and	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	85 of 551	

	cerebrovascular accidents		
Haemorrhagic infarction	Non-site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Haemorrhagic stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Haemorrhoids thrombosed	Haemorrhoids and gastrointestinal varices (excl oesophageal)	Gastrointestinal vascular conditions	Gastrointestinal disorders
Heart block congenital	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Heart rate abnormal	Heart rate and pulse investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Heart rate decreased	Heart rate and pulse investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Heart rate increased	Heart rate and pulse investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Heart rate irregular	Heart rate and pulse investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Heart transplant	Cardiac therapeutic procedures NEC	Cardiac therapeutic procedures	Surgical and medical procedures
Hemiparesis	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Hemiplegia	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Henoch-Schonlein purpura	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Hepatic artery embolism	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic artery thrombosis	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic congestion	Hepatobiliary signs and symptoms	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic infarction	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	86 of 551	l

Hepatic vein thrombosis	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatomegaly	Hepatobiliary signs and symptoms	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatorenal failure	Hepatic failure and associated disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hypersensitivity vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Hypertrophic cardiomyopathy	Cardiac septal defects congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Hypovolaemic shock	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Iliac artery embolism	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Injection site thrombosis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Intestinal infarction	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Intra-cerebral aneurysm operation	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Intracranial aneurysm	Central nervous system aneurysms and dissections	Central nervous system vascular disorders	Nervous system disorders
Intracranial tumour haemorrhage	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraventricular haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Intraventricular haemorrhage neonatal	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Jugular vein thrombosis	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Kawasaki's disease	Arterial inflammations	Vascular inflammations	Vascular disorders
Labile blood pressure	Blood pressure disorders NEC	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Lateral medullary syndrome	Central nervous system haemorrhages and	Central nervous system vascular disorders	Nervous system disorders

					r	
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	87 of 551	

	cerebrovascular accidents		
Left ventricular failure	Left ventricular failures	Heart failures	Cardiac disorders
Leriche syndrome	Aortic necrosis and vascular insufficiency	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Long QT syndrome	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Loss of consciousness	Disturbances in consciousness NEC	Neurological disorders NEC	Nervous system disorders
Low cardiac output syndrome	Heart failures NEC	Heart failures	Cardiac disorders
Lown-Ganong-Levine syndrome	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Mesenteric arterial occlusion	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric artery embolism	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric artery stenosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric artery thrombosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric vascular insufficiency	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric vein thrombosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Mesenteric venous occlusion	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Monoparesis	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Monoplegia	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Moyamoya disease	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Multi-organ failure	General signs and symptoms NEC	General system disorders NEC	General disorders and administration site conditions
Multiple gated acquisition scan abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	88 of 551	

Myocardial fibrosis	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Myocardial infarction	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Myocardial ischaemia	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Myocardial necrosis	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Myocarditis	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders
Myocarditis meningococcal	Neisseria infections	Bacterial infectious disorders	Infections and infestations
Myocarditis septic	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations
Myocarditis syphilitic	Treponema infections	Bacterial infectious disorders	Infections and infestations
Myocarditis toxoplasmal	Toxoplasma infections	Protozoal infectious disorders	Infections and infestations
Myoglobinuria	Urinary abnormalities	Urinary tract signs and symptoms	Renal and urinary disorders
Neonatal respiratory failure	Neonatal hypoxic conditions	Neonatal respiratory disorders	Respiratory, thoracic and mediastinal disorders
Nocturia	Urinary tract signs and symptoms NEC	Urinary tract signs and symptoms	Renal and urinary disorders
Nodal arrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Nodal rhythm	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Nodular vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Obstetrical pulmonary embolism	Pulmonary thrombotic and embolic conditions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Oedema	Oedema NEC	General system disorders NEC	General disorders and administration site conditions
Oedema peripheral	Oedema NEC	General system disorders NEC	General disorders and administration site conditions
Optic nerve infarction	Optic nerve bleeding and vascular disorders	Ocular haemorrhages and vascular disorders NEC	Eye disorders
Orthopnoea	Breathing abnormalities	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	89 of 551	I

Orthostatic hypotension	Vascular hypotensive disorders	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Palpitations	Cardiac signs and symptoms NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Papillary muscle infarction	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Paralysis	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Paralysis flaccid	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Paraparesis	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Paraplegia	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Parasystole	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Paresis	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Pelvic venous thrombosis	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Penile vein thrombosis	Penile disorders NEC (excl erection and ejaculation)	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Pituitary infarction	Hypothalamic and pituitary disorders NEC	Hypothalamus and pituitary gland disorders	Endocrine disorders
Plasma viscosity abnormal	Haematological analyses NEC	Haematology investigations (incl blood groups)	Investigations
Polyarteritis nodosa	Vasculitides NEC	Vascular inflammations	Vascular disorders
Polymyalgia rheumatica	Connective tissue disorders NEC	Connective tissue disorders (excl congenital)	Musculoskeletal and connective tissue disorders
Portal shunt	Hepatic therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Portal vein thrombosis	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Postpartum venous thrombosis	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Precerebral artery occlusion	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	90 of 551	

Prinzmetal angina	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Pulmonary arterial wedge pressure increased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Pulmonary artery thrombosis	Pulmonary thrombotic and embolic conditions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Pulmonary congestion	Pulmonary oedemas	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders
Pulmonary embolism	Pulmonary thrombotic and embolic conditions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Pulmonary infarction	Pulmonary thrombotic and embolic conditions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Pulmonary microemboli	Pulmonary thrombotic and embolic conditions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Pulmonary oedema	Pulmonary oedemas	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders
Pulmonary thrombosis	Pulmonary thrombotic and embolic conditions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Pulmonary vasculitis	Lower respiratory tract inflammatory and immunologic conditions	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders
Pulmonary veno-occlusive disease	Vascular pulmonary disorders NEC	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Pulmonary venous thrombosis	Pulmonary thrombotic and embolic conditions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Pulse absent	Heart rate and pulse investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Quadriplegia	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Red blood cells CSF positive	Cerebrospinal fluid tests (excl microbiology)	Neurological, special senses and psychiatric investigations	Investigations
Renal arteritis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal artery thrombosis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	91 of 551	

Renal failure	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal failure acute	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal failure neonatal	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal infarct	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal vasculitis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal vein embolism	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal vein thrombosis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Respiratory failure	Respiratory failures (excl neonatal)	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Restrictive cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Retinal artery embolism	Retinal bleeding and vascular disorders (excl retinopathy)	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Retinal artery occlusion	Retinal bleeding and vascular disorders (excl retinopathy)	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Retinal artery thrombosis	Retinal bleeding and vascular disorders (excl retinopathy)	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Retinal vasculitis	Retinal, choroid and vitreous infections and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Retinal vein occlusion	Retinal bleeding and vascular disorders (excl retinopathy)	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Retinal vein thrombosis	Retinal bleeding and vascular disorders (excl retinopathy)	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Rhythm idioventricular	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Right ventricular failure	Right ventricular failures	Heart failures	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo No	rdisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	92 of 551	

Ruptured cerebral aneurysm	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Septic shock	Sepsis, bacteraemia, viraemia and fungaemia NEC	Infections - pathogen unspecified	Infections and infestations
Shock	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Shock hypoglycaemic	Hypoglycaemic conditions NEC	Glucose metabolism disorders (incl diabetes mellitus)	Metabolism and nutrition disorders
Shunt occlusion	Non-site specific procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Sick sinus syndrome	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Sinoatrial block	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Sinus arrest	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Sinus arrhythmia	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Sinus bradycardia	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Sinus tachycardia	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Spastic paralysis	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Spinal vessel congenital anomaly	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Splenic infarction	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders
Splenic vein thrombosis	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders
Stroke volume decreased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Subarachnoid haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan Trial ID: NN9924-3790	UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	Date: Version:	21 January 2015Status:1.0Page:	FinalNovo Nordisk93 of 551
Subarachnoid haemorrhage neonatal	Central nervous system haemorrhages and cerebrovascular accidents	Central 1	nervous system vascular disorders	Nervous system disorders
Subclavian artery embolism	Peripheral embolism and thrombosis	Embolis	m and thrombosis	Vascular disorders
Subclavian artery thrombosis	Peripheral embolism and thrombosis	Embolis	m and thrombosis	Vascular disorders
Subclavian steal syndrome	Site specific vascular disorders NEC	Vascular	r disorders NEC	Vascular disorders
Subdural haematoma	Cerebral injuries NEC	Injuries	NEC	Injury, poisoning and procedural complications

Subclavian steal syndrome	Site specific vascular disorders NEC	Vascular disorders NEC	Vascular disorders
Subdural haematoma	Cerebral injuries NEC	Injuries NEC	Injury, poisoning and procedural complications
Subdural haematoma evacuation	Skull and brain therapeutic procedures	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Subdural haemorrhage	Cerebral injuries NEC	Injuries NEC	Injury, poisoning and procedural complications
Subdural haemorrhage neonatal	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Sudden death	Death and sudden death	Fatal outcomes	General disorders and administration site conditions
Superior sagittal sinus thrombosis	Cerebrovascular venous and sinus thrombosis	Central nervous system vascular disorders	Nervous system disorders
Superior vena cava syndrome	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Supraventricular extrasystoles	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Supraventricular tachycardia	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Syncope	Disturbances in consciousness NEC	Neurological disorders NEC	Nervous system disorders
Tachycardia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Tachycardia foetal	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Tachycardia paroxysmal	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Takayasu's arteritis	Arterial inflammations	Vascular inflammations	Vascular disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	94 of 551	

Temporal arteritis	Arterial inflammations	Vascular inflammations	Vascular disorders
Testicular infarction	Testicular and epididymal disorders NEC	Testicular and epididymal disorders	Reproductive system and breast disorders
Thrombectomy	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Thromboangiitis obliterans	Vasculitides NEC	Vascular inflammations	Vascular disorders
Thrombolysis	Haematological therapeutic procedures NEC	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Thrombophlebitis	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Thrombophlebitis migrans	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Thrombophlebitis neonatal	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Thrombophlebitis superficial	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Thrombosed varicose vein	Varicose veins non-site specific	Venous varices	Vascular disorders
Thrombosis	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Thrombosis mesenteric vessel	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Thrombosis prophylaxis	Prophylactic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Thrombotic microangiopathy	Coagulopathies	Coagulopathies and bleeding diatheses (excl thrombocytopenic)	Blood and lymphatic system disorders
Thrombotic stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Thrombotic thrombocytopenic purpura	Thrombocytopenias	Platelet disorders	Blood and lymphatic system disorders
Thyroid infarction	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Torsade de pointes	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Toxic shock syndrome	Infections NEC	Infections - pathogen unspecified	Infections and infestations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	95 of 551	

Transient ischaemic attack	Transient cerebrovascular events	Central nervous system vascular disorders	Nervous system disorders
Transverse sinus thrombosis	Cerebrovascular venous and sinus thrombosis	Central nervous system vascular disorders	Nervous system disorders
Trifascicular block	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Tumour embolism	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ultrasound Doppler abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Vascular purpura	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Vasculitic rash	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Vasculitis cerebral	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Vasculitis necrotising	Vasculitides NEC	Vascular inflammations	Vascular disorders
Vena cava embolism	Vena caval embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Vena cava thrombosis	Vena caval embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Venogram abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Venoocclusive liver disease	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Venous pressure increased	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Venous pressure jugular abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Venous pressure jugular increased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	96 of 551	

Venous thrombosis	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Ventricular arrhythmia	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Ventricular asystole	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Ventricular extrasystoles	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Ventricular fibrillation	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Ventricular flutter	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Ventricular hypertrophy	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Ventricular septal defect acquired	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Ventricular tachycardia	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Vertebral artery stenosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Vertebrobasilar insufficiency	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Viral myocarditis	Viral infections NEC	Viral infectious disorders	Infections and infestations
Visual acuity reduced transiently	Partial vision loss	Vision disorders	Eye disorders
Wandering pacemaker	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Withdrawal arrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Wolff-Parkinson-White syndrome	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Mental status changes	Mental disorders NEC	Psychiatric disorders NEC	Psychiatric disorders
Vasculitis gastrointestinal	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Cardiomyopathy acute	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Spinal haematoma	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	97 of 551	

Post thrombotic syndrome	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Allergic granulomatous angiitis	Vasculitides	Immune disorders NEC	Immune system disorders
Cardiotoxicity	Cardiac disorders NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Intracardiac thrombus	Cardiac disorders NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Atrial hypertrophy	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Rheumatoid vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Coronary artery dissection	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Atrial thrombosis	Cardiac disorders NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Agnosia	Cortical dysfunction NEC	Neurological disorders NEC	Nervous system disorders
Spastic paraplegia	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Myocardial haemorrhage	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Ischaemic cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Phlebectomy	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Vena cava filter insertion	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Basilar artery occlusion	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Carotid artery occlusion	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Vertebral artery occlusion	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cardiac pseudoaneurysm	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Renal artery occlusion	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	98 of 551	

Spinal cord haemorrhage	Spinal cord and nerve root disorders NEC	Spinal cord and nerve root disorders	Nervous system disorders
Accelerated idioventricular rhythm	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Vascular graft occlusion	Transplantation complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Vascular operation	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Cerebrovascular accident prophylaxis	Prophylactic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Electrocardiogram ST-T segment depression	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram ST-T segment elevation	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Nocturnal dyspnoea	Breathing abnormalities	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Spinal epidural haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Wolff-Parkinson-White syndrome congenital	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Sudden cardiac death	Death and sudden death	Fatal outcomes	General disorders and administration site conditions
Peripartum cardiomyopathy	Pregnancy complicated by maternal disorders	Maternal complications of pregnancy	Pregnancy, puerperium and perinatal conditions
Spinal artery embolism	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Subclavian vein thrombosis	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Tachyarrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Oedema due to cardiac disease	Oedema NEC	General system disorders NEC	General disorders and administration site conditions
Quadriparesis	Paralysis and paresis (excl cranial nerve)	Movement disorders (incl parkinsonism)	Nervous system disorders
Left ventricular dysfunction	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	99 of 551	

Pituitary haemorrhage	Hypothalamic and pituitary disorders NEC	Hypothalamus and pituitary gland disorders	Endocrine disorders
Ventricular pre-excitation	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Bradyarrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Silent myocardial infarction	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Shock haemorrhagic	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Neonatal tachycardia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Neonatal anuria	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Peripheral oedema neonatal	Oedema NEC	General system disorders NEC	General disorders and administration site conditions
Neonatal cardiac failure	Heart failures NEC	Heart failures	Cardiac disorders
Atrial pressure increased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Non-obstructive cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Bone infarction	Bone disorders NEC	Bone disorders (excl congenital and fractures)	Musculoskeletal and connective tissue disorders
Cardio-respiratory distress	Heart failures NEC	Heart failures	Cardiac disorders
Coronary revascularisation	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Cardiac death	Death and sudden death	Fatal outcomes	General disorders and administration site conditions
Paroxysmal arrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Cardiomyopathy neonatal	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Cerebral haemorrhage foetal	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Spinal epidural haematoma	Central nervous system haemorrhages and	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	100 of 551	

	cerebrovascular accidents		
Spinal subdural haematoma	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Paget-Schroetter syndrome	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Coronary angioplasty	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Electrocardiogram T wave abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram P wave abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Neonatal multi-organ failure	General signs and symptoms NEC	General system disorders NEC	General disorders and administration site conditions
Carotid artery dissection	Central nervous system aneurysms and dissections	Central nervous system vascular disorders	Nervous system disorders
Pulmonary oedema neonatal	Pulmonary oedemas	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders
Reversible ischaemic neurological deficit	Transient cerebrovascular events	Central nervous system vascular disorders	Nervous system disorders
Ventricular hypokinesia	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Ejection fraction decreased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Anti-neutrophil cytoplasmic antibody positive vasculitis	Vasculitides	Immune disorders NEC	Immune system disorders
Increased ventricular preload	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Postoperative thrombosis	Non-site specific procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Decreased ventricular preload	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	101 of 551	

Homans' sign positive	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Deep vein thrombosis	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Lacunar infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cardiopulmonary failure	Heart failures NEC	Heart failures	Cardiac disorders
Blood pressure inadequately controlled	Blood pressure disorders NEC	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Electrocardiogram Q wave abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Graft thrombosis	Transplantation complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Blood viscosity increased	Haematological analyses NEC	Haematology investigations (incl blood groups)	Investigations
Carotid aneurysm rupture	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Hepatojugular reflux	Heart failure signs and symptoms	Heart failures	Cardiac disorders
Acute coronary syndrome	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Myocardial reperfusion injury	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Retinal infarction	Retinal bleeding and vascular disorders (excl retinopathy)	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Cerebrovascular operation	Skull and brain therapeutic procedures	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Hepatic artery occlusion	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Pacemaker syndrome	Cardiac complications associated with device	Complications associated with device	General disorders and administration site conditions
Femoral artery occlusion	Peripheral vasoconstriction, necrosis and vascular	Arteriosclerosis, stenosis, vascular insufficiency	Vascular disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	102 of 551	

	insufficiency	and necrosis	
Coronary arterial stent insertion	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Cerebrospinal thrombotic tamponade	Increased intracranial pressure disorders	Increased intracranial pressure and hydrocephalus	Nervous system disorders
Electrocardiogram ST-T segment abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Diastolic dysfunction	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Left ventricular heave	Cardiac signs and symptoms NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Ventricular assist device insertion	Cardiac device therapeutic procedures	Cardiac therapeutic procedures	Surgical and medical procedures
Electrocardiogram repolarisation abnormality	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Meningorrhagia	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Catheterisation venous	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Cardiac flutter	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Coronary artery insufficiency	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Angiogram cerebral abnormal	Central nervous system imaging procedures	Neurological, special senses and psychiatric investigations	Investigations
Arterial therapeutic procedure	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Venous repair	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Intra-aortic balloon placement	Aortic therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Carotid artery bypass	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Organ failure	General signs and symptoms NEC	General system disorders NEC	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	103 of 551	

Coronary artery reocclusion	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Peripheral revascularisation	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Central venous catheterisation	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Brain natriuretic peptide increased	Metabolism tests NEC	Metabolic, nutritional and blood gas investigations	Investigations
Brain natriuretic peptide abnormal	Metabolism tests NEC	Metabolic, nutritional and blood gas investigations	Investigations
Atrial natriuretic peptide abnormal	Metabolism tests NEC	Metabolic, nutritional and blood gas investigations	Investigations
Atrial natriuretic peptide increased	Metabolism tests NEC	Metabolic, nutritional and blood gas investigations	Investigations
Cardiac monitoring abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac ventriculogram right abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac ventriculogram abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac telemetry abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac imaging procedure abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Pacemaker generated arrhythmia	Cardiac complications associated with device	Complications associated with device	General disorders and administration site conditions
Cardiac ventriculogram left abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme Investigations tests)	
Foetal cerebrovascular disorder	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	104 of 551	

Cerebellar artery occlusion	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Electrocardiogram PQ interval prolonged	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram PR prolongation	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Compression stockings application	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Sneddon's syndrome	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cerebral haematoma	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cardiac ventricular thrombosis	Cardiac disorders NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Agonal rhythm	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Myocardial calcification	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Malarial myocarditis	Plasmodia infections	Protozoal infectious disorders	Infections and infestations
Superior mesenteric artery syndrome	Vascular malformations and acquired anomalies	Vascular disorders NEC	Vascular disorders
Charcot-Bouchard microaneurysms	Central nervous system aneurysms and dissections	Central nervous system vascular disorders	Nervous system disorders
Cardiac cirrhosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Cardiac stress test abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Electrocardiogram U-wave abnormality	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Haemorrhagic transformation stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Haemorrhage coronary artery	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	105 of 551	

Cytomegalovirus myocarditis	Cytomegaloviral infections	Viral infectious disorders	Infections and infestations
Viral vasculitis	Viral infections NEC	Viral infectious disorders	Infections and infestations
Renal vein occlusion	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Congestive cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Cerebrovascular arteriovenous malformation	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Intraoperative cerebral artery occlusion	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Heart and lung transplant	Cardiac therapeutic procedures NEC	Cardiac therapeutic procedures	Surgical and medical procedures
Arterial bypass operation	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Bradycardia neonatal	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Ventricular hyperkinesia	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Coronary artery restenosis	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Cogan's syndrome	Iris and uveal tract infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Palpable purpura	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Blood brain barrier defect	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Balint's syndrome	Cortical dysfunction NEC	Neurological disorders NEC	Nervous system disorders
Bifascicular block	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Choroidal infarction	Choroid and vitreous haemorrhages and vascular disorders	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Renal artery angioplasty	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	106 of 551	

Angiogram peripheral abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Peripheral artery angioplasty	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
ECG P wave inverted	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac septal hypertrophy	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Aortic bypass	Aortic therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Vertebral artery thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Aortogram abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Computerised tomogram thorax abnormal	Respiratory tract and thoracic imaging procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Long QT syndrome congenital	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Arrhythmogenic right ventricular dysplasia	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Neurogenic shock	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Lupus vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Postinfarction angina	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Subendocardial ischaemia	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Pulseless electrical activity	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Heart alternation	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Reperfusion arrhythmia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	107 of 551	

Ventricular parasystole	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Hypertensive cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Troponin increased	Skeletal and cardiac muscle analyses	Enzyme investigations NEC	Investigations
Troponin I increased	Skeletal and cardiac muscle analyses	Enzyme investigations NEC	Investigations
Troponin T increased	Skeletal and cardiac muscle analyses	Enzyme investigations NEC	Investigations
ECG signs of myocardial ischaemia	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Surgical vascular shunt	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Myocardiac abscess	Cardiac infections	Infections - pathogen unspecified	Infections and infestations
Cardiac function test abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Hypoperfusion	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Arteriovenous fistula occlusion	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Spinal cord infarction	Spinal cord and nerve root disorders NEC	Spinal cord and nerve root disorders	Nervous system disorders
Right ventricular dysfunction	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Nuclear magnetic resonance imaging thoracic abnormal	Respiratory tract and thoracic imaging procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Embolia cutis medicamentosa	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Myoglobinaemia	Muscle related signs and symptoms NEC	Muscle disorders	Musculoskeletal and connective tissue disorders
Vasodilation procedure	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Cerebrovascular insufficiency	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	108 of 551	

Thalamus haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Putamen haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Inferior vena caval occlusion	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Superior vena cava occlusion	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Portal vein occlusion	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Venous occlusion	Non-site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Hepatic vein occlusion	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Iliac vein occlusion	Peripheral vasoconstriction, necrosis and vascular insufficiency	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Coronary bypass thrombosis	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Myocarditis mycotic	Fungal infections NEC	Fungal infectious disorders	Infections and infestations
Brugada syndrome	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Shunt thrombosis	Non-site specific procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Ventricular dysfunction	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Cerebral vasoconstriction	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Ventricular dyskinesia	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Papillary muscle haemorrhage	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Intracranial haematoma	Central nervous system haemorrhages and	Central nervous system vascular disorders	Nervous system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	109 of 551	

	cerebrovascular accidents		
Stroke in evolution	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Fahr's disease	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Pneumatic compression therapy	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Cardiac resynchronisation therapy	Cardiac device therapeutic procedures	Cardiac therapeutic procedures	Surgical and medical procedures
Jugular vein distension	Site specific vascular disorders NEC	Vascular disorders NEC	Vascular disorders
Left ventricular end-diastolic pressure decreased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Antineutrophil cytoplasmic antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Antineutrophil cytoplasmic antibody increased	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Right ventricular systolic pressure decreased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Computerised tomogram coronary artery abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Embolic cerebral infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Ischaemic cerebral infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Ventricular failure	Heart failures NEC	Heart failures	Cardiac disorders
Angiogram abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac operation	Cardiac therapeutic procedures NEC	Cardiac therapeutic procedures	Surgical and medical procedures
Cerebellar haematoma	Central nervous system haemorrhages and	Central nervous system vascular disorders	Nervous system disorders

	1	1				
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	110 of 551	

	cerebrovascular accidents		
Electrocardiogram change	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Foetal heart rate disorder	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Embolism	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Infarction	Non-site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Intracranial venous sinus thrombosis	Cerebrovascular venous and sinus thrombosis	Central nervous system vascular disorders	Nervous system disorders
Ischaemic stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Oedema neonatal	Oedema NEC	General system disorders NEC	General disorders and administration site conditions
Papillary muscle disorder	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Peripheral embolism	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Spinal vascular disorder	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Venous thrombosis limb	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Antibody test abnormal	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Antibody test positive	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Scan myocardial perfusion abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Cardiac fibrillation	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Echocardiogram abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Ultrasonic angiogram abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	111 of 551	

		tests)	
Aortic surgery	Aortic therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Arterial graft	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Arterial stent insertion	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Arteriogram abnormal	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Carotid artery disease	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cerebrovascular stenosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cardiac electrophysiologic study abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Intracerebral haematoma evacuation	Skull and brain therapeutic procedures	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Retinal vascular thrombosis	Retinal bleeding and vascular disorders (excl retinopathy)	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Venoocclusive disease	Non-site specific vascular disorders NEC	Vascular disorders NEC	Vascular disorders
Venous operation	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Congenital cerebrovascular anomaly	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Truncus coeliacus thrombosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Heparin-induced thrombocytopenia	Thrombocytopenias	Platelet disorders	Blood and lymphatic system disorders
Thrombosis in device	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Brain stem thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Peripheral arterial occlusive disease	Peripheral vasoconstriction, necrosis and vascular	Arteriosclerosis, stenosis, vascular insufficiency	Vascular disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	112 of 551	I

	insufficiency	and necrosis	
Arterial occlusive disease	Non-site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Atherectomy	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Acute left ventricular failure	Left ventricular failures	Heart failures	Cardiac disorders
Acute right ventricular failure	Right ventricular failures	Heart failures	Cardiac disorders
Chronic left ventricular failure	Left ventricular failures	Heart failures	Cardiac disorders
Chronic right ventricular failure	Right ventricular failures	Heart failures	Cardiac disorders
Basilar artery thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Anaphylactoid shock	Anaphylactic responses	Allergic conditions	Immune system disorders
Propofol infusion syndrome	Metabolic acidoses (excl diabetic acidoses)	Acid-base disorders	Metabolism and nutrition disorders
Microscopic polyangiitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Vascular stent insertion	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Venous stent insertion	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Cardiac siderosis	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Hypothenar hammer syndrome	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Renal embolism	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Cerebral artery stenosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Vascular encephalopathy	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Pulmonary artery therapeutic procedure	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	113 of 551	ĺ

Electrocardiogram QT interval abnormal	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations	
Implant site thrombosis	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions	
Post procedural pulmonary embolism	Respiratory tract and thoracic cavity procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications	
Central pain syndrome	Sensory abnormalities NEC	Neurological disorders NEC	Nervous system disorders	
Atrial conduction time prolongation	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders	
Right ventricle outflow tract obstruction	Cardiovascular disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Autoimmune myocarditis	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders	
Myocarditis post infection	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders	
Iliac artery occlusion	Peripheral vasoconstriction, necrosis and vascular insufficiency	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders	
Venous thrombosis neonatal	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders	
Placental infarction	Placental abnormalities (excl neoplasms)	Placental, amniotic and cavity disorders (excl haemorrhages)	Pregnancy, puerperium and perinatal conditions	
Device occlusion	Device malfunction events NEC	Device issues	General disorders and administration site conditions	
Carotid artery insufficiency	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders	
Thromboembolectomy	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures	
Thalamic infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders	
Subclavian coronary steal syndrome	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders	
Myocarditis bacterial	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations	
Myocarditis helminthic	Helminthic infections NEC	Helminthic disorders	Infections and infestations	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	114 of 551	

Pseudovasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Ventricular tachyarrhythmia	Ventricular arrhythmias and cardiac arrest	Cardiac arrhythmias	Cardiac disorders
Supraventricular tachyarrhythmia	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Cerebral hypoperfusion	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Infusion site thrombosis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
NIH stroke scale score increased	Neurologic diagnostic procedures	Neurological, special senses and psychiatric investigations	Investigations
NIH stroke scale score decreased	Neurologic diagnostic procedures	Neurological, special senses and psychiatric investigations	Investigations
NIH stroke scale abnormal	Neurologic diagnostic procedures	Neurological, special senses and psychiatric investigations	Investigations
Cerebral arteriosclerosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Mesenteric arteriosclerosis	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Percutaneous coronary intervention	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Embolic pneumonia	Lower respiratory tract and lung infections	Infections - pathogen unspecified	Infections and infestations
Cardiovascular insufficiency	Cardiac disorders NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Paradoxical embolism	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Intracardiac mass	Cardiac disorders NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Carotid artery stent insertion	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Stress cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Lupus myocarditis	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders
Post procedural stroke	Neurological and psychiatric procedural	Procedural related injuries and complications	Injury, poisoning and procedural complications

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	115 of 551	

	complications	NEC	
Post procedural myocardial infarction Cardiac and vascular procedural complications Procedural related injuries and complications NEC		Injury, poisoning and procedural complications	
Visual midline shift syndrome	Sensory abnormalities NEC	Neurological disorders NEC	Nervous system disorders
Myocarditis infectious	Cardiac infections	Infections - pathogen unspecified	Infections and infestations
Deep vein thrombosis postoperative	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Ocular vasculitis	Ocular infections, inflammations and associated manifestations	Ocular infections, irritations and inflammations	Eye disorders
Venous thrombosis in pregnancy	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Basal ganglia haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Anaphylactic transfusion reaction	Transfusion related complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Carotid arteriosclerosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cerebellar embolism	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Rebound tachycardia	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Thrombosis corpora cavernosa	Penile disorders NEC (excl erection and ejaculation)	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Cerebral microhaemorrhage	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Right atrial dilatation	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Right atrial pressure increased	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Vascular resistance pulmonary increased	Vascular tests NEC (incl blood pressure)	Cardiac and vascular investigations (excl enzyme	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	116 of 551	

		tests)	
Left atrial dilatation	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Thrombotic cerebral infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Millard-Gubler syndrome	Nervous system disorders NEC	Neurological disorders NEC	Nervous system disorders
Cerebral microangiopathy	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Segmented hyalinising vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Accessory cardiac pathway	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Reduction ventriculoplasty	Cardiac therapeutic procedures NEC	Cardiac therapeutic procedures	Surgical and medical procedures
Electrocardiogram RR interval prolonged	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Vascular graft	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Capsular warning syndrome	Transient cerebrovascular events	Central nervous system vascular disorders	Nervous system disorders
External counterpulsation	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Brain injury	Structural brain disorders NEC	Structural brain disorders	Nervous system disorders
Injection site vasculitis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Penile artery occlusion	Penile disorders NEC (excl erection and ejaculation)	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Cerebral amyloid angiopathy	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Tumour thrombosis	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic vein occlusion	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	117 of 551	

Atrioventricular conduction time shortened	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Cardiorenal syndrome	Heart failures NEC	Heart failures	Cardiac disorders
Pancreatic infarction	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Hyperdynamic left ventricle	Cardiac signs and symptoms NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Femoral artery embolism	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Capillaritis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
SI QIII TIII pattern	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Coronary no-reflow phenomenon	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Venous recanalisation	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Cerebellar ischaemia	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Chronotropic incompetence	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Prosthetic vessel implantation	Vascular therapeutic procedures NEC	Vascular therapeutic procedures	Surgical and medical procedures
Brain stem stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Splenic embolism	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders
Pulmonary vein occlusion	Vascular pulmonary disorders NEC	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders
Viral cardiomyopathy	Viral infections NEC	Viral infectious disorders	Infections and infestations
Basal ganglia infarction	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Hepatic vein dilatation	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	118 of 551	l

Myocardial depression	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Kounis syndrome	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Peripheral arterial reocclusion	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Henoch-Schonlein purpura nephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Atrioventricular dissociation	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
HIV cardiomyopathy	Retroviral infections	Viral infectious disorders	Infections and infestations
Brachiocephalic artery occlusion	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Subclavian artery occlusion	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Coeliac artery occlusion	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Langerhans' cell histiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
May-Thurner syndrome	Peripheral vasoconstriction, necrosis and vascular insufficiency	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Collateral circulation	Non-site specific vascular disorders NEC	Vascular disorders NEC	Vascular disorders
Vascular graft thrombosis	Transplantation complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Carotid artery stent removal	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Hypoxic-ischaemic encephalopathy	Encephalopathies NEC	Encephalopathies	Nervous system disorders
Type 2 lepra reaction	Leprous infections	Mycobacterial infectious disorders	Infections and infestations
Distributive shock	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	119 of 551	

Superficial siderosis of central nervous system	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Acute haemorrhagic oedema of infancy	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Post stroke depression	Depressive disorders	Depressed mood disorders and disturbances	Psychiatric disorders
Vessel puncture site thrombosis	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Cerebral septic infarct	Sepsis, bacteraemia, viraemia and fungaemia NEC	Infections - pathogen unspecified	Infections and infestations
Cerebral haemosiderin deposition	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Stress echocardiogram abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Inner ear infarction	Inner ear disorders NEC	Inner ear and VIIIth cranial nerve disorders	Ear and labyrinth disorders
Cerebral gas embolism	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Cerebral small vessel ischaemic disease	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Metabolic cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Inferior vena cava syndrome	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Right ventricular heave	Cardiac signs and symptoms NEC	Cardiac disorder signs and symptoms	Cardiac disorders
Arterectomy	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Basal ganglia stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Ventricular dyssynchrony	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Retrograde p-waves	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	120 of 551	

Brain stem microhaemorrhage	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cerebellar microhaemorrhage	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Haemorrhagic vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Carotid angioplasty	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Mesenteric artery stent insertion	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Spinal artery thrombosis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
CSF bilirubin positive	Cerebrospinal fluid tests (excl microbiology)	Neurological, special senses and psychiatric investigations	Investigations
Internal carotid artery kinking	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Congenital hemiparesis	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Systolic dysfunction	Myocardial disorders NEC	Myocardial disorders	Cardiac disorders
Vertebrobasilar dolichoectasia	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Cerebral revascularisation	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Susac's syndrome	Vasculitides NEC	Vascular inflammations	Vascular disorders
Popliteal artery entrapment syndrome	Peripheral vasoconstriction, necrosis and vascular insufficiency	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Umbilical cord thrombosis	Umbilical cord complications	Neonatal and perinatal conditions	Pregnancy, puerperium and perinatal conditions
N-terminal prohormone brain natriuretic peptide abnormal	Metabolism tests NEC	Metabolic, nutritional and blood gas investigations	Investigations
N-terminal prohormone brain natriuretic peptide increased	Metabolism tests NEC	Metabolic, nutritional and blood gas investigations	Investigations
Atrial parasystole	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	121 of 551	

Lenegre's disease	Cardiac conduction disorders	Cardiac arrhythmias	Cardiac disorders
Vertebral artery dissection	Central nervous system aneurysms and dissections	Central nervous system vascular disorders	Nervous system disorders
Central nervous system haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Ovarian vein thrombosis	Ovarian and fallopian tube disorders NEC	Ovarian and fallopian tube disorders	Reproductive system and breast disorders
Artificial heart implant	Cardiac device therapeutic procedures	Cardiac therapeutic procedures	Surgical and medical procedures
Myocardial stunning	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Renal vascular thrombosis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
ECG electrically inactive area	ECG investigations	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Prerenal failure	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Carotid artery restenosis	Cardiac and vascular procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Carotid revascularisation	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Peripheral endarterectomy	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Peripheral artery bypass	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Peripheral artery stent insertion	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Peripheral artery thrombosis	Peripheral embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Granulomatosis with polyangiitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Amyloid related imaging abnormalities	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Microvascular coronary artery disease	Ischaemic coronary artery disorders	Coronary artery disorders	Cardiac disorders
Chronic pigmented purpura	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	122 of 551	

Alcohol septal ablation	Cardiac therapeutic procedures NEC	Cardiac therapeutic procedures	Surgical and medical procedures
Modified Rankin score increased	Neurologic diagnostic procedures	Neurological, special senses and psychiatric investigations	Investigations
Modified Rankin score decreased	Neurologic diagnostic procedures	Neurological, special senses and psychiatric investigations	Investigations
Pulmonary endarterectomy	Arterial therapeutic procedures (excl aortic)	Vascular therapeutic procedures	Surgical and medical procedures
Brain stem haematoma	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Spinal subdural haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Spinal subarachnoid haemorrhage	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Intracranial artery dissection	Central nervous system aneurysms and dissections	Central nervous system vascular disorders	Nervous system disorders
Instillation site thrombosis	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Epidural haemorrhage	Cerebral injuries NEC	Injuries NEC	Injury, poisoning and procedural complications
Obstructive shock	Circulatory collapse and shock	Decreased and nonspecific blood pressure disorders and shock	Vascular disorders
Microembolism	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Perinatal stroke	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Portal vein cavernous transformation	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Tachycardia induced cardiomyopathy	Cardiomyopathies	Myocardial disorders	Cardiac disorders
Acute aortic syndrome	Aortic aneurysms and dissections	Aneurysms and artery dissections Vascular disorders	
Ophthalmic vein thrombosis	Ocular bleeding and vascular disorders NEC	Ocular haemorrhages and vascular disorders NEC	Eye disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	123 of 551	I

Cardiopulmonary exercise test abnormal	Respiratory and pulmonary function diagnostic procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Vena cava filter removal	Venous therapeutic procedures	Vascular therapeutic procedures	Surgical and medical procedures
Brain stem embolism	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Dural arteriovenous fistula	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Hepatic vascular thrombosis	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Stoma site thrombosis	Stoma complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Mesenteric vascular occlusion	Gastrointestinal vascular occlusion and infarction	Gastrointestinal vascular conditions	Gastrointestinal disorders
Splenic artery thrombosis	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders
Splenic thrombosis	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders
Foetal heart rate deceleration abnormality	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Baseline foetal heart rate variability disorder	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Junctional ectopic tachycardia	Supraventricular arrhythmias	Cardiac arrhythmias	Cardiac disorders
Nonreassuring foetal heart rate pattern	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Foetal heart rate acceleration abnormality	Rate and rhythm disorders NEC	Cardiac arrhythmias	Cardiac disorders
Radiation vasculitis	Radiation injuries	Injuries by physical agents	Injury, poisoning and procedural complications
Precerebral artery thrombosis	Central nervous system haemorrhages and cerebrovascular accidents	Central nervous system vascular disorders	Nervous system disorders
Infusion site vasculitis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	124 of 551	

## 4.6 Gallbladder disease adverse events

Preferred term	High level term	High level group term	System organ class
Abnormal faeces	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Bile duct stone	Obstructive bile duct disorders (excl neoplasms)	Bile duct disorders	Hepatobiliary disorders
Biliary cirrhosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Biliary cirrhosis primary	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Biliary colic	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders
Biliary fibrosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Biliary fistula	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Bilirubin conjugated increased	Liver function analyses	Hepatobiliary investigations	Investigations
Bilirubinuria	Urinary abnormalities	Urinary tract signs and symptoms	Renal and urinary disorders
Blood bilirubin increased	Liver function analyses	Hepatobiliary investigations	Investigations
Blood bilirubin unconjugated increased	Liver function analyses	Hepatobiliary investigations	Investigations
Cholangiogram abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations
Cholangiolitis	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders
Cholangitis	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders
Cholangitis acute	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders
Cholangitis sclerosing	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders
Cholecystectomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Cholecystitis	Cholecystitis and cholelithiasis	Gallbladder disorders	Hepatobiliary disorders
Cholecystitis acute	Cholecystitis and cholelithiasis	Gallbladder disorders	Hepatobiliary disorders
Cholecystitis chronic	Cholecystitis and cholelithiasis	Gallbladder disorders	Hepatobiliary disorders
Cholecystogram intravenous abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations
Cholecystostomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Choledochotomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Cholelithiasis	Cholecystitis and cholelithiasis	Gallbladder disorders	Hepatobiliary disorders
Cholelithiasis obstructive	Cholecystitis and cholelithiasis	Gallbladder disorders	Hepatobiliary disorders
Cholestasis	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	125 of 551	

Endoscopic retrograde cholangiopancreatography abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations
Endoscopy biliary tract abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations
Faeces pale	Faecal abnormalities NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Gallbladder cholesterolosis	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder disorder	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder fistula	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder non-functioning	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder obstruction	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder oedema	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder pain	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder perforation	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder injury	Abdominal injuries NEC	Injuries NEC	Injury, poisoning and procedural complications
Gallstone ileus	Gastrointestinal stenosis and obstruction NEC	Gastrointestinal stenosis and obstruction	Gastrointestinal disorders
Hepatitis cholestatic	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hyperbilirubinaemia	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hyperplastic cholecystopathy	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Jaundice	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Jaundice cholestatic	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Jaundice extrahepatic obstructive	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Perforation bile duct	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Cholestasis of pregnancy	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Choledochoenterostomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Cholecystocholangitis	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders
Urine bilirubin increased	Liver function analyses	Hepatobiliary investigations	Investigations
Porcelain gallbladder	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Gallbladder empyema	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Bile duct stenosis	Obstructive bile duct disorders (excl neoplasms)	Bile duct disorders	Hepatobiliary disorders
Bile duct stenosis traumatic	Abdominal injuries NEC	Injuries NEC	Injury, poisoning and procedural complications

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	126 of 551	

Bile output decreased	Liver function analyses	Hepatobiliary investigations	Investigations
Bile output abnormal	Liver function analyses	Hepatobiliary investigations	Investigations
Bile duct stent insertion	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Gallbladder abscess	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Pancreatobiliary sphincterotomy	Pancreatic therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Biliary sphincterotomy	Pancreatic therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Dilatation intrahepatic duct acquired	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Choledochectomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Choledochostomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Cholelithotomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Cholecystogram oral abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations
Cholangiectasis acquired	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Vanishing bile duct syndrome	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Bile duct obstruction	Obstructive bile duct disorders (excl neoplasms)	Bile duct disorders	Hepatobiliary disorders
Biliary anastomosis	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Hepatobiliary infection	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Biliary dyskinesia	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
X-ray hepatobiliary abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations
Emphysematous cholecystitis	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Hydrocholecystis	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Biliary dilatation	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Biliary tract dilation procedure	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Post cholecystectomy syndrome	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Gallbladder palpable	Physical examination procedures and organ system	Physical examination and organ system status	Investigations
Post procedural bile leak	status Gastrointestinal and hepatobiliary procedural complications	topics Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Choledocholithotomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Biliary sepsis	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Ultrasound biliary tract abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	127 of 551	

Gallbladder mucocoele	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Biopsy bile duct abnormal	Hepatobiliary histopathology procedures	Hepatobiliary investigations	Investigations
Biliary fistula repair	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Gallbladder fistula repair	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Biliary ischaemia	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Blood bilirubin abnormal	Liver function analyses	Hepatobiliary investigations	Investigations
Bile output increased	Liver function analyses	Hepatobiliary investigations	Investigations
Bile duct necrosis	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Haemobilia	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Biloma	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Gallbladder necrosis	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Blood alkaline phosphatase increased	Tissue enzyme analyses NEC	Enzyme investigations NEC	Investigations
Blood alkaline phosphatase abnormal	Tissue enzyme analyses NEC	Enzyme investigations NEC	Investigations
Bile culture positive	Microbiology and serology tests NEC	Microbiology and serology investigations	Investigations
Biliary tract disorder	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Bilirubin excretion disorder	Hepatic enzymes and function abnormalities	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Biliary tract infection	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Biliary tract operation	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Cholangitis chronic	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders
Gallbladder operation	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Hepatobiliary disease	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Cholecystitis infective	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Gallbladder enlargement	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Biliary abscess	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Biliary anastomosis complication	Gastrointestinal and hepatobiliary procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Bile duct pressure increased	Liver function analyses	Hepatobiliary investigations	Investigations
Sphincter of Oddi dysfunction	Obstructive bile duct disorders (excl neoplasms)	Bile duct disorders	Hepatobiliary disorders
Lemmel's syndrome	Bile duct infections and inflammations	Bile duct disorders	Hepatobiliary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	128 of 551	

AIDS cholangiopathy	Retroviral infections	Viral infectious disorders	Infections and infestations
Ampulla of Vater stenosis	Obstructive bile duct disorders (excl neoplasms)	Bile duct disorders	Hepatobiliary disorders
Cholecystoenterostomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Bilirubin conjugated abnormal	Liver function analyses	Hepatobiliary investigations	Investigations
Cholelithiasis migration	Cholecystitis and cholelithiasis	Gallbladder disorders	Hepatobiliary disorders
Hepatolithectomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Bile duct stent removal	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Urobilinogen urine decreased	Liver function analyses	Hepatobiliary investigations	Investigations
Reynold's syndrome	Connective tissue disorders NEC	Connective tissue disorders (excl congenital)	Musculoskeletal and connective tissue disorders
Biliary cast syndrome	Obstructive bile duct disorders (excl neoplasms)	Bile duct disorders	Hepatobiliary disorders
Deficiency of bile secretion	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Biloma rupture	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Gallbladder varices	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Limy bile syndrome	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Cholangiostomy	Biliary tract and gallbladder therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Biliary ascites	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Parenteral nutrition associated liver disease	Gastrointestinal and hepatobiliary procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Gallbladder volvulus	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	129 of 551	l

## 4.7 Immune complex adverse events

Preferred term	High level term	High level group term	System organ class
Acute psychosis	Psychotic disorder NEC	Schizophrenia and other psychotic disorders	Psychiatric disorders
Aortitis	Aortic inflammatory disorders	Vascular inflammations	Vascular disorders
Arteritis	Arterial inflammations	Vascular inflammations	Vascular disorders
Arteritis coronary	Coronary artery disorders NEC	Coronary artery disorders	Cardiac disorders
Arthritis	Arthropathies NEC	Joint disorders	Musculoskeletal and connective tissue disorders
Atonic seizures	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Behcet's syndrome	Vasculitides NEC	Vascular inflammations	Vascular disorders
Cardiolipin antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Cerebral arteritis	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Complex partial seizures	Partial complex seizures	Seizures (incl subtypes)	Nervous system disorders
Convulsion	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Convulsions local	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Cryoglobulinaemia	Vasculitides NEC	Vascular inflammations	Vascular disorders
Cryoglobulins present	Immunoglobulin analyses	Immunology and allergy investigations	Investigations
Cutaneous vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Diffuse vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Epilepsy	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Erythema induratum	Tuberculous infections	Mycobacterial infectious disorders	Infections and infestations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	130 of 551	

Generalised non-convulsive epilepsy	Absence seizures	Seizures (incl subtypes)	Nervous system disorders
Glomerulonephritis membranoproliferative	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Glomerulonephritis membranous	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Glomerulonephritis proliferative	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Goodpasture's syndrome	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Guillain-Barre syndrome	Acute polyneuropathies	Peripheral neuropathies	Nervous system disorders
Haemolysis	Haemolyses NEC	Haemolyses and related conditions	Blood and lymphatic system disorders
Haemolytic anaemia	Anaemias haemolytic NEC	Haemolyses and related conditions	Blood and lymphatic system disorders
Henoch-Schonlein purpura	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Hypersensitivity vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
IgA nephropathy	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Kawasaki's disease	Arterial inflammations	Vascular inflammations	Vascular disorders
LE cells present	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Leukopenia	Leukopenias NEC	White blood cell disorders	Blood and lymphatic system disorders
Lupus encephalitis	Encephalitis NEC	Central nervous system infections and inflammations	Nervous system disorders
Lupus nephritis	Nephritis NEC	Nephropathies	Renal and urinary disorders
Lymphocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Lymphopenia	Leukopenias NEC	White blood cell disorders	Blood and lymphatic system disorders
Mouth ulceration	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Nephritis	Nephritis NEC	Nephropathies	Renal and urinary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	131 of 551	

Nodular vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Pericardial effusion	Pericardial disorders NEC	Pericardial disorders	Cardiac disorders
Pericarditis	Noninfectious pericarditis	Pericardial disorders	Cardiac disorders
Petit mal epilepsy	Absence seizures	Seizures (incl subtypes)	Nervous system disorders
Pharyngeal ulceration	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Photosensitivity reaction	Photosensitivity and photodermatosis conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Plasma viscosity abnormal	Haematological analyses NEC	Haematology investigations (incl blood groups)	Investigations
Platelet count decreased	Platelet analyses	Haematology investigations (incl blood groups)	Investigations
Pleural effusion	Pneumothorax and pleural effusions NEC	Pleural disorders	Respiratory, thoracic and mediastinal disorders
Pleural rub	Respiratory signs and symptoms NEC	Respiratory disorders NEC	Respiratory, thoracic and mediastinal disorders
Pleurisy	Pleural infections and inflammations	Pleural disorders	Respiratory, thoracic and mediastinal disorders
Polyarteritis nodosa	Vasculitides NEC	Vascular inflammations	Vascular disorders
Polyarthritis	Arthropathies NEC	Joint disorders	Musculoskeletal and connective tissue disorders
Polymyalgia rheumatica	Connective tissue disorders NEC	Connective tissue disorders (excl congenital)	Musculoskeletal and connective tissue disorders
Polyserositis	Inflammations	General system disorders NEC	General disorders and administration site conditions
Proteinuria	Urinary abnormalities	Urinary tract signs and symptoms	Renal and urinary disorders
Psychomotor seizures	Partial complex seizures	Seizures (incl subtypes)	Nervous system disorders
Psychotic behaviour	Psychotic disorder NEC	Schizophrenia and other psychotic disorders	Psychiatric disorders
Pulmonary vasculitis	Lower respiratory tract inflammatory and immunologic conditions	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	132 of 551	

Renal arteritis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal vasculitis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Retinal vasculitis	Retinal, choroid and vitreous infections and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Simple partial seizures	Partial simple seizures NEC	Seizures (incl subtypes)	Nervous system disorders
SLE arthritis	Arthropathies NEC	Joint disorders	Musculoskeletal and connective tissue disorders
Solar dermatitis	Photosensitivity and photodermatosis conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Status epilepticus	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Systemic lupus erythematosus	Lupus erythematosus (incl subtypes)	Connective tissue disorders (excl congenital)	Musculoskeletal and connective tissue disorders
Systemic lupus erythematosus rash	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Takayasu's arteritis	Arterial inflammations	Vascular inflammations	Vascular disorders
Temporal arteritis	Arterial inflammations	Vascular inflammations	Vascular disorders
Temporal lobe epilepsy	Partial complex seizures	Seizures (incl subtypes)	Nervous system disorders
Thromboangiitis obliterans	Vasculitides NEC	Vascular inflammations	Vascular disorders
Thrombocytopenia	Thrombocytopenias	Platelet disorders	Blood and lymphatic system disorders
Tongue ulceration	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Tonic convulsion	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Uncinate fits	Partial complex seizures	Seizures (incl subtypes)	Nervous system disorders
Vascular purpura	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Vasculitic rash	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	133 of 551	

Vasculitis cerebral	Central nervous system vascular disorders NEC	Central nervous system vascular disorders	Nervous system disorders
Vasculitis necrotising	Vasculitides NEC	Vascular inflammations	Vascular disorders
White blood cell count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Vasculitis gastrointestinal	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Allergic granulomatous angiitis	Vasculitides	Immune disorders NEC	Immune system disorders
Rheumatoid vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Antiphospholipid antibodies positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Frontal lobe epilepsy	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Miller Fisher syndrome	Acute polyneuropathies	Peripheral neuropathies	Nervous system disorders
Autonomic seizure	Partial simple seizures NEC	Seizures (incl subtypes)	Nervous system disorders
Pericardial rub	Pericardial disorders NEC	Pericardial disorders	Cardiac disorders
Double stranded DNA antibody	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Lupus-like syndrome	Lupus erythematosus (incl subtypes)	Connective tissue disorders (excl congenital)	Musculoskeletal and connective tissue disorders
Anti-neutrophil cytoplasmic antibody positive vasculitis	Vasculitides	Immune disorders NEC	Immune system disorders
Photodermatosis	Photosensitivity and photodermatosis conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Blood viscosity increased	Haematological analyses NEC	Haematology investigations (incl blood groups)	Investigations
Protein urine present	Urinalysis NEC	Renal and urinary tract investigations and urinalyses	Investigations
Clonic convulsion	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Histone antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	134 of 551	

Myoclonic epilepsy	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Partial seizures with secondary generalisation	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Viral vasculitis	Viral infections NEC	Viral infectious disorders	Infections and infestations
Cutaneous lupus erythematosus	Connective tissue disorders	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Cogan's syndrome	Iris and uveal tract infections, irritations and inflammations	Ocular infections, irritations and inflammations	Eye disorders
Atypical benign partial epilepsy	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Palpable purpura	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Lupus pneumonitis	Lower respiratory tract inflammatory and immunologic conditions	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders
Chronic inflammatory demyelinating polyradiculoneuropathy	Chronic polyneuropathies	Peripheral neuropathies	Nervous system disorders
Neonatal lupus erythematosus	Connective tissue disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Subacute cutaneous lupus erythematosus	Connective tissue disorders	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Acute cutaneous lupus erythematosus	Connective tissue disorders	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Chronic cutaneous lupus erythematosus	Connective tissue disorders	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Lupus vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Pericarditis lupus	Noninfectious pericarditis	Pericardial disorders	Cardiac disorders
Lupus endocarditis	Endocarditis NEC	Endocardial disorders	Cardiac disorders
Serositis	Inflammations	General system disorders NEC	General disorders and administration site conditions
Pleuropericarditis	Noninfectious pericarditis	Pericardial disorders	Cardiac disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	135 of 551	

Antinuclear antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Antineutrophil cytoplasmic antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Antineutrophil cytoplasmic antibody increased	Autoimmunity analyses	Immunology and allergy investigations	Investigations
DNA antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Partial seizures	Seizures and seizure disorders NEC	Seizures (incl subtypes)	Nervous system disorders
Antibody test abnormal	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Antibody test positive	Immunology analyses NEC	Immunology and allergy investigations	Investigations
Demyelinating polyneuropathy	Chronic polyneuropathies	Peripheral neuropathies	Nervous system disorders
Psychotic disorder	Psychotic disorder NEC	Schizophrenia and other psychotic disorders	Psychiatric disorders
Peritonitis lupus	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Microscopic polyangiitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Neuropsychiatric lupus	Nervous system disorders NEC	Neurological disorders NEC	Nervous system disorders
Oral mucosa erosion	Stomatitis and ulceration	Oral soft tissue conditions	Gastrointestinal disorders
Antinuclear antibody increased	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Plateletcrit decreased	Platelet analyses	Haematology investigations (incl blood groups)	Investigations
Pseudovasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Nephritic syndrome	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Lupus myocarditis	Noninfectious myocarditis	Myocardial disorders	Cardiac disorders
Beta-2 glycoprotein antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Mesangioproliferative glomerulonephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	136 of 551	

Ocular vasculitis	Ocular infections, inflammations and associated manifestations	Ocular infections, irritations and inflammations	Eye disorders
Segmented hyalinising vasculitis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Urinary casts present	Urinalysis NEC	Renal and urinary tract investigations and urinalyses	Investigations
Systemic lupus erythematosus disease activity index increased	Investigations NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Systemic lupus erythematosus disease activity index decreased	Investigations NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Systemic lupus erythematosus disease activity index abnormal	Investigations NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Lupus hepatitis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Lupus enteritis	Gastrointestinal inflammatory disorders NEC	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
Shrinking lung syndrome	Diaphragmatic disorders	Thoracic disorders (excl lung and pleura)	Respiratory, thoracic and mediastinal disorders
Lupus pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Butterfly rash	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Injection site vasculitis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Capillaritis	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Henoch-Schonlein purpura nephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Langerhans' cell histiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Double stranded DNA antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Antiribosomal P antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	137 of 551	

Type 2 lepra reaction	Leprous infections	Mycobacterial infectious disorders	Infections and infestations
Acute haemorrhagic oedema of infancy	Skin vasculitides	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Haemorrhagic vasculitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Anti-neuronal antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Granulomatosis with polyangiitis	Vasculitides NEC	Vascular inflammations	Vascular disorders
Chronic pigmented purpura	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Lupus pleurisy	Pleural infections and inflammations	Pleural disorders	Respiratory, thoracic and mediastinal disorders
Radiation vasculitis	Radiation injuries	Injuries by physical agents	Injury, poisoning and procedural complications
Lupus cystitis	Bladder infections and inflammations	Bladder and bladder neck disorders (excl calculi)	Renal and urinary disorders
Infusion site vasculitis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	138 of 551	

## 4.8 Injection site reactions

Preferred term	High level term	High level group term	System organ class
Administration site reaction	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Application site anaesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site atrophy	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site dermatitis	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site erythema	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site irritation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site necrosis	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site oedema	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site pain	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site pruritus	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site rash	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site reaction	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site ulcer	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site warmth	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Injection site abscess	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Injection site abscess sterile	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site anaesthesia	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site atrophy	Injection site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	139 of 551	

Injection site bruising	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site cyst	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site dermatitis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site erosion	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site erythema	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site extravasation	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site fibrosis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site granuloma	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site haematoma	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site haemorrhage	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site hypersensitivity	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site hypertrophy	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site induration	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Injection site inflammation	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site irritation	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site mass	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site necrosis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site nerve damage	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site oedema	Injection site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	140 of 551	

Injection site pain	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site paraesthesia	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site phlebitis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site pruritus	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site rash	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site reaction	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site thrombosis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site ulcer	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site urticaria	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site vesicles	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site warmth	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site pain	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Malabsorption from injection site	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site erythema	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Injection site ischaemia	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site vesicles	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site dryness	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Application site inflammation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site papules	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	141 of 551	

Application site pustules	Skin structures and soft tissue infections	Infections - pathogen unspecified	Infections and infestations
Injection site joint swelling	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site joint pain	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site joint warmth	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site joint redness	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Puncture site abscess	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Injection site cellulitis	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations
Injection site coldness	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site cold feeling	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site eczema	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site hyperaesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site nodule	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site pallor	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site paraesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site urticaria	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site bruise	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Puncture site haemorrhage	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site discolouration	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site discharge	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Injection site photosensitivity reaction	Injection site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	142 of 551	

Application site swelling	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Injection site swelling	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site induration	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site pain	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site warmth	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site swelling	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site phlebitis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site pruritus	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Injection site joint movement impairment	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Puncture site reaction	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Infusion site oedema	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site haemorrhage	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site discomfort	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site calcification	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site perspiration	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Injection site pustule	Skin structures and soft tissue infections	Infections - pathogen unspecified	Infections and infestations
Infusion site ulcer	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site reaction	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site infection	Vascular infections	Infections - pathogen unspecified	Infections and infestations
Instillation site irritation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	143 of 551	

Injection site movement impairment	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site inflammation	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Injected limb mobility decreased	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site lymphadenopathy	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site nodule	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site abscess	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Administration site pain	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Infusion site abscess	Vascular infections	Infections - pathogen unspecified	Infections and infestations
Application site mass	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Embolia cutis medicamentosa	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site photosensitivity reaction	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site discolouration	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site scar	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Injection site scar	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site alopecia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site folliculitis	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations
Infusion site bruising	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site rash	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Oral administration complication	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Application site discomfort	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	144 of 551	

Venipuncture site rash	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Puncture site infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Application site hypersensitivity	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site erythema	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site pruritus	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site reaction	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site foreign body sensation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site dryness	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site induration	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site reaction	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Vessel puncture site bruise	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Vessel puncture site discharge	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site joint inflammation	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site joint effusion	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site exfoliation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site extravasation	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Application site burn	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site cellulitis	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations
Application site fissure	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site atrophy	Infusion site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	145 of 551	

Infusion site cellulitis	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations
Infusion site coldness	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site cyst	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site dermatitis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site discolouration	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site erosion	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site fibrosis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site haematoma	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site haemorrhage	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site hypersensitivity	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site hypertrophy	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site irritation	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site ischaemia	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site lymphadenopathy	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site mass	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site mobility decreased	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site necrosis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site nerve damage	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site paraesthesia	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site photosensitivity reaction	Infusion site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	146 of 551	

Infusion site pustule	Skin structures and soft tissue infections	Infections - pathogen unspecified	Infections and infestations
Infusion site scar	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site thrombosis	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site urticaria	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site vesicles	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site anaesthesia	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site granuloma	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Application site erosion	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Puncture site pain	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site discharge	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Systemic leakage	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Instillation site discomfort	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site lacrimation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site haematoma	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Infusion site hypoaesthesia	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Injection site pallor	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site papule	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site injury	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site odour	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site scab	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	147 of 551	

Injection site scab	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site scab	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Administration site infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Injection site eczema	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site streaking	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site recall reaction	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site pain	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Vessel puncture site anaesthesia	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site dryness	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site laceration	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site pruritus	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site macule	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site paraesthesia	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Puncture site induration	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site vasculitis	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site haematoma	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site exfoliation	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Injection site exfoliation	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Administration site abscess	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Puncture site discharge	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	148 of 551	

Injection site dysaesthesia	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Infusion site discomfort	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site inflammation	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Vessel puncture site swelling	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Vessel puncture site thrombosis	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Administration site rash	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Instillation site complication	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Puncture site swelling	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Application site telangiectasia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site haemorrhage	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site induration	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Vessel puncture site infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Injection site plaque	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Injection site hyperaesthesia	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Application site acne	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Injection site joint discomfort	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site paraesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site exfoliation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site abscess	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Instillation site anaesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	149 of 551	

Instillation site atrophy	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site burn	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site discharge	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site discolouration	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site erosion	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site haematoma	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site haemorrhage	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site hyperaesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site hypersensitivity	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site induration	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Instillation site inflammation	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site necrosis	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site nodule	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site odour	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site oedema	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site papules	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site pustules	Skin structures and soft tissue infections	Infections - pathogen unspecified	Infections and infestations
Instillation site rash	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site scab	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	150 of 551	

Instillation site swelling	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site thrombosis	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site ulcer	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site urticaria	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site vesicles	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site warmth	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site bruise	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site laceration	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Puncture site oedema	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Application site hypertrophy	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Application site hypoaesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Injection site hypoaesthesia	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Instillation site hypoaesthesia	Application and instillation site reactions	Administration site reactions	General disorders and administration site conditions
Vessel puncture site hypoaesthesia	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Injection site joint infection	Bone and joint infections	Infections - pathogen unspecified	Infections and infestations
Administration site inflammation	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Puncture site erythema	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Vessel puncture site erythema	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Puncture site hypoaesthesia	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions
Administration site erythema	Administration site reactions NEC	Administration site reactions	General disorders and administration site conditions

	~	UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	Date: Version:	21 January 2015   Sta 1.0   Pa	atus: Final ge: 151 of 551	Novo Nordisk
•	Infusion site eczema	Infusion site reactions	Administrat	ion site reactions	General disorders and administration	site conditions

Administration site reactions

General disorders and administration site conditions

Infusion site reactions

Infusion site vasculitis

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	152 of 551

## 4.9 Elevated lipase and/or amylase adverse events

Preferred term	High level term	High level group term	System organ class
Amylase	Digestive enzymes	Gastrointestinal investigations	Investigations
Amylase increased	Digestive enzymes	Gastrointestinal investigations	Investigations
Lipase increased	Digestive enzymes	Gastrointestinal investigations	Investigations
Lipase	Digestive enzymes	Gastrointestinal investigations	Investigations
Lipase abnormal	Digestive enzymes	Gastrointestinal investigations	Investigations
Hyperamylasaemia	Metabolic disorders NEC	Metabolism disorders NEC	Metabolism and nutrition disorders
Hyperlipasaemia	Metabolic disorders NEC	Metabolism disorders NEC	Metabolism and nutrition disorders
Amylase abnormal	Digestive enzymes	Gastrointestinal investigations	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	153 of 551	I

## 4.10 Medication error adverse events

Preferred term	High level term	High level group term	System organ class		
Accidental overdose	lental overdoses Overdoses Medication errors		Injury, poisoning and procedural complications		
Complication of device removal	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions		
Device breakage	Device physical property and chemical issues	Device issues	General disorders and administration site conditions		
Device expulsion	Device issues NEC	Device issues	General disorders and administration site conditions		
Device extrusion	Device issues NEC	Device issues	General disorders and administration site conditions		
Device leakage	Device issues NEC	Device issues	General disorders and administration site conditions		
Drug administered at inappropriate site	Maladministrations	Medication errors	Injury, poisoning and procedural complications		
Inappropriate schedule of drug administration	Maladministrations	Medication errors	Injury, poisoning and procedural complications		
Intentional overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications		
Medication error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications		
Overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications		
Wrong drug administered	Maladministrations	Medication errors	Injury, poisoning and procedural complications		
Wrong patient received medication	Maladministrations	Medication errors	Injury, poisoning and procedural		

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	154 of 551

			complications
Prescribed overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications
Medical device discomfort	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Feeding tube complication	Gastrointestinal and hepatobiliary procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Device failure	Device issues NEC	Device issues	General disorders and administration site conditions
Medical device complication	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Underdose	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Poor quality drug administered	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Medical device pain	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Device ineffective	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Thrombosis in device	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Medical device site reaction	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Device malfunction	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Electromagnetic interference	Device electrical issues	Device issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	155 of 551	

Oversensing	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Undersensing	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Vaccination error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Drug dose omission	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Drug administration error	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Drug prescribing error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Counterfeit drug administered	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Incorrect route of drug administration	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Incorrect drug dosage form administered	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Incorrect drug administration rate	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Incorrect drug administration duration	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Wrong technique in drug usage process	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Drug dispensing error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Incorrect dose administered	Maladministrations	Medication errors	Injury, poisoning and procedural complications

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	156 of 551	

Extra dose administered	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Documented hypersensitivity to administered drug	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Labelled drug-drug interaction medication error	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Labelled drug-food interaction medication error	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Labelled drug-disease interaction medication error	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Intercepted medication error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Circumstance or information capable of leading to medication error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Device psychogenic complication	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Complication of device insertion	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Device dislocation	Device issues NEC	Device issues	General disorders and administration site conditions
Device occlusion	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device related infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Device lead issue	Device issues NEC	Device issues	General disorders and administration site conditions
Device connection issue	Device issues NEC	Device issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	157 of 551	

Drug dispensed to wrong patient	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Intercepted drug dispensing error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Intercepted drug administration error	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Intercepted wrong patient selected	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Device electrical finding	Device electrical issues	Device issues	General disorders and administration site conditions
Device lead damage	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Failure of child resistant mechanism for pharmaceutical product	Product packaging issues	Product quality issues	General disorders and administration site conditions
Device misuse	Device issues NEC	Device issues	General disorders and administration site conditions
Device toxicity	Poisoning and toxicity	Exposures, chemical injuries and poisoning	Injury, poisoning and procedural complications
Device intolerance	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Radiation overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications
Radiation underdose	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Incorrect dose administered by device	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Product contamination	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	158 of 551	

Product contamination chemical	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions
Product contamination microbial	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions
Product contamination physical	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions
Product sterility lacking	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions
Needle issue	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Syringe issue	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Product friable	Product physical issues	Product quality issues	General disorders and administration site conditions
Product colour issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Product coating issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Product shape issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Liquid product physical issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Product reconstitution issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Product odour abnormal	Product physical issues	Product quality issues	General disorders and administration site conditions
Product taste abnormal	Product physical issues	Product quality issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	159 of 551	

Product formulation issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product solubility abnormal	Product physical issues	Product quality issues	General disorders and administration site conditions
Product gel formation	Product physical issues	Product quality issues	General disorders and administration site conditions
Product dosage form issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Product size issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Product deposit	Product physical issues	Product quality issues	General disorders and administration site conditions
Product lot number issue	Product label issues	Product quality issues	General disorders and administration site conditions
Product identification number issue	Product label issues	Product quality issues	General disorders and administration site conditions
Product label on wrong product	Product label issues	Product quality issues	General disorders and administration site conditions
Product barcode issue	Product label issues	Product quality issues	General disorders and administration site conditions
Product label counterfeit	Product label issues	Product quality issues	General disorders and administration site conditions
Product expiration date issue	Product label issues	Product quality issues	General disorders and administration site conditions
Physical product label issue	Product label issues	Product quality issues	General disorders and administration site conditions
Product label confusion	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications

Product label issue	Product label issues	Product quality issues	General disorders and administration site conditions
Product outer packaging issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product container issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product dropper issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product closure issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product closure removal difficult	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product commingling	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product container seal issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product packaging quantity issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product blister packaging issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product packaging counterfeit	Product packaging issues	Product quality issues	General disorders and administration site conditions
Product measured potency issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product substitution issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product quality issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	161 of 551	

Incorrect product storage	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Product compounding quality issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product tampering	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product counterfeit	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product name confusion	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Product packaging issue	Product packaging issues	Product quality issues	General disorders and administration site conditions
Device related sepsis	Sepsis, bacteraemia, viraemia and fungaemia NEC	Infections - pathogen unspecified	Infections and infestations
Injury associated with device	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Neurological complication associated with device	Complications associated with device NEC	Complications associated with device	General disorders and administration site conditions
Device alarm issue	Device information output issues	Device issues	General disorders and administration site conditions
Device information output issue	Device information output issues	Device issues	General disorders and administration site conditions
Device computer issue	Device computer issues	Device issues	General disorders and administration site conditions
Device electrical impedance issue	Device electrical issues	Device issues	General disorders and administration site conditions
Device-device incompatibility	Device incompatibility issues	Device issues	General disorders and administration site conditions

			21.7 2015		<b>T</b> ' 1	Nova Nordiak
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	162 of 551	

Patient-device incompatibility	Device incompatibility issues	Device issues	General disorders and administration site conditions
Device difficult to use	Device operational issues NEC	Device issues	General disorders and administration site conditions
Device signal detection issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device stimulation issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Stent malfunction	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device optical issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device pacing issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device power source issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device capturing issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device issue	Device issues NEC	Device issues	General disorders and administration site conditions
Device damage	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Device material issue	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Device chemical property issue	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Device colour issue	Device physical property and chemical issues	Device issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	163 of 551	

Product cleaning inadequate	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions
Product contamination with body fluid	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions
Device material opacification	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Device physical property issue	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Product adhesion issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Device kink	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Wrong device used	Device issues NEC	Device issues	General disorders and administration site conditions
Wrong device dispensed	Device issues NEC	Device issues	General disorders and administration site conditions
Drug administered in wrong device	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Device extension damage	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Device infusion issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Device inversion	Device issues NEC	Device issues	General disorders and administration site conditions
Pump reservoir issue	Device issues NEC	Device issues	General disorders and administration site conditions
Device deployment issue	Device issues NEC	Device issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	164 of 551	

Device deposit issue	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Medical device entrapment	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Intentional medical device removal by patient	Device issues NEC	Device issues	General disorders and administration site conditions
Drug administered to patient of inappropriate age	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Out of specification test results	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product physical issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Product distribution issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Device battery issue	Device malfunction events NEC	Device issues	General disorders and administration site conditions
Product origin unknown	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Suspected counterfeit product	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product dosage form confusion	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Incomplete course of vaccination	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Cardiac haemolytic anaemia	Anaemias haemolytic mechanical factor	Haemolyses and related conditions	Blood and lymphatic system disorders
Red cell fragmentation syndrome	Anaemias haemolytic mechanical factor	Haemolyses and related conditions	Blood and lymphatic system disorders
Product quality control issue	Product quality issues NEC	Product quality issues	General disorders and administration site

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final I	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	165 of 551	

			conditions
Product process control issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Product raw material issue	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Multiple use of single-use product	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Intercepted drug prescribing error	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Inadequate aseptic technique in use of product	Product contamination and sterility issues	Product quality issues	General disorders and administration site conditions
Product package associated injury	Non-site specific injuries NEC	Injuries NEC	Injury, poisoning and procedural complications
Transmission of an infectious agent via product	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Suspected transmission of an infectious agent via product	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Device allergy	Allergic conditions NEC	Allergic conditions	Immune system disorders
Device use error	Device issues NEC	Device issues	General disorders and administration site conditions
Unintentional medical device removal	Device issues NEC	Device issues	General disorders and administration site conditions
Accidental device ingestion	Device issues NEC	Device issues	General disorders and administration site conditions
Prescribed underdose	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Booster dose missed	Maladministrations	Medication errors	Injury, poisoning and procedural complications

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	166 of 551	

Exposure via contaminated device	Pathways and sources of exposure	Exposures, chemical injuries and poisoning	Injury, poisoning and procedural complications
Accidental exposure to product	Accidental exposures to product	Medication errors	Injury, poisoning and procedural complications
Accidental exposure to product by child	Accidental exposures to product	Medication errors	Injury, poisoning and procedural complications
Expired device used	Device issues NEC	Device issues	General disorders and administration site conditions
Therapeutic drug monitoring analysis not performed	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Therapeutic drug monitoring analysis incorrectly performed	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Lack of injection site rotation	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Accidental use of placebo	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Product physical consistency issue	Product physical issues	Product quality issues	General disorders and administration site conditions
Incorrect dosage administered	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Intentional underdose	Maladministrations	Medication errors	Injury, poisoning and procedural complications
Device end of service	Device issues NEC	Device issues	General disorders and administration site conditions
Device telemetry issue	Device information output issues	Device issues	General disorders and administration site conditions
Circumstance or information capable of leading to device use error	Device issues NEC	Device issues	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	167 of 551	

Product difficult to remove	Product quality issues NEC	Product quality issues	General disorders and administration site conditions
Device defective	Device physical property and chemical issues	Device issues	General disorders and administration site conditions
Medication monitoring error	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications
Embedded device	Device issues NEC	Device issues	General disorders and administration site conditions
Product packaging confusion	Medication errors NEC	Medication errors	Injury, poisoning and procedural complications
Implant subsidence	Device issues NEC	Device issues	General disorders and administration site conditions
Radiolucency around implant	Musculoskeletal procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Drug titration error	Medication monitoring errors	Medication errors	Injury, poisoning and procedural complications

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	168 of 551	I

## 4.11 Neoplasm adverse events

Preferred term	High level term     High level group term		System organ class
Acanthosis nigricans	Skin hyperplasias and hypertrophies	Cornification and dystrophic skin disorders	Skin and subcutaneous tissue disorders
Acoustic neuroma	Neuromas	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acral lentiginous melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acral lentiginous melanoma stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acral lentiginous melanoma stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acral lentiginous melanoma stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acral lentiginous melanoma stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acrochordon	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACTH-producing pituitary tumour	Hormone secreting pituitary neoplasms	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Actinic keratosis	Skin preneoplastic conditions NEC	Cornification and dystrophic skin disorders	Skin and subcutaneous tissue disorders
Acute leukaemia	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute lymphocytic leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute lymphocytic leukaemia (in remission)	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

		i i				
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	169 of 551	

Acute megakaryocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute monocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute monocytic leukaemia (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myelomonocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute promyelocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma gastric	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoma benign	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous carcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	170 of 551	

Adenosquamous cell lung cancer recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal adenoma	Adrenal neoplasms benign	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenocortical carcinoma	Adrenal neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia recurrent	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia refractory	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia stage I	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia stage II	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia stage III	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	171 of 551	

Adult T-cell lymphoma/leukaemia stage IV	ell lymphoma/leukaemia stage IV Adult T-cell lymphomas/leukaemias Lymphomas non-Hodgkin's T-cell		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Aesthesioneuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Aleukaemic leukaemia	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alpha 1 foetoprotein abnormal	Protein analyses NEC	Protein and chemistry analyses NEC	Investigations
Alpha 1 foetoprotein increased	Protein analyses NEC	Protein and chemistry analyses NEC	Investigations
Alpha interferon therapy	Cytokine therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Alveolar soft part sarcoma	Alveolar soft part sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alveolar soft part sarcoma metastatic	Alveolar soft part sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alveolar soft part sarcoma recurrent	Alveolar soft part sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Amputation of penis	Penile therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Anal cancer recurrent	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage 0	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage I	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage II	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage III	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	172 of 551	

Anal cancer stage IV	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal leukoplakia	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Anal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Anal polypectomy	Anorectal therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Anaplastic astrocytoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types recurrent	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types refractory	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage I	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage II	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage III	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage IV	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Androgen therapy	Hormonal therapeutic procedures NEC	Endocrine gland therapeutic procedures	Surgical and medical procedures
Aneurysmal bone cyst	Bone disorders NEC	Bone disorders (excl congenital and fractures)	Musculoskeletal and connective tissue disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	173 of 551	

Angiocentric lymphoma	homa Angiocentric lymphomas Lymphomas non-Hodgkin's T-cell		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma recurrent	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma refractory	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage I	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage II	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage III	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage IV	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiofibroma	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma recurrent	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma refractory	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma stage I	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma stage II	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma stage III	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	174 of 551	

Angioimmunoblastic T-cell lymphoma stage IV	oimmunoblastic T-cell lymphoma stage IV Angioimmunoblastic T-cell lymphomas Lymphomas non-Hodgkin's T-cell		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma metastatic	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma recurrent	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Antiandrogen therapy	Hormonal therapeutic procedures NEC	Endocrine gland therapeutic procedures	Surgical and medical procedures
Antioestrogen therapy	Hormonal therapeutic procedures NEC	Endocrine gland therapeutic procedures	Surgical and medical procedures
APUDoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Arsenical keratosis	Hyperkeratoses	Cornification and dystrophic skin disorders	Skin and subcutaneous tissue disorders
Aspiration bone marrow abnormal	Bone marrow and immune tissue histopathology procedures	Haematology investigations (incl blood groups)	Investigations
Astrocytoma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Aural polyp	Ear disorders NEC	Aural disorders NEC	Ear and labyrinth disorders
Autologous bone marrow transplantation therapy	Blood and blood product treatment	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
B precursor type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma recurrent	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	175 of 551	

B-cell lymphoma refractory	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage I	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage II	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage III	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage IV	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma recurrent	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma refractory	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage I	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage II	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage III	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage IV	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell unclassifiable lymphoma high grade	B-cell unclassifiable lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	176 of 551	

B-cell unclassifiable lymphoma low grade	cell unclassifiable lymphoma low grade B-cell unclassifiable lymphomas Lymphomas non-Hodgkin's B-cell		Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Barrett's oesophagus	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders	
Bartholin's cyst	Vulvovaginal cysts and neoplasms	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders	
Basal cell carcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Basosquamous carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Basosquamous carcinoma of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Becker's naevus	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Bence Jones proteinuria	Urinary abnormalities	Urinary tract signs and symptoms	Renal and urinary disorders	
Benign breast neoplasm	Breast and nipple neoplasms benign	Breast neoplasms benign (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Benign cardiac neoplasm	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Benign duodenal neoplasm	Upper gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Benign gastric neoplasm	Upper gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Benign hepatic neoplasm	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Benign hydatidiform mole	Reproductive neoplasms female benign NEC	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	177 of 551	

Benign laryngeal neoplasm	Pharyngeal and laryngeal neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign lung neoplasm	Respiratory tract and pleural neoplasms benign NEC	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign mediastinal neoplasm	Mediastinal neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign middle ear neoplasm	Aural neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of adrenal gland	Adrenal neoplasms benign	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of bladder	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of cervix uteri	Cervix neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of choroid	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of conjunctiva	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of cornea	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of epididymis	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of eye	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of islets of Langerhans	Endocrine neoplasms benign NEC	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of lacrimal duct	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

	1	1				
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	178 of 551	

Benign neoplasm of lacrimal gland	Ocular neoplasms benign Ocular neoplasms		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of orbit	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of pineal gland	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of prostate	Prostatic neoplasms benign	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of retina	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of scrotum	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of skin	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of spinal cord	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of testis	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of thymus	Mediastinal neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of thyroid gland	Thyroid neoplasms benign	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of ureter	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of urethra	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign oesophageal neoplasm	Upper gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	179 of 551	

Benign ovarian tumour	Ovarian neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign penile neoplasm	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign peritoneal neoplasm	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign pleural mesothelioma	Mesotheliomas benign	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign pleural neoplasm	Respiratory tract and pleural neoplasms benign NEC	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign salivary gland neoplasm	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign tracheal neoplasm	Respiratory tract and pleural neoplasms benign NEC	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign vaginal neoplasm	Vaginal neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign vulval neoplasm	Vulval neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Beta interferon therapy	Cytokine therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Bile duct adenocarcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct adenosquamous carcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer recurrent	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	180 of 551	

Bile duct squamous cell carcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biliary neoplasm	Hepatobiliary neoplasms malignancy unspecified	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biopsy abdominal wall abnormal	Musculoskeletal and soft tissue histopathology procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Biopsy adrenal gland abnormal	Adrenal gland histopathology procedures	Endocrine investigations (incl sex hormones)	Investigations
Biopsy anus abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy bladder abnormal	Urinary tract histopathology procedures	Renal and urinary tract investigations and urinalyses	Investigations
Biopsy bone abnormal	Musculoskeletal and soft tissue histopathology procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Biopsy bone marrow abnormal	Bone marrow and immune tissue histopathology procedures	Haematology investigations (incl blood groups)	Investigations
Biopsy brain abnormal	Central nervous system histopathology procedures	Neurological, special senses and psychiatric investigations	Investigations
Biopsy breast abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy bronchus abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy cartilage abnormal	Musculoskeletal and soft tissue histopathology procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Biopsy cervix abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy colon abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy conjunctiva abnormal	Ophthalmic histopathology and imaging procedures	Neurological, special senses and psychiatric investigations	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	181 of 551	

Biopsy cornea abnormal	Ophthalmic histopathology and imaging procedures	Neurological, special senses and psychiatric investigations	Investigations
Biopsy endometrium abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy epididymis abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy heart abnormal	Cardiac histopathology procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Biopsy kidney abnormal	Urinary tract histopathology procedures	Renal and urinary tract investigations and urinalyses	Investigations
Biopsy larynx abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy lip abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy liver abnormal	Hepatobiliary histopathology procedures	Hepatobiliary investigations	Investigations
Biopsy lung abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy lymph gland abnormal	Bone marrow and immune tissue histopathology procedures	Haematology investigations (incl blood groups)	Investigations
Biopsy mucosa abnormal	Histopathology procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Biopsy muscle abnormal	Musculoskeletal and soft tissue histopathology procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Biopsy oesophagus abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy ovary abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy palate abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	182 of 551	

Biopsy parathyroid gland abnormal	Parathyroid histopathology procedures	Endocrine investigations (incl sex hormones)	Investigations
Biopsy penis abnormal	Reproductive organ and breast histopathology procedures	rgan and breast histopathology Reproductive organ and breast investigations (excl hormone analyses)	
Biopsy pericardium abnormal	Cardiac histopathology procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Biopsy peripheral nerve abnormal	Peripheral nervous system histopathology procedures	Neurological, special senses and psychiatric investigations	Investigations
Biopsy peritoneum abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy pharynx abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy pleura abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy rectum abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy retina abnormal	Ophthalmic histopathology and imaging procedures	Neurological, special senses and psychiatric investigations	Investigations
Biopsy salivary gland abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy sclera abnormal	Ophthalmic histopathology and imaging procedures	Neurological, special senses and psychiatric investigations	Investigations
Biopsy site unspecified abnormal	Histopathology procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Biopsy skin abnormal	Skin histopathology procedures	Skin investigations	Investigations
Biopsy spinal cord abnormal	Central nervous system histopathology procedures	Neurological, special senses and psychiatric investigations	Investigations
Biopsy stomach abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy testes abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	183 of 551	

Biopsy thymus gland abnormal	Bone marrow and immune tissue histopathology procedures	Haematology investigations (incl blood groups)	Investigations
Biopsy thyroid gland abnormal	Thyroid histopathology procedures	Endocrine investigations (incl sex hormones)	Investigations
Biopsy tongue abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy trachea abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy urethra abnormal	Urinary tract histopathology procedures	Renal and urinary tract investigations and urinalyses	Investigations
Biopsy vagina abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy vulva abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Bladder adenocarcinoma recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage 0	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage I	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage unspecified	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	184 of 551	

		and unspecified	unspecified (incl cysts and polyps)
Bladder cancer recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage 0, with cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage 0, without cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage I, with cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage I, without cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder neck resection	Bladder therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Bladder neoplasm	Urinary tract neoplasms unspecified malignancy NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder papilloma	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage 0	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage I	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	185 of 551	

		and unspecified	unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage unspecified	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blast cell proliferation	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone cancer	Bone neoplasms malignant (excl sarcomas)	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone cyst	Bone disorders NEC	Bone disorders (excl congenital and fractures)	Musculoskeletal and connective tissue disorders
Bone giant cell tumour	Bone neoplasms unspecified malignancy	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone giant cell tumour benign	Bone neoplasms benign (excl cysts)	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone neoplasm	Bone neoplasms unspecified malignancy	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone sarcoma	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Borderline ovarian tumour	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	186 of 551	

Bowen's disease	ase Skin neoplasms malignant and unspecified (excl melanoma) Skin neoplasms malignant and unspecified		Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Bowenoid papulosis	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Brain neoplasm benign	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Brain neoplasm malignant	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Brain stem glioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Brain stem glioma benign	Gliomas benign	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Branchial cyst	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Breast cancer in situ	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Breast cancer recurrent	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Breast cancer stage I	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Breast cancer stage II	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Breast cancer stage III	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Breast cancer stage IV	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	

Statistical Analysis Plan Trial ID: NN9924-3790	UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	Date: Version:	21 January 2015		Final 187 of 551	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	187 of 551	

Breast cyst	Benign and malignant breast neoplasms	Breast disorders	Reproductive system and breast disorders
Breast dysplasia	Breast disorders NEC	Breast disorders	Reproductive system and breast disorders
Breast neoplasm	Breast neoplasms unspecified malignancy	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast prosthesis implantation	Breast therapeutic procedures NEC	Breast therapeutic procedures	Surgical and medical procedures
Breast reconstruction	Breast therapeutic procedures NEC	Breast therapeutic procedures	Surgical and medical procedures
Bronchial carcinoma	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma recurrent	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma refractory	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage I	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage II	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage III	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage IV	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cachexia	General nutritional disorders NEC	Appetite and general nutritional disorders	Metabolism and nutrition disorders
Carcinoembryonic antigen increased	Cell marker analyses	Cytogenetic investigations	Investigations
Carcinogenic effect in offspring	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	188 of 551	

Carcinogenicity	Poisoning and toxicity	Exposures, chemical injuries and poisoning	Injury, poisoning and procedural complications
Carcinoid syndrome	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Carcinoid tumour	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the appendix	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the caecum	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the gastrointestinal tract	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the prostate	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the stomach	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour pulmonary	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of eye	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of penis	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of trachea	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carotid body tumour	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	189 of 551	I

Central nervous system dermoid tumour	nervous system dermoid tumour Congenital disorders NEC Congenital and hereditary disorders NEC		Congenital, familial and genetic disorders		
Central nervous system lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Central nervous system neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Cervical cyst	Cervix neoplasms	Cervix disorders (excl infections and inflammations)	Reproductive system and breast disorders		
Cervical dysplasia	Cervix disorders NEC	Cervix disorders (excl infections and inflammations)	Reproductive system and breast disorders		
Cervical polyp	Cervix neoplasms	Cervix disorders (excl infections and inflammations)	Reproductive system and breast disorders		
Cervix adenomatous polyp	Cervix neoplasms	Cervix disorders (excl infections and inflammations)	Reproductive system and breast disorders		
Cervix carcinoma	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Cervix carcinoma recurrent	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Cervix carcinoma stage I	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Cervix carcinoma stage II	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Cervix carcinoma stage III	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Cervix carcinoma stage IV	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Cervix neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	190 of 551	

Chemotherapy cardiotoxicity attenuation	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Chemotherapy multiple agents systemic	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Chemotherapy neurotoxicity attenuation	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Chemotherapy single agent systemic	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Chemotherapy urothelial toxicity attenuation	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Chloroma	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chloroma (in remission)	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholangioadenoma	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholangiocarcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choledochal cyst	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Cholesteatoma	Aural neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholesterin granuloma of middle ear	Aural neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholesterol granuloma	Aural neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chondroblastoma	Cartilage neoplasms benign	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis PlanUTN: U111-1136-4716Trial ID: NN9924-3790EudraCT No.: 2012-004994-16	Date: Version:		Status: Page:	Final 191 of 551	Novo Nordisk
--	-------------------	--	------------------	---------------------	--------------

Chondroma	Cartilage neoplasms benign	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chondrosarcoma	Cartilage sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chondrosarcoma metastatic	Cartilage sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chondrosarcoma recurrent	Cartilage sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chordoma	Bone neoplasms unspecified malignancy	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choriocarcinoma	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroid melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroid plexus papilloma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroid tumour excision	Choroid and conjunctival therapeutic procedures	Eye therapeutic procedures	Surgical and medical procedures
Chronic leukaemia	Leukaemias chronic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia (in remission)	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia recurrent	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia refractory	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan Trial ID: NN9924-3790	UTN: U111-1136-4716 EudraCT No.: 2012-004994-16	Date: Version:	2	Status: Page:	Final   <b>Novo Nordis</b> 192 of 551	k
--	--	-------------------	---	------------------	--	---

Chronic lymphocytic leukaemia stage 0	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 1	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 2	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 3	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 4	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia (in remission)	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myelomonocytic leukaemia	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myelomonocytic leukaemia (in remission)	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell sarcoma of the kidney	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colectomy total	Large intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Colon cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	193 of 551	

Colon cancer stage I	on cancer stage I Colorectal neoplasms malignant Gastrointestinal neoplasms malignant and unspecified		Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colon cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colon cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colon cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colony stimulating factor therapy	Cytokine therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures	
Colorectal cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colorectal cancer stage I	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colorectal cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colorectal cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colorectal cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colorectal carcinoma stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Congenital cystic disease of liver	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders	
Congenital cystic kidney disease	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders	
Congenital renal cyst	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders	
Conjunctival cyst	Ocular cysts and polyps	Ocular neoplasms	Eye disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	194 of 551	

Craniopharyngioma	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Craniopharyngioma benign	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Crohn's disease	Colitis (excl infective)	Gastrointestinal inflammatory conditions	Gastrointestinal disorders
CSF lymphocyte count abnormal	Cerebrospinal fluid tests (excl microbiology)	Neurological, special senses and psychiatric investigations	Investigations
CSF lymphocyte count increased	Cerebrospinal fluid tests (excl microbiology)	Neurological, special senses and psychiatric investigations	Investigations
Cyclotron therapy	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Cyst	Mass conditions NEC	Tissue disorders NEC	General disorders and administration site conditions
Cystic eyeball, congenital	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Dermal cyst	Skin cysts and polyps	Cutaneous neoplasms benign	Skin and subcutaneous tissue disorders
Dermoid cyst	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Diffuse large B-cell lymphoma	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma recurrent	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma refractory	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma stage I	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma stage II	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	195 of 551	

Diffuse large B-cell lymphoma stage III	Diffuse large B-cell lymphomas	l lymphomas Lymphomas non-Hodgkin's B-cell	
Diffuse large B-cell lymphoma stage IV	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Duodenal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Duodenectomy	Small intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Dysplastic naevus syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Ectopic ACTH syndrome	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic aldosterone secretion	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic antidiuretic hormone secretion	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic calcitonin production	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic chorionic gonadotrophin secretion	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic growth hormone secretion	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic parathyroid hormone production	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic prolactin secretion	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Ectopic renin secretion	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Electron radiation therapy to bladder	Bladder radiotherapies	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to bone	Bone radiotherapies	Bone and joint therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to brain	Brain radiotherapies	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to breast	Breast radiotherapies	Breast therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	196 of 551	

Electron radiation therapy to colon	adiation therapy to colon Gastrointestinal radiotherapies Gastrointestinal therapeutic procedures		Surgical and medical procedures
Electron radiation therapy to ear, nose, or throat	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to lung	Pulmonary radiotherapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to pancreas	Pancreatic radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to prostate	Prostatic radiotherapies	Male genital tract therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to skin	Skin radiotherapies	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to uterus	Uterine radiotherapies	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Enchondromatosis	Cartilage neoplasms benign	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endobronchial lipoma	Respiratory tract and pleural neoplasms benign NEC	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial adenocarcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial adenoma	Uterine neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer metastatic	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer recurrent	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage 0	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage I	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	197 of 551	

		unspecified	unspecified (incl cysts and polyps)
Endometrial cancer stage II	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage III	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage IV	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial hyperplasia	Uterine disorders NEC	Uterine, pelvic and broad ligament disorders	Reproductive system and breast disorde
Endometrial neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eosinophilic leukaemia	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ependymoma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ependymoma malignant	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ependymoma benign	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epididymal cyst	Testicular and epididymal neoplasms	Testicular and epididymal disorders	Reproductive system and breast disorde
Epithelioid sarcoma	Epithelioid sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioid sarcoma metastatic	Epithelioid sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioid sarcoma recurrent	Epithelioid sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioma adenoides cysticum	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	198 of 551	

Erythraemic myelosis (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Erythroleukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Essential thrombocythaemia	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ewing's sarcoma	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ewing's sarcoma metastatic	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ewing's sarcoma recurrent	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ex vivo gene therapy	Gene therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Extended radical mastectomy	Mastectomies	Breast therapeutic procedures	Surgical and medical procedures
Extra-osseous Ewing's sarcoma	Extraskeletal Ewing's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extra-osseous Ewing's sarcoma metastatic	Extraskeletal Ewing's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extra-osseous Ewing's sarcoma recurrent	Extraskeletal Ewing's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary embryonal carcinoma	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour mixed stage I	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour mixed stage II	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	199 of 551	

Extragonadal primary germ cell tumour mixed stage III	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage I	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage II	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage III	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage IV	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure) stage I	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure) stage II	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure) stage III	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure) stage IV	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) refractory	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) stage I	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) stage II	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) stage III	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	200 of 551	

Extranodal marginal zone B-cell lymphoma (MALT type) stage IV			Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraocular retinoblastoma	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal chondrosarcoma metastatic	Extraskeletal chondrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal chondrosarcoma recurrent	Extraskeletal chondrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal osteosarcoma	Extraskeletal osteosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal osteosarcoma metastatic	Extraskeletal osteosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal osteosarcoma recurrent	Extraskeletal osteosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer metastatic	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage I	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage II	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage III	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage IV	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibroadenoma of breast	Breast and nipple neoplasms benign	Breast neoplasms benign (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	201 of 551	

Fibrocystic breast disease	Benign and malignant breast neoplasms	Breast disorders	Reproductive system and breast disorders
Fibroma	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrosarcoma	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrosarcoma excision	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Fibrosarcoma metastatic	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma recurrent	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma refractory	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma stage I	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma stage II	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma stage III	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma stage IV	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III recurrent	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III refractory	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III stage I	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	202 of 551	

Follicle centre lymphoma, follicular grade I, II, III stage II	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III stage III	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III stage IV	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicular thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer recurrent	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gamma interferon therapy	Cytokine therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Gamma radiation therapy to bladder	Bladder radiotherapies	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to bone	Bone radiotherapies	Bone and joint therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to brain	Brain radiotherapies	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to breast	Breast radiotherapies	Breast therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to colon	Gastrointestinal radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to ear, nose, or throat	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to lung	Pulmonary radiotherapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to pancreas	Pancreatic radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to pleura	Pleural radiation therapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to prostate	Prostatic radiotherapies	Male genital tract therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	203 of 551	

Gamma radiation therapy to skin	Skin radiotherapies	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to uterus	Uterine radiotherapies	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Ganglioglioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ganglioneuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ganglioneuroma	Neuromas	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer recurrent	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage 0	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage I	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage II	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage III	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric polypectomy	Gastric therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Gastric polyps	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Gastrinoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	204 of 551	

Gastrointestinal carcinoma	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genital neoplasm malignant female	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Giant cell epulis	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Giant cell tumour of tendon sheath	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gingival polyp	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Glioblastoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma multiforme	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gliosarcoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glomus tumour	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glossectomy	Tongue therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Glottis carcinoma	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glucagonoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Growth hormone-producing pituitary tumour	Hormone secreting pituitary neoplasms	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioblastoma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	205 of 551	I

Haemangioma	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma congenital	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Haemangioma of breast	Breast and nipple neoplasms benign	Breast neoplasms benign (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of liver	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of retina	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Haemangioma of skin	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangiopericytoma	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangiopericytoma of meninges	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hair follicle tumour benign	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hairy cell leukaemia	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Heavy chain disease	Plasma cell neoplasms NEC	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic adenoma	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cyst	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic neoplasm	Hepatobiliary neoplasms malignancy unspecified	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatoblastoma recurrent	Hepatoblastomas	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	206 of 551	

High grade B-cell lymphoma Burkitt-like lymphoma	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma recurrent	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma refractory	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage I	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage II	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage III	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage IV	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Histiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage I site unspecified	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage I subdiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage I supradiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage II site unspecified	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage II subdiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	207 of 551	

Hodgkin's disease lymphocyte depletion stage II supradiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type recurrent	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type refractory	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type stage III	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type stage IV	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type stage unspecified	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage I site unspec	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage I subdiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage I supradiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage II site unspec	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage II subdiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage II supradiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type recurrent	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type refractory	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	208 of 551	

Hodgkin's disease lymphocyte predominance type stage III	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type stage IV	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type stage unspecified	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity recurrent	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity refractory	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage I site unspecified	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage I subdiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage I supradiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage II subdiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage II supradiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage III	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage IV	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage unspecified	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	209 of 551	

Hodgkin's disease nodular sclerosis recurrent	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis refractory	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis stage III	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis stage IV	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease recurrent	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease refractory	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage I	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage II	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage III	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease unclassifiable	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hormone-secreting ovarian tumour	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Horner's syndrome	Autonomic nervous system disorders	Neuromuscular disorders	Nervous system disorders
Hypercalcaemia of malignancy	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Hypergammaglobulinaemia benign monoclonal	Plasma cell neoplasms NEC	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hyperthermia therapy	Therapeutic procedures NEC	Therapeutic procedures and supportive care	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	210 of 551	

		NEC	
Hypertrophic osteoarthropathy	Bone disorders NEC	Bone disorders (excl congenital and fractures)	Musculoskeletal and connective tissue disorders
Hypopharyngeal cancer	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer recurrent	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage 0	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage I	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage II	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage III	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage IV	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal neoplasm benign	Pharyngeal and laryngeal neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hysterectomy	Uterine therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Inflammatory carcinoma of breast recurrent	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory carcinoma of breast stage III	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory carcinoma of breast stage IV	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	211 of 551	

Inflammatory carcinoma of the breast	nmatory carcinoma of the breast Breast and nipple neoplasms malignant Breast neoplasms malignant and unspecified (incl nipple)		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Injection site cyst	Injection site reactions	Administration site reactions	General disorders and administration site conditions
Insulinoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Interleukin therapy	Cytokine therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Intestinal T-cell lymphoma recurrent	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma refractory	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma stage I	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma stage II	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma stage III	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma stage IV	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intra-abdominal haemangioma	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intracranial haemangioma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intracranial meningioma malignant	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intracranial tumour haemorrhage	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	212 of 551	

Intraductal papilloma of breast	actal papilloma of breast Breast and nipple neoplasms benign Breast neoplasms benign (incl nipple)		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Iris cyst	Ocular cysts and polyps	Ocular neoplasms	Eye disorders
Jaw cyst	Bone disorders NEC	Bone disorders (excl congenital and fractures)	Musculoskeletal and connective tissue disorders
Juvenile chronic myelomonocytic leukaemia	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Juvenile melanoma benign	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Kaposi's sarcoma	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Kaposi's sarcoma AIDS related	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Kaposi's sarcoma classical type	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratoacanthoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	213 of 551	

Large cell lung cancer stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large granular lymphocytosis	Leukaemias chronic T-cell	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer recurrent	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage 0	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage I	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage II	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage III	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage IV	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal neoplasm	Laryngeal neoplasms malignancy unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal papilloma	Pharyngeal and laryngeal neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal polyp	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Laryngeal polypectomy	Laryngeal therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	214 of 551	I

Laryngeal squamous cell carcinoma	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
		manghant and unspectified	unspectned (mer cysts and poryps)
Leiomyoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyosarcoma metastatic	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyosarcoma recurrent	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna recurrent	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia basophilic	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia granulocytic	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	215 of 551	

Leukaemia monocytic	Leukaemias myeloid NEC	NEC Leukaemias	
Leukaemic lymphoma	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukoerythroblastosis	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukoplakia oesophageal	Oesophageal disorders NEC	Gastrointestinal conditions NEC	Gastrointestinal disorders
Leukoplakia of penis	Penile disorders NEC (excl erection and ejaculation)	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Leukoplakia oral	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
Leydig cell tumour of the testis	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Light chain disease	Plasma cell neoplasms NEC	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Linitis plastica	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer recurrent	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage 0	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage I	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage II	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage III	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage IV	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	216 of 551	I

		unspecified	unspecified (incl cysts and polyps)
Lip neoplasm benign	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip neoplasm malignant stage unspecified	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipoma of breast	Breast and nipple neoplasms benign	Breast neoplasms benign (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liposarcoma metastatic	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liposarcoma recurrent	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung lobectomy	Bronchial and pulmonary therapeutic procedures	Respiratory tract therapeutic procedures	Surgical and medical procedures
Lung adenocarcinoma	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage III	Non-small cell neoplasms malignant of the respiratory	Respiratory and mediastinal neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	217 of 551	

	tract cell type specified	malignant and unspecified	unspecified (incl cysts and polyps)
Lung adenocarcinoma stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified recurrent	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage 0	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage I	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage II	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage III	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage IV	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

			21.7 2015		T. 1	Novo Nordiok
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	218 of 551	

Lymphangioma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphangiosarcoma	Lymphangiosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphocyte adoptive therapy	Cellular antitumour therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Lymphocytic leukaemia	Leukaemias lymphocytic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoid leukaemia (in remission)	Leukaemias lymphocytic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma AIDS related	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma recurrent	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma refractory	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage I	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage II	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage III	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage IV	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	219 of 551	

Malignant ascites	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant breast lump removal	Breast neoplasm removal	Breast therapeutic procedures	Surgical and medical procedures
Malignant fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma metastatic	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma of bone	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma recurrent	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant haemangiopericytoma	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant haemangiopericytoma metastatic	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant haemangiopericytoma recurrent	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant histiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant hydatidiform mole	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant lymphoma unclassifiable high grade	Lymphomas unclassifiable malignant	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant lymphoma unclassifiable low grade	Lymphomas unclassifiable malignant	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mast cell neoplasm	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	220 of 551	

Malignant melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma of sites other than skin	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mesenchymoma metastatic	Mesenchymomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mesenchymoma recurrent	Mesenchymomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of ampulla of Vater	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of choroid	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of conjunctiva	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of cornea	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of eye	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	221 of 551	

Malignant neoplasm of islets of Langerhans	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of lacrimal duct	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of lacrimal gland	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of orbit	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of paraurethral glands	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of placenta	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of pleura	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of renal pelvis	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of retina	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of spermatic cord	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of spinal cord	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of thorax	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of uterine adnexa	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant oligodendroglioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	222 of 551	I

Malignant ovarian cyst	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant palate neoplasm	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pituitary tumour	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pleural effusion	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant splenic neoplasm	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma recurrent	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma refractory	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma stage I	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma stage II	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma stage III	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma stage IV	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Marrow hyperplasia	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mastectomy	Mastectomies	Breast therapeutic procedures	Surgical and medical procedures
Mastocytoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	223 of 551	

Mastoidectomy	Mastoid therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Mature B-cell type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Maxillofacial sinus neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mediastinum neoplasm	Mediastinal neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medullary carcinoma of breast	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medullary thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medulloblastoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Megaloblasts increased	Bone marrow and immune tissue histopathology procedures	Haematology investigations (incl blood groups)	Investigations
Meigs' syndrome	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanocytic naevus	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma benign	Meningiomas benign	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma malignant	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesonephric duct cyst	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	224 of 551	

Mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to abdominal cavity	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to adrenals	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to breast	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to kidney	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to large intestine	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to liver	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lung	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to neck	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to ovary	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	225 of 551	

Metastases to pleura	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to skin	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to small intestine	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to spine	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to the mediastinum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic malignant melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic pain	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mixed hepatocellular cholangiocarcinoma	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Modified radical mastectomy	Mastectomies	Breast therapeutic procedures	Surgical and medical procedures
Mouth cyst	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Mucinous endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucosal cyst of postmastoidectomy cavity	Mastoid disorders	Middle ear disorders (excl congenital)	Ear and labyrinth disorders
Multiple gated acquisition scan abnormal	Cardiac function diagnostic procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Myasthenic syndrome	Neuromuscular junction dysfunction	Neuromuscular disorders	Nervous system disorders
Mycosis fungoides	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	226 of 551	

Mycosis fungoides recurrent	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides refractory	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage I	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage II	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage III	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage IV	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myectomy	Muscle therapeutic procedures	Soft tissue therapeutic procedures	Surgical and medical procedures
Myelodysplastic syndrome	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome unclassifiable	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelofibrosis	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myeloid leukaemia	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myeloproliferative disorder	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal cavity cancer	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal polyps	Nasal disorders NEC	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	227 of 551	

Nasal sinus cancer	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer recurrent	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage 0	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage I	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage II	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage III	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage IV	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal neoplasm benign	Oropharyngeal, nasopharyngeal and tonsillar neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Natural killer-cell leukaemia	Leukaemias chronic T-cell	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Needle biopsy site unspecified abnormal	Histopathology procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Neonatal leukaemia	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Neoplasm	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm malignant	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm prostate	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	228 of 551	

Neoplasm skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nephrectomy	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Nephroblastoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurilemmoma benign	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma of the skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibroma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibromatosis	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Neurofibrosarcoma metastatic	Neurofibrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibrosarcoma recurrent	Neurofibrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroma	Neuromas	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurotensinoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma recurrent	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma refractory	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	229 of 551	

			unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma stage I	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma stage II	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma stage III	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma stage IV	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodular melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage IIIA	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage IIIB	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	230 of 551	I

Non-Hodgkin's lymphoma	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-secretory adenoma of pituitary	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma recurrent	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma refractory	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage I	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage II	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage III	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage IV	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive recurrent	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive refractory	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage I	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage II	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage III	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage IV	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	231 of 551	

Non-Hodgkin's lymphoma unspecified histology indolent stage I	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent stage II	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent stage III	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent stage IV	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Obstructive uropathy	Renal obstructive disorders	Renal disorders (excl nephropathies)	Renal and urinary disorders
Oesophageal adenocarcinoma	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma recurrent	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage 0	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage I	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage II	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage III	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage IV	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma recurrent	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	232 of 551	

Oesophageal carcinoma stage 0	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma recurrent	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage 0	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage I	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage II	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage III	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage IV	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophagectomy	Oesophageal therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Oligodendroglioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oligodendroglioma benign	Gliomas benign	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Omentectomy	Abdominal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Oophorectomy bilateral	Ovarian therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Oral hairy leukoplakia	Epstein-Barr viral infections	Viral infectious disorders	Infections and infestations
Oral neoplasm benign	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Orchidectomy	Testicular and scrotal therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	233 of 551	

Oropharyngeal cancer	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer recurrent	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage 0	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage I	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage II	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage III	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal lymphoepithelioma	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal neoplasm benign	Oropharyngeal, nasopharyngeal and tonsillar neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal squamous cell carcinoma	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteoma	Bone neoplasms benign (excl cysts)	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteosarcoma	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteosarcoma metastatic	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteosarcoma recurrent	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	234 of 551	

Ovarian cyst	Ovarian and fallopian tube cysts and neoplasms	Ovarian and fallopian tube disorders	Reproductive system and breast disorders
Ovarian cyst ruptured	Ovarian and fallopian tube cysts and neoplasms	Ovarian and fallopian tube disorders	Reproductive system and breast disorders
Ovarian dysgerminoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer metastatic	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer recurrent	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage I	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage II	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage III	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage IV	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	235 of 551	

		unspecified	unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	236 of 551	

Ovarian germ cell teratoma benign	Ovarian neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian low malignant potential tumour	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of nipple	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of penis	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of the vulva	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancoast's tumour	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatectomy	Pancreatic therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Pancreatic carcinoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	237 of 551	

Pancreatic carcinoma recurrent	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic cyst	Cystic pancreatic disorders	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreaticoduodenectomy	Abdominal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Papillary serous endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary tumour of renal pelvis	Renal neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papilloma	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraganglion neoplasm benign	Endocrine neoplasms benign NEC	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraganglion neoplasm malignant	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal biopsy abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Paranasal sinus and nasal cavity malignant neoplasm recurrent	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage 0	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage I	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage II	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm	Paranasal sinus and nasal cavity neoplasms malignant	Respiratory and mediastinal neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	238 of 551	

stage III	and unspecified	malignant and unspecified	unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage IV	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parapsoriasis	Papulosquamous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Parathyroid tumour	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign	Endocrine neoplasms benign NEC	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour malignant	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroidectomy	Parathyroid gland therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Parotidectomy	Salivary gland therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Pathological fracture	Fractures NEC	Fractures	Musculoskeletal and connective tissue disorders
Penile cancer	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile wart	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile warts excision	Penile therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Penis carcinoma metastatic	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma recurrent	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma stage I	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma stage II	Penile neoplasms malignant	Reproductive neoplasms male malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	239 of 551	

		unspecified	unspecified (incl cysts and polyps)
Penis carcinoma stage III	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma stage IV	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pericardial mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pericarditis malignant	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral nerve sheath tumour malignant	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of bone metastatic	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of bone recurrent	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified recurrent	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified refractory	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified stage I	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified stage II	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified stage III	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	240 of 551	I

Peripheral T-cell lymphoma unspecified stage IV	Peripheral T-cell lymphoma unspecified stage IV Peripheral T-cell lymphomas NEC Lymphomas r		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peutz-Jeghers syndrome	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Phaeochromocytoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer recurrent	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage 0	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage I	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage II	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage III	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage IV	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cyst	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Pharyngeal neoplasm benign	Pharyngeal and laryngeal neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Photon radiation therapy to bladder	Bladder radiotherapies	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to bone	Bone radiotherapies	Bone and joint therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	241 of 551	

Photon radiation therapy to brain	Brain radiotherapies	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to breast	Breast radiotherapies	Breast therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to colon	Gastrointestinal radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to ear, nose, or throat	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to lung	Pulmonary radiotherapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to pancreas	Pancreatic radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to pleura	Pleural radiation therapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to prostate	Prostatic radiotherapies	Male genital tract therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to skin	Skin radiotherapies	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to uterus	Uterine radiotherapies	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Pineal germinoma	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pinealoma	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pineocytoma	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumour	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Placental polyp	Placental abnormalities (excl neoplasms)	Placental, amniotic and cavity disorders (excl haemorrhages)	Pregnancy, puerperium and perinatal conditions
Plasma cell leukaemia	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	242 of 551	

			unspecified (incl cysts and polyps)
Plasma cell myeloma	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleurectomy	Pleural therapeutic procedures	Respiratory tract therapeutic procedures	Surgical and medical procedures
Pneumonectomy	Bronchial and pulmonary therapeutic procedures	Respiratory tract therapeutic procedures	Surgical and medical procedures
Polycythaemia vera	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Polyneuropathy in malignant disease	Chronic polyneuropathies	Peripheral neuropathies	Nervous system disorders
Postcricoid cancer	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Postmastectomy lymphoedema syndrome	Reproductive tract and breast procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Precursor B-lymphoblastic lymphoma	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma stage I	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma stage II	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma stage III	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	243 of 551	

Precursor B-lymphoblastic lymphoma stage IV	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia recurrent	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia refractory	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage I	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage II	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage III	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage IV	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma recurrent	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma refractory	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma stage I	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma stage II	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma stage III	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	244 of 551	

Primary mediastinal large B-cell lymphoma stage IV	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prolactin-producing pituitary tumour	Hormone secreting pituitary neoplasms	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prolactinoma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prolymphocytic leukaemia	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prophylactic chemotherapy	Prophylactic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Prostate cancer metastatic	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer recurrent	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage 0	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage I	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage II	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage III	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage IV	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic adenoma	Prostatic neoplasms benign	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic specific antigen increased	Cell marker analyses	Cytogenetic investigations	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	245 of 551	

Pseudomyxoma peritonei	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pyoderma gangrenosum	Skin and subcutaneous tissue ulcerations	Skin and subcutaneous tissue disorders NEC	Skin and subcutaneous tissue disorders
Pyogenic granuloma	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Queyrat erythroplasia	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radical hysterectomy	Uterine therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Radical mastectomy	Mastectomies	Breast therapeutic procedures	Surgical and medical procedures
Radicular cyst	Dental disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Radioactive iodine therapy	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Radiotherapy	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Rectal adenocarcinoma	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage I	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	246 of 551	

Rectal cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Rectal polypectomy	Anorectal therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Rectosigmoid cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage I	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Recurrent cancer	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Refractory anaemia with an excess of blasts	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Refractory anaemia with ringed sideroblasts	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	247 of 551	l

		and unspecified	unspecified (incl cysts and polyps)
Renal cancer recurrent	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage I	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage II	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage III	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage IV	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma recurrent	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage I	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage II	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage III	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage IV	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cyst	Renal neoplasms	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal tumour excision	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Resection of rectum	Anorectal therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Respiratory papilloma	Respiratory tract and pleural neoplasms benign NEC	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	248 of 551	

Respiratory tract carcinoma in situ	biratory tract carcinoma in situ Respiratory tract and pleural neoplasms malignant cell type unspecified NEC Respiratory and mediastinal neoplasms malignant and unspecified		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retinal melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retinal tumour excision	Retinal therapeutic procedures	Eye therapeutic procedures	Surgical and medical procedures
Retinoblastoma	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retro-orbital neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retro-pubic prostatectomy	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Retroperitoneal cancer	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdoid tumour of the kidney	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdomyoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdomyosarcoma	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdomyosarcoma recurrent	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer recurrent	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage 0	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage I	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage II	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	249 of 551	

		unspecified	unspecified (incl cysts and polyps)
Salivary gland cancer stage III	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage IV	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland resection	Salivary gland therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Salpingectomy	Fallopian tube therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Salpingo-oophorectomy	Fallopian tube therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Salpingo-oophorectomy bilateral	Fallopian tube therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Salpingo-oophorectomy unilateral	Fallopian tube therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcoma excision	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Sarcoma of skin	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcoma uterus	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcomatosis	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Scan gallium abnormal	Imaging procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Schwannoma	Nervous system neoplasms unspecified malignancy	Nervous system neoplasms malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	250 of 551	

	NEC	unspecified NEC	unspecified (incl cysts and polyps)
Scrotal cancer	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sebaceous naevus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Seborrhoeic keratosis	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Second primary malignancy	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Secretory adenoma of pituitary	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seminoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Silicon granuloma	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Simple mastectomy	Mastectomies	Breast therapeutic procedures	Surgical and medical procedures
Sinus polyp	Paranasal sinus disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Sinus polyp degeneration	Paranasal sinus disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Skin cancer	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin papilloma	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell carcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	251 of 551	

		unspecified	unspecified (incl cysts and polyps)
Small cell lung cancer	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer extensive stage	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer limited stage	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer recurrent	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestinal resection	Small intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Small intestine carcinoma metastatic	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma recurrent	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Somatostatinoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spermatocele	Scrotal disorders NEC	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorder
Spinal meningioma benign	Meningiomas benign	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal meningioma malignant	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenectomy	Lymphoid tissue therapeutic procedures	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Splenic marginal zone lymphoma recurrent	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final <b>No</b>	ovo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	252 of 551	

			unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma refractory	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage I	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage II	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage III	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage IV	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the hypopharynx	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the oral cavity	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the tongue	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the vagina	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	253 of 551	

Squamous cell carcinoma of the vulva	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage unspecified	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superior vena cava syndrome	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Suprapubic prostatectomy	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Sweat gland tumour	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Synovial cyst	Synovial disorders	Synovial and bursal disorders	Musculoskeletal and connective tissue disorders
Synovial sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Synovial sarcoma metastatic	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Synovial sarcoma recurrent	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	254 of 551	

T-cell chronic lymphocytic leukaemia	Leukaemias chronic T-cell	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma recurrent	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma refractory	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage I	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage II	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage III	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage IV	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell prolymphocytic leukaemia	Leukaemias chronic T-cell	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell unclassifiable lymphoma high grade	T-cell unclassifiable lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell unclassifiable lymphoma low grade	T-cell unclassifiable lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Teratoma	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	255 of 551	

Testicular choriocarcinoma stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular embryonal carcinoma stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular embryonal carcinoma stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular embryonal carcinoma stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure) stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure) stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure) stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	256 of 551	I

Testicular teratoma benign	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular yolk sac tumour stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular yolk sac tumour stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular yolk sac tumour stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Throat cancer	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thymoma	Mediastinal neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thymoma malignant recurrent	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid adenoma	Thyroid neoplasms benign	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cyst	Thyroid neoplasms	Thyroid gland disorders	Endocrine disorders
Thyroid electron radiation therapy	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Thyroid neoplasm	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid stimulating hormone-producing pituitary tumour	Hormone secreting pituitary neoplasms	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue neoplasm benign	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue neoplasm malignant stage unspecified	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tonsil cancer	Oropharyngeal, nasopharyngeal and tonsillar	Respiratory and mediastinal neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	•	Page:	257 of 551	

	neoplasms malignant and unspecified	malignant and unspecified	unspecified (incl cysts and polyps)
Tonsillar neoplasm benign	Oropharyngeal, nasopharyngeal and tonsillar neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tracheal cancer	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of renal pelvis and ureter metastatic	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter localised	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter recurrent	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter regional	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma urethra	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transurethral prostatectomy	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Tumour embolism	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour flare	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour lysis syndrome	Electrolyte imbalance NEC	Electrolyte and fluid balance conditions	Metabolism and nutrition disorders
Tumour pain	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	258 of 551	

Ultrasound scan vagina abnormal	scan vagina abnormal Reproductive organ and breast imaging procedures Reproductive organ and breast investigations (excl hormone analyses)		Investigations
Undifferentiated sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer local	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer metastatic	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer recurrent	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer regional	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer metastatic	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer recurrent	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral papilloma	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urinary cystectomy	Bladder therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Uterine cancer	Uterine neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine carcinoma in situ	Uterine neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	1 mui	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	259 of 551	

Uterine leiomyoma	Uterine neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine polyp	Uterine neoplasms	Uterine, pelvic and broad ligament disorders	Reproductive system and breast disorders
Vaginal cancer	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer metastatic	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer recurrent	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage 0	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage I	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage II	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage III	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage IVA	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage IVB	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cyst	Vulvovaginal cysts and neoplasms	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	260 of 551	

Vaginal dysplasia	Vulvovaginal disorders NEC	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Vaginal polyp	Vulvovaginal cysts and neoplasms	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Vipoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vocal cord polyp	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Vulval cancer	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer metastatic	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer recurrent	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage 0	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage I	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage II	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage III	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage IV	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval polyp	Vulvovaginal cysts and neoplasms	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Vulval warts removal	External female genital therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	261 of 551	l

Vulvectomy	etomy External female genital therapeutic procedures Obstetric and gynaecological therapeutic procedures		Surgical and medical procedures
Waldenstrom's macroglobulinaemia	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia recurrent	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia refractory	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage I	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage II	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage III	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage IV	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
X-ray therapy to bladder	Bladder radiotherapies	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
X-ray therapy to bone	Bone radiotherapies	Bone and joint therapeutic procedures	Surgical and medical procedures
X-ray therapy to brain	Brain radiotherapies	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
X-ray therapy to breast	Breast radiotherapies	Breast therapeutic procedures	Surgical and medical procedures
X-ray therapy to colon	Gastrointestinal radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
X-ray therapy to ear, nose, or throat	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures
X-ray therapy to lung	Pulmonary radiotherapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
X-ray therapy to pancreas	Pancreatic radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	262 of 551	

X-ray therapy to pleura	Pleural radiation therapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
X-ray therapy to prostate	Prostatic radiotherapies	Male genital tract therapeutic procedures	Surgical and medical procedures
X-ray therapy to skin	Skin radiotherapies	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures
X-ray therapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
X-ray therapy to uterus	Uterine radiotherapies	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
X-ray treatment	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Yolk sac tumour site unspecified	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial stromal sarcoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Teratoma benign	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biopsy prostate abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy chorionic villous abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Chemotherapy extravasation management	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Intestinal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Tumour marker increased	Cell marker analyses	Cytogenetic investigations	Investigations
Pericardial effusion malignant	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphocele	Lymphangiopathies	Lymphatic vessel disorders	Vascular disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	263 of 551	

Infantile septic granulomatosis	granulomatosis Infections congenital NEC Infections and infestations congenital		Congenital, familial and genetic disorders
Phakomatosis	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Oncocytoma	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast calcifications	Breast disorders NEC	Breast disorders	Reproductive system and breast disorders
Cancer hormonal therapy	Hormonal therapeutic procedures NEC	Endocrine gland therapeutic procedures	Surgical and medical procedures
Congenital choroid plexus cyst	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Cerebral haemangioma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biliary adenoma	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal adenoma	Lower gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon adenoma	Lower gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraosseous angioma	Bone neoplasms unspecified malignancy	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular cyst	Testicular and epididymal neoplasms	Testicular and epididymal disorders	Reproductive system and breast disorders
Osteoma cutis	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Steatocystoma multiplex	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital cerebral haemangioma	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Uterine cyst	Uterine neoplasms	Uterine, pelvic and broad ligament disorders	Reproductive system and breast disorders
Angiolipoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	264 of 551	l

			unspecified (incl cysts and polyps)
Lymphadenectomy	Lymphoid tissue therapeutic procedures	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Ovarian adenoma	Ovarian neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Arachnoid cyst	Nervous system cysts and polyps	Nervous system neoplasms benign	Nervous system disorders
Spindle cell sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chemotherapy cytokine prophylaxis	Prophylactic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Hysterosalpingo-oophorectomy	Uterine therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Pharyngeal mass	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Precancerous skin lesion	Skin preneoplastic conditions NEC	Cornification and dystrophic skin disorders	Skin and subcutaneous tissue disorders
Fibromatosis	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cyst	Urethral neoplasms	Urethral disorders (excl calculi)	Renal and urinary disorders
Tissue polypeptide antigen increased	Cell marker analyses	Cytogenetic investigations	Investigations
Bone marrow tumour cell infiltration	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone marrow leukaemic cell infiltration	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphohistiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal cyst	Adrenal neoplasms	Adrenal gland disorders	Endocrine disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	265 of 551	I

Ovarian cyst torsion	rian cyst torsion Ovarian and fallopian tube cysts and neoplasms Ovarian and fallopian tube disorders		Reproductive system and breast disorders
Endometrial dysplasia	Uterine disorders NEC	Uterine, pelvic and broad ligament disorders	Reproductive system and breast disorders
Gallbladder polyp	Gallbladder disorders NEC	Gallbladder disorders	Hepatobiliary disorders
Metastases to heart	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to stomach	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pancreas	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bladder	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to thyroid	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to eye	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to placenta	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to uterus	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to fallopian tube	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pituitary gland	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to muscle	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	266 of 551	

Neonatal neuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and	Neoplasms benign, malignant and
		unspecified NEC	unspecified (incl cysts and polyps)
Urinary bladder polyp	Bladder neoplasms	Bladder and bladder neck disorders (excl calculi)	Renal and urinary disorders
Renal cyst ruptured	Renal structural abnormalities and trauma	Renal disorders (excl nephropathies)	Renal and urinary disorders
Lung cancer metastatic	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer metastatic	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the duodenum	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Gastric dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Mediastinal cyst	Mediastinal disorders	Thoracic disorders (excl lung and pleura)	Respiratory, thoracic and mediastinal disorders
Oesophageal dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Renal oncocytoma	Renal neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adnexa uteri cyst	Pelvis and broad ligament disorders NEC	Uterine, pelvic and broad ligament disorders	Reproductive system and breast disorders
Hygroma colli	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Castleman's disease	Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blast crisis in myelogenous leukaemia	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	267 of 551	

			unspecified (incl cysts and polyps)
Tumour ulceration	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulva cyst	Vulvovaginal cysts and neoplasms	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Pinealoblastoma	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eyelid tumour	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Infected naevus	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic renal cell carcinoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cyst	Ovarian and fallopian tube cysts and neoplasms	Ovarian and fallopian tube disorders	Reproductive system and breast disorders
Congenital acrochordon	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Radical prostatectomy	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Liver carcinoma ruptured	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eye naevus	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Congenital eye naevus	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Gastrointestinal stromal tumour	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraneural cyst	Nervous system cysts and polyps	Nervous system neoplasms benign	Nervous system disorders
Myeloblastoma	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	268 of 551	

		and lymphomas)	unspecified (incl cysts and polyps)
Splenic cyst	Haematological cysts and polyps	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Blood and lymphatic system disorders
Chemodectoma	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Xanthogranuloma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder leukoplakia	Bladder disorders NEC	Bladder and bladder neck disorders (excl calculi)	Renal and urinary disorders
Thyroglossal cyst	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorde
Post transplant lymphoproliferative disorder	Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Buccal polyp	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Carbohydrate antigen 125 increased	Cell marker analyses	Cytogenetic investigations	Investigations
Carbohydrate antigen 15-3 increased	Cell marker analyses	Cytogenetic investigations	Investigations
Carbohydrate antigen 549 increased	Cell marker analyses	Cytogenetic investigations	Investigations
Carbohydrate antigen 19-9 increased	Cell marker analyses	Cytogenetic investigations	Investigations
Carbohydrate antigen 27.29 increased	Cell marker analyses	Cytogenetic investigations	Investigations
Pharyngectomy	Pharyngeal therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Pylorectomy	Gastric therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Chondromatosis	Cartilage neoplasms benign	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	269 of 551	l

Ureteral polyp	Ureteric disorders NEC	Ureteric disorders	Renal and urinary disorders
Urethral polyp	Urethral neoplasms	Urethral disorders (excl calculi)	Renal and urinary disorders
Vocal cord cyst	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Acquired bronchial cyst	Bronchial conditions NEC	Bronchial disorders (excl neoplasms)	Respiratory, thoracic and mediastinal disorders
Cardiac neoplasm unspecified	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large intestine polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Abdominal wall cyst	Abdominal wall conditions NEC	Abdominal hernias and other abdominal wall conditions	Gastrointestinal disorders
Gastrointestinal tract adenoma	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland adenoma	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicle adenoma	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral adenoma	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urinary bladder adenoma	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chest wall cyst	Benign musculoskeletal and connective tissue neoplasms	Musculoskeletal and connective tissue neoplasms	Musculoskeletal and connective tissue disorders
Tongue dysplasia	Tongue disorders	Tongue conditions	Gastrointestinal disorders
Large intestine fibroma	Lower gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final 270 of 551
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	

Oral fibroma	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone marrow	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to chest wall	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to abdominal wall	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to diaphragm	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to Eustachian tube	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to gallbladder	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to larynx	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to mouth	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to nasal sinuses	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to oesophagus	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to penis	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to perineum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peripheral nervous system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

		_				
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	271 of 551	

Metastases to peritoneum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pharynx	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to prostate	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to rectum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to retroperitoneum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to salivary gland	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to spleen	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to testicle	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to thorax	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to trachea	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary cyst	Pituitary neoplasms	Hypothalamus and pituitary gland disorders	Endocrine disorders
Retroperitoneum cyst	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Urinary bladder sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginectomy	Vaginal therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Metastases to meninges	Metastases to specified sites	Metastases	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	272 of 551	

			unspecified (incl cysts and polyps)
Hepatic cyst infection	Hepatobiliary and spleen infections	Infections - pathogen unspecified	Infections and infestations
Lymphoma cutis	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrinoma malignant	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Phaeochromocytoma malignant	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal neoplasm benign	Nasal and paranasal sinus neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal cyst	Nasal disorders NEC	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Ota's naevus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Pericardial cyst	Cardiac neoplasms NEC	Cardiac neoplasms	Cardiac disorders
Pharyngeal leukoplakia	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Multiple endocrine neoplasia	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Perineurial cyst	Nervous system cysts and polyps	Nervous system neoplasms benign	Nervous system disorders
Pseudosarcoma	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiomyolipoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cyst	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Tongue cyst	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	273 of 551	

Cowden's disease	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Hereditary non-polyposis colorectal cancer syndrome	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Intestinal adenocarcinoma	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diaphragm neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Peritoneal cyst	Peritoneal and retroperitoneal disorders	Peritoneal and retroperitoneal conditions	Gastrointestinal disorders
Pharyngeal polyp	Pharyngeal disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Renal adenoma	Renal neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal sarcoma	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural sarcoma	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uvulectomy	Palatal therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Anogenital dysplasia	Anal and rectal disorders NEC	Anal and rectal conditions NEC	Gastrointestinal disorders
Foetal cystic hygroma	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Congenital teratoma	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Lymphocytic lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Aural cystadenoma	Aural neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	274 of 551	

Tumour associated fever	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial neoplasm benign	Respiratory tract and pleural neoplasms benign NEC	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cyst	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Focal nodular hyperplasia	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epidermodysplasia verruciformis	Papilloma viral infections	Viral infectious disorders	Infections and infestations
Colorectal cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenocarcinoma	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration pulmonary	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebral hygroma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biliary cyst	Structural and other bile duct disorders	Bile duct disorders	Hepatobiliary disorders
Neuroendocrine tumour	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ocular neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parovarian cyst	Ovarian and fallopian tube cysts and neoplasms	Ovarian and fallopian tube disorders	Reproductive system and breast disorders
Seminal vesicular cyst	Reproductive tract disorders NEC (excl neoplasms)	Reproductive tract disorders NEC	Reproductive system and breast disorders
Epiglottidectomy	Laryngeal therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	275 of 551	

Hemilaryngectomy	Laryngeal therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Vocal cordectomy	Laryngeal therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Laryngopharyngectomy	Laryngeal therapeutic procedures	Head and neck therapeutic procedures	Surgical and medical procedures
Uterine tumour excision	Uterine therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Transurethral bladder resection	Bladder therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Adenocarcinoma pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrous cortical defect	Bone neoplasms benign (excl cysts)	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal polypectomy	Gastrointestinal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Ovarian dysgerminoma stage unspecified	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oral polypectomy	Head, neck and oral cavity therapeutic procedures NEC	Head and neck therapeutic procedures	Surgical and medical procedures
Carcinoid tumour of the small bowel	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Erythroplasia of penis	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Erythroplasia of vulva	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Erythroplasia of lip	Lip and oral cavity neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Electron radiation therapy to blood	Haematological radiotherapies	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to blood	Haematological radiotherapies	Haematological and lymphoid tissue	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	276 of 551	

		therapeutic procedures	
Photon radiation therapy to blood	Haematological radiotherapies	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
X-ray therapy to blood	Haematological radiotherapies	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to liver	Hepatobiliary radiotherapies	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to liver	Hepatobiliary radiotherapies	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to liver	Hepatobiliary radiotherapies	Hepatobiliary therapeutic procedures	Surgical and medical procedures
X-ray therapy to liver	Hepatobiliary radiotherapies	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Electron radiation therapy to soft tissue	Soft tissue radiotherapies	Soft tissue therapeutic procedures	Surgical and medical procedures
Gamma radiation therapy to soft tissue	Soft tissue radiotherapies	Soft tissue therapeutic procedures	Surgical and medical procedures
Photon radiation therapy to soft tissue	Soft tissue radiotherapies	Soft tissue therapeutic procedures	Surgical and medical procedures
X-ray therapy to soft tissue	Soft tissue radiotherapies	Soft tissue therapeutic procedures	Surgical and medical procedures
Neoplasm of cornea unspecified malignancy	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma operation	Lymphoid tissue therapeutic procedures	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Lymphoid tissue operation	Lymphoid tissue therapeutic procedures	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Hysterosalpingectomy	Uterine therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Malignant nipple neoplasm male	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant nipple neoplasm female	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015		Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	277 of 551	

Lymphangiosis carcinomatosa	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genital cyst	Reproductive tract neoplasms NEC	Reproductive tract disorders NEC	Reproductive system and breast disorders
Leukaemia cutis	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic neoplasm malignancy unspecified	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoid cystic carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ostectomy	Bone therapeutic procedures NEC	Bone and joint therapeutic procedures	Surgical and medical procedures
Biopsy ear abnormal	Ear and labyrinth histopathology procedures	Neurological, special senses and psychiatric investigations	Investigations
Biopsy small intestine abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Nephroureterectomy	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Pancreaticosplenectomy	Abdominal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Nervous system neoplasm surgery	Nervous system therapeutic procedures NEC	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Oral cavity neoplasm surgery	Head, neck and oral cavity therapeutic procedures NEC	Head and neck therapeutic procedures	Surgical and medical procedures
Venous angioma of brain	Venous disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Hemipelvectomy	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Scan bone marrow abnormal	Bone marrow and immune tissue imaging procedures	Haematology investigations (incl blood groups)	Investigations
Gastrointestinal cancer metastatic	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	278 of 551	

Immunoblastic lymphoma	Non-Hodgkin's lymphomas unspecified histology aggressive		
Optic nerve neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrous histiocytoma	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blast cell crisis	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain tumour operation	Skull and brain therapeutic procedures	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Sigmoidectomy	Large intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Free prostate-specific antigen positive	Cell marker analyses	Cytogenetic investigations	Investigations
Free prostate-specific antigen increased	Cell marker analyses	Cytogenetic investigations	Investigations
Benign fallopian tube neoplasm	Reproductive neoplasms female benign NEC	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
POEMS syndrome	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cyst ruptured	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hemicorporectomy	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Oestrogen receptor assay positive	Cell marker analyses	Cytogenetic investigations	Investigations
Progesterone receptor assay positive	Cell marker analyses	Cytogenetic investigations	Investigations
Tumour necrosis	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemorrhagic tumour necrosis	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	279 of 551	

Small intestine carcinoma	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
		anspoonied	unspective (incresses and polypo)
Total adrenalectomy	Adrenal gland therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Intestinal resection	Gastrointestinal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Contralateral breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myolipoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic haemangioma rupture	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cystadenocarcinoma ovary	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Serous cystadenocarcinoma ovary	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous cystadenocarcinoma ovary	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulvar dysplasia	Vulvovaginal disorders NEC	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders
Pericardial neoplasm	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pericardial neoplasm	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign pericardium neoplasm	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Disseminated large cell lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Congenital cerebral cyst	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	280 of 551	

Pancreatic sarcoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the pancreas	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric sarcoma	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cardiac fibroma	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cardiac lymphangioma	Lymphatic system disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Cardiac haemangioma benign	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cardiac neurofibroma	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ear neoplasm	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ear neoplasm malignant	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gingival cyst	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Vascular neoplasm	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular papilloma	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain cancer metastatic	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix cancer metastatic	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	281 of 551	

Adrenal gland cancer metastatic	Adrenal neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer metastatic	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oral cavity cancer metastatic	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ocular cancer metastatic	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Otic cancer metastatic	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone cancer metastatic	Bone neoplasms malignant (excl sarcomas)	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal cancer metastatic	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular cancer metastatic	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer metastatic	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sinus cancer metastatic	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary cancer metastatic	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer metastatic	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thymic cancer metastatic	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	282 of 551	

Tongue cancer metastatic	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer metastatic	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biliary cancer metastatic	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer metastatic	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer metastatic	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to urinary tract	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign vascular neoplasm	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian embryonal carcinoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nipple neoplasm	Breast neoplasms unspecified malignancy	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm of appendix	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm of thymus	Mediastinal neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal neoplasm	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mastocytic leukaemia	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	283 of 551	

Radiotherapy to thymus	Lymphoid tissue therapeutic procedures	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Benign biliary neoplasm	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glomus jugulare tumour	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Exploratory operation	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Retroperitoneal neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroectodermal neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Placental chorioangioma	Reproductive neoplasms female benign NEC	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanomatous meningitis	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cyst	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Adenomatous polyposis coli	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Ileectomy	Small intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Jejunectomy	Small intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Cystoprostatectomy	Bladder therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Oesophagogastrectomy	Gastrointestinal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Vocal cord neoplasm	Laryngeal neoplasms malignancy unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	284 of 551	

Paraneoplastic pemphigus	Paraneoplastic syndromes NEC	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dermatofibrosarcoma protuberans	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blast cells present	Haematological analyses NEC	Haematology investigations (incl blood groups)	Investigations
Hypophysectomy	Pituitary and hypothalamic therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Acute megakaryocytic leukaemia (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal dysplasia	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Signet-ring cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucoepidermoid carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of auricular cartilage	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumour recurrent	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenolipoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial polyp	Bronchial conditions NEC	Bronchial disorders (excl neoplasms)	Respiratory, thoracic and mediastinal disorders
Metastatic carcinoma of the bladder	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	285 of 551	I

		and unspecified	unspecified (incl cysts and polyps)
Ovarian granulosa-theca cell tumour	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroid neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conjunctival neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retinal neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lacrimal duct neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Iris neoplasm	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ocular haemangiopericytoma	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of optic nerve	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retinal melanocytoma	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epiglottic cyst	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Epiglottic carcinoma	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epiglottic mass	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Oropharyngeal neoplasm	Lip and oral cavity neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	286 of 551	

Paranasal sinus benign neoplasm	Nasal and paranasal sinus neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tonsillar cyst	Upper respiratory tract neoplasms	Respiratory tract neoplasms	Respiratory, thoracic and mediastinal disorders
Cardiac teratoma	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer metastatic	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary gland radiotherapy	Pituitary and hypothalamic therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Testis cancer	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of soft tissue	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial sarcoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer female	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biopsy chest wall abnormal	Musculoskeletal and soft tissue histopathology procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Angiosarcoma non-metastatic	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary neoplasm malignant recurrent	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primitive neuroectodermal tumour	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

					<b>E</b> <sup>1</sup> 1	Maria Mandal
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	287 of 551	

Blepharal papilloma	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epulis	Gingival disorders NEC	Dental and gingival conditions	Gastrointestinal disorders
Prostatic specific antigen abnormal	Cell marker analyses	Cytogenetic investigations	Investigations
Infected neoplasm	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Infected cyst	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Cancer pain	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radiotherapy to pleura	Pleural radiation therapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
Phaeochromocytoma excision	Adrenal gland therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Gallbladder cancer stage II	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage III	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage IV	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder adenocarcinoma	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic bronchial carcinoma	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peripheral vascular system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dysplasia	Trophic disorders	Tissue disorders NEC	General disorders and administration site conditions
Bronchioloalveolar carcinoma	Respiratory tract and pleural neoplasms malignant cell	Respiratory and mediastinal neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	288 of 551	I

	type unspecified NEC	malignant and unspecified	unspecified (incl cysts and polyps)
Biopsy artery abnormal	Vascular and lymphatic histopathology procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Biopsy bile duct abnormal	Hepatobiliary histopathology procedures	Hepatobiliary investigations	Investigations
Biopsy diaphragm abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy eyelid abnormal	Histopathology procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Biopsy fallopian tube abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy foetal abnormal	Foetal and neonatal histopathology procedures	Foetal and neonatal investigations	Investigations
Biopsy intestine abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy ligament abnormal	Musculoskeletal and soft tissue histopathology procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Biopsy tendon abnormal	Musculoskeletal and soft tissue histopathology procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Biopsy pancreas abnormal	Gastrointestinal histopathology procedures	Gastrointestinal investigations	Investigations
Biopsy seminal vesicle abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy uterus abnormal	Reproductive organ and breast histopathology procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Biopsy vocal cord abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Mediastinal biopsy abnormal	Respiratory tract and thoracic histopathology procedures	Respiratory and pulmonary investigations (excl blood gases)	Investigations
Biopsy blood vessel abnormal	Vascular and lymphatic histopathology procedures	Cardiac and vascular investigations (excl	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nor	rdisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	289 of 551	

		enzyme tests)	
Haemangioma-thrombocytopenia syndrome	Skin vascular conditions NEC	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Tongue carcinoma stage 0	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage I	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage II	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage III	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage IV	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cyst	Bladder neoplasms	Bladder and bladder neck disorders (excl calculi)	Renal and urinary disorders
Oesophageal adenocarcinoma metastatic	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma metastatic	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cyst infection	Urinary tract infections	Infections - pathogen unspecified	Infections and infestations
Leukaemic infiltration hepatic	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia transformation	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Richter's syndrome	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	290 of 551	

Cystic lymphangioma	Lymphatic system disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Extradural neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Natural killer-cell lymphoblastic lymphoma	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superior vena cava occlusion	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Acute myeloid leukaemia recurrent	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Amyloidoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm swelling	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blood chromogranin A increased	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Haemorrhagic cyst	Mass conditions NEC	Tissue disorders NEC	General disorders and administration site conditions
Biopsy spleen abnormal	Bone marrow and immune tissue histopathology procedures	Haematology investigations (incl blood groups)	Investigations
Leukaemic retinopathy	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebellar haemangioma	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anogenital warts	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	291 of 551	l

Gallbladder cancer stage 0	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage I	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage I	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage II	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage 0	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage I	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage II	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage III	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage III	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage IV	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage IV	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Desmoid tumour	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Infected lymphocele	Vascular infections	Infections - pathogen unspecified	Infections and infestations
Small intestine carcinoma stage 0	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	292 of 551	

Small intestine carcinoma stage I	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage II	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage III	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage IV	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage I	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage II	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage III	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage IV	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage 0	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acanthoma	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraneoplastic syndrome	Paraneoplastic syndromes NEC	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign spleen tumour	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Buschke-Lowenstein's tumour	Genitourinary neoplasms malignancy and gender unspecified	Reproductive and genitourinary neoplasms gender unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin neoplasm excision	Skin lesion excisions	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	293 of 551	

Stewart-Treves syndrome	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Palliative care	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Small cell lung cancer metastatic	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteochondroma	Cartilage neoplasms benign	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile squamous cell carcinoma	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cyst haemorrhage	Renal neoplasms	Renal disorders (excl nephropathies)	Renal and urinary disorders
Proctocolectomy	Large intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Squamous cell carcinoma of head and neck	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell leukaemia in remission	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intravascular papillary endothelial hyperplasia	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin neoplasm bleeding	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal neoplasm	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemorrhagic ovarian cyst	Ovarian and fallopian tube cysts and neoplasms	Ovarian and fallopian tube disorders	Reproductive system and breast disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	294 of 551	

Erdheim-Chester disease	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Necrolytic migratory erythema	Erythemas	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Gastric adenoma	Upper gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Monoclonal gammopathy	Plasma cell neoplasms NEC	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Trousseau's syndrome	Non-site specific embolism and thrombosis	Embolism and thrombosis	Vascular disorders
Precursor B-lymphoblastic lymphoma recurrent	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma refractory	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Abdominal neoplasm	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute leukaemia in remission	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Astrocytoma malignant	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Granular cell tumour	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign anorectal neoplasm	Lower gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign bone neoplasm	Bone neoplasms benign (excl cysts)	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign endocrine neoplasm	Endocrine neoplasms benign NEC	Endocrine neoplasms benign	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	295 of 551	

			unspecified (incl cysts and polyps)
Benign female reproductive tract neoplasm	Reproductive neoplasms female benign NEC	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign gastrointestinal neoplasm	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign lymph node neoplasm	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign male reproductive tract neoplasm	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign pancreatic neoplasm	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign renal neoplasm	Renal neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign respiratory tract neoplasm	Respiratory tract and pleural neoplasms benign NEC	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign small intestinal neoplasm	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign soft tissue neoplasm	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cardiac myxoma	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign urinary tract neoplasm	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign uterine neoplasm	Uterine neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	296 of 551	

Brachytherapy	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Brain neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer male	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cardiac neoplasm malignant	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thymoma malignant	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic leukaemia in remission	Leukaemias chronic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon neoplasm	Colorectal and anal neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Connective tissue neoplasm	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cranial nerve neoplasm benign	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ectopic hormone secretion	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Endocrine neoplasm	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endocrine neoplasm malignant	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Female reproductive neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Female reproductive tract carcinoma in situ	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	297 of 551	I

Gastrointestinal carcinoma in situ	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genitourinary tract neoplasm	Genitourinary neoplasms malignancy and gender unspecified	Reproductive and genitourinary neoplasms gender unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Germ cell cancer	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haematopoietic neoplasm	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hamartoma	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Hepatobiliary neoplasm	Hepatobiliary neoplasms malignancy unspecified	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia in remission	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoproliferative disorder	Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoproliferative disorder in remission	Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Male reproductive tract neoplasm	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant anorectal neoplasm	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant cranial nerve neoplasm	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	298 of 551	

Malignant lymphoid neoplasm	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mediastinal neoplasm	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraocular melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lacrimal cyst	Ocular cysts and polyps	Ocular neoplasms	Eye disorders
Malignant middle ear neoplasm	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant nervous system neoplasm	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant peritoneal neoplasm	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant respiratory tract neoplasm	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant urinary tract neoplasm	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningeal neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nervous system neoplasm benign	Nervous system neoplasms benign NEC	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to nervous system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to reproductive organ	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	299 of 551	

Metastatic neoplasm	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Monocytic leukaemia in remission	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myeloid leukaemia in remission	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm progression	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nervous system neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oral neoplasm	Lip and oral cavity neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraganglion neoplasm	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraproteinaemia	Plasma cell neoplasms NEC	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pelvic neoplasm	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of bone	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pineal neoplasm	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	300 of 551	

Placental neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tendon neoplasm	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell cancer	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular neoplasm	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour excision	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Urinary tract carcinoma in situ	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urinary tract neoplasm	Urinary tract neoplasms unspecified malignancy NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebral cyst	Nervous system cysts and polyps	Nervous system neoplasms benign	Nervous system disorders
Carcinoma in situ	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal neoplasm	Urinary tract neoplasms unspecified malignancy NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Respiratory tract neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	301 of 551	

Salivary gland neoplasm	Salivary gland neoplasms unspecified malignancy	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
		-	
Scan abnormal	Imaging procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Scan myocardial perfusion abnormal	Cardiac imaging procedures	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Scan abdomen abnormal	Gastrointestinal and abdominal imaging procedures	Gastrointestinal investigations	Investigations
Lip and/or oral cavity cancer	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mesenchymoma	Mesenchymomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibrosarcoma	Neurofibrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Polyp	Mucosal findings abnormal	General system disorders NEC	General disorders and administration site conditions
Oesophageal squamous cell carcinoma	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pineal parenchymal neoplasm malignant	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary tumour benign	Endocrine neoplasms benign NEC	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radiotherapy to brain	Brain radiotherapies	Nervous system, skull and spine therapeutic procedures	Surgical and medical procedures
Radiotherapy to lung	Pulmonary radiotherapies	Respiratory tract therapeutic procedures	Surgical and medical procedures
Radiotherapy to prostate	Prostatic radiotherapies	Male genital tract therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	302 of 551	

Radiotherapy to skin	Skin radiotherapies	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures
Radiotherapy to urinary bladder	Bladder radiotherapies	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Radiotherapy to uterus	Uterine radiotherapies	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Adrenal neoplasm	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage IV	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to the respiratory system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ultrasound scan abnormal	Imaging procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Abdominal wall neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal neoplasm	Colorectal and anal neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign mesothelioma	Mesotheliomas benign	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign muscle neoplasm	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast lump removal	Breast neoplasm removal	Breast therapeutic procedures	Surgical and medical procedures
Cartilage neoplasm	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cerebellar tumour	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chemotherapy	Chemotherapies	Therapeutic procedures and supportive care	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	303 of 551	

		NEC	
Colectomy	Large intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Corneal cyst	Ocular cysts and polyps	Ocular neoplasms	Eye disorders
Cyst rupture	Mass conditions NEC	Tissue disorders NEC	General disorders and administration site conditions
Cervix carcinoma stage 0	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Duodenal neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Electron radiation therapy	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Extragonadal primary malignant teratoma	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type)	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm of orbit	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm recurrence	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma transformed recurrent	Non-Hodgkin's lymphomas transformed recurrent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-renal cell carcinoma of kidney	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	304 of 551	

Non-small cell lung cancer	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal neoplasm	Oesophageal neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oophorectomy	Ovarian therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Ovarian germ cell cancer	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile neoplasm	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatectomy	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Radioisotope scan abnormal	Imaging procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Salivary gland cancer	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	305 of 551	

Scan adrenal gland abnormal	Endocrine analyses and imaging NEC	Endocrine investigations (incl sex hormones)	Investigations
Bone scan abnormal	Musculoskeletal and soft tissue imaging procedures	Musculoskeletal and soft tissue investigations (excl enzyme tests)	Investigations
Brain scan abnormal	Central nervous system imaging procedures	Neurological, special senses and psychiatric investigations	Investigations
Liver scan abnormal	Hepatobiliary imaging procedures	Hepatobiliary investigations	Investigations
Lymph nodes scan abnormal	Bone marrow and immune tissue imaging procedures	Haematology investigations (incl blood groups)	Investigations
Parathyroid scan abnormal	Endocrine analyses and imaging NEC	Endocrine investigations (incl sex hormones)	Investigations
Renal scan abnormal	Urinary tract imaging procedures	Renal and urinary tract investigations and urinalyses	Investigations
Salivary gland scan abnormal	Gastrointestinal and abdominal imaging procedures	Gastrointestinal investigations	Investigations
Follicle centre lymphoma diffuse small cell lymphoma	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gamma radiation therapy	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Gastrectomy	Gastric therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Gastric cancer stage IV	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gestational trophoblastic tumour	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatectomy	Hepatic therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Hepatoblastoma	Hepatoblastomas	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	306 of 551	

Intestinal cyst	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Leukoplakia	Skin preneoplastic conditions NEC	Cornification and dystrophic skin disorders	Skin and subcutaneous tissue disorders
Lip neoplasm	Lip and oral cavity neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung infiltration malignant	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphatic system neoplasm	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphocyte morphology abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Malignant muscle neoplasm	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant nipple neoplasm	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile operation	Penile therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Peripheral nervous system neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal neoplasm	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Photon radiation therapy	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Radiotherapy to blood	Haematological radiotherapies	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Radiotherapy to bone	Bone radiotherapies	Bone and joint therapeutic procedures	Surgical and medical procedures
Radiotherapy to breast	Breast radiotherapies	Breast therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	307 of 551	

Radiotherapy to ear	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures
Radiotherapy to gastrointestinal tract	Gastrointestinal radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Radiotherapy to liver	Hepatobiliary radiotherapies	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Radiotherapy to nose	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures
Radiotherapy to pancreas	Pancreatic radiotherapies	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Radiotherapy to soft tissue	Soft tissue radiotherapies	Soft tissue therapeutic procedures	Surgical and medical procedures
Radiotherapy to throat	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures
Radiotherapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Rectal neoplasm	Colorectal and anal neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular embryonal carcinoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure)	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroidectomy	Thyroid therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Tongue neoplasm	Lip and oral cavity neoplasms malignancy unspecified	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tonsillar neoplasm	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tracheal neoplasm	Respiratory tract and pleural neoplasms malignancy unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	308 of 551	

Vulval neoplasm	Ival neoplasmFemale reproductive neoplasms unspecified malignancyReproductive neop unspecified		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval operation	External female genital therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures
Somatostatin receptor scan abnormal	Endocrine analyses and imaging NEC	Endocrine investigations (incl sex hormones)	Investigations
Spleen scan abnormal	Bone marrow and immune tissue imaging procedures	Haematology investigations (incl blood groups)	Investigations
Stomach scan abnormal	Gastrointestinal and abdominal imaging procedures	Gastrointestinal investigations	Investigations
Testicular scan abnormal	Reproductive organ and breast imaging procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Thyroid gland scan abnormal	Endocrine analyses and imaging NEC	Endocrine investigations (incl sex hormones)	Investigations
Scan with contrast abnormal	Imaging procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Vaginal neoplasm	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastasis	Metastases to unknown and unspecified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to biliary tract	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to gastrointestinal tract	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to soft tissue	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour vaccine therapy	Tumour vaccine therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Ureteral neoplasm	Urinary tract neoplasms unspecified malignancy NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	309 of 551	l

Urethral neoplasm	Urinary tract neoplasms unspecified malignancy NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Smooth muscle cell neoplasm	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal cord neoplasm	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blast cell count increased	Haematological analyses NEC	Haematology investigations (incl blood groups)	Investigations
Paranasal cyst	Paranasal sinus disorders (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Congenital cyst	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Retroperitoneal neoplasm metastatic	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia recurrent	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cementoblastoma	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
In vivo gene therapy	Gene therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Dysplastic naevus	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrooesophageal cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hormone-refractory prostate cancer	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cronkhite-Canada syndrome	Gastrointestinal neoplasms NEC	Malignant and unspecified neoplasms gastrointestinal NEC	Gastrointestinal disorders
Sebaceous adenoma	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	310 of 551	

			unspecified (incl cysts and polyps)
Naevus haemorrhage	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Muir-Torre syndrome	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
X-ray therapy to joint	Joint therapeutic procedures	Bone and joint therapeutic procedures	Surgical and medical procedures
Breast adenoma	Breast and nipple neoplasms benign	Breast neoplasms benign (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast fibroma	Breast and nipple neoplasms benign	Breast neoplasms benign (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Trisomy 12	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Erythroplasia	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic glioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rosai-Dorfman syndrome	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Odontogenic cyst	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital vaginal cyst	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Laryngeal leukoplakia	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Colon cancer stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulvar adenocarcinoma	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	311 of 551	

Metastatic squamous cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Stem cell transplant	Haematological therapeutic procedures NEC	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures	
Bladder polypectomy	Bladder therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures	
Porocarcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Radical neck dissection	Head, neck and oral cavity therapeutic procedures NEC	Head and neck therapeutic procedures	Surgical and medical procedures	
Lung neoplasm surgery	Bronchial and pulmonary therapeutic procedures	Respiratory tract therapeutic procedures	Surgical and medical procedures	
Radiotherapy to eye	Eye therapeutic procedures NEC	Eye therapeutic procedures	Surgical and medical procedures	
Radiotherapy to ovary	Ovarian therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures	
Radiotherapy to vagina	Vaginal therapeutic procedures	Obstetric and gynaecological therapeutic procedures	Surgical and medical procedures	
Radiotherapy to lymph nodes	Lymphoid tissue therapeutic procedures	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures	
Acute lymphocytic leukaemia recurrent	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Malignant neoplasm of eyelid	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Malignant melanoma of eyelid	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Benign neoplasm of eyelid	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Implant site cyst	Implant and catheter site reactions	Administration site reactions	General disorders and administration site conditions	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	312 of 551	

Non-Hodgkin's lymphoma unspecified histology aggressive			Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Metastatic gastric cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Ileocolectomy	Gastrointestinal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures	
Vulvovaginal adenosis	Vulvovaginal disorders NEC	Vulvovaginal disorders (excl infections and inflammations)	Reproductive system and breast disorders	
Percutaneous ethanol injection therapy	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures	
Lung adenocarcinoma metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Lip squamous cell carcinoma	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Immune enhancement therapy	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures	
Hormone suppression therapy	Hormonal therapeutic procedures NEC	Endocrine gland therapeutic procedures	Surgical and medical procedures	
Cell marker increased	Cell marker analyses	Cytogenetic investigations	Investigations	
Oropharyngeal cancer stage IV	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Endometrial metaplasia	Uterine disorders NEC	Uterine, pelvic and broad ligament disorders	Reproductive system and breast disorders	
Ovarian fibroma	Ovarian neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Bladder neoplasm surgery	Bladder therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures	
Calcifying fibrous pseudotumour	Neoplasms benign site unspecified NEC	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Lymphoma transformation	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	313 of 551	

			unspecified (incl cysts and polyps)
Tumour invasion	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breakthrough pain	Pain and discomfort NEC	General system disorders NEC	General disorders and administration site conditions
Desmoplastic small round cell tumour	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sezary cells increased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Atypical fibroxanthoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Micrographic skin surgery	Skin and subcutaneous tissue therapeutic procedures NEC	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures
Malignant transformation	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour perforation	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High frequency ablation	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Plasmablastic lymphoma	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epidermal growth factor receptor increased	Cell marker analyses	Cytogenetic investigations	Investigations
Clonal evolution	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acrokeratosis paraneoplastica	Papulosquamous conditions	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Pancoast's syndrome	Peripheral neuropathies NEC	Peripheral neuropathies	Nervous system disorders
Cancer in remission	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	314 of 551	I

		malignant and unspecified	unspecified (incl cysts and polyps)
Paraneoplastic retinopathy	Retinopathies NEC	Retina, choroid and vitreous haemorrhages and vascular disorders	Eye disorders
Vaginal adenocarcinoma	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leser-Trelat sign	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HER-2 positive breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alcoholisation procedure	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Radiotherapy to kidney	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Malignant glioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radiosensitisation therapy	Cellular antitumour therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Infusion site cyst	Infusion site reactions	Administration site reactions	General disorders and administration site conditions
Hormone therapy	Hormonal therapeutic procedures NEC	Endocrine gland therapeutic procedures	Surgical and medical procedures
Scrotal cyst	Scrotal disorders NEC	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorders
CNS germinoma	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic eosinophilic leukaemia	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	315 of 551	

Primary effusion lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian stromal cancer	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Congenital fibrosarcoma	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Alveolar rhabdomyosarcoma	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Embryonal rhabdomyosarcoma	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Astrocytoma, low grade	Gliomas benign	Nervous system neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nongerminomatous germ cell tumour of the CNS	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Atypical teratoid/rhabdoid tumour of CNS	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteral cyst	Ureteric disorders NEC	Ureteric disorders	Renal and urinary disorders
Nodular fasciitis	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mueller's mixed tumour	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Perineal cyst	Reproductive tract neoplasms NEC	Reproductive tract disorders NEC	Reproductive system and breast disorders
Huerthle cell carcinoma	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Apocrine breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gliomatosis cerebri	Glial tumours malignant	Nervous system neoplasms malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	316 of 551	

		unspecified NEC	unspecified (incl cysts and polyps)
Paraneoplastic dermatomyositis	Paraneoplastic syndromes NEC	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conjunctival melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile dysplasia	Penile disorders NEC (excl erection and ejaculation)	Penile and scrotal disorders (excl infections and inflammations)	Reproductive system and breast disorde
Squamous cell carcinoma of pharynx	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haematological malignancy	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medulloblastoma recurrent	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroblastoma recurrent	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanoma recurrent	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer recurrent	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage 0	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage I	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	317 of 551	

Bladder transitional cell carcinoma stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ameloblastoma	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer metastatic	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic salivary gland cancer	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HER-2 positive gastric cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conjunctival primary acquired melanosis	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Numb chin syndrome	Trigeminal disorders	Cranial nerve disorders (excl neoplasms)	Nervous system disorders
Myxofibrosarcoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatosplenic T-cell lymphoma	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial sarcoma recurrent	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial sarcoma metastatic	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraperitoneal hyperthermic chemotherapy	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	318 of 551	

Leukaemic infiltration extramedullary Leukaemias NEC Leukaemias		Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papilloma conjunctival	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tracheal papilloma	Pharyngeal and laryngeal neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Congenital naevus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Chiasma syndrome	Neurologic visual problems NEC	Neurological disorders of the eye	Nervous system disorders
Palmar fasciitis	Musculoskeletal and connective tissue infections and inflammations NEC	Musculoskeletal and connective tissue disorders NEC	Musculoskeletal and connective tissue disorders
Malignant mesenteric neoplasm	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal meningeal cyst	Nervous system cysts and polyps	Nervous system neoplasms benign	Nervous system disorders
Myelodysplastic syndrome transformation	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic angiosarcoma	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute biphenotypic leukaemia	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration gingiva	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroid plexus carcinoma	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	319 of 551	

		unspecified	unspecified (incl cysts and polyps)
Malignant dysphagia	Gastrointestinal signs and symptoms NEC	Gastrointestinal signs and symptoms	Gastrointestinal disorders
Prostatic cyst	Prostatic signs, symptoms and disorders NEC	Prostatic disorders (excl infections and inflammations)	Reproductive system and breast disorders
Birt-Hogg-Dube syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Parathyroid cyst	Parathyroid disorders NEC	Parathyroid gland disorders	Endocrine disorders
Oncologic complication	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemorrhagic hepatic cyst	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Gingival cancer	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipofibroma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory myofibroblastic tumour	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hereditary papillary renal carcinoma	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Hereditary leiomyomatosis renal cell carcinoma	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Renal cell carcinoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Refractory cytopenia with multilineage dysplasia	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eastern Cooperative Oncology Group performance status worsened	Physical examination procedures and organ system status	Physical examination and organ system status topics	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	320 of 551	

Melanoplakia oral	Oral soft tissue disorders NEC	Oral soft tissue conditions	Gastrointestinal disorders
PHACES syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Tumour thrombosis	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic carcinoid tumour	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic uterine cancer	Uterine neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic ocular melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma of spleen	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of seminal vesicle	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign neoplasm of seminal vesicle	Reproductive neoplasms male benign NEC	Reproductive neoplasms male benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extramammary Paget's disease	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia transformation	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour compression	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oral papilloma	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	321 of 551	

Inflammatory pseudotumour	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
X-linked lymphoproliferative syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Biliary polyp	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Precancerous mucosal lesion	Mucosal findings abnormal	General system disorders NEC	General disorders and administration site conditions
Brain teratoma	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cytokeratin 18 increased	Cell marker analyses	Cytogenetic investigations	Investigations
Chemotherapy sensitivity and resistance assay	Therapeutic drug monitoring analyses	Toxicology and therapeutic drug monitoring	Investigations
5q minus syndrome	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast sarcoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast sarcoma metastatic	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast sarcoma recurrent	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcoma metastatic	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioneuronal tumour	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pineal gland cyst	Nervous system cysts and polyps	Nervous system neoplasms benign	Nervous system disorders
Testicular germ cell cancer metastatic	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cardiac valve fibroelastoma	Cardiovascular neoplasms benign	Miscellaneous and site unspecified neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	322 of 551	

		benign	unspecified (incl cysts and polyps)
Lung cyst	Parenchymal lung disorders NEC	Lower respiratory tract disorders (excl obstruction and infection)	Respiratory, thoracic and mediastinal disorders
Soft tissue neoplasm	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Phaeochromocytoma crisis	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sebaceous carcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Histiocytic medullary reticulosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fungating wound	Skin and subcutaneous tissue ulcerations	Skin and subcutaneous tissue disorders NEC	Skin and subcutaneous tissue disorders
Warty dyskeratoma	Skin neoplasms benign	Cutaneous neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour metastatic	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primitive neuroectodermal tumour metastatic	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Implantable pleural catheter insertion	Pleural therapeutic procedures	Respiratory tract therapeutic procedures	Surgical and medical procedures
Germ cell cancer metastatic	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radiotherapy to joint	Joint therapeutic procedures	Bone and joint therapeutic procedures	Surgical and medical procedures
Peritoneal carcinoma metastatic	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	323 of 551	

Peritoneal fluid protein increased	al fluid protein increased Peritoneal fluid and membrane function analyses Gastrointestinal investigations		Investigations
Carcinoid heart disease	Cardiac valve disorders NEC	Cardiac valve disorders	Cardiac disorders
Benign ear neoplasm	Aural neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritonectomy	Abdominal therapeutic procedures NEC	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Enchondroma	Cartilage neoplasms benign	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Histiocytic necrotising lymphadenitis	Lymphoproliferative disorders NEC (excl leukaemias and lymphomas)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Omenn syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Epididymal neoplasm	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Stauffer's syndrome	Paraneoplastic syndromes NEC	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Multiple hereditary exostosis	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Solid pseudopapillary tumour of the pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestinal polypectomy	Small intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Leukaemic infiltration renal	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Solitary epithelioid histiocytoma	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radiation therapy to ear, nose, or throat	Ear, nose and throat radiotherapies	Head and neck therapeutic procedures	Surgical and medical procedures

		1 -		l -		
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	324 of 551	

Bladder dysplasia	Bladder disorders NEC	Bladder and bladder neck disorders (excl calculi)	Renal and urinary disorders
Carcinomatous polyarthritis	Arthropathies NEC	Joint disorders	Musculoskeletal and connective tissue disorders
Regional chemotherapy	Chemotherapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Posterior fossa syndrome	Neurological and psychiatric procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Paraneoplastic encephalomyelitis	Encephalitis NEC	Central nervous system infections and inflammations	Nervous system disorders
Bone marrow reticulin fibrosis	Haematological disorders	Haematological disorders NEC	Blood and lymphatic system disorders
Eccrine carcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Langerhans' cell histiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eastern Cooperative Oncology Group performance status improved	Physical examination procedures and organ system status	Physical examination and organ system status topics	Investigations
Cerebellopontine angle tumour	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma recurrent	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testis cancer recurrent	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	325 of 551	I

Renal haemangioma	Renal neoplasms benign	neoplasms benign Renal and urinary tract neoplasms benign	
Metastatic pulmonary embolism	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glomus tympanicum tumour	Aural neoplasms benign	Miscellaneous and site unspecified neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anti-androgen withdrawal syndrome	Withdrawal and rebound effects	Therapeutic and nontherapeutic effects (excl toxicity)	General disorders and administration site conditions
Denys-Drash syndrome	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Refractory cancer	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenolymphoma	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radical cystectomy	Bladder therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Skin cryotherapy	Skin and subcutaneous tissue therapeutic procedures NEC	Skin and subcutaneous tissue therapeutic procedures	Surgical and medical procedures
Photodynamic diagnostic procedure	Imaging procedures NEC	Investigations, imaging and histopathology procedures NEC	Investigations
Pepsinogen test positive	Digestive enzymes	Gastrointestinal investigations	Investigations
Peritoneal gliomatosis	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage 0	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid C-cell hyperplasia	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Oestrogen receptor positive breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	326 of 551	l

Multicentric reticulohistiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour rupture	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Knuckle pads	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesoblastic nephroma	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Urethrectomy	Urethral therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Cementoplasty	Bone therapeutic procedures NEC	Bone and joint therapeutic procedures	Surgical and medical procedures
Tumour cell mobilisation	Site specific procedural complications NEC	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications
Laryngeal cancer metastatic	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Familial haemophagocytic lymphohistiocytosis	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Ovarian cancer stage I	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer stage II	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer stage III	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer stage IV	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inferior vena cava syndrome	Site specific necrosis and vascular insufficiency NEC	Arteriosclerosis, stenosis, vascular insufficiency and necrosis	Vascular disorders
Metastases to pelvis	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	327 of 551	I

Muscle neoplasm	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroidal haemangioma	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal papillary mucinous neoplasm	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostatic dysplasia	Prostatic signs, symptoms and disorders NEC	Prostatic disorders (excl infections and inflammations)	Reproductive system and breast disorders
Abdominal wall neoplasm benign	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Abdominal wall neoplasm malignant	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Elephantiasis nostras verrucosa	Lymphoedemas	Lymphatic vessel disorders	Vascular disorders
Thyroid cancer stage I	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage II	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage III	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage IV	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eye haemangioma	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eyelid haemangioma	Ocular neoplasms benign	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Corneoconjunctival intraepithelial neoplasia	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	328 of 551	

Transitional cell carcinoma metastatic	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hormone-dependent prostate cancer	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon dysplasia	Gastrointestinal mucosal dystrophies and secretion disorders	Gastrointestinal conditions NEC	Gastrointestinal disorders
Angiogenesis biomarker increased	Cell marker analyses	Cytogenetic investigations	Investigations
Oesophageal papilloma	Upper gastrointestinal neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue cancer recurrent	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural cyst	Pleural conditions NEC	Pleural disorders	Respiratory, thoracic and mediastinal disorders
Partial lung resection	Bronchial and pulmonary therapeutic procedures	Respiratory tract therapeutic procedures	Surgical and medical procedures
Gorham's disease	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Human chorionic gonadotropin increased	Reproductive hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Human chorionic gonadotropin positive	Reproductive hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Vocal cord leukoplakia	Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms)	Upper respiratory tract disorders (excl infections)	Respiratory, thoracic and mediastinal disorders
Salivary gland induration	Salivary gland disorders NEC	Salivary gland conditions	Gastrointestinal disorders
Infected dermal cyst	Skin structures and soft tissue infections	Infections - pathogen unspecified	Infections and infestations
Pancreatic cyst rupture	Cystic pancreatic disorders	Exocrine pancreas conditions	Gastrointestinal disorders
Epstein-Barr virus associated lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	329 of 551	

Metastatic choriocarcinoma	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma metastatic	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage IV	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage III	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage II	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage I	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer metastatic	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma metastatic	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal stromal cancer	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma metastatic	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sinonasal papilloma	Nasal and paranasal sinus neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intravenous leiomyomatosis	Uterine neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	330 of 551	

Phyllodes tumour	Breast neoplasms unspecified malignancy	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic lymphoma kinase gene and nucleophosmin gene fusion overexpression	Acquired gene mutations and other alterations	General system disorders NEC	General disorders and administration site conditions
Hypercalcitoninaemia	Calcium metabolism disorders	Bone, calcium, magnesium and phosphorus metabolism disorders	Metabolism and nutrition disorders
Radiofrequency ablation of oesophagus	Oesophageal therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Benign mesenteric neoplasm	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesenteric neoplasm	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Congenital melanocytic naevus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Benign nipple neoplasm	Breast and nipple neoplasms benign	Breast neoplasms benign (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraneoplastic neurological syndrome	Paraneoplastic syndromes NEC	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acquired thalassaemia	Thalassaemic disorders	Haemoglobinopathies	Blood and lymphatic system disorders
Meniscus cyst	Bone and joint injuries NEC	Bone and joint injuries	Injury, poisoning and procedural complications
Thyroid cancer recurrent	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid crisis	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Haemorrhagic thyroid cyst	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Neuromyotonia	Neuromuscular disorders NEC	Neuromuscular disorders	Nervous system disorders
Peritumoural oedema	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	331 of 551	I

			unspecified (incl cysts and polyps)
Encephalitis autoimmune	Encephalitis NEC	Central nervous system infections and inflammations	Nervous system disorders
Malignant neoplasm of pleura metastatic	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant blue naevus	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Desmoplastic melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spitzoid melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anti-NMDA antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Anti-VGCC antibody positive	Autoimmunity analyses	Immunology and allergy investigations	Investigations
Haemangioma of bone	Bone neoplasms benign (excl cysts)	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal submucosal tumour	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid B-cell lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
White sponge naevus	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Refractory cytopenia with unilineage dysplasia	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pelvic cyst	Pelvis and broad ligament disorders NEC	Uterine, pelvic and broad ligament disorders	Reproductive system and breast disorders
Tonsil cancer metastatic	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	332 of 551	

Urethral melanoma metastatic	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intratumoural aneurysm	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cyst rupture	Benign and malignant breast neoplasms	Breast disorders	Reproductive system and breast disorders
Breast angiosarcoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast angiosarcoma metastatic	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour fistulisation	Oncologic complications and emergencies	Neoplasm related morbidities	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphatic mapping	Vascular imaging procedures NEC	Cardiac and vascular investigations (excl enzyme tests)	Investigations
Skin angiosarcoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vitreous cyst	Ocular cysts and polyps	Ocular neoplasms	Eye disorders
Benign cartilage neoplasm	Cartilage neoplasms benign	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chest wall tumour	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour mixed	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure)	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	333 of 551	

		malignant and unspecified	unspecified (incl cysts and polyps)
Malignant neoplasm of unknown primary site	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biphasic mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Desmoplastic mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioid mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcomatoid mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pericardial mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder adenosquamous carcinoma	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder squamous cell carcinoma	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer recurrent	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatocellular carcinoma	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder neoplasm	Hepatobiliary neoplasms malignancy unspecified	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatobiliary cancer	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	334 of 551	

Hepatobiliary cancer in situ	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Iris melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant sweat gland neoplasm	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hidradenocarcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal proliferative breast lesion	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive lobular breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive papillary breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lobular breast carcinoma in situ	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metaplastic breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine breast tumour	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tubular breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone giant cell tumour malignant	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	335 of 551	

Peripheral primitive neuroectodermal bone tumour	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epididymal cancer	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genital cancer male	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sertoli cell testicular tumour	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spermatocytic seminoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular yolk sac tumour	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genital cancer male in situ	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic meningioma	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic oligodendroglioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric glioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Central nervous system neuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oligoastrocytoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	336 of 551	

Plasma cell myeloma in remission	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma recurrent	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal myxoid chondrosarcoma	Extraskeletal chondrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dedifferentiated liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mixed-type liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myxoid liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleomorphic liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Round cell liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell sarcoma of soft tissue	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant giant cell fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory malignant fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleomorphic malignant fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral primitive neuroectodermal tumour of soft tissue	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Multiple endocrine neoplasia Type 2A	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	337 of 551	

Multiple endocrine neoplasia Type 2	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Multiple endocrine neoplasia Type 1	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Multiple endocrine neoplasia Type 2B	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Adrenal gland cancer	Adrenal neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Familial medullary thyroid cancer	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Prostate interstitial hyperthermia therapy	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Prostate cryoablation	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Clear cell renal cell carcinoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoadjuvant therapy	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Brenner tumour	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell tumour mixed	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian granulosa cell tumour	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian theca cell tumour	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	338 of 551	

Ovarian germ cell teratoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Borderline mucinous tumour of ovary	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Borderline serous tumour of ovary	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian clear cell carcinoma	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian endometrioid carcinoma	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian Sertoli-Leydig cell tumour	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreastatin increased	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Pancreastatin abnormal	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Intravascular lipoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratinising squamous cell carcinoma of nasopharynx	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nonkeratinising carcinoma of nasopharynx	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Undifferentiated nasopharyngeal carcinoma	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdoid tumour	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Optic glioma	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	339 of 551	

Gallbladder papilloma	Hepatobiliary neoplasms benign	Hepatic and biliary neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal squamous cell carcinoma	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of appendix	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Appendix cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous adenocarcinoma of appendix	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Undifferentiated carcinoma of colon	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acinar cell carcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ductal adenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal papillary-mucinous carcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous cystadenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatoblastoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Serous cystadenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acinic cell carcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoid cystic carcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	340 of 551	

Mucoepidermoid carcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleomorphic adenoma	Lip and oral cavity neoplasms benign	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine adenocarcinoma	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large intestine benign neoplasm	Gastrointestinal neoplasms benign NEC	Gastrointestinal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine polyp	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Congenital retinoblastoma	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Anaplastic large-cell lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute undifferentiated leukaemia	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell prolymphocytic leukaemia	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Enteropathy-associated T-cell lymphoma	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lipodermoid tumour	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital malignant neoplasm	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Congenital benign neoplasm	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Hodgkin's disease nodular sclerosis stage II	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis stage I	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal papillary breast neoplasm	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	341 of 551	

		(incl nipple)	unspecified (incl cysts and polyps)
Dermatofibrosarcoma protuberans metastatic	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myeloma cast nephropathy	Nephropathies and tubular disorders NEC	Nephropathies	Renal and urinary disorders
Juvenile angiofibroma	Nasal and paranasal sinus neoplasms benign	Respiratory and mediastinal neoplasms benign (excl mesotheliomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intracranial germ cell tumour	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemophilic pseudotumour	Mass conditions NEC	Tissue disorders NEC	General disorders and administration site conditions
Tumour of ampulla of Vater	Hepatobiliary neoplasms malignancy unspecified	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteofibroma	Bone neoplasms benign (excl cysts)	Skeletal neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain sarcoma	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Radioembolisation	Radiotherapies site unspecified	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Composite lymphoma	Lymphomas unclassifiable malignant	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous carcinoma of vagina	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant connective tissue neoplasm	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Benign genitourinary tract neoplasm	Urinary tract neoplasms benign	Renal and urinary tract neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant genitourinary tract neoplasm	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	342 of 551	I

.

		and unspecified	unspecified (incl cysts and polyps)
Cancer surgery	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Prostate ablation	Prostatic therapeutic procedures	Male genital tract therapeutic procedures	Surgical and medical procedures
Gastrointestinal polyp haemorrhage	Benign neoplasms gastrointestinal (excl oral cavity)	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Uterine myoma expulsion	Uterine neoplasms benign	Reproductive neoplasms female benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Computerised tomogram breast abnormal	Reproductive organ and breast imaging procedures	Reproductive organ and breast investigations (excl hormone analyses)	Investigations
Lipoblastoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukostasis syndrome	Leukocytoses NEC	White blood cell disorders	Blood and lymphatic system disorders
Biliary hamartoma	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Colloid brain cyst	Nervous system cysts and polyps	Nervous system neoplasms benign	Nervous system disorders
Large intestinal polypectomy	Large intestine therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Paraneoplastic rash	Rashes, eruptions and exanthems NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Angiomyofibroblastoma	Soft tissue neoplasms benign NEC	Soft tissue neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liver ablation	Hepatic therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Tongue polyp	Benign oral cavity neoplasms	Benign neoplasms gastrointestinal	Gastrointestinal disorders
Carcinoembryonic antigen decreased	Cell marker analyses	Cytogenetic investigations	Investigations
Hyperreactio luteinalis	Ovarian and fallopian tube cysts and neoplasms	Ovarian and fallopian tube disorders	Reproductive system and breast disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	343 of 551	

# 4.12 Overdose adverse events

Preferred term	High level term	High level group term	System organ class
Accidental overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications
Completed suicide	Suicidal and self-injurious behaviour	Suicidal and self-injurious behaviours NEC	Psychiatric disorders
Intentional overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications
Overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications
Suicide attempt	Suicidal and self-injurious behaviour	Suicidal and self-injurious behaviours NEC	Psychiatric disorders
Prescribed overdose	Overdoses	Medication errors	Injury, poisoning and procedural complications

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	344 of 551	

# 4.13 Pancreatic carcinoma adverse events

Preferred term	High level term	High level group term	System organ class
Glucagonoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of islets of Langerhans	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma recurrent	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pancreas	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrinoma malignant	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic sarcoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the pancreas	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage 0	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage I	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage II	Pancreatic neoplasms malignant (excl islet cell and	Gastrointestinal neoplasms malignant and	Neoplasms benign, malignant and unspecified (incl cysts

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	345 of 551	

	carcinoid)	unspecified	and polyps)
Pancreatic carcinoma stage III	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage IV	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour metastatic	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Solid pseudopapillary tumour of the pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acinar cell carcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ductal adenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal papillary-mucinous carcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous cystadenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatoblastoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Serous cystadenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	346 of 551	

# 4.14 Pancreatitis adverse events

Preferred term	High level term	High level group term	System organ class
Pancreatic haemorrhage	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatic pseudocyst	Cystic pancreatic disorders	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatic pseudocyst drainage	Pancreatic therapeutic procedures	Gastrointestinal therapeutic procedures	Surgical and medical procedures
Pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatitis acute	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatitis chronic	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatitis haemorrhagic	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatitis mumps	Mumps viral infections	Viral infectious disorders	Infections and infestations
Pancreatitis necrotising	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatitis relapsing	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatic abscess	Abdominal and gastrointestinal infections	Infections - pathogen unspecified	Infections and infestations
Cytomegalovirus pancreatitis	Cytomegaloviral infections	Viral infectious disorders	Infections and infestations
Pancreas infection	Abdominal and gastrointestinal infections	Infections - pathogen unspecified	Infections and infestations
Oedematous pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Pancreatorenal syndrome	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Pancreatic phlegmon	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Hereditary pancreatitis	Pancreatic disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Alcoholic pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	347 of 551	

Pancreatic necrosis	Pancreatic disorders NEC	Exocrine pancreas conditions	Gastrointestinal disorders
Cullen's sign	Purpura and related conditions	Skin vascular abnormalities	Skin and subcutaneous tissue disorders
Pancreatitis helminthic	Helminthic infections NEC	Helminthic disorders	Infections and infestations
Pancreatitis fungal	Fungal infections NEC	Fungal infectious disorders	Infections and infestations
Pancreatitis bacterial	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations
Pancreatitis viral	Viral infections NEC	Viral infectious disorders	Infections and infestations
Ischaemic pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Lupus pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders
Autoimmune pancreatitis	Acute and chronic pancreatitis	Exocrine pancreas conditions	Gastrointestinal disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	348 of 551	ł

# 4.15 Thyroid adverse events

Preferred term	High level term	High level group term	System organ class
Anaplastic thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basedow's disease	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Benign neoplasm of thyroid gland	Thyroid neoplasms benign	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biopsy thyroid gland abnormal	Thyroid histopathology procedures	Endocrine investigations (incl sex hormones)	Investigations
Blood calcitonin abnormal	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Blood calcitonin increased	Gastrointestinal, pancreatic and APUD hormone analyses	Endocrine investigations (incl sex hormones)	Investigations
Blood thyroid stimulating hormone abnormal	Pituitary analyses anterior	Endocrine investigations (incl sex hormones)	Investigations
Blood thyroid stimulating hormone decreased	Pituitary analyses anterior	Endocrine investigations (incl sex hormones)	Investigations
Blood thyroid stimulating hormone increased	Pituitary analyses anterior	Endocrine investigations (incl sex hormones)	Investigations
Butanol-extractable iodine decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Butanol-extractable iodine increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Calcitonin secretion disorder	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Congenital hypothyroidism	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Ectopic calcitonin production	Ectopic endocrine disorders	Neoplastic and ectopic endocrinopathies	Endocrine disorders
Euthyroid sick syndrome	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	349 of 551	I

Exophthalmos	Structural change, deposit and degeneration of eye NEC	Ocular structural change, deposit and degeneration NEC	Eye disorders
Follicular thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gamma radiation therapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Generalised resistance to thyroid hormone	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Goitre	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Goitre congenital	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Hyperthyroidism	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Hypothyroidism	Thyroid hypofunction disorders	Thyroid gland disorders	Endocrine disorders
Iodine uptake abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Iodine uptake decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Iodine uptake increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Lid lag	Eyelid movement disorders	Ocular neuromuscular disorders	Eye disorders
Medullary thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myxoedema	Thyroid hypofunction disorders	Thyroid gland disorders	Endocrine disorders
Papillary thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Photon radiation therapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Primary hypothyroidism	Thyroid hypofunction disorders	Thyroid gland disorders     Endocrine disorders	
Protein bound iodine decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	350 of 551	

Protein bound iodine increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Radioactive iodine therapy	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Secondary hypothyroidism	Thyroid hypofunction disorders	Thyroid gland disorders	Endocrine disorders
Tertiary hypothyroidism	Thyroid hypofunction disorders	Thyroid gland disorders	Endocrine disorders
Thyroid adenoma	Thyroid neoplasms benign	Endocrine neoplasms benign	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid atrophy	Thyroid hypofunction disorders	Thyroid gland disorders	Endocrine disorders
Thyroid cyst	Thyroid neoplasms	Thyroid gland disorders	Endocrine disorders
Thyroid disorder	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Thyroid echinococciasis	Cestode infections	Helminthic disorders	Infections and infestations
Thyroid electron radiation therapy	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Thyroid function test abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroid infarction	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Thyroid neoplasm	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid pain	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Thyroid releasing hormone challenge test abnormal	Hypothalamic analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroid tuberculosis	Tuberculous infections	Mycobacterial infectious disorders	Infections and infestations
Thyroiditis	Acute and chronic thyroiditis	Thyroid gland disorders	Endocrine disorders
Thyroiditis acute	Acute and chronic thyroiditis	Thyroid gland disorders	Endocrine disorders
Thyroiditis chronic	Acute and chronic thyroiditis	Thyroid gland disorders	Endocrine disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	351 of 551	

Thyroiditis fibrous chronic	Acute and chronic thyroiditis	Thyroid gland disorders	Endocrine disorders
Thyroiditis subacute	Acute and chronic thyroiditis	Thyroid gland disorders	Endocrine disorders
Thyrotoxic crisis	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Thyrotoxic periodic paralysis	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Thyroxine abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroxine decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroxine increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Toxic nodular goitre	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Tri-iodothyronine abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine uptake decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine uptake increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
X-ray therapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Autoimmune thyroiditis	Acute and chronic thyroiditis	Thyroid gland disorders	Endocrine disorders
Metastases to thyroid	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Free thyroxine index abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Free thyroxine index decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Free thyroxine index increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroglossal cyst	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	352 of 551	

Thyroxin binding globulin increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroxin binding globulin decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroxin binding globulin abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroid gland abscess	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Thyroglossal cyst infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Thyroxine therapy	Thyroid therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Secondary hyperthyroidism	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Tri-iodothyronine free increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine free decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine free normal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine free abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroglobulin increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroglobulin decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroglobulin present	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroglobulin absent	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroid cancer metastatic	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroxine free abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroxine free decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroxine free increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Thyroid dysfunction in pregnancy	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	353 of 551	I

Thyroid mass	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Hypothyroidic goitre	Thyroid hypofunction disorders	Thyroid gland disorders	Endocrine disorders
Reverse tri-iodothyronine increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Reverse tri-iodothyronine decreased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Anti-thyroid antibody positive	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Anti-thyroid antibody	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Endocrine ophthalmopathy	Structural change, deposit and degeneration of eye NEC	Ocular structural change, deposit and degeneration NEC	Eye disorders
Myxoedema coma	Coma states	Neurological disorders NEC	Nervous system disorders
Ultrasound thyroid abnormal	Endocrine analyses and imaging NEC	Endocrine investigations (incl sex hormones)	Investigations
Radiotherapy to thyroid	Thyroid radiotherapies	Endocrine gland therapeutic procedures	Surgical and medical procedures
Thyroid malformation	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Thyroid operation	Thyroid therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Thyroidectomy	Thyroid therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Thyroid gland scan abnormal	Endocrine analyses and imaging NEC	Endocrine investigations (incl sex hormones)	Investigations
Tri-iodothyronine uptake abnormal	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Congenital hyperthyroidism	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Thyroglossal fistula	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Radiation thyroiditis	Radiation injuries	Injuries by physical agents	Injury, poisoning and procedural complications
Thyroid haemorrhage	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Post procedural hypothyroidism	Endocrine procedural complications	Procedural related injuries and complications NEC	Injury, poisoning and procedural complications

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	354 of 551	

Thyroid therapy	Thyroid therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Thyreostatic therapy	Thyroid therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Huerthle cell carcinoma	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hashitoxicosis	Endocrine autoimmune disorders	Autoimmune disorders	Immune system disorders
Thyroid hormone replacement therapy	Thyroid therapeutic procedures	Endocrine gland therapeutic procedures	Surgical and medical procedures
Thyroid fibrosis	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Marine Lenhart syndrome	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Hashimoto's encephalopathy	Encephalopathies NEC	Encephalopathies	Nervous system disorders
Ectopic thyroid	Thyroid disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Thyroid dermatopathy	Thyroid hyperfunction disorders	Thyroid gland disorders	Endocrine disorders
Thyroid cancer stage 0	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid C-cell hyperplasia	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Thyroid cancer stage I	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage II	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage III	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage IV	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	355 of 551	

Infectious thyroiditis	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Thyroid stimulating immunoglobulin increased	Thyroid analyses	Endocrine investigations (incl sex hormones)	Investigations
Hypercalcitoninaemia	Calcium metabolism disorders	Bone, calcium, magnesium and phosphorus metabolism disorders	Metabolism and nutrition disorders
Orbital decompression	Orbit and globe therapeutic procedures	Eye therapeutic procedures	Surgical and medical procedures
Thyroid cancer recurrent	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemorrhagic thyroid cyst	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Thyroid B-cell lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid size decreased	Thyroid disorders NEC	Thyroid gland disorders	Endocrine disorders
Antithyroid arthritis syndrome	Arthropathies NEC	Joint disorders	Musculoskeletal and connective tissue disorders
Familial medullary thyroid cancer	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	356 of 551	

# 4.16 Transmission adverse events

Preferred term	High level term	High level group term	System organ class
Air-borne transmission	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Bacterial disease carrier	Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Diphtheria carrier	Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Direct infection transmission	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Faecal-oral transmission of infection	Infectious transmissions	Ancillary infectious topics	Infections and infestations
HIV carrier	Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Indirect infection transmission	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Infection transmission via personal contact	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Infection via vaccinee	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Nosocomial infection	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Sexual transmission of infection	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Sexually transmitted disease carrier	Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Typhoid carrier	Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Vector-borne transmission of infection	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Vertical infection transmission	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Viral hepatitis carrier	Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Secondary transmission	Infectious transmissions	Ancillary infectious topics	Infections and infestations
Primary transmission	Infectious transmissions	Ancillary infectious topics	Infections and infestations

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	357 of 551	l

Infectious transmissions	Ancillary infectious topics	Infections and infestations
Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Infectious transmissions	Ancillary infectious topics	Infections and infestations
Infectious transmissions	Ancillary infectious topics	Infections and infestations
Infectious disorders carrier	Ancillary infectious topics	Infections and infestations
Infectious transmissions	Ancillary infectious topics	Infections and infestations
Infectious transmissions	Ancillary infectious topics	Infections and infestations
Infectious transmissions	Ancillary infectious topics	Infections and infestations
	Infectious disorders carrier         Infectious transmissions         Infectious transmissions         Infectious disorders carrier         Infectious transmissions         Infectious transmissions         Infectious transmissions         Infectious transmissions	Infectious disorders carrier       Ancillary infectious topics         Infectious transmissions       Ancillary infectious topics         Infectious transmissions       Ancillary infectious topics         Infectious disorders carrier       Ancillary infectious topics         Infectious transmissions       Ancillary infectious topics

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	358 of 551	

# 4.17 Rare adverse events

Preferred term	High level term	High level group term	System organ class	
11-beta-hydroxylase deficiency	Inborn errors of steroid synthesis	bid synthesis Metabolic and nutritional disorders congenital		
17,20-desmolase deficiency	Inborn errors of steroid synthesis	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
17-alpha-hydroxylase deficiency	Inborn errors of steroid synthesis	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
20,22-desmolase deficiency	Inborn errors of steroid synthesis	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
21-hydroxylase deficiency	Inborn errors of steroid synthesis	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
5-alpha-reductase deficiency	Inborn errors of steroid synthesis	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Abdominal transposition	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Abdominal wall anomaly	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Abnormal palmar/plantar creases	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders	
ABO haemolytic disease of newborn	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Accessory auricle	External ear disorders congenital Ear and labyrinthine disorders congenital		Congenital, familial and genetic disorders	
Accessory carpal bone	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Accessory muscle	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue	Congenital, familial and genetic	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	359 of 551	

		disorders congenital	disorders
Accessory salivary gland	y salivary gland disorders congenital Gastrointestinal tract disorders congenital		Congenital, familial and genetic disorders
Acrodermatitis enteropathica	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Acute hepatic failure	Hepatic failure and associated disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Adrenal insufficiency neonatal	Adrenal disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Aglossia	Tongue disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Agranulocytosis	Neutropenias	White blood cell disorders	Blood and lymphatic system disorders
Albinism	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Alkaptonuria	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Alpha-1 anti-trypsin deficiency	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Alport's syndrome	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Amblyopia congenital	Ocular disorders congenital NEC	Ocular disorders congenital NEC Eye disorders congenital	
Aminoaciduria	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Anal atresia	Anorectal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Anencephaly	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	360 of 551	

			disorders
Aniridia	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Anodontia	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Anomaly of orbit, congenital	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Anophthalmos	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Anorchism	hism Male reproductive tract disorders congenital Reproductive tract and breast disorders congenital		Congenital, familial and genetic disorders
Anotia	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Antithrombin III deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Apert's syndrome	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Aphakia congenital	Lens disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Aplasia	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Aplasia cutis congenita	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Aplastic anaemia	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Arnold-Chiari malformation	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	361 of 551	

Arteriovenous malformation	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Asterixis	Tremor (excl congenital)	Movement disorders (incl parkinsonism)	Nervous system disorders
Ataxia telangiectasia	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Atrial septal defect	Cardiac septal defects congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Autoimmune hepatitis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Basophil count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Benign familial pemphigus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Bicuspid aortic valve	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Birth mark	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Blindness congenital	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Branchial cleft sinus	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Breast malformation	Breast disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Cardiac malposition	Cardiac malpositions congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Carpus curvus	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cataract congenital	Lens disorders congenital	Eye disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	362 of 551

			disorders
Cerebellar hypoplasia	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Cerebral palsy	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Cervical auricle	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cervical rib	Musculoskeletal and connective tissue disorders of trunk congenital (excl spine)	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Chediak-Higashi syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Choanal atresia	Pharyngeal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Chondrodystrophy	Non-site specific cartilage disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Chondroectodermal dysplasia	Non-site specific cartilage disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Chordee	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Chorioretinal degeneration congenital	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Chronic granulomatous disease	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Chronic hepatitis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Cleft lip	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cleft lip and palate	Palate disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic

Novo Nordisk

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final No	ovo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	363 of 551	

			disorders
Cleft palate	Palate disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Clostridium difficile colitis	Clostridia infections	Bacterial infectious disorders	Infections and infestations
Coarctation of the aorta	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Cockayne's syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Collodion baby	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Coloboma	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Colour blindness	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Coma hepatic	Coma states	Neurological disorders NEC	Nervous system disorders
Combined immunodeficiency	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Congenital absence of bile ducts	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Congenital absence of cranial vault	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital absence of vertebra	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital anaemia	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Congenital anomalies of ear ossicles	Ear disorders congenital NEC	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	364 of 551	

Congenital anomaly	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Congenital aortic atresia	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital aortic stenosis	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital aortic valve incompetence	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital aortic valve stenosis	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital arteriovenous fistula	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital bladder diverticulum	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Congenital bladder neck obstruction	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Congenital brain damage	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital bronchiectasis	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital bronchomalacia	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital central nervous system anomaly	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital clavicular agenesis	Musculoskeletal and connective tissue disorders of trunk congenital (excl spine)	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital claw toe	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	365 of 551	

Congenital cleft hand	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital cystic lung	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital cytomegalovirus infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital deformity of clavicle	Musculoskeletal and connective tissue disorders of trunk congenital (excl spine)	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital diaphragmatic eventration	Diaphragmatic disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital diaphragmatic hernia	Diaphragmatic disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital ectodermal dysplasia	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital ectopic bladder	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Congenital elevation of scapula	Musculoskeletal and connective tissue disorders of trunk congenital (excl spine)	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital emphysema	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital flaccid paralysis	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital flat feet	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital genital malformation female	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Congenital hearing disorder	Hearing disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders

	<u>.</u>				
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	366 of 551

Congenital hepatitis B infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital hiatus hernia	Gastric disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital HIV infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital hydrocephalus	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital hypertrichosis	Hair and nail disorders congenital	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital knee dislocation	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital lacrimal gland anomaly	Lacrimal system disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital large intestinal atresia	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital laryngeal stridor	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital lip fistula	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital lymphoedema	Lymphatic system disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Congenital malaria	Protozoal infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital megacolon	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital megaureter	Ureteric disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	367 of 551	

Congenital melanosis	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital methaemoglobinaemia	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Congenital mitral valve incompetence	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital mitral valve stenosis	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital muscle absence	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital nail disorder	Hair and nail disorders congenital	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital neurological degeneration	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital night blindness	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital nystagmus	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital oesophageal stenosis	Oesophageal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital oesophageal web Oesophageal disorders congenital		Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital osteodystrophy	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital perforated nasal septum	Nasal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital pigmentation disorder	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	368 of 551	

Congenital pneumonia	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital rubella infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital salivary gland anomaly	Salivary gland disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital small intestinal atresia	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital spinal fusion	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital spondylolisthesis	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital spondylolysis	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital syphilis	Bacterial infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital syphilitic encephalitis	Bacterial infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital syphilitic meningitis	Bacterial infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital torticollis	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital toxoplasmosis	Protozoal infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital tracheomalacia	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital tricuspid valve stenosis	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	369 of 551	

Congenital tuberculosis	Mycobacterial infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital umbilical hernia	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital urinary tract obstruction	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Congenital varicella infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Congenital vas deferens absence	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Congenital vesicoureteric reflux	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Conjoined twins	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Conjunctivitis gonococcal neonatal	Bacterial infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Cor biloculare	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Cor triatriatum	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Corneal dystrophy	Corneal and scleral disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Corneal opacity congenital	Corneal and scleral disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Corrected transposition of great vessels	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Craniorachischisis	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	370 of 551	

Cri du Chat syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders	
Crigler-Najjar syndrome	Inborn errors of bilirubin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Cryptophthalmos	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders	
Cryptorchism	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Cystic fibrosis	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders	
Cystic fibrosis lung	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders	
Cystic fibrosis pancreatic	Pancreatic disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Cystinosis	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Cystinuria	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Dacryostenosis congenital	Lacrimal system disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders	
Deaf mutism	Hearing disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders	
Deafness congenital	Hearing disorders congenital Ear and la		Congenital, familial and genetic disorders	
Delta-beta thalassaemia	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Dentofacial anomaly	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	371 of 551	

Developmental glaucoma	Anterior and posterior chamber disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Dextrocardia	Cardiac malpositions congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Diaphragmatic aplasia	Diaphragmatic disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Diastematomyelia	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Diencephalic syndrome of infancy	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Diethylstilboestrol syndrome	Chemically-induced congenital syndromes	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Differential white blood cell count abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
DiGeorge's syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Dilatation intrahepatic duct congenital	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Diverticulitis Meckel's	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Diverticulum of pharynx, congenital	Pharyngeal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Double heterozygous sickling disorders	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Double outlet right ventricle	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Double ureter	Ureteric disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	372 of 551	

Duane's syndrome	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Dubin-Johnson syndrome	Inborn errors of bilirubin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Duchenne muscular dystrophy	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Ductus arteriosus stenosis foetal	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Duodenal atresia	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Ear malformation	Ear disorders congenital NEC	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Ebstein's anomaly	cardiac valve disorders congenital Cardiac valve		Congenital, familial and genetic disorders
Ectopia cordis	Cardiac malpositions congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Ectopic ureter	Ureteric disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Ehlers-Danlos syndrome	Connective tissue disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Elliptocytosis hereditary	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Encephalocele	phalocele Central nervous system disorders congenital NEC		Congenital, familial and genetic disorders
Entropion congenital	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Eosinopenia	Leukopenias NEC	White blood cell disorders	Blood and lymphatic system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	373 of 551	

Eosinophil count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Epidermal naevus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders	
Epilepsy congenital	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders	
Epispadias	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Erythroblastosis foetalis	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Essential fructosuria	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Exomphalos	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Eyelid ptosis congenital	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders	
Fabry's disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Factor I deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Factor II deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Factor IX deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Factor VII deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Factor VIII deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	374 of 551	

Factor XI deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Fallot's tetralogy	Multiple cardiac abnormalities congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Familial amyloidosis	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Familial mediterranean fever	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders	
Familial periodic paralysis	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders	
Familial polycythaemia	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Familial tremor	Non-site specific muscle disorders congenital		Congenital, familial and genetic disorders	
Fanconi syndrome	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders	
Febrile neutropenia	Neutropenias	White blood cell disorders	Blood and lymphatic system disorders	
Fibrous dysplasia of bone	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Fissure of tongue, congenital	Tongue disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Foetal alcohol syndrome	drome Chemically-induced congenital syndromes Co.		Congenital, familial and genetic disorders	
Fragile X syndrome	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders	
Friedreich's ataxia	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	375 of 551	

Full blood count abnormal	Blood counts NEC	Haematology investigations (incl blood groups)	Investigations
Full blood count decreased	Blood counts NEC	Haematology investigations (incl blood groups)	Investigations
Galactosaemia	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Gastroenteritis clostridial	Clostridia infections	Bacterial infectious disorders	Infections and infestations
Gastrointestinal arteriovenous malformation	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Gastroschisis	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Gaucher's disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Genitalia external ambiguous	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Gilbert's syndrome	Inborn errors of bilirubin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Glomerulonephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Glomerulonephritis acute	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Glomerulonephritis chronic	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Glomerulonephritis minimal lesion	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Glomerulonephritis rapidly progressive	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Glucose-6-phosphate dehydrogenase deficiency	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Glycogen storage disease type V	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders

		1 -				Maria Mandal
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	376 of 551	

Glycogen storage disease type I	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Gonadal dysgenesis	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Granulocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Granulocytes abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Granulocytopenia	Neutropenias	White blood cell disorders	Blood and lymphatic system disorders
Granulocytopenia neonatal	Neutropenias	White blood cell disorders	Blood and lymphatic system disorders
Granulomatous liver disease	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Haemoglobin C disease	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Hamartoma vascular	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Harlequin foetus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Hartnup disease	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Heart disease congenital	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Hemihypertrophy	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Hemivertebra	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	377 of 551	

Hepatic arteriovenous malformation	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Hepatic atrophy	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic cirrhosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic encephalopathy	Encephalopathies toxic and metabolic	Encephalopathies	Nervous system disorders
Hepatic failure	Hepatic failure and associated disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic fibrosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic necrosis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatic steatosis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatitis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatitis acute	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatitis chronic active	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatitis chronic persistent	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatitis fulminant	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatitis toxic	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepato-lenticular degeneration	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Hepatocellular injury	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatorenal syndrome	Hepatic failure and associated disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hepatotoxicity	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hereditary choroidal dystrophy	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	378 of 551	

Hereditary fructose intolerance	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Hereditary haemorrhagic telangiectasia	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Hereditary neuropathic amyloidosis	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Hereditary optic atrophy	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Hereditary retinal dystrophy	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Hereditary sideroblastic anaemia	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Hereditary spastic paraplegia	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Hereditary spherocytosis	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Hermaphroditism	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Hernia congenital	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital herpes simplex infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Hexokinase deficiency anaemia	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
High arched palate	Palate disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Homocystinuria	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	379 of 551	I

Hydrocele	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Hydronephrosis	Renal obstructive disorders	Renal disorders (excl nephropathies)	Renal and urinary disorders	
Hydroureter	Ureteric disorders NEC	Ureteric disorders	Renal and urinary disorders	
Hypertelorism of orbit	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Hyperthermia malignant	Body temperature altered	Body temperature conditions	General disorders and administration site conditions	
Hypochondroplasia	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Hypopituitarism foetal	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders	
Hypoplastic left heart syndrome	Cardiac hypoplasias congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Hypospadias	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Ichthyosis	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders	
Icterus index increased	Liver function analyses	Hepatobiliary investigations	Investigations	
Ileal atresia	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Immunodeficiency congenital	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders	
Imperforate hymen	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Imperforate oesophagus	Oesophageal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	380 of 551	

Iniencephaly	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Interruption of aortic arch	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Intestinal transposition	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Ischaemic hepatitis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Jaundice hepatocellular	Cholestasis and jaundice	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Keratosis follicular	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Kidney duplex	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Kidney malformation	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Klinefelter's syndrome	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Klippel-Feil syndrome	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Krabbe's disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Lacrimal punctum agenesis	Lacrimal system disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Laryngeal web	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Laryngocele	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Lens abnormality, congenital	Lens disorders congenital	Eye disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nor	disk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	381 of 551	

			disorders
Leukodystrophy	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Lichen spinulosus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Limb malformation	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Limb reduction defect	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Lipidosis	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Liver disorder	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Liver transplant	Hepatic therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Low set ears	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Lupoid hepatic cirrhosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Lymphocyte count abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Lymphocytopenia neonatal	Leukopenias NEC	White blood cell disorders	Blood and lymphatic system disorders
Macrocheilia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Macrodactyly	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Macrogenia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	382 of 551	

Macroglossia	Tongue disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Macrostomia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Macrotia	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Macular dystrophy congenital	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Malformation biliary	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Malformation venous	Venous disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Maple syrup disease	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Marfan's syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Megakaryocytes decreased	Bone marrow and immune tissue histopathology procedures	Haematology investigations (incl blood groups)	Investigations
Melkersson-Rosenthal syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Meningocele	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Meningomyelocele	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Menkes' syndrome	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Metatarsus primus varus	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	383 of 551	

Microcephaly	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Microcheilia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Microgenia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Microglossia	Tongue disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Micrognathia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Microphthalmos	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Microstomia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Microtia	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Mitochondrial myopathy	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Moebius II syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Monocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Monocytopenia	Leukopenias NEC	White blood cell disorders	Blood and lymphatic system disorders
Morning glory syndrome	Optic nerve and optic disc disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Mucopolysaccharidosis	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	384 of 551	1

Mucopolysaccharidosis IV	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Multiple carboxylase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Multiple cardiac defects	Multiple cardiac abnormalities congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Multiple congenital abnormalities	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Multiple epiphyseal dysplasia	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Multiple gastrointestinal atresias	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Muscular dystrophy	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Mutagenic effect	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders	
Myeloid maturation arrest	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders	
Myotonia congenita	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Nephritis haemorrhagic	Nephritis NEC	Nephropathies	Renal and urinary disorders	
Nephritis radiation	Radiation injuries	Injuries by physical agents	Injury, poisoning and procedural complications	
Nephrotic syndrome	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders	
Neuroleptic malignant syndrome	Muscle tone abnormal	Neuromuscular disorders	Nervous system disorders	
Neutropenia	Neutropenias	White blood cell disorders	Blood and lymphatic system disorders	

		-		~		N
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	385 of 551	

Neutropenia neonatal			Blood and lymphatic system disorders
Neutrophil count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Niemann-Pick disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Noonan syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Oesophageal atresia	Oesophageal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Osteogenesis imperfecta	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Osteopetrosis	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Osteopoikilosis	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Ovarian agenesis	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Pancytopenia	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Patent ductus arteriosus	Persistent foetal circulation disorders	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Pectus carinatum	Musculoskeletal and connective tissue disorders of trunk congenital (excl spine)	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Pectus excavatum	Musculoskeletal and connective tissue disorders of trunk congenital (excl spine)	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Pelvi-ureteric obstruction	Renal obstructive disorders	Renal disorders (excl nephropathies)	Renal and urinary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	386 of 551	

Pelvic fibrosis	Fibrosis NEC	Tissue disorders NEC	General disorders and administration site conditions
Pelvic kidney	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Peroneal muscular atrophy	Peripheral nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Persistent foetal circulation	Persistent foetal circulation disorders	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Phenylketonuria	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Phimosis	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Pierre Robin syndrome	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Plasma cells absent	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Platelet maturation arrest	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Platelet production decreased	Thrombocytopenias	Platelet disorders	Blood and lymphatic system disorders
Poland's syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Polydactyly	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Porencephaly	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Porokeratosis	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	387 of 551	1

Porphyria	Inborn errors of porphyrin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Porphyria acute	Inborn errors of porphyrin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Porphyria non-acute	Inborn errors of porphyrin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Porphyrinuria	Inborn errors of porphyrin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Portal hypertension	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders	
Post streptococcal glomerulonephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders	
Postauricular fistula	Ear disorders congenital NEC	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders	
Potter's syndrome	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders	
Prader-Willi syndrome	Neurological disorders congenital NEC         Neurological		Congenital, familial and genetic disorders	
Preauricular cyst	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Primary cerebellar degeneration	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders	
Progeria	Congenital disorders NEC Congenital and hereditary disorders NEC		Congenital, familial and genetic disorders	
Progressive cerebellar degeneration	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders	
Progressive external ophthalmoplegia	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders	
Pseudohermaphroditism	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders	Congenital, familial and genetic	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	388 of 551	

		congenital	disorders
Pseudohermaphroditism female	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Pseudohermaphroditism male	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Pseudohypoparathyroidism	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Pseudomembranous colitis	Clostridia infections	Bacterial infectious disorders	Infections and infestations
Pseudoxanthoma elasticum	Connective tissue disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Pulmonary aplasia	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Pulmonary arteriovenous fistula	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Pulmonary artery atresia	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Pulmonary artery stenosis congenital	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Pulmonary hypoplasia	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Pulmonary malformation	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Pulmonary valve stenosis congenital	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Pyloric stenosis	Gastric disorders congenital Gastrointestinal tract disorders co		Congenital, familial and genetic disorders
Pyruvate kinase deficiency anaemia	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	389 of 551	ļ

		congenital	disorders
Radioulnar synostosis	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Rectal atresia	Anorectal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Refsum's disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Renal arteriovenous malformation	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Renal dysplasia	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Renal vessel congenital anomaly	Vascular anomalies congenital NEC	ngenital NEC Cardiac and vascular disorders congenital	
Respiratory tract malformation	Respiratory tract disorders congenital NEC	Respiratory disorders congenital	Congenital, familial and genetic disorders
Retinal anomaly congenital	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Retinal arteriovenous malformation	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Retinitis pigmentosa	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Retinoschisis congenital	Retinal disorders congenital     Eye disorders congenital		Congenital, familial and genetic disorders
Rett's disorder	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Reye's syndrome	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Rhesus haemolytic disease of newborn	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	390 of 551

		congenital	disorders
Rickets familial hypophosphataemic	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Riley-Day syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Rotor's syndrome	Inborn errors of bilirubin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Rubinstein-Taybi syndrome	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Sensory neuropathy hereditary	Peripheral nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Serotonin syndrome	Muscle tone abnormal	Neuromuscular disorders	Nervous system disorders
Sickle cell anaemia	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Sickle cell trait	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Skin hypoplasia	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Skin malformation	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Special senses congenital anomaly	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Spherophakia	Lens disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Spina bifida	Central nervous system disorders congenital NEC	Central nervous system disorders congenital NEC Neurological disorders congenital	
Spina bifida occulta	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Nov	vo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	391 of 551	

			disorders
Spinal muscular atrophy	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Spine malformation	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Strabismus congenital	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Sturge-Weber syndrome	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Supernumerary nipple	Breast disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Syndactyly	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Syringomyelia	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Talipes	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Tay-Sachs disease	Lysosomal storage disorders	Lysosomal storage disorders Metabolic and nutritional disorders congenital	
Teratogenicity	Congenital disorders NEC Congenital and hereditary disorders NEC		Congenital, familial and genetic disorders
Thalassaemia	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Thalassaemia alpha	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Thalassaemia beta	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	392 of 551	

Thalassaemia sickle cell	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Thalassaemia trait	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Tooth discolouration congenital	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Tooth hypoplasia	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Tooth malformation hereditary	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Tourette's disorder	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Tracheo-oesophageal fistula	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Transposition of the great vessels	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Trisomy 11	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Trisomy 13	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Trisomy 21	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Trisomy 22	2 Autosomal chromosomal abnormalities		Congenital, familial and genetic disorders
Truncus arteriosus persistent	Incus arteriosus persistent Great vessel disorders congenital		Congenital, familial and genetic disorders
Tuberous sclerosis	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	393 of 551	

Turner's syndrome	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Type II hyperlipidaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Type IIa hyperlipidaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Type IIb hyperlipidaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Umbilical artery hypoplasia	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Umbilical malformation	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Univentricular heart	Cardiac septal defects congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Ureteric dilatation	Ureteric disorders NEC	Ureteric disorders	Renal and urinary disorders
Ureteric obstruction	Ureteric disorders NEC	Ureteric disorders	Renal and urinary disorders
Ureteric stenosis	Ureteric disorders NEC	Ureteric disorders	Renal and urinary disorders
Urethral valves	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Urinary tract malformation	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Vaginal atresia	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Ventricular hypoplasia	Cardiac hypoplasias congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Ventricular septal defect	Cardiac septal defects congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	394 of 551	

Virilism foetal	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Von Willebrand's disease	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Von Hippel-Lindau disease	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
White blood cell count abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Wiskott-Aldrich syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Xeroderma pigmentosum	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
XXXY syndrome	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
XXYY syndrome	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Yellow skin	Dermal and epidermal conditions NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Brain malformation	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Dandy-Walker syndrome	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Limb hypoplasia congenital	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Kyphosis congenital	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Plagiocephaly	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	395 of 551	

Cholaemia	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Wyburn Mason's syndrome	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Sjogren-Larsson syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Schimke immunoosseous dysplasia	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Homocystinaemia	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital dermal sinus	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Accessory kidney	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Congenital cerebellar agenesis	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Keratitis-ichthyosis-deafness syndrome	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Congenital scrotal hypertrophy	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Congenital thymus absence	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Kearns-Sayre syndrome	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Polycystic liver disease	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Congenital kyphoscoliosis	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	396 of 551	

Rib hypoplasia	Musculoskeletal and connective tissue disorders of trunk congenital (excl spine)	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Pachygyria	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Lissencephaly	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Factor V deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Uhl's anomaly	Cardiac hypoplasias congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital hyperextension of spine	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital hyperextension of knee	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Angelman's syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Congenital limb hyperextension	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Camptodactyly congenital	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Erythrokeratodermia variabilis	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital adrenal gland hypoplasia	Adrenal disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Cohen syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Renal hypoplasia	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	397 of 551	

Neutropenic sepsis	Sepsis, bacteraemia, viraemia and fungaemia NEC	Infections - pathogen unspecified	Infections and infestations
Red blood cell enzymes abnormal	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Adactyly	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Aorta hypoplasia	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Mitral valve hypoplasia	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Phalangeal hypoplasia	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Monopodia	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Blepharophimosis congenital	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Ankyloglossia congenital	Tongue disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Hypersplenism congenital	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Scaphocephaly	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Werner's syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Congenital facial nerve hypoplasia	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Oedema due to hepatic disease	Oedema NEC	General system disorders NEC	General disorders and administration site conditions

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	398 of 551	

Williams syndrome	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital tricuspid valve atresia	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Accessory breast	Breast disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Single umbilical artery	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Thanatophoric dwarfism	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Achromotrichia congenital	Hair and nail disorders congenital	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Craniosynostosis	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Hypophosphatasia	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital pyelocaliectasis	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Ductus arteriosus premature closure	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Panmyelopathy	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Pseudotruncus arteriosus	Cardiovascular disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Lipomeningocele	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Macrocephaly	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	399 of 551	

Carnitine palmitoyltransferase deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital labia pudendi adhesions	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Beckwith-Wiedemann syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Wolf-Hirschhorn syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Granulocytes maturation arrest	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Holt-Oram syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Leukopenia neonatal	Neonatal haematologic disorders (excl blood incompatibility)	Neonatal and perinatal conditions	Pregnancy, puerperium and perinatal conditions
Langer-Giedion syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Congenital scoliosis	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Exophthalmos congenital	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital pulmonary hypertension	Respiratory tract disorders congenital NEC	Respiratory disorders congenital	Congenital, familial and genetic disorders
Retinopathy congenital Retinal disorders congenital		Eye disorders congenital	Congenital, familial and genetic disorders
Bartter's syndrome	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Naevus spider congenital	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	400 of 551	

Myeloblast count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Congenital hydronephrosis	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Metamyelocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Myelocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Promyelocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Radiation hepatitis	Radiation injuries	Injuries by physical agents	Injury, poisoning and procedural complications
Eagle Barrett syndrome	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Hyper IgE syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Nodular regenerative hyperplasia	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Angiotensin converting enzyme inhibitor foetopathy	Chemically-induced congenital syndromes	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Congenital dysfibrinogenaemia	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Congenital hepatomegaly	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Congenital hydrocele renalis	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Hypermethioniuria	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	401 of 551	

Hypermethioninaemia	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Adrenoleukodystrophy	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Protein S deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Protein C deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
B-lymphocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Congenital hypoparathyroidism	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
T-lymphocyte count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Mitochondrial DNA deletion	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Foetal warfarin syndrome Chemically-induced congenital syndromes		Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Klippel-Trenaunay syndrome	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Mandibulofacial dysostosis	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital multiplex arthrogryposis	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Idiopathic neutropenia	Neutropenias	White blood cell disorders	Blood and lymphatic system disorders
Haemophilia carrier	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	402 of 551	I

Lipid proteinosis	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Pachydermoperiostosis	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Oculocerebrorenal syndrome	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Bone marrow toxicity	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Factor XII deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Tangier disease	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Benign congenital hypotonia	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Oculoauriculovertebral dysplasia	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Scimitar syndrome	Venous disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Trichorhinophalangeal syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Pterygium colli	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Albright's disease Non-site specific bone disorders congenital		Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Neural tube defect Central nervous system disorders congenital NEC		Neurological disorders congenital	Congenital, familial and genetic disorders
Oculopharyngeal dystrophy	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	-	Page:	403 of 551	

Infantile genetic agranulocytosis	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Basophil percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Eosinophil percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Neutrophil percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Myeloblast percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Myelocyte percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Monocyte percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Lymphocyte percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Cerebral atrophy congenital Cerebral disorders congenital		Neurological disorders congenital	Congenital, familial and genetic disorders	
Hepatopulmonary syndrome	Vascular pulmonary disorders NEC	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders	
Renal and liver transplant	Therapeutic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures	
Liver and small intestine transplant Therapeutic procedures NEC		Therapeutic procedures and supportive care NEC	Surgical and medical procedures	
Myocardial bridging	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Keratolysis exfoliativa congenital	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders	

			21.7 2015		<b>D</b> . 1	Neve Neveliels
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	404 of 551	

Kaufman-McKusick syndrome	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Liddle's syndrome	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders	
Ornithine transcarbamoylase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Osteoporosis-pseudoglioma syndrome	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Congenital poikiloderma	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders	
Factor III deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Factor X deficiency	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Dihydropyrimidine dehydrogenase deficiency	Pyrimidine metabolism disorders congenital	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Mitochondrial DNA duplication	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders	
Mitochondrial DNA mutation	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders	
Iris coloboma	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders	
Retinal coloboma	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders	
Congenital pulmonary valve atresia	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Thymus hypoplasia	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0		405 of 551	

Cancer gene carrier	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Amyotrophic lateral sclerosis gene carrier	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Duchenne muscular dystrophy gene carrier	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Cystic fibrosis carrier	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Fragile X carrier	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Macrognathia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Accessory liver lobe	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Oroticaciduria congenital	Pyrimidine metabolism disorders congenital	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital aplastic anaemia	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Olfacto genital dysplasia	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Hydroxyprolinaemia	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital floppy infant	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cyclic neutropenia	Neutropenias	White blood cell disorders	Blood and lymphatic system disorders
Glycogen storage disease type II	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	406 of 551	

Posterior segment of eye anomaly congenital	Anterior and posterior chamber disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Febrile bone marrow aplasia	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Haemoglobin E disease	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Non-alcoholic steatohepatitis	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Glycogen storage disease type VI	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Glycogen storage disease type VII	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Glycogen storage disease type VIII	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Hepatocellular foamy cell syndrome	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Glycogen storage disease type IV	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Glycogen storage disease type III	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Uvula aplasia	Oral cavity disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Cleft uvula	Oral cavity disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital generalised lipodystrophy	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Hereditary stomatocytosis	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Asplenia	Lymphatic system disorders congenital	Blood and lymphatic system disorders	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Nove	o Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	407 of 551	

		congenital	disorders
Cholangiectasis congenital	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Brachycephaly	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cerebrohepatorenal syndrome	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Wolman's disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
B-lymphocyte abnormalities	White blood cell abnormal findings NEC	White blood cell disorders	Blood and lymphatic system disorders
Vaginal hypoplasia	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Alagille syndrome	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Trisomy 8	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
MELAS syndrome	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Congenital oculomotor apraxia	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Greig's syndrome	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Trisomy 18	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Trisomy 17	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders

			01 I 0015		<b>T</b> ' 1	Neve Nevdiels
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	408 of 551	

Congenital syphilitic osteochondritis	Bacterial infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Dentinogenesis imperfecta	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Pilonidal cyst congenital	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Lafora's myoclonic epilepsy	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital bowing of long bones	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Clostridium difficile sepsis	Clostridia infections	Bacterial infectious disorders	Infections and infestations
Congenital aural fistula	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Clostridium difficile infection	Clostridia infections	Bacterial infectious disorders	Infections and infestations
Lymphangiectasia intestinal congenital	Lymphatic system disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
External auditory canal atresia	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Phalangeal agenesis	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Fibula agenesis	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Baltic myoclonic epilepsy	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Aicardi's syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Tracheal atresia	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	409 of 551

			disorders
Hypodontia	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Haemoglobin D disease	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Haemoglobin D trait	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and geneti disorders
Haemoglobin C trait	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and geneti disorders
Anorectal agenesis	Anorectal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and geneti disorders
Androgen insensitivity syndrome	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and geneti disorders
Holoprosencephaly	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and geneti disorders
De Lange's syndrome	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and geneti disorders
Blood incompatibility haemolytic anaemia of newborn	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and geneti disorders
Congenital ureterocele	Ureteric disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and geneti disorders
Cerebral dysgenesis	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and geneti disorders
Haemophilia A without inhibitors	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and geneti disorders
Haemophilia B without inhibitors	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and geneti disorders

		1 -		1 ~		
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final N	lovo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	410 of 551	

Congenital epiblepharon	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital hepatic fibrosis	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
X-linked chromosomal disorder	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Y-linked chromosomal disorder	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Bladder agenesis	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Sacral hypoplasia	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Laurence-Moon-Bardet-Biedl syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Dermatofibrosis lenticularis disseminata	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Mucopolysaccharidosis I	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucopolysaccharidosis II	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucopolysaccharidosis III	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucopolysaccharidosis V	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucopolysaccharidosis VI	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucopolysaccharidosis VII	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	411 of 551	I

XYY syndrome	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Subacute hepatic failure	Hepatic failure and associated disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Congenital ectopic pancreas	Pancreatic disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital cutis laxa	Connective tissue disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Platybasia	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
T-lymphocyte count abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Choroidal coloboma	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital iris anomaly	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Microcornea	Corneal and scleral disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Periodontal congenital anomaly	Dental disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital calyceal diverticulum	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Bone marrow myelogram abnormal	Bone marrow and immune tissue imaging procedures	Haematology investigations (incl blood groups)	Investigations
Chronic hepatic failure	Hepatic failure and associated disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Partial hypoxanthine-guanine phosphoribosyl transferase deficiency	Purine metabolism disorders congenital	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Total hypoxanthine-guanine phosphoribosyl transferase	Purine metabolism disorders congenital	Metabolic and nutritional disorders	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo N	lordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	412 of 551	

deficiency		congenital	disorders
Interferon gamma receptor deficiency	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Central core disease	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Asphyxiating thoracic dystrophy	Non-site specific cartilage disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cyclopia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Encephalocutaneous angiomatosis	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Spinocerebellar ataxia	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Hypotelorism of orbit	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Reproductive tract hypoplasia, male	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Hereditary haemochromatosis	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Congenital choroidal anomaly	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Band neutrophil count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Congenital mitochondrial cytopathy	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Anomalous pulmonary venous connection	Venous disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	413 of 551	

Ocular icterus	Ocular disorders NEC	Eye disorders NEC	Eye disorders	
Otocephaly	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Congenital aortic dilatation	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Branchiogenic syndrome	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Hyperexplexia	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders	
Factor V Leiden mutation	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Carbamoyl phosphate synthetase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Argininosuccinate synthetase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Argininosuccinate lyase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Lysinuric protein intolerance	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Clostridium colitis	Clostridia infections	Bacterial infectious disorders	Infections and infestations	
Hyperprolinaemia	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Eisenmenger's syndrome	Cardiovascular disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Clinodactyly	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Monoblast count decreased	White blood cell analyses	Haematology investigations (incl blood	Investigations	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	414 of 551

		groups)	
Plasmablast count decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Mitochondrial encephalomyopathy	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Bone marrow necrosis	Haematological disorders	Haematological disorders NEC	Blood and lymphatic system disorders
Clostridium bacteraemia	Clostridia infections	Bacterial infectious disorders	Infections and infestations
Congenital thrombocyte disorder	ongenital thrombocyte disorder Coagulation disorders congenital Blood and lym congenital		Congenital, familial and genetic disorders
Nephritis autoimmune	Nephritis NEC	Nephropathies	Renal and urinary disorders
Bicytopenia	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Rathke's cleft cyst	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Diabetic foetopathy	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Becker's muscular dystrophy	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Band neutrophil percentage decreased	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Congenital visual acuity reduced	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital eye disorder	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Pulmonary sequestration	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	415 of 551	

Familial hypertriglyceridaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Anterior chamber cleavage syndrome	Anterior and posterior chamber disorders congenital	exterior chamber disorders congenital Eye disorders congenital	
Fallot's pentalogy	Multiple cardiac abnormalities congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Macrocornea	nea Corneal and scleral disorders congenital Eye disorders congenital		Congenital, familial and genetic disorders
Testicular dysplasia	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Sarcosinaemia	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Caudal regression syndrome	ression syndrome Musculoskeletal and connective tissue disorders of spine disorders congenital Musculoskeletal and connective disorders congenital		Congenital, familial and genetic disorders
Mitochondrial DNA depletion	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Platelet toxicity	Platelet disorders NEC	Platelet disorders	Blood and lymphatic system disorders
Neutropenic infection	Infections NEC	Infections - pathogen unspecified	Infections and infestations
Congenital genital malformation male	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Methylmalonic aciduria	onic aciduria Inborn errors of amino acid metabolism Metabolic and nu congenital		Congenital, familial and genetic disorders
Dubowitz syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Preduodenal portal vein	Venous disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	416 of 551	

Persistent urogenital sinus	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Bruton's agammaglobulinaemia	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders	
Congenital nephrotic syndrome	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders	
Congenital hypogammaglobulinaemia	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders	
Type I hyperlipidaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Type III hyperlipidaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Type IV hyperlipidaemia     Inborn errors of lipid metabolism		Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Type V hyperlipidaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Laryngomalacia	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders	
Hollow visceral myopathy	athy Intestinal disorders congenital Gastr		Congenital, familial and genetic disorders	
Benign familial haematuria	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders	
Haemoglobinopathy	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Hereditary haemolytic anaemia	Anaemias congenital (excl haemoglobinopathies)	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Foetal malformation	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	417 of 551	

Anomaly of middle ear congenital	Ear disorders congenital NEC	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Autosomal chromosome anomaly	osomal chromosome anomaly Autosomal chromosomal abnormalities Chromosomal abnormalities and abnormal gene carriers		Congenital, familial and genetic disorders
Basophil count abnormal	phil count abnormal White blood cell analyses Haematology investigations (incl blood groups)		Investigations
Carbohydrate metabolism disorder			Congenital, familial and genetic disorders
Clostridial infection	Clostridia infections	Bacterial infectious disorders	Infections and infestations
Eye anterior chamber congenital anomaly	e anterior chamber congenital anomaly Anterior and posterior chamber disorders congenital Eye disorders congenital		Congenital, familial and genetic disorders
Congenital aortic anomaly	Great vessel disorders congenital Cardiac and vascular disorders congenital		Congenital, familial and genetic disorders
Congenital bladder anomaly	ngenital bladder anomaly Bladder disorders congenital Renal and urinary tract disord congenital		Congenital, familial and genetic disorders
Congenital cardiovascular anomaly	Cardiovascular disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital corneal anomaly	Corneal and scleral disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital coronary artery malformation	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital diaphragmatic anomaly	Diaphragmatic disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital fallopian tube anomaly	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Congenital gastric anomaly	Gastric disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	418 of 551	

Congenital hair disorder	Hair and nail disorders congenital	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital hepatobiliary anomaly	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Congenital intestinal malformation	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital knee deformity	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital oesophageal anomaly	Congenital oesophageal anomaly     Oesophageal disorders congenital     Gastrointestinal tract disorders congenital		Congenital, familial and genetic disorders
Congenital oral malformation	Oral cavity disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital ovarian anomaly	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Congenital pancreatic anomaly	Pancreatic disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital pharyngeal anomaly	Pharyngeal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital pulmonary artery anomaly	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital pulmonary valve disorder	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital spinal cord anomaly	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital tongue anomaly	Tongue disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Congenital ureteric anomaly	Ureteric disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	419 of 551	

Congenital uterine anomaly	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Congenital great vessel anomaly	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital vitreous anomaly Anterior and posterior chamber disorders congenitat		Eye disorders congenital	Congenital, familial and genetic disorders
Congenital white blood cell disorder	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Eosinophil count abnormal	sinophil count abnormal White blood cell analyses Haematology investigations (incl blood groups)		Investigations
Congenital eyelid malformation	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Gallbladder anomaly congenital	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Haematotoxicity	Haematological disorders	Haematological disorders NEC	Blood and lymphatic system disorders
Hereditary cerebral degeneration	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Hereditary disorder	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Monocyte count abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations
Neutrophil count abnormal         White blood cell analyses		Haematology investigations (incl blood groups)	Investigations
Porphyrin metabolism disorder	Inborn errors of porphyrin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
White blood cell disorder	White blood cell abnormal findings NEC	White blood cell disorders	Blood and lymphatic system disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	420 of 551	

Dermatoglyphic anomaly	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Sex chromosome abnormality	Sex chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Congenital optic nerve anomaly	Optic nerve and optic disc disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital scleral disorder	Corneal and scleral disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital pseudarthrosis	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Telangiectasia congenital	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Blood disorder	Haematological disorders	Haematological disorders NEC	Blood and lymphatic system disorders
Gastrointestinal malformation	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Adrenogenital syndrome	Adrenal disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Asymptomatic gene carrier	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Bone marrow disorder	Haematological disorders	Haematological disorders NEC	Blood and lymphatic system disorders
Chromosomal deletion	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Chromosomal mutation	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Gastrointestinal disorder congenital	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	421 of 551	

Glycogen storage disorder	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Haemophilia	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Hepatic lesion	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Inborn error of bilirubin metabolism	Inborn errors of bilirubin metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Inborn error of metabolism	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Intestinal atresia	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Liver operation	Hepatic therapeutic procedures	Hepatobiliary therapeutic procedures	Surgical and medical procedures
Plasma cell disorder White blood cell abnormal findings NEC		White blood cell disorders	Blood and lymphatic system disorders
Septum pellucidum agenesis	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Silver-Russell syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital arterial malformation	Arterial disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital endocrine anomaly	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Congenital epiglottal anomaly	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital Eustachian tube anomaly	Ear disorders congenital NEC	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Congenital foot malformation	Musculoskeletal and connective tissue disorders of limbs	Musculoskeletal and connective tissue	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	422 of 551

congenital	disorders congenital	disorders
Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Lacrimal system disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Ear disorders congenital NEC	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Adrenal disorders congenital	Endocrine disorders congenital	Congenital, familial and genetic disorders
Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Infections congenital NEC	Infections and infestations congenital	Congenital, familial and genetic disorders
Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
	Reproductive tract disorders congenital NEC         Renal and urinary tract disorders congenital NEC         Musculoskeletal and connective tissue disorders of limbs congenital         Musculoskeletal and connective tissue disorders of face, neck and jaw congenital         Musculoskeletal disorders congenital NEC         Lacrimal system disorders congenital         External ear disorders congenital         Ear disorders congenital NEC         Adrenal disorders congenital         Vascular anomalies congenital NEC         Infections congenital NEC         Musculoskeletal disorders congenital NEC	Reproductive tract disorders congenital NECReproductive tract and breast disorders congenitalRenal and urinary tract disorders congenital NECRenal and urinary tract disorders congenitalMusculoskeletal and connective tissue disorders of limbs congenitalMusculoskeletal and connective tissue 

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	423 of 551	

Congenital neuropathy	Peripheral nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital nose malformation	Nasal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Skull malformation	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital urethral anomaly	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Spleen malformation	Lymphatic system disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Congenital myopathy	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Lowry-Wood syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Accessory navicular syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Pseudocholinesterase deficiency	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Arginase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital carnitine deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Trisomy 15	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Congenital dyskeratosis	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Stargardt's disease	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	424 of 551	

Basal cell naevus syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Multiple lentigines syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Gitelman's syndrome	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Netherton's syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Haemoglobin E-thalassaemia disease	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Spondyloepiphyseal dysplasia	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Mitochondrial hepatopathy	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Neuropathy, ataxia, retinitis pigmentosa syndrome	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Pearson's syndrome	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Optic nerve hypoplasia	Optic nerve and optic disc disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Alpers' disease	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Laryngo-onycho-cutaneous syndrome	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Kinematic imbalances due to suboccipital strain	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Ectopic kidney	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	425 of 551	

Cryptogenic cirrhosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders		
Uterine cervix hypoplasia	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders		
Uterine hypoplasia	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders		
Lymphocyte percentage abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations		
Wagner's disease	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders		
Usher's syndrome	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders		
Stickler's syndrome	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders		
Lumbarisation	sation Musculoskeletal and connective tissue disorders of spine du		Congenital, familial and genetic disorders		
Aase syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders		
Nail-patella syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders		
Tyrosinaemia	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders		
Hereditary areflexic dystasia	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders		
Congenital androgen deficiency	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders		
Schinzel-Giedion syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders		

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	426 of 551	

Congenital coagulopathy	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Testotoxicosis	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Young's syndrome	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Oculodentodigital dysplasia	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Congenital anomaly in offspring	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Bicuspid pulmonary valve	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Aorticopulmonary septal defect	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Haemoglobin E trait	Haemoglobinopathies congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders	
Atrioventricular septal defect	Cardiac septal defects congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Arachnodactyly	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Dolichocolon	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Kabuki make-up syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Phytosterolaemia	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Fallot's trilogy	Multiple cardiac abnormalities congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan         UTN: U111-1136-4716           Trial ID: NN9924-3790         EudraCT No.: 2012-004994-16	Date: Version:	21 January 2015 1.0		Final 427 of 551	Novo Nordisk
---	-------------------	------------------------	--	---------------------	--------------

Cardiac septal defect	Cardiac septal defects congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Intestinal malrotation	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Foetal chromosome abnormality	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
CHARGE syndrome	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Congenital heart valve disorder	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Facioscapulohumeral muscular dystrophy	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Amniotic band syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Foramen magnum stenosis	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cholestatic pruritus	Pruritus NEC	Epidermal and dermal conditions	Skin and subcutaneous tissue disorders
Parachute mitral valve	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Persistent left superior vena cava	Venous disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Blood count abnormal	Blood counts NEC	Haematology investigations (incl blood groups)	Investigations
Sotos' syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Vaginal septum	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	428 of 551	

Femoral retroversion	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Tibial torsion	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Femoral anteversion	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Umbilical cord haemorrhage	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Chronic infantile neurological cutaneous and articular syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Muckle-Wells syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Familial cold autoinflammatory syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Gene mutation	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Marcus Gunn syndrome	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Bronchogenic cyst	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Haemorrhagic arteriovenous malformation	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Berdon's syndrome	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Renal aplasia	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Congenital lenticonus	Lens disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	429 of 551	

Hepatic infiltration eosinophilic	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Graft versus host disease in liver	Immune and associated conditions NEC	Immune disorders NEC	Immune system disorders
Primary immunodeficiency syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Urethral atresia	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Anomalous arrangement of pancreaticobiliary duct	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Preternatural anus	Anorectal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Sacralisation	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Penoscrotal fusion	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Hypoplastic right heart syndrome	Cardiac hypoplasias congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Weill-Marchesani syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Factor II mutation	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Membranous lipodystrophy	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mayer-Rokitansky-Kuster-Hauser syndrome	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Mitochondrial neurogastrointestinal encephalopathy	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Prominent epicanthal folds	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final <b>No</b>	ovo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	430 of 551	

			disorders
Hepatic calcification	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Ocular albinism	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Craniotabes	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Coagulation factor mutation	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Bone marrow failure	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Mount-Reback syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Left ventricle outflow tract obstruction	Cardiovascular disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
VACTERL syndrome	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Dysmorphism	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital aqueductal stenosis	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Urachal abnormality	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Distichiasis	Eyelid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Hyper IgM syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final No.	ovo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	431 of 551	

			disorders
Congenital central hypoventilation syndrome	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Metaphyseal dysplasia	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Vertical talus	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Acute graft versus host disease in liver	Immune and associated conditions NEC	Immune disorders NEC	Immune system disorders
Sucrase-isomaltase deficiency	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Glucose-galactose malabsorption	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Velo-cardio-facial syndrome	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Foetal anticonvulsant syndrome	Chemically-induced congenital syndromes	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Hepatic encephalopathy prophylaxis	Prophylactic procedures NEC	Therapeutic procedures and supportive care NEC	Surgical and medical procedures
Mixed liver injury	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Li-Fraumeni syndrome	Abnormal gene carriers	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Heterochromia iridis	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Mitral valve atresia	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Aortic valve atresia	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	432 of 551	

Shone complex	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Sertoli-cell-only syndrome	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Periventricular nodular heterotopia	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital renal disorder	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Vertebral artery hypoplasia	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Congenital condyloma	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
Craniofacial dysostosis	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Vitello-intestinal duct remnant	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Familial hemiplegic migraine	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Liver injury	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Buried penis syndrome	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Faciodigitogenital dysplasia	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Septo-optic dysplasia	Optic nerve and optic disc disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital abdominal hernia	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	433 of 551	

Naevus flammeus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders	
Heterotaxia	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Portopulmonary hypertension	Pulmonary hypertensions	Pulmonary vascular disorders	Respiratory, thoracic and mediastinal disorders	
Penoscrotal transposition	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Retrograde portal vein flow	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders	
Radiation leukopenia	Radiation injuries	Injuries by physical agents	Injury, poisoning and procedural complications	
Hepatic hydrothorax	Pneumothorax and pleural effusions NEC	Pleural disorders	Respiratory, thoracic and mediastinal disorders	
Costello syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Right aortic arch	Great vessel disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders	
Cloacal exstrophy	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Cytogenetic abnormality	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders	
Dysmyelination	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Canavan disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Metachromatic leukodystrophy	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	434 of 551	ł

Pelizaeus-Merzbacher disease	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Uterine aplasia	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Beta ketothiolase deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mitochondrial enzyme deficiency	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Focal segmental glomerulosclerosis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Congenital skin disorder	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Tumour necrosis factor receptor-associated periodic syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Splenic varices	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders
Arcuate foramen	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Nijmegen breakage syndrome	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Benign familial neonatal convulsions	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Immunotactoid glomerulonephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Kidney malrotation	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Congenital tricuspid valve incompetence	Cardiac valve disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Shwachman-Diamond syndrome	Pancreatic disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final N	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	435 of 551	

			disorders
Cholestatic liver injury	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Renal fusion anomaly	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Pure white cell aplasia	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders
Chimerism	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Mosaicism	Chromosomal abnormalities NEC	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Accessory spleen	Lymphatic system disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Congenital ureterovesical junction anomaly	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Aspartylglucosaminuria	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Trimethylaminuria	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Cystic fibrosis related diabetes	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Fibrillary glomerulonephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Cystic fibrosis hepatic disease	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders
Congenital nephrogenic diabetes insipidus	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Microencephaly	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	436 of 551	

Congenital inguinal hernia	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Femur-fibula-ulna complex	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Septate hymen	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Microvillous inclusion disease	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Pulmonary renal syndrome	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
18q minus syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Bacterascites	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations
Congenital oxalosis	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Bulbospinal muscular atrophy congenital	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Hepatitis virus-associated nephropathy	Hepatitis viral infections	Viral infectious disorders	Infections and infestations
Platyspondylia	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Dowling-Degos disease	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Splenic varices haemorrhage	Spleen disorders	Spleen, lymphatic and reticuloendothelial system disorders	Blood and lymphatic system disorders
Liver sarcoidosis	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Ductus venosus agenesis	Venous disorders congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	437 of 551	

Familial hypocalciuric hypercalcaemia	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Umbilical haematoma	Gastrointestinal tract disorders congenital NEC	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Fibrodysplasia ossificans progressiva	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Alstroem syndrome	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Sticky platelet syndrome	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Metabolic myopathy	Inborn errors of carbohydrate metabolism (excl glucose)	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Cobb syndrome	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Olmsted syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Gnathoschisis	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Cryopyrin associated periodic syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Myotonic dystrophy	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Tubulointerstitial nephritis and uveitis syndrome	Nephritis NEC	Nephropathies	Renal and urinary disorders
Cutaneovisceral angiomatosis with thrombocytopenia	Vascular anomalies congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Laryngeal cleft	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	438 of 551	ĺ

Tetrahydrobiopterin deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital myopia	Ocular disorders congenital NEC	Eye disorders congenital	Congenital, familial and genetic disorders
Dent's disease	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Waardenburg syndrome	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Naevus anaemicus	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Hereditary neuropathy with liability to pressure palsies	Peripheral nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Chiari network	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Wildervanck syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Rippling muscle disease	Non-site specific muscle disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Pancreas divisum	Pancreatic disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Persistent cloaca	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Acrokeratosis verruciformis	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Azygos lobe	Pulmonary and bronchial disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital monorchidism	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	439 of 551	

Autoimmune lymphoproliferative syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Cartilage-hair hypoplasia	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Molybdenum cofactor deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Nasopharyngeal atresia	Pharyngeal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Primary ciliary dyskinesia	Respiratory tract disorders congenital NEC	Respiratory disorders congenital	Congenital, familial and genetic disorders
Norrie's disease	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Congenital cranial nerve paralysis	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Os trigonum	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Myoclonic epilepsy and ragged-red fibres	Genetic mitochondrial abnormalities NEC	Cytoplasmic disorders congenital	Congenital, familial and genetic disorders
Clostridium test positive	Bacteria identification and serology (excl mycobacteria)	Microbiology and serology investigations	Investigations
Penile torsion	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Inherited cardiac conduction disorder	Cardiac disorders congenital NEC	Cardiac and vascular disorders congenital	Congenital, familial and genetic disorders
Methylenetetrahydrofolate reductase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital intrinsic factor deficiency	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	440 of 551	

Sclerotylosis	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Fibrous dysplasia of jaw	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Disorder of sex development	Reproductive tract disorders congenital NEC	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Meier-Gorlin syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Nonketotic hyperglycinaemia	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Cortical dysplasia	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Leber's congenital amaurosis	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Huntington's disease	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
HIV associated nephropathy	Retroviral infections	Viral infectious disorders	Infections and infestations
Acute yellow liver atrophy	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Persistent pupillary membrane	Iris and choroid disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders
Inborn error in primary bile acid synthesis	Inborn errors of steroid synthesis	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Congenital hypercoagulation	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Spina bifida cystica	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Laevocardia	Cardiac malpositions congenital	Cardiac and vascular disorders congenital	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	441 of 551

			disorders
Platelet glycoprotein gene mutation	Coagulation disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Primary insulin like growth factor-1 deficiency	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
N-acetylglutamate synthase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Cystathionine beta-synthase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Branchio-oto-renal syndrome	Ear disorders congenital NEC	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Subependymal nodular heterotopia	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Foetal methotrexate syndrome	Chemically-induced congenital syndromes	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Protuberant ear	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Constricted ear deformity	External ear disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Thalidomide embryopathy	Chemically-induced congenital syndromes	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Diabetic hepatopathy	Hepatic and hepatobiliary disorders NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Hereditary motor neurone disease	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Biotinidase deficiency	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Acetylcholinesterase deficiency	Inborn errors of metabolism NEC	Metabolic and nutritional disorders	Congenital, familial and genetic

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	442 of 551	

		congenital	disorders	
Dyschondrosteosis	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Trisomy 9	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders	
Autoimmune aplastic anaemia	Marrow depression and hypoplastic anaemias	Anaemias nonhaemolytic and marrow depression	Blood and lymphatic system disorders	
Anterior displaced anus	Anorectal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Micropenis	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Thrombocytopenia-absent radius syndrome	mbocytopenia-absent radius syndrome Musculoskeletal and connective tissue disorders of limbs disorders disorders of limbs disorders disorders disorders and connective tissue disorders di		Congenital, familial and genetic disorders	
Acute focal bacterial nephritis	Bacterial infections NEC	Bacterial infectious disorders	Infections and infestations	
Blau syndrome	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Annular pancreas	Pancreatic disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Trisomy 14	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders	
Hermansky-Pudlak syndrome	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Frenulum breve	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders	
Hyper IgD syndrome	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders	
Renal malposition	Renal disorders congenital	Renal and urinary tract disorders	Congenital, familial and genetic	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	443 of 551

		congenital	disorders
Perinephritis	Nephritis NEC	Nephropathies	Renal and urinary disorders
Fatal familial insomnia	Autosomal chromosomal abnormalities	Chromosomal abnormalities and abnormal gene carriers	Congenital, familial and genetic disorders
Congenital haematological disorder	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Craniolacunia	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Hooded prepuce	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Chronic graft versus host disease in liver	Immune and associated conditions NEC	Immune disorders NEC	Immune system disorders
Auditory neuropathy spectrum disorder	Hearing disorders congenital	Ear and labyrinthine disorders congenital	Congenital, familial and genetic disorders
Mevalonic aciduria	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Mevalonate kinase deficiency	Inborn errors of metabolism NEC	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Majeed's syndrome	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Deficiency of the interleukin-1 receptor antagonist	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders
Familial scaphocephaly syndrome	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Drug-induced liver injury	Hepatocellular damage and hepatitis NEC	Hepatic and hepatobiliary disorders	Hepatobiliary disorders

	I	1		L		
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	444 of 551	

Inborn error of lipid metabolism	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
3-hydroxyacetyl-coenzyme A dehydrogenase deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Intracranial lipoma	Central nervous system disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Hand-foot-genital syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Sirenomelia	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Hereditary palmoplantar keratoderma	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Platonychia	Hair and nail disorders congenital	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Adenine phosphoribosyl transferase deficiency	Purine metabolism disorders congenital	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Skeletal dysplasia	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Long-chain acyl-coenzyme A dehydrogenase deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Medium-chain acyl-coenzyme A dehydrogenase deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Short-chain acyl-coenzyme A dehydrogenase deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Very long-chain acyl-coenzyme A dehydrogenase deficiency	Inborn errors of lipid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Extrarenal pelvis	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	445 of 551	

Brachydactyly	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Mucolipidosis type I	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucolipidosis type II	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucolipidosis type III	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucolipidosis type IV	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Mucolipidosis	Lysosomal storage disorders	rs Metabolic and nutritional disorders congenital	
Olfactory nerve agenesis	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Cerebellar dysplasia	Cerebellar disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders
Congenital skin dimples	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Congenital central diabetes insipidus	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Chronic autoimmune glomerulonephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Bloom syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Infantile cortical hyperostosis	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital intestinal obstruction	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	446 of 551	

Portal vein dilatation	Hepatic vascular disorders	Hepatic and hepatobiliary disorders	Hepatobiliary disorders	
Haemochromatosis trait	Hepatobiliary abnormalities congenital	Hepatobiliary disorders congenital	Congenital, familial and genetic disorders	
Kenny-Caffey syndrome	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
White blood cell analysis abnormal	White blood cell analyses	Haematology investigations (incl blood groups)	Investigations	
Twin reversed arterial perfusion sequence malformation	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Microcolon	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	
Hydranencephaly	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders	
Schizencephaly	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders	
Polymicrogyria	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders	
Double cortex syndrome	Cerebral disorders congenital	Neurological disorders congenital	Congenital, familial and genetic disorders	
Triple A syndrome	Autosomal chromosomal abnormalities     Chromosomal abnormal abnormal gene carriers		Congenital, familial and genetic disorders	
Congenital trichomegaly	Hair and nail disorders congenital	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders	
Freeman-Sheldon syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders	
Intestinal neuronal dysplasia	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	447 of 551	

Foetal megacystis	Bladder disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Pulmonary lymphangiectasia	Lymphatic system disorders congenital	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Hypocalvaria	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Severe myoclonic epilepsy of infancy	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Familial renal glycosuria	Renal disorders congenital	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Foetal retinoid syndrome	Chemically-induced congenital syndromes	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders
Developmental hip dysplasia	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Osteopathia striata	Non-site specific bone disorders congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Larsen syndrome	Musculoskeletal and connective tissue disorders of limbs congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
CANDLE syndrome	Skin and subcutaneous tissue disorders congenital NEC	Skin and subcutaneous tissue disorders congenital	Congenital, familial and genetic disorders
Choanal stenosis	Pharyngeal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Proteus syndrome	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Craniofacial deformity	Musculoskeletal and connective tissue disorders of skull congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Congenital high airway obstruction syndrome	Laryngeal and tracheal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	448 of 551	

Ectopic ovary	Female reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Transitional vertebrae	Musculoskeletal and connective tissue disorders of spine congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Mobile caecum syndrome	Intestinal disorders congenital	Gastrointestinal tract disorders congenital	Congenital, familial and genetic disorders
Dysgnathia	Musculoskeletal and connective tissue disorders of face, neck and jaw congenital	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Paranasal sinus aplasia	Nasal disorders congenital	Respiratory disorders congenital	Congenital, familial and genetic disorders
Congenital varicocele	Male reproductive tract disorders congenital	Reproductive tract and breast disorders congenital	Congenital, familial and genetic disorders
Post infection glomerulonephritis	Glomerulonephritis and nephrotic syndrome	Nephropathies	Renal and urinary disorders
Shigella sepsis	Shigella infections	Bacterial infectious disorders	Infections and infestations
Congenital Horner's syndrome	Neurological disorders congenital NEC	Neurological disorders congenital	Congenital, familial and genetic disorders
Neuronal ceroid lipofuscinosis	Lysosomal storage disorders	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Portal fibrosis	Hepatic fibrosis and cirrhosis	Hepatic and hepatobiliary disorders	Hepatobiliary disorders
Methylenetetrahydrofolate reductase gene mutation	Inborn errors of amino acid metabolism	Metabolic and nutritional disorders congenital	Congenital, familial and genetic disorders
Myeloperoxidase deficiency	Immune system abnormalities congenital	Immune system disorders congenital	Congenital, familial and genetic disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	449 of 551	

## 4.18 Renal failure adverse events

Preferred term	High level term	High level group term	System organ class
Acute prerenal failure	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Albuminuria	Urinary abnormalities	Urinary tract signs and symptoms	Renal and urinary disorders
Anuria	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Azotaemia	Renal failure complications	Renal disorders (excl nephropathies)	Renal and urinary disorders
Blood creatinine abnormal	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Blood creatinine increased	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Blood urea abnormal	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Blood urea increased	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Creatinine renal clearance decreased	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Glomerular filtration rate abnormal	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Glomerular filtration rate decreased	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Haemodialysis	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Nephritis	Nephritis NEC	Nephropathies	Renal and urinary disorders
Nephropathy toxic	Nephropathies and tubular disorders NEC	Nephropathies	Renal and urinary disorders
Oliguria	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Peritoneal dialysis	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Proteinuria	Urinary abnormalities	Urinary tract signs and symptoms	Renal and urinary disorders
Renal failure	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	450 of 551	I

Renal failure acute	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal failure neonatal	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Renal transplant	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Renal tubular disorder	Nephropathies and tubular disorders NEC	Nephropathies	Renal and urinary disorders
Renal tubular necrosis	Renal vascular and ischaemic conditions	Renal disorders (excl nephropathies)	Renal and urinary disorders
Urea renal clearance decreased	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Tubulointerstitial nephritis	Nephritis NEC	Nephropathies	Renal and urinary disorders
Oedema due to renal disease	Oedema NEC	General system disorders NEC	General disorders and administration site conditions
Renal impairment neonatal	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Neonatal anuria	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Blood urea nitrogen/creatinine ratio increased	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Haemofiltration	Haematological therapeutic procedures NEC	Haematological and lymphoid tissue therapeutic procedures	Surgical and medical procedures
Protein urine present	Urinalysis NEC	Renal and urinary tract investigations and urinalyses	Investigations
Creatinine urine decreased	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Urine output decreased	Urinary tract function analyses NEC	Renal and urinary tract investigations and urinalyses	Investigations
Dialysis	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures
Renal function test abnormal	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Renal impairment	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Hypercreatininaemia	Metabolic disorders NEC	Metabolism disorders NEC	Metabolism and nutrition disorders
Continuous haemodiafiltration	Renal therapeutic procedures	Renal and urinary tract therapeutic procedures	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	451 of 551	

Creatinine renal clearance abnormal	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Acute phosphate nephropathy	Nephropathies and tubular disorders NEC	Nephropathies	Renal and urinary disorders
Creatinine urine abnormal	Renal function analyses	Renal and urinary tract investigations and urinalyses	Investigations
Crystal nephropathy	Nephropathies and tubular disorders NEC	Nephropathies	Renal and urinary disorders
Prerenal failure	Renal failure and impairment	Renal disorders (excl nephropathies)	Renal and urinary disorders
Intradialytic parenteral nutrition	Dietary and nutritional therapies	Therapeutic procedures and supportive care NEC	Surgical and medical procedures

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	452 of 551	

## 4.19 Malignant tumour adverse events

•

Preferred term	High level term	High level group term	System organ class		
Acral lentiginous melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acral lentiginous melanoma stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acral lentiginous melanoma stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acral lentiginous melanoma stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acral lentiginous melanoma stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute leukaemia	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute lymphocytic leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute lymphocytic leukaemia (in remission)	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute megakaryocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute monocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute monocytic leukaemia (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute myeloid leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)		
Acute myeloid leukaemia (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and		

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	453 of 551	

			unspecified (incl cysts and polyps)
Acute myelomonocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute promyelocytic leukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma gastric	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous carcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell lung cancer stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	454 of 551	

Adenosquamous cell lung cancer stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenocortical carcinoma	Adrenal neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia recurrent	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia refractory	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia stage I	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia stage II	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia stage III	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adult T-cell lymphoma/leukaemia stage IV	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Aesthesioneuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Aleukaemic leukaemia	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alveolar soft part sarcoma	Alveolar soft part sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alveolar soft part sarcoma metastatic	Alveolar soft part sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Alveolar soft part sarcoma recurrent	Alveolar soft part sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	455 of 551	I

Anal cancer recurrent	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage 0	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage I	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage II	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage III	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer stage IV	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic astrocytoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types recurrent	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types refractory	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage I	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage II	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage III	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic large cell lymphoma T- and null-cell types stage IV	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	456 of 551	

Anaplastic thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma recurrent	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma refractory	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage I	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage II	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage III	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric lymphoma stage IV	Angiocentric lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma recurrent	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma refractory	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma stage I	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma stage II	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angioimmunoblastic T-cell lymphoma stage III	Angioimmunoblastic T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	457 of 551	

Angioimmunoblastic T-cell lymphoma stage IV	stic T-cell lymphoma stage IV Angioimmunoblastic T-cell lymphomas Lymphomas non-Hodgkin's T-cell		Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma metastatic	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma recurrent	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Astrocytoma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B precursor type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma recurrent	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma refractory	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage I	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage II	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage III	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell lymphoma stage IV	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	458 of 551	

B-cell small lymphocytic lymphoma recurrent	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma refractory	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage I	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage II	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage III	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell small lymphocytic lymphoma stage IV	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell unclassifiable lymphoma high grade	B-cell unclassifiable lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-cell unclassifiable lymphoma low grade	B-cell unclassifiable lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basosquamous carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basosquamous carcinoma of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct adenocarcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct adenosquamous carcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	459 of 551	

Bile duct cancer	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer recurrent	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct squamous cell carcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage 0	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage I	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder adenocarcinoma stage unspecified	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage 0, with cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage 0, without cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	460 of 551	

Bladder cancer stage I, with cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage I, without cancer in situ	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder cancer stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage 0	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage I	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder squamous cell carcinoma stage unspecified	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone cancer	Bone neoplasms malignant (excl sarcomas)	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	461 of 551	

Bone sarcoma	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bowen's disease	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain neoplasm malignant	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain stem glioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer in situ	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer recurrent	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer stage I	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer stage II	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer stage III	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer stage IV	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchial carcinoma	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma recurrent	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

	1	1 -		l -		
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	462 of 551	

Burkitt's lymphoma refractory	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage I	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage II	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage III	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Burkitt's lymphoma stage IV	Burkitt's lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinogenicity	Poisoning and toxicity	Exposures, chemical injuries and poisoning	Injury, poisoning and procedural complications
Carcinoid tumour	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the appendix	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the caecum	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the gastrointestinal tract	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the prostate	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the stomach	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour pulmonary	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of eye	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	463 of 551	l

Carcinoma in situ of penis	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma in situ of trachea	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Central nervous system lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma recurrent	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma stage I	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma stage II	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma stage III	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma stage IV	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chloroma	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chloroma (in remission)	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholangiocarcinoma	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chondrosarcoma	Cartilage sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	464 of 551	

Chondrosarcoma metastatic	Cartilage sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chondrosarcoma recurrent	Cartilage sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chordoma	Bone neoplasms unspecified malignancy	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choriocarcinoma	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroid melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic leukaemia	Leukaemias chronic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia (in remission)	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia recurrent	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia refractory	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 0	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 1	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 2	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia stage 3	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	465 of 551	

Chronic lymphocytic leukaemia stage 4	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia (in remission)	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myelomonocytic leukaemia	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myelomonocytic leukaemia (in remission)	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell sarcoma of the kidney	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage I	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	466 of 551	I

Colorectal cancer stage I	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal carcinoma stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma recurrent	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma refractory	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma stage I	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma stage II	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma stage III	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Diffuse large B-cell lymphoma stage IV	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial adenocarcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	467 of 551	

Endometrial cancer metastatic	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer recurrent	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage 0	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage I	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage II	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage III	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer stage IV	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eosinophilic leukaemia	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ependymoma malignant	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioid sarcoma	Epithelioid sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioid sarcoma metastatic	Epithelioid sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioid sarcoma recurrent	Epithelioid sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Erythraemic myelosis (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Erythroleukaemia	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

	1	1 -		1 -		
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	468 of 551	

Ewing's sarcoma	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ewing's sarcoma metastatic	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ewing's sarcoma recurrent	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extra-osseous Ewing's sarcoma	Extraskeletal Ewing's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extra-osseous Ewing's sarcoma metastatic	Extraskeletal Ewing's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extra-osseous Ewing's sarcoma recurrent	Extraskeletal Ewing's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary embryonal carcinoma	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour mixed stage I	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour mixed stage II	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour mixed stage III	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage I	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage II	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage III	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma stage IV	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	469 of 551	

Extragonadal primary seminoma (pure) stage I	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure) stage II	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure) stage III	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure) stage IV	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) recurrent	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) refractory	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) stage I	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) stage II	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) stage III	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type) stage IV	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraocular retinoblastoma	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal chondrosarcoma metastatic	Extraskeletal chondrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal chondrosarcoma recurrent	Extraskeletal chondrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal osteosarcoma	Extraskeletal osteosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	470 of 551	

Extraskeletal osteosarcoma metastatic	Extraskeletal osteosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal osteosarcoma recurrent	Extraskeletal osteosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer metastatic	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage I	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage II	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage III	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fallopian tube cancer stage IV	Fallopian tube neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrosarcoma	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Fibrosarcoma metastatic	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma recurrent	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma refractory	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma stage I	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma stage II	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	471 of 551	ĺ

Follicle centre lymphoma diffuse small cell lymphoma stage III	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma stage IV	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III recurrent	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III refractory	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III stage I	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III stage II	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III stage III	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III stage IV	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicular thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer recurrent	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ganglioglioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ganglioneuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	472 of 551	

Gastric cancer recurrent	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage 0	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage I	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage II	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage III	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal carcinoma	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genital neoplasm malignant female	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma multiforme	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gliosarcoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glottis carcinoma	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glucagonoma	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangiopericytoma	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0		473 of 551	

Haemangiopericytoma of meninges	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hairy cell leukaemia	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatoblastoma recurrent	Hepatoblastomas	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma recurrent	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma refractory	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage I	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage II	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage III	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
High grade B-cell lymphoma Burkitt-like lymphoma stage IV	High grade B-cell lymphomas Burkitt-like lymphoma	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage I site unspecified	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage I subdiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage I supradiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	474 of 551	

Hodgkin's disease lymphocyte depletion stage II site unspecified	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage II subdiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion stage II supradiaphragm	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type recurrent	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type refractory	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type stage III	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type stage IV	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte depletion type stage unspecified	Hodgkin's disease lymphocyte depletion type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage I site unspec	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage I subdiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage I supradiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage II site unspec	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage II subdiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance stage II supradiaphragm	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	475 of 551	

Hodgkin's disease lymphocyte predominance type recurrent	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type refractory	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type stage III	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type stage IV	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease lymphocyte predominance type stage unspecified	Hodgkin's disease lymphocyte predominance type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity recurrent	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity refractory	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage I site unspecified	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage I subdiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage I supradiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage II subdiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage II supradiaphragmatic	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage III	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease mixed cellularity stage IV	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	476 of 551	

Hodgkin's disease mixed cellularity stage unspecified	Hodgkin's disease mixed cellularity type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis recurrent	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis refractory	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis stage III	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease nodular sclerosis stage IV	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease recurrent	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease refractory	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage I	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage II	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage III	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease unclassifiable	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer recurrent	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	477 of 551	

Hypopharyngeal cancer stage 0	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage I	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage II	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage III	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hypopharyngeal cancer stage IV	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory carcinoma of breast recurrent	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory carcinoma of breast stage III	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory carcinoma of breast stage IV	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory carcinoma of the breast	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma recurrent	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma refractory	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma stage I	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma stage II	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal T-cell lymphoma stage III	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	478 of 551	

Intestinal T-cell lymphoma stage IV	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intracranial meningioma malignant	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Juvenile chronic myelomonocytic leukaemia	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Kaposi's sarcoma	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Kaposi's sarcoma AIDS related	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Kaposi's sarcoma classical type	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratoacanthoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	479 of 551	

Laryngeal cancer	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer recurrent	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage 0	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage I	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage II	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage III	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer stage IV	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal squamous cell carcinoma	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyosarcoma metastatic	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leiomyosarcoma recurrent	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna recurrent	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	480 of 551	

Lentigo maligna stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lentigo maligna stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia basophilic	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia granulocytic	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia monocytic	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic lymphoma	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leydig cell tumour of the testis	Reproductive neoplasms male unspecified malignancy	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Linitis plastica	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer recurrent	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage 0	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage I	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage II	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	481 of 551	

Lip and/or oral cavity cancer stage III	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer stage IV	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip neoplasm malignant stage unspecified	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liposarcoma metastatic	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Liposarcoma recurrent	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified recurrent	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	482 of 551	

Lung carcinoma cell type unspecified stage 0	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage I	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage II	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage III	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung carcinoma cell type unspecified stage IV	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphangiosarcoma	Lymphangiosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphocytic leukaemia	Leukaemias lymphocytic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoid leukaemia (in remission)	Leukaemias lymphocytic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	483 of 551	

Lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma AIDS related	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma recurrent	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma refractory	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage I	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage II	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage III	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoplasmacytoid lymphoma/immunocytoma stage IV	Lymphoplasmacytoid lymphomas/immunocytomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma metastatic	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma of bone	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant fibrous histiocytoma recurrent	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant haemangiopericytoma	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	484 of 551	

Malignant haemangiopericytoma metastatic	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant haemangiopericytoma recurrent	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant histiocytosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant hydatidiform mole	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant lymphoma unclassifiable high grade	Lymphomas unclassifiable malignant	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant lymphoma unclassifiable low grade	Lymphomas unclassifiable malignant	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mast cell neoplasm	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma in situ	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma of sites other than skin	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	485 of 551	

Malignant mesenchymoma metastatic	Mesenchymomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mesenchymoma recurrent	Mesenchymomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of ampulla of Vater	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of choroid	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of conjunctiva	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of cornea	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of eye	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of islets of Langerhans	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of lacrimal duct	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of lacrimal gland	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of orbit	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of paraurethral glands	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of placenta	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of pleura	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	486 of 551	

Malignant neoplasm of renal pelvis	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of retina	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of spermatic cord	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of spinal cord	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of thorax	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of uterine adnexa	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant oligodendroglioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant ovarian cyst	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant palate neoplasm	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant pituitary tumour	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant splenic neoplasm	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma recurrent	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma refractory	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma stage I	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	487 of 551	

Mantle cell lymphoma stage II	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma stage III	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma stage IV	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mature B-cell type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medullary carcinoma of breast	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medullary thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medulloblastoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Meningioma malignant	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to abdominal cavity	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to adrenals	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to breast	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	488 of 551	

Metastases to kidney	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to large intestine	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to liver	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lung	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to lymph nodes	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to neck	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to ovary	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pleura	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to skin	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to small intestine	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to spine	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to the mediastinum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic malignant melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mixed hepatocellular cholangiocarcinoma	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	489 of 551	

Mucinous endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides recurrent	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides refractory	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage I	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage II	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage III	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mycosis fungoides stage IV	Mycoses fungoides	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myeloid leukaemia	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal cavity cancer	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasal sinus cancer	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer recurrent	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage 0	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage I	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	490 of 551	

Nasopharyngeal cancer stage II	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage III	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer stage IV	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Natural killer-cell leukaemia	Leukaemias chronic T-cell	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neonatal leukaemia	Haematological disorders congenital NEC	Blood and lymphatic system disorders congenital	Congenital, familial and genetic disorders
Neoplasm malignant	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nephroblastoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma of the skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibrosarcoma metastatic	Neurofibrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibrosarcoma recurrent	Neurofibrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma recurrent	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma refractory	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	491 of 551	1

Nodal marginal zone B-cell lymphoma stage I	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma stage II	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma stage III	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodal marginal zone B-cell lymphoma stage IV	Nodal marginal zone B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nodular melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer recurrent	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage 0	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage I	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage II	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage III	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage IIIA	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage IIIB	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer stage IV	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	492 of 551	

Non-Hodgkin's lymphoma recurrent	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma refractory	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage I	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage II	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage III	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma stage IV	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive recurrent	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive refractory	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage I	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage II	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage III	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive stage IV	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent stage I	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent stage II	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	493 of 551	

Non-Hodgkin's lymphoma unspecified histology indolent stage III	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent stage IV	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma recurrent	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage 0	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage I	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage II	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage III	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma stage IV	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma recurrent	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal carcinoma stage 0	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma recurrent	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage 0	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	494 of 551	

Oesophageal squamous cell carcinoma stage I	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage II	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage III	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma stage IV	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oligodendroglioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer recurrent	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage 0	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage I	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage II	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage III	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal lymphoepithelioma	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal squamous cell carcinoma	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteosarcoma	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	495 of 551	

Osteosarcoma metastatic	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Osteosarcoma recurrent	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer metastatic	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer recurrent	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage I	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage II	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage III	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer stage IV	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	496 of 551	

Ovarian germ cell choriocarcinoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell embryonal carcinoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	497 of 551	

Ovarian germ cell polyembryoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian low malignant potential tumour	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of nipple	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of penis	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paget's disease of the vulva	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancoast's tumour	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma metastatic	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma recurrent	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	498 of 551	

Papillary serous endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Papillary thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paraganglion neoplasm malignant	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm recurrent	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage 0	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage I	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage II	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage III	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm stage IV	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour malignant	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile cancer	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma metastatic	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma recurrent	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma stage I	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	499 of 551	

Penis carcinoma stage II	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma stage III	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penis carcinoma stage IV	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pericardial mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral nerve sheath tumour malignant	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of bone metastatic	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of bone recurrent	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified recurrent	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified refractory	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified stage I	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified stage II	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified stage III	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral T-cell lymphoma unspecified stage IV	Peripheral T-cell lymphomas NEC	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	500 of 551	

Peritoneal mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer recurrent	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage 0	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage I	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage II	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage III	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pharyngeal cancer stage IV	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pineal germinoma	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell leukaemia	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural mesothelioma malignant recurrent	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	501 of 551	I

Postcricoid cancer	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma stage I	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma stage II	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma stage III	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma stage IV	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia recurrent	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia refractory	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage I	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage II	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage III	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor T-lymphoblastic lymphoma/leukaemia stage IV	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	502 of 551	

Primary mediastinal large B-cell lymphoma recurrent	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma refractory	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma stage I	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma stage II	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma stage III	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary mediastinal large B-cell lymphoma stage IV	Primary mediastinal large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prolymphocytic leukaemia	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer metastatic	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer recurrent	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage 0	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage I	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage II	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage III	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer stage IV	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	503 of 551	

Queyrat erythroplasia	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal adenocarcinoma	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage I	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer recurrent	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage I	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage II	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	504 of 551	I

Rectosigmoid cancer stage III	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer stage IV	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Recurrent cancer	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer recurrent	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage I	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage II	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage III	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer stage IV	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma recurrent	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage I	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage II	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage III	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cell carcinoma stage IV	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	505 of 551	

Respiratory tract carcinoma in situ	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retinal melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retinoblastoma	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retroperitoneal cancer	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdoid tumour of the kidney	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdomyosarcoma	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdomyosarcoma recurrent	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer recurrent	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage 0	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage I	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage II	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage III	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer stage IV	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	506 of 551	

Sarcoma of skin	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcoma uterus	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcomatosis	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Scrotal cancer	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Second primary malignancy	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Seminoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin cancer	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell carcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer extensive stage	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer limited stage	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer recurrent	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma metastatic	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	507 of 551	

Small intestine carcinoma recurrent	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spinal meningioma malignant	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma recurrent	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma refractory	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage I	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage II	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage III	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma stage IV	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of lung	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the cervix	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the hypopharynx	Hypopharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	508 of 551	

Squamous cell carcinoma of the oral cavity	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the tongue	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the vagina	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of the vulva	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous endometrial carcinoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage I	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage II	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage III	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage IV	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Superficial spreading melanoma stage unspecified	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Synovial sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Synovial sarcoma metastatic	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Synovial sarcoma recurrent	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell chronic lymphocytic leukaemia	Leukaemias chronic T-cell	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	509 of 551	

T-cell lymphoma	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma recurrent	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma refractory	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage I	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage II	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage III	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell lymphoma stage IV	Anaplastic large cell lymphomas T- and null-cell types	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell prolymphocytic leukaemia	Leukaemias chronic T-cell	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell type acute leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell unclassifiable lymphoma high grade	T-cell unclassifiable lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
T-cell unclassifiable lymphoma low grade	T-cell unclassifiable lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	510 of 551	

Testicular embryonal carcinoma stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular embryonal carcinoma stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular embryonal carcinoma stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure) stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure) stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure) stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular yolk sac tumour stage I	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular yolk sac tumour stage II	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	511 of 551	

Testicular yolk sac tumour stage III	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Throat cancer	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thymoma malignant recurrent	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue neoplasm malignant stage unspecified	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tonsil cancer	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tracheal cancer	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of renal pelvis and ureter metastatic	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter localised	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter recurrent	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell cancer of the renal pelvis and ureter regional	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Transitional cell carcinoma urethra	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Undifferentiated sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	512 of 551	

Ureteric cancer	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer local	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer metastatic	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer recurrent	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ureteric cancer regional	Renal pelvis and ureter neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer metastatic	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral cancer recurrent	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine cancer	Uterine neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine carcinoma in situ	Uterine neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer metastatic	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer recurrent	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	513 of 551	

Vaginal cancer stage 0	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage I	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage II	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage III	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage IVA	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal cancer stage IVB	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer metastatic	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer recurrent	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage 0	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage I	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage II	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage III	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulval cancer stage IV	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	514 of 551	

Waldenstrom's macroglobulinaemia	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia recurrent	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia refractory	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage I	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage II	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage III	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Waldenstrom's macroglobulinaemia stage IV	Waldenstrom's macroglobulinaemias	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial stromal sarcoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spindle cell sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone marrow tumour cell infiltration	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bone marrow leukaemic cell infiltration	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to heart	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to stomach	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pancreas	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	D	515 of 551	

Metastases to bladder	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to thyroid	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to eye	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to placenta	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to uterus	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to fallopian tube	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pituitary gland	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to muscle	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neonatal neuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung cancer metastatic	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer metastatic	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the duodenum	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blast crisis in myelogenous leukaemia	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pinealoblastoma	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	516 of 551	

Metastatic renal cell carcinoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myeloblastoma	Myeloproliferative disorders (excl leukaemias)	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm progression	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to bone marrow	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to chest wall	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to abdominal wall	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to diaphragm	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to Eustachian tube	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to gallbladder	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to larynx	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to mouth	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to nasal sinuses	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to oesophagus	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to penis	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

			<b>21 T 2015</b>		E' 1	Nova Novdiala
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	517 of 551	

Metastases to perineum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peripheral nervous system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peritoneum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pharynx	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to prostate	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to rectum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to retroperitoneum	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to salivary gland	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to spleen	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to testicle	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to thorax	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to trachea	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urinary bladder sarcoma	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to meninges	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	518 of 551	I

Lymphoma cutis	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrinoma malignant	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Phaeochromocytoma malignant	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pseudosarcoma	Neoplasms unspecified malignancy and site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intestinal adenocarcinoma	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal sarcoma	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural sarcoma	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphocytic lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal adenocarcinoma	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration pulmonary	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine tumour	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian dysgerminoma stage unspecified	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	519 of 551	I

Carcinoid tumour of the small bowel	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant nipple neoplasm male	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant nipple neoplasm female	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphangiosis carcinomatosa	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia cutis	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoid cystic carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal cancer metastatic	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Immunoblastic lymphoma	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Blast cell crisis	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Contralateral breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cystadenocarcinoma ovary	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Serous cystadenocarcinoma ovary	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous cystadenocarcinoma ovary	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	520 of 551	ĺ

Malignant pericardial neoplasm	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Disseminated large cell lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic sarcoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoid tumour of the pancreas	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric sarcoma	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ear neoplasm malignant	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain cancer metastatic	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix cancer metastatic	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal gland cancer metastatic	Adrenal neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer metastatic	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oral cavity cancer metastatic	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ocular cancer metastatic	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Otic cancer metastatic	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	521 of 551	

Bone cancer metastatic	Bone neoplasms malignant (excl sarcomas)	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Oesophageal cancer metastatic	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Testicular cancer metastatic	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Pharyngeal cancer metastatic	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Sinus cancer metastatic	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Pituitary cancer metastatic	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Thyroid cancer metastatic	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Thymic cancer metastatic	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Tongue cancer metastatic	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Hepatic cancer metastatic	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Biliary cancer metastatic	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Breast cancer metastatic	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Colon cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Skin cancer metastatic	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	522 of 551	I

Metastases to urinary tract	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian embryonal carcinoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mastocytic leukaemia	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanomatous meningitis	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dermatofibrosarcoma protuberans	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute megakaryocytic leukaemia (in remission)	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Signet-ring cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucoepidermoid carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of auricular cartilage	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular leiomyosarcoma	Leiomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic carcinoma of the bladder	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian granulosa-theca cell tumour	Female reproductive neoplasms unspecified malignancy	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	523 of 551	

Ocular haemangiopericytoma	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epiglottic carcinoma	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer metastatic	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testis cancer	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of soft tissue	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial sarcoma	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer female	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiosarcoma non-metastatic	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pituitary neoplasm malignant recurrent	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primitive neuroectodermal tumour	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage II	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage III	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage IV	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder adenocarcinoma	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	524 of 551	

Metastatic bronchial carcinoma	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to peripheral vascular system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bronchioloalveolar carcinoma	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage 0	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage I	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage II	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage III	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue carcinoma stage IV	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung neoplasm malignant	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal adenocarcinoma metastatic	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma metastatic	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration hepatic	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic lymphocytic leukaemia transformation	Leukaemias chronic lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Richter's syndrome	Diffuse large B-cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	525 of 551	

Natural killer-cell lymphoblastic lymphoma	Precursor T-lymphoblastic lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia recurrent	Leukaemias acute myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic retinopathy	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to central nervous system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage 0	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer stage I	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage I	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage II	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage 0	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage I	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage II	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic carcinoma stage III	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage III	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer stage IV	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	526 of 551	

Pancreatic carcinoma stage IV	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage 0	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage I	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage II	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage III	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small intestine carcinoma stage IV	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage I	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage II	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage III	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage IV	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bile duct cancer stage 0	Bile duct neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Buschke-Lowenstein's tumour	Genitourinary neoplasms malignancy and gender unspecified	Reproductive and genitourinary neoplasms gender unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Stewart-Treves syndrome	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small cell lung cancer metastatic	Respiratory tract small cell carcinomas	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	527 of 551	ĺ

Non-small cell lung cancer metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleural mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Penile squamous cell carcinoma	Penile neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of head and neck	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell leukaemia in remission	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma recurrent	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Precursor B-lymphoblastic lymphoma refractory	Precursor B-lymphoblastic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute leukaemia in remission	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Astrocytoma malignant	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer male	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cardiac neoplasm malignant	Cardiovascular neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thymoma malignant	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic leukaemia in remission	Leukaemias chronic NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	528 of 551	

Endocrine neoplasm malignant	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Female reproductive tract carcinoma in situ	Female reproductive neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrointestinal carcinoma in situ	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma, follicular grade I, II, III	Follicle centre lymphomas, follicular grade I, II, III	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Germ cell cancer	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia in remission	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant anorectal neoplasm	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant cranial nerve neoplasm	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant lymphoid neoplasm	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mediastinal neoplasm	Mediastinal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraocular melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant middle ear neoplasm	Aural neoplasms malignant and unspecified	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant nervous system neoplasm	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant peritoneal neoplasm	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	529 of 551	

Malignant respiratory tract neoplasm	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant urinary tract neoplasm	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mantle cell lymphoma	Mantle cell lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to nervous system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to reproductive organ	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic neoplasm	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Monocytic leukaemia in remission	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myeloid leukaemia in remission	Leukaemias myeloid NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nasopharyngeal cancer	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian epithelial cancer	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral neuroepithelioma of bone	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell cancer	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urinary tract carcinoma in situ	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anal cancer	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	530 of 551	l

Carcinoma in situ	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip and/or oral cavity cancer	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mesenchymoma	Mesenchymomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neurofibrosarcoma	Neurofibrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma	Oesophageal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pineal parenchymal neoplasm malignant	Pineal neoplasms	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hodgkin's disease stage IV	Hodgkin's disease NEC	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to the respiratory system	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cervix carcinoma stage 0	Cervix neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary malignant teratoma	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary non-seminoma	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extranodal marginal zone B-cell lymphoma (MALT type)	Extranodal marginal zone B-cell lymphomas (low grade B-cell)	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma transformed recurrent	Non-Hodgkin's lymphomas transformed recurrent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	531 of 551	

Non-renal cell carcinoma of kidney	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-small cell lung cancer	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage I	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage II	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage III	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell cancer stage IV	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Paranasal sinus and nasal cavity malignant neoplasm	Paranasal sinus and nasal cavity neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Salivary gland cancer	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Follicle centre lymphoma diffuse small cell lymphoma	Follicle centre lymphomas diffuse predominantly small cell	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastric cancer stage IV	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gestational trophoblastic tumour	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatoblastoma	Hepatoblastomas	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung infiltration malignant	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	532 of 551	

Malignant muscle neoplasm	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant nipple neoplasm	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Splenic marginal zone lymphoma	Splenic marginal zone lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular embryonal carcinoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular seminoma (pure)	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastasis	Metastases to unknown and unspecified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to biliary tract	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to gastrointestinal tract	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to soft tissue	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Retroperitoneal neoplasm metastatic	Gastrointestinal neoplasms malignancy unspecified NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemia recurrent	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gastrooesophageal cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hormone-refractory prostate cancer	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	533 of 551	

Metastatic glioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon cancer stage 0	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vulvar adenocarcinoma	Vulval neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic squamous cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Porocarcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute lymphocytic leukaemia recurrent	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of eyelid	Ocular neoplasms malignant (excl melanomas)	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant melanoma of eyelid	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology aggressive	Non-Hodgkin's lymphomas unspecified histology aggressive	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic gastric cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lip squamous cell carcinoma	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oropharyngeal cancer stage IV	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lymphoma transformation	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	534 of 551	

Desmoplastic small round cell tumour	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant transformation	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmablastic lymphoma	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer in remission	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal adenocarcinoma	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HER-2 positive breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant glioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CNS germinoma	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic eosinophilic leukaemia	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma unspecified histology indolent	Non-Hodgkin's lymphomas unspecified histology indolent	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primary effusion lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian stromal cancer	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Congenital fibrosarcoma	Musculoskeletal disorders congenital NEC	Musculoskeletal and connective tissue disorders congenital	Congenital, familial and genetic disorders
Alveolar rhabdomyosarcoma	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	535 of 551	

Embryonal rhabdomyosarcoma	Rhabdomyosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nongerminomatous germ cell tumour of the CNS	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Atypical teratoid/rhabdoid tumour of CNS	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Huerthle cell carcinoma	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Apocrine breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gliomatosis cerebri	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conjunctival melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of pharynx	Pharyngeal neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haematological malignancy	Haematologic neoplasms NEC	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Medulloblastoma recurrent	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroblastoma recurrent	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Melanoma recurrent	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer recurrent	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	536 of 551	I

Bladder transitional cell carcinoma stage 0	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma recurrent	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage I	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage IV	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage II	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma stage III	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder cancer metastatic	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic salivary gland cancer	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HER-2 positive gastric cancer	Gastric neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myxofibrosarcoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatosplenic T-cell lymphoma	Adult T-cell lymphomas/leukaemias	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial sarcoma recurrent	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial sarcoma metastatic	Endometrial neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration extramedullary	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Dlan	UTN: U111-1136-4716	Deter	21 January 2015	States-	<b>D</b> :1	Novo Nordisk
Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	NOVO NOI UISK
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	537 of 551	

Burkitt's leukaemia	Leukaemias acute lymphocytic	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant mesenteric neoplasm	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic angiosarcoma	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute biphenotypic leukaemia	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration gingiva	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Choroid plexus carcinoma	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gingival cancer	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory myofibroblastic tumour	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hereditary papillary renal carcinoma	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Hereditary leiomyomatosis renal cell carcinoma	Renal and urinary tract disorders congenital NEC	Renal and urinary tract disorders congenital	Congenital, familial and genetic disorders
Renal cell carcinoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic carcinoid tumour	Carcinoid tumours	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	538 of 551	

			unspecified (incl cysts and polyps)
Metastatic uterine cancer	Uterine neoplasms malignant NEC	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic ocular melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of seminal vesicle	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extramammary Paget's disease	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Chronic myeloid leukaemia transformation	Leukaemias chronic myeloid	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
5q minus syndrome	Myelodysplastic syndromes	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast sarcoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast sarcoma metastatic	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast sarcoma recurrent	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcoma metastatic	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioneuronal tumour	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell cancer metastatic	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sebaceous carcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	539 of 551	

Histiocytic medullary reticulosis	Histiocytoses	Haematopoietic neoplasms (excl leukaemias and lymphomas)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenosquamous cell carcinoma	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatic neuroendocrine tumour metastatic	Islet cell neoplasms and APUDoma NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Primitive neuroectodermal tumour metastatic	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Germ cell cancer metastatic	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peritoneal carcinoma metastatic	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Solid pseudopapillary tumour of the pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration renal	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Leukaemic infiltration	Leukaemias NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Eccrine carcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectosigmoid cancer metastatic	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Large cell lung cancer metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular choriocarcinoma recurrent	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testis cancer recurrent	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	540 of 551	

Refractory cancer	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage 0	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oestrogen receptor positive breast cancer	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Laryngeal cancer metastatic	Laryngeal neoplasms malignant	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer stage I	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer stage II	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer stage III	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian cancer stage IV	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases to pelvis	Metastases to specified sites	Metastases	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Abdominal wall neoplasm malignant	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage I	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage II	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage III	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer stage IV	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	541 of 551	

Transitional cell carcinoma metastatic	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hormone-dependent prostate cancer	Prostatic neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tongue cancer recurrent	Lip and oral cavity neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epstein-Barr virus associated lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic choriocarcinoma	Germ cell neoplasms site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung squamous cell carcinoma metastatic	Non-small cell neoplasms malignant of the respiratory tract cell type specified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's lymphoma metastatic	Non-Hodgkin's lymphomas NEC	Lymphomas non-Hodgkin's unspecified histology	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage IV	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage III	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage II	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer stage I	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Head and neck cancer metastatic	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastatic lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine carcinoma metastatic	Endocrine neoplasms malignant and unspecified NEC	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	542 of 551	

Gastrointestinal stromal cancer	Gastrointestinal neoplasms malignant NEC	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder transitional cell carcinoma metastatic	Bladder neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid cancer recurrent	Thyroid neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of pleura metastatic	Respiratory tract and pleural neoplasms malignant cell type unspecified NEC	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant blue naevus	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Desmoplastic melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spitzoid melanoma	Skin melanomas (excl ocular)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid B-cell lymphoma	B-cell lymphomas NEC	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tonsil cancer metastatic	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urethral melanoma metastatic	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma	Kaposi's sarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast angiosarcoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast angiosarcoma metastatic	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin angiosarcoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	543 of 551	

Extragonadal primary germ cell tumour	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary germ cell tumour mixed	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extragonadal primary seminoma (pure)	Extragonadal primary germ cell neoplasms	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant neoplasm of unknown primary site	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Biphasic mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Desmoplastic mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epithelioid mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Sarcomatoid mesothelioma	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pericardial mesothelioma malignant	Mesotheliomas malignant and unspecified	Mesotheliomas	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder adenosquamous carcinoma	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder squamous cell carcinoma	Gallbladder neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic cancer recurrent	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatocellular carcinoma	Hepatic neoplasms malignant	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	544 of 551	

Hepatobiliary cancer	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatobiliary cancer in situ	Hepatobiliary neoplasms malignant NEC	Hepatobiliary neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Iris melanoma	Ocular melanomas	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant sweat gland neoplasm	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hidradenocarcinoma	Skin neoplasms malignant and unspecified (excl melanoma)	Skin neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal proliferative breast lesion	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive ductal breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive lobular breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Invasive papillary breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lobular breast carcinoma in situ	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metaplastic breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neuroendocrine breast tumour	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tubular breast carcinoma	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	545 of 551	

Bone giant cell tumour malignant	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral primitive neuroectodermal bone tumour	Bone sarcomas	Skeletal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Epididymal cancer	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genital cancer male	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Spermatocytic seminoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular germ cell tumour mixed	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular malignant teratoma	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Testicular yolk sac tumour	Testicular neoplasms malignant	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Genital cancer male in situ	Reproductive neoplasms male malignant NEC	Reproductive neoplasms male malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic meningioma	Meningiomas malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Anaplastic oligodendroglioma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Angiocentric glioma	Nervous system neoplasms unspecified malignancy NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Central nervous system neuroblastoma	Nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oligoastrocytoma	Glial tumours malignant	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	546 of 551	

Plasma cell myeloma in remission	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma recurrent	Plasma cell myelomas	Plasma cell neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Extraskeletal myxoid chondrosarcoma	Extraskeletal chondrosarcomas	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Dedifferentiated liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mixed-type liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myxoid liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleomorphic liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Round cell liposarcoma	Liposarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear cell sarcoma of soft tissue	Soft tissue sarcomas histology unspecified	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant giant cell fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Inflammatory malignant fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pleomorphic malignant fibrous histiocytoma	Fibrous histiocytomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Peripheral primitive neuroectodermal tumour of soft tissue	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adrenal gland cancer	Adrenal neoplasms malignant	Endocrine neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	547 of 551	

Familial medullary thyroid cancer	Endocrine disorders congenital NEC	Endocrine disorders congenital	Congenital, familial and genetic disorders
Clear cell renal cell carcinoma	Renal neoplasms malignant	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell tumour mixed	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell choriocarcinoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell endodermal sinus tumour	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell polyembryoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian germ cell teratoma	Ovarian germ cell neoplasms malignant	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian clear cell carcinoma	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian endometrioid carcinoma	Ovarian neoplasms malignant (excl germ cell)	Reproductive neoplasms female malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Keratinising squamous cell carcinoma of nasopharynx	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Nonkeratinising carcinoma of nasopharynx	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Undifferentiated nasopharyngeal carcinoma	Oropharyngeal, nasopharyngeal and tonsillar neoplasms malignant and unspecified	Respiratory and mediastinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rhabdoid tumour	Neoplasms malignant site unspecified NEC	Miscellaneous and site unspecified neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Optic glioma	Ocular neoplasms malignancy unspecified	Ocular neoplasms	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	548 of 551	

Anal squamous cell carcinoma	Anal canal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of appendix	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Appendix cancer	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous adenocarcinoma of appendix	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Undifferentiated carcinoma of colon	Colorectal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acinar cell carcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ductal adenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal papillary-mucinous carcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucinous cystadenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Pancreatoblastoma	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Serous cystadenocarcinoma of pancreas	Pancreatic neoplasms malignant (excl islet cell and carcinoid)	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acinic cell carcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenoid cystic carcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Mucoepidermoid carcinoma of salivary gland	Salivary gland neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	549 of 551	

Small intestine adenocarcinoma	Small intestinal neoplasms malignant	Gastrointestinal neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Congenital retinoblastoma	Retinal disorders congenital	Eye disorders congenital	Congenital, familial and genetic disorders	
Anaplastic large-cell lymphoma	Lymphomas unspecified NEC	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Acute undifferentiated leukaemia	Leukaemias acute NEC	Leukaemias	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
B-cell prolymphocytic leukaemia	B-cell small lymphocytic lymphomas	Lymphomas non-Hodgkin's B-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Enteropathy-associated T-cell lymphoma	Intestinal T-cell lymphomas	Lymphomas non-Hodgkin's T-cell	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Congenital malignant neoplasm	Congenital disorders NEC	Congenital and hereditary disorders NEC	Congenital, familial and genetic disorders	
Hodgkin's disease nodular sclerosis stage II	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Hodgkin's disease nodular sclerosis stage I	Hodgkin's disease nodular sclerosis type	Lymphomas Hodgkin's disease	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Intraductal papillary breast neoplasm	Breast and nipple neoplasms malignant	Breast neoplasms malignant and unspecified (incl nipple)	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Dermatofibrosarcoma protuberans metastatic	Fibrosarcomas malignant	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Intracranial germ cell tumour	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Brain sarcoma	Central nervous system neoplasms malignant NEC	Nervous system neoplasms malignant and unspecified NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Composite lymphoma	Lymphomas unclassifiable malignant	Lymphomas NEC	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	
Adenosquamous carcinoma of vagina	Vaginal neoplasms malignant	Reproductive neoplasms female malignant and	Neoplasms benign, malignant and	

Statistical Analysis Plan	UTN: U111-1136-4716	Date:	21 January 2015	Status:	Final	Novo Nordisk
Trial ID: NN9924-3790	EudraCT No.: 2012-004994-16	Version:	1.0	Page:	550 of 551	

		unspecified	unspecified (incl cysts and polyps)
Malignant connective tissue neoplasm	Soft tissue neoplasms malignant and unspecified NEC (excl sarcomas)	Soft tissue neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant genitourinary tract neoplasm	Urinary tract neoplasms malignant NEC	Renal and urinary tract neoplasms malignant and unspecified	Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Statistical Analysis Plan		Date:	21 January 2015	Novo Nordisk
Trial ID: NN9924-3790	CONFIDENTIAL	Version:	1.0	
UTN: U111-1136-4716	CUNFIDEN HAL	Status:	Final	
EudraCT No.: 2012-004994-16		Page:	551 of 551	

## 5 References

<sup>ii</sup> Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79(3):777-781. <sup>iii</sup> Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L et al. Hypoglycemia and diabetes: a report of a

<sup>&</sup>lt;sup>i</sup> Casella, G. and Berger, R. L. (2002), Statistical Inference, 2nd ed.

workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36(5):1384-1395.